

SECURITIES AND EXCHANGE COMMISSION

FORM 10-K

Annual report pursuant to section 13 and 15(d)

Filing Date: **2018-03-16** | Period of Report: **2017-12-31**
SEC Accession No. [0001638833-18-000004](#)

[\(HTML Version on secdatabase.com\)](#)

FILER

Surgery Partners, Inc.

CIK: **1638833** | IRS No.: **473620923** | State of Incorpor.: **DE** | Fiscal Year End: **1231**
Type: **10-K** | Act: **34** | File No.: **001-37576** | Film No.: **18696401**
SIC: **8062** General medical & surgical hospitals, nec

Mailing Address

*310 SEVEN SPRINGS WAY
SUITE 500
BRENTWOOD TN 37027*

Business Address

*310 SEVEN SPRINGS WAY
SUITE 500
BRENTWOOD TN 37027
615-234-5900*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2017

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Commission file number: 001-37576

Surgery Partners, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

47-3620923
(I.R.S. Employer
Identification No.)

**310 Seven Springs Way, Suite 500
Brentwood, Tennessee 37027**
(Address of principal executive offices and zip code)
(615) 234-5900
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Class	Name of Exchange on Which Registered
Common Stock, par value \$0.01 per share	NASDAQ Global Select Market

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer

Accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The aggregate market value of the registrant's voting and non-voting common equity held by non-affiliates of the registrant based on the closing price of the shares of common stock on The NASDAQ Stock Market on June 30, 2017, was \$484.1 million.

As of March 15, 2018, there were 48,611,578 shares of the registrant's common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the definitive proxy statement for the registrant's annual stockholders' meeting to be held May 4, 2018 are incorporated by reference into Part III of this report.

SURGERY PARTNERS, INC.
FORM 10-K
TABLE OF CONTENTS

	<u>Page</u>
PART I	
Item 1. Business	1
Item 1A. Risk Factors	15
Item 1B. Unresolved Staff Comments	36
Item 2. Properties	36
Item 3. Legal Proceedings	36
Item 4. Mine Safety Disclosures	36
PART II	
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	37
Item 6. Selected Financial Data	40
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	41
Item 7A. Quantitative and Qualitative Disclosure About Market Risk	60
Item 8. Financial Statements and Supplementary Data	60
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	60
Item 9A. Controls and Procedures	60
Item 9B. Other Information	63
PART III	
Item 10. Directors, Executive Officers and Corporate Governance	64
Item 11. Executive Compensation.	64
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	64
Item 13. Certain Relationships and Related Transactions, and Director Independence	64
Item 14. Principal Accounting Fees and Services	64
PART IV	
Item 15. Exhibits, Financial Statement Schedules	65
Item 16. Form 10-K Summary	67
Signatures	

Explanatory Note

On August 31, 2017, we completed the acquisition of NSH Holdco, Inc. (the “NSH Merger”). Also on August 31, 2017, (i) we completed the sale and issuance of 310,000 shares of our 10.00% Series A Convertible Perpetual Participating Preferred Stock (the “Series A Preferred Stock”) to a fund advised by an affiliate of Bain Capital Private Equity LP (“Bain Capital”), at a purchase price of \$1,000 per share in cash (the “Preferred Private Placement”), and (ii) Bain Capital completed its purchase of 26,455,651 shares (the “Purchased Shares”) of our common stock from H.I.G. Surgery Centers, LLC (“H.I.G.”). As a result of the Preferred Private Placement and the Private Sale, Bain Capital became our controlling stockholder, holding Series A Preferred Stock and Common Stock that collectively represent approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017, and H.I.G. and its affiliated investment funds no longer own any capital stock of the Company. We refer to the Preferred Private Placement and the Private Sale collectively in this Annual report on Form 10-K as the “Transactions.”

Cautionary Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report, including statements regarding our future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “will” and similar expressions are generally intended to identify forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We believe that these risks and uncertainties include, but are not limited to, those described in the “Risk Factors” section of this Annual Report, which include but are not limited to the following:

- the impact of future legislation and other healthcare regulatory reform actions, and the effect of that legislation and other regulatory actions on our business;
- reductions in payments from government healthcare programs and managed care organizations;
- our ability to contract with private third-party payors;
- changes in our payor mix or surgical case mix;
- failure to maintain relationships with our physicians on beneficial terms, or at all;
- the impact of payor controls designed to reduce the number of surgical procedures;
- our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities;
- shortages or quality control issues with surgery-related products, equipment and medical supplies;
- competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts;
- our ability to attract and retain qualified healthcare professionals;
- our ability to enforce non-compete restrictions against our physicians;
- our ability to manage material liabilities incurred as a result of acquiring surgical facilities;
- economic and competitive conditions;
- the outcome of legal and regulatory proceedings that have or may be brought against us;
- changes in the regulatory, economic and other conditions of the states where our surgical facilities are located;
- substantial payments we are required to make under the TRA;
- our substantial indebtedness.

Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this Annual Report .We have based these forward-looking statements on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. They can be affected by known or unknown risks, uncertainties and assumptions, including, among other things, the risks, uncertainties and assumptions described in Item 1A. "Risk Factors."

Our forward-looking statements speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, press releases, and our website.

PART 1

Item 1. Business

Overview

We are a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for U.S. surgical and related ancillary care in support of our patients and physicians. Founded in 2004, we are now one of the largest and fastest growing surgical services businesses in the country. We were incorporated in Delaware in 2015 ahead of our initial public offering.

The following discussion of our business covers periods both prior to and subsequent to the Transactions (as defined in the Explanatory Note above). As discussed in the notes to the consolidated financial statements included in this report, in connection with the change of control effected by the Private Sale, we elected to apply “pushdown” accounting. We have presented the information for the year ended December 31, 2017 on a Predecessor period and Successor period combined basis (each as defined in Note 1. "Organization" of our consolidated financial statements) to facilitate meaningful comparisons of operating results to the prior year periods. You should read the following discussion together with our historical financial statements and related notes included elsewhere herein.

As of December 31, 2017, we owned or operated primarily in partnership with physicians, a portfolio of 124 surgical facilities in the United States comprised of 106 ASCs and 18 surgical hospitals (“surgical hospitals,” and together with ASCs referred to as “surgical facilities” or “facilities”) across 32 states and we owned a majority interest in 84 of these facilities. Additionally, approximately 77% of these facilities were multi-specialty focused. During 2017, our physicians provided services to patients in our surgical facilities generating \$1.2 billion in revenue.

We understand that the priority of our business is the consumer - our patients. Our business model aligns with, and empowers, our physician partners, to provide them with the resources necessary to delivery high quality, affordable healthcare to our patients. This alignment of the consumer and physician is key to a successful clinical model. As we also align with payors as they seek to make healthcare more affordable, we have the ingredients for a successful business model as well.

Our Growth Strategies

Our differentiated operating model employs a multifaceted strategy to grow revenue, earnings and cash flow. We believe the following are key components to this strategy:

- Deliver outstanding patient care and clinical outcomes;
- Continue to execute and expand upon our physician engagement strategy in attractive markets;
- Become the partner of choice for physicians seeking to become or stay independent;
- Drive organic growth at existing facilities through targeted physician recruitment, service line expansion and implementing our efficient operating model;
- Seek partnership opportunities with payors to make healthcare more affordable for their members;
- Continue our disciplined acquisition strategy;
- Introduce new service offerings to provide a more comprehensive continuum of care; and
- Enhance operational efficiencies and productivity by delivering on integration.

In addition, we believe favorable industry trends such as an aging population and advancements in technology will further drive growth.

Operations

We operate in three reporting segments throughout the United States: surgical facility services, ancillary services and optical services.

Surgical Facility Services Segment: Our surgical facility services segment consists of the operation of ASCs and surgical hospitals, and includes our anesthesia services. Our surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology ("GI"), general surgery, ophthalmology, orthopedics, and pain management.

Ancillary Services Segment: Our ancillary services segment consists of a diagnostic laboratory and multi-specialty physician practices. These physician practices include our owned and operated physician practices pursuant to long-term management service agreements.

Optical Services Segment: Our optical services segment consists of an optical laboratory and an optical products group purchasing organization. Our optical laboratory manufactures eyewear, while our optical products purchasing organization negotiates volume buying discounts with optical product manufacturers.

Surgical Facility Services Segment

Surgical Facility Operations

As of December 31, 2017, we owned (primarily with physician investors or healthcare systems) or operated 124 surgical facilities in the United States, including 18 that are licensed as hospitals. For further information regarding our surgical facilities, see Item 2. "Properties" of this report.

Our surgical facility services segment contributed approximately 93%, 91% and 92% of our total revenue for the years ended December 31, 2017, 2016 and 2015, respectively. Our typical ASC is a free-standing facility for planned surgical procedures performed on an outpatient basis on patients not requiring hospitalization and for whom an overnight stay is not expected after surgery. Each center typically has one to four operating or procedure rooms with areas for reception, pre-operative care, recovery and administration. The staff of our ASCs generally includes a center administrator, registered nurses, operating room technicians, as well as other administrative staff.

Our surgical hospitals are generally larger than our ASCs and include inpatient hospital rooms and, in two cases, a limited scope emergency department. Our surgical hospitals also provide ancillary services such as diagnostic imaging, pharmacy, laboratory, obstetrics, physical therapy, oncology and wound care.

We operate both multi-specialty and single-specialty facilities. In multi-specialty facilities, a variety of surgical procedures are performed, including: GI, general surgery, ophthalmology, orthopedics and pain management. We have diversified our facility procedure mix by strategically introducing select specialties that will complement existing facilities. In many cases, we keep certain facilities as single-specialty where it suits an individual facility or market demand.

Our surgical facilities are generally located in close proximity to physicians' offices. We provide each of our surgical facilities with a full range of financial, marketing and operating services. For example, our regional managed care directors assist the local management team at each of our surgical facilities in developing relationships with managed care providers and negotiating managed care contracts.

Surgical Facility Ownership Structure

We own and operate our surgical facilities through partnerships or limited liability companies with physicians, physician groups and healthcare systems. One of our wholly owned subsidiaries typically serves as the general partner or managing member of our surgical facilities. We generally seek to own a majority interest in our surgical facilities, or otherwise have sufficient control over the facilities to be able to consolidate the financial results of operations of the facilities with ours. In some instances, we will acquire ownership in a surgical facility with the prior owners retaining ownership, and, in some cases, we offer new ownership to other physicians or healthcare systems. We hold majority ownership in 84 of the 124 surgical facilities in which we own an interest. We provide intercompany loans to our consolidated facilities which often are secured by a pledge of assets of the partnership or limited liability company. We also have a management agreement with the majority of our surgical facilities, under which we provide day-to-day management services for a management fee, which is typically equal to a percentage of the revenues of the facility.

Strategic Relationships

When attractive opportunities arise, we may develop, acquire or operate surgical facilities through strategic relationships with payors, healthcare systems, and other healthcare providers. We believe that forming a relationship with a healthcare system can enhance our ability to attract physicians and access managed care contracts for our surgical facilities in that market.

The strategic relationships through which we own and operate surgical facilities are governed by partnership and operating agreements that are generally comparable to the partnership and operating agreements of the other surgical facilities in which we own an interest. The primary difference between the structure of these strategic relationships and the other surgical facilities in which we hold ownership is that, in these strategic relationships, a healthcare system holds ownership in the surgical facility, in addition to physician investors. In each of these strategic relationships, we also have entered into a management agreement under which we provide day-to-day management services for a management fee equal to a percentage of the revenues of the surgical facility. The terms of those management agreements are comparable to the terms of our management agreements with other surgical facilities in which we own an interest.

Sources of Revenue

Revenue from our surgical facilities is earned from facility fees related to healthcare services performed in our surgical facilities and is included in our patient service revenues. The fee charged for surgical services varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, supplies, nursing staff and medications. Our fees do not typically include professional

fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor.

We are dependent upon private and government third-party sources of payment for the surgical services we provide. The amounts that our surgical facilities receive in payment for their services may be adversely affected by market and cost factors as well as other factors over which we have no control, including Medicare, Medicaid and state regulations as well as cost containment and utilization decisions and reduced reimbursement schedules of third-party payors. Approximately 38%, 40% and 38% of our patient service revenues were from government sources, mostly Medicare, for the years ended December 31, 2017, 2016 and 2015, respectively.

[Table of Contents](#)

The following table sets forth the percentage of our total patient service revenues for our consolidated surgical facilities by type of payor for the periods indicated:

	Year Ended December 31,		
	2017	2016	2015
Private Insurance	54%	51%	55%
Government	38%	40%	38%
Self-pay	2%	2%	2%
Other	6%	7%	5%
Total patient service revenues	100%	100%	100%

We receive reimbursement from Medicare for surgical services based on three different payment systems depending on the site of service: hospital outpatient surgical services, hospital inpatient surgical services and outpatient surgical services provided in our ASCs.

Medicare Reimbursement - Hospital Outpatient Departments

Surgical services that are provided in hospital outpatient departments (“HOPDs”) are generally reimbursed by Medicare on the Outpatient Prospective Payment System (the “OPPS”). The OPPS is a system established by the Secretary of the Department of Health and Human Services (“HHS”) that determines payment amounts prospectively for various categories of medical services performed in HOPDs. On November 13, 2017, the Centers for Medicare and Medicaid Services (“CMS”) published its OPPS final rule for CY 2018. The final rule provides for a payment rate increase of 1.35%. Hospitals that do not meet the reporting requirements of the Medicare Hospital Outpatient Quality Reporting Program will be subject to an additional 2.0% payment rate decrease.

Additionally, as a result of legislative changes related to off-campus HOPDs, certain off-campus HOPDs that began billing under the OPPS (or underwent certain changes) on or after November 2, 2015 are no longer paid for most services under the OPPS. Instead, these facilities are paid under the Medicare Physician Fee Schedule (“MPFS”), which typically results in lower reimbursements. Services provided in a dedicated emergency department are still paid under the OPPS. This change has not significantly affected reimbursement to any of our HOPDs, but we cannot assure you that our HOPDs will not be impacted in the future.

Medicare Reimbursement - ASCs

Payments under the Medicare program to ASCs are also made based on the OPPS. However, the payment received from the Medicare program by an ASC is a percentage of the payment to HOPDs. Reimbursement rates for ASCs are updated annually based on changes in the consumer price index offset by multifactor productivity adjustments. Based on the OPPS Final Rule, ASC reimbursement rates have increased by an additional 1.2% for 2018. CMS has established the Ambulatory Surgical Center Quality Reporting (“ASCQR”) Program as a pay-for-reporting, quality data program. Our ASCs that participate in the ASCQR Program receive the full annual update to the ASC payment rate. Those ASCs that do not successfully report quality data under the ASCQR Program may receive a payment reduction

Medicare Reimbursement - Hospital Inpatient Services

Eighteen of our surgical facilities are licensed as hospitals. Most inpatient services provided by hospitals are reimbursed by Medicare under the inpatient prospective payment system (“IPPS”). Under the IPPS, a hospital receives a fixed amount for inpatient hospital services based on each patient's final assigned Medicare-severity diagnosis related group (“MS-DRG”). Each MS-DRG is assigned a payment rate that is prospectively set using national average resources used per case for treating a patient with a particular diagnosis. This MS-DRG assignment also affects the prospectively determined capital rate paid with each MS-DRG. MS-DRG and capital payments are adjusted by a predetermined geographic adjustment factor assigned to the geographic area in which the hospital is located. The index used to adjust the MS-DRG rates, known as the “hospital market basket index,” gives consideration to the inflation experienced by hospitals in purchasing goods and services.

On August 14, 2017, CMS published the IPPS final rule for federal fiscal year (“FFY”) 2018, which began on October 1, 2017. Under the FFY 2018 final rule, rates for inpatient stays in hospitals paid under the IPPS that successfully report certain quality data under the Hospital Inpatient Quality Reporting (“IQR”) Program and demonstrate meaningful use of certified electronic health record (“EHR”) technology will be increased by 1.35%. Those hospitals that do not successfully report quality data under the IQR Program (but are meaningful EHR users) may receive a payment rate increase of only 0.675%. In addition to the IQR Program, hospitals will be subject to payment adjustments under the Value Based Purchasing Program, Readmissions Reduction Program and Hospital Acquired Conditions Reduction Programs that have been implemented by HHS.

Annual Cost Reports

Hospitals participating in the Medicare and some Medicaid programs, whether paid on a reasonable cost basis or under a prospective payment system, are required to meet certain financial reporting requirements. Federal and, where applicable, state regulations require submission of annual cost reports identifying medical costs and expenses associated with the services provided by each hospital to Medicare beneficiaries and Medicaid recipients. Annual cost reports required under the Medicare and some Medicaid programs are subject to routine governmental audits. These audits may result in adjustments to the amounts ultimately determined to be payable to us under these reimbursement programs. Finalization of these audits often takes several years. Providers may appeal any final determination made in connection with an

audit. While ASCs are not currently subject to federal cost reporting requirements, it is possible that such requirements, which could be costly for us, will be implemented by CMS in the future.

Other Segments

Ancillary Services

Our portfolio of outpatient surgical facilities is complemented by our suite of ancillary services, which supports our physicians in providing high quality and cost-efficient patient care. Rather than contracting with third-party providers, in some geographies we own ancillary businesses including a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, and anesthesia services. Our Company, physicians and patients benefit from these services through improved clinical efficiency and scheduling, and from incremental revenue associated with retaining these fees. Our ancillary services segment contributed approximately 6%, 8% and 6% of our total revenue for the years ended December 31, 2017, 2016 and 2015, respectively.

- **Diagnostic Laboratory:** We offer physicians toxicology testing services through our diagnostic laboratory, Logan Laboratories, a wholly-owned subsidiary based in Tampa, Florida. Advanced toxicology screening provides physicians with the ability to identify when a patient is taking too much of a prescribed substance, when a patient is non-compliant with a prescribed substance or when a patient is taking unprescribed or illicit substances. Our diagnostic laboratory offerings support the needs of our physicians across our existing specialties and new service lines.
- **Multi-Specialty Physician Practices:** We employ two models in connection with our network of physician practices. In the state of Florida, where the law does not preclude a business corporation from employing physicians, we own and operate Tampa Pain Relief Center, Inc., a wholly-owned business with several locations throughout Florida. In states other than Florida, we operate physician practices pursuant to long-term management service agreements with separate professional corporations that are wholly-owned by physicians.
- **Urgent Care Facilities:** Our urgent care facilities primarily treat injuries or illnesses requiring immediate care, but not serious enough to require an emergency room visit. Urgent care centers have become an increasingly viable alternative for patients as wait times for both primary care and emergency care providers continue to rise. Our urgent care facilities fill an access gap by providing walk-in care, especially during evening and weekend hours. In addition to the convenience they provide patients, our urgent care facilities also offer one of the lowest cost settings for both patients and payors. As of December 31, 2017, we owned and operated eight urgent care facilities in proximity to our surgical hospitals. Our urgent care facilities provide support and additional access points to our surgical hospitals.

Optical Services

Our optical services segment contributed approximately 1%, 1% and 2% of our total revenue for the years ended December 31, 2017, 2016 and 2015, respectively.

Sources of Revenue - Other Segments

The fees charged for services in our other segments depend on the type of service provided, the location in which the service is provided and the provider of the service. Service fees are received from both private and government third-party sources of payment. The amounts that we receive in payment for the provision of ancillary and optical services may be adversely affected by market and cost factors as well as other factors over which we have no control, including Medicare, Medicaid and state regulations as well as cost containment and utilization decisions and reduced reimbursement schedules of third-party payors.

Our ancillary services revenue primarily consists of fee for service revenue that is derived principally from the provision of physician and laboratory services to patients of our surgical facilities. Medicare pays for physician services based upon the MPFS. Payment rates under the MPFS are determined based on (i) relative value units for the services provided, (ii) a geographic adjustment factor and (iii) a conversion factor. Payment rates under the MPFS are updated annually by HHS. The primary element in each year's update calculation is the Medicare Economic Index ("MEI"), which is a measure of the inflation of the cost of operating a physician practice. The update is then adjusted in conformity with the Medicare Access and CHIP Reauthorization Act of 2015 ("MACRA"), which was enacted in April 2015. MACRA established a fixed 0.5% annual adjustment through calendar year 2018. Beginning in 2019, Medicare compensation to physicians and physician practices will be subject to adjustment under the Merit-Based Incentive Payment System ("MIPS"). Under MIPS, physicians will be assigned a composite performance score based on measures of quality, resource use, meaningful use of electronic health records, and clinical practice improvement activities. A threshold performance score will be set annually by CMS at the mean or median of all composite scores for a prior annual performance period. Performance exceeding the threshold will result in a positive adjustment, performance below the threshold will result in a negative adjustment, and performance at the threshold will result in no adjustment. Physicians who participate in certain alternative payment models, such as accountable care organizations, will be guaranteed a positive payment adjustment under MACRA. The effect of the payment methodology changes under MACRA on our physician practices cannot be predicted.

Certain of our laboratory ancillary services are reimbursed by Medicare under the Medicare Clinical Laboratory Fee Schedule (“CLFS”). Under a June 23, 2016 final rule that implements the Protecting Access to Medicare Act of 2014 (“PAMA”), as of January 1, 2018 the CLFS payment methodology was adjusted so that payment amounts for laboratory tests on the CLFS is determined by calculating a weighted median of private payor rates using reported private payor rates and associated volume (number of tests). For tests that were

paid on the CLFS prior to the implementation of PAMA, any reduction in payment amount will be phased in over the first 6 years of payment under the new system.

Acquisitions and Developments

On August 31, 2017, we completed the acquisition of NSH Holdco, Inc. for approximately \$760 million, adding NSH's surgical facilities specializing in orthopedic surgery, spine and back, pain management and neurosurgery to our portfolio. At the same time, we completed the sale and issuance of 310,000 shares of preferred stock to Bain Capital at a purchase price of \$1,000 per share in cash and Bain Capital completed its purchase of 26,455,651 shares from our prior controlling stockholder.

In the last five years we have also completed the acquisition of Symbion, which materially expanded our network of existing facilities and ancillary services.

Acquisition Program. In addition to our corporate strategy, we continuously evaluate opportunities to expand our presence in the surgical facility market by making strategic acquisitions of existing surgical facilities and by developing new surgical facilities in cooperation with local physician partners and, when appropriate, with healthcare systems and other strategic partners. We generally structure our partnerships as two-way arrangements where either we are a majority owner partnered with physicians or we are a minority owner with buy-up rights. These buy-up rights give us the option to own a controlling interest at some point in the future. Alternatively, we may choose to pursue a three-way arrangement with physicians and a healthcare system.

We employ a dedicated acquisition team with experience in healthcare services. Our team seeks to acquire surgical facilities that meet our criteria, including prominence and quality of physician partners, specialty mix, opportunities for growth, level of competition in the local market, level of managed care penetration and our ability to access managed care organization contracts. We carefully evaluate each of our acquisition opportunities through an extensive due diligence process to determine which facilities have the greatest potential for growth and profitability improvements under our operating structure. Our team may also identify opportunities to attract additional physicians to increase the acquired facility's revenues and profitability.

Development Program. We develop surgical facilities in markets in which we identify substantial interest by physicians and payors. We have experience in developing both single and multi-specialty surgical facilities. When we develop a new surgical facility, we generally provide all of the services necessary to complete the project. We offer in-house capabilities for structuring partnerships and financing facilities and work with architects and construction firms in the design and development of surgical facilities. Before and during the development phase of a new surgical facility, we analyze the competitive environment in the local market, review market data to identify appropriate services to provide, prepare and analyze financial forecasts, evaluate regulatory and licensing issues and assist in designing the surgical facility and identifying appropriate equipment to purchase or lease. After the surgical facility is developed, we generally provide startup operational support, including information systems, equipment procurement and financing.

Marketing

We primarily direct our sales and marketing efforts at physicians who would utilize our surgical facilities. Marketing activities directed at physicians and other healthcare providers are coordinated locally by the individual surgical facility and are supplemented by dedicated corporate personnel. These activities generally emphasize the benefits offered by our surgical facilities compared to other facilities in the market, such as the proximity of our surgical facilities to physicians' offices, the ability to schedule consecutive cases without preemption by inpatient or emergency procedures, the efficient turnaround time between cases, our advanced surgical equipment and our simplified administrative procedures. Although the facility administrator is the primary point of contact, physicians who utilize our surgical facilities are important sources of recommendations to other physicians regarding the benefits of using our surgical facilities. Recruiting teams develop a target list of physicians, and we continually review our progress in successfully recruiting additional local physicians.

We also market our surgical facilities directly to payors, such as health maintenance organizations ("HMOs"), preferred provider organizations ("PPOs"), and other managed care organizations and employers. Payor marketing activities conducted by our corporate office management and facility administrators emphasize the high quality of care, cost advantages and convenience of our surgical facilities, and are focused on making each surgical facility an approved provider under local managed care plans.

Competition

In each market in which we operate a surgical facility, we compete with hospitals and operators of other surgical facilities to attract physicians and patients. We believe that the competitive factors that affect our surgical facilities' ability to compete for physicians are convenience of location of the surgical facilities, access to capital and participation in managed care programs. In addition, we believe the national prominence, scale and reputation of our company are instrumental in attracting physicians. We believe that our surgical facilities attract patients based upon our quality of care, the specialties

and reputations of the physicians who operate in our surgical facilities, participation in managed care programs, ease of access and convenient scheduling and registration procedures.

In developing or acquiring existing surgical facilities, we compete with other public and private surgical facility and hospital companies. Several large national companies own and/or manage surgical facilities, in some cases in connection with other lines of business with which we do not compete, including HCA Holdings, Inc., Surgical Care Affiliates, Inc., Envision Healthcare Corporation and Tenet Healthcare Corporation. We also face competition from local hospitals, physicians and other providers who may compete with us in the ownership and operation of surgical facilities, as well as the trend of physicians choosing to perform procedures in an office-based setting rather than in a surgical facility.

Seasonality

Our net revenue fluctuates based on the number of business days in each calendar quarter, because the majority of services provided by physicians in our surgical facilities consist of scheduled procedures and office visits that occur during business hours. In addition, revenue in the fourth quarter could also be impacted by an increased utilization of services due to annual deductibles which are not usually met until later in the year and also as patients utilize their healthcare benefits before they expire at year-end.

Employees

At December 31, 2017, we had approximately 10,600 employees, including approximately 7,300 full-time employees. None of our employees are represented by a collective bargaining agreement. We believe that we have a good relationship with our employees.

Environmental

We are subject to various federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including those governing the management and disposal of hazardous substances and wastes, the cleanup of contaminated sites and the maintenance of a safe workplace. Our operations include the use, generation and disposal of hazardous materials. We may, in the future, incur liability under environmental statutes and regulations with respect to contamination of sites we own or operate (including contamination caused by prior owners or operators of such sites, adjoining properties or other persons) and the off-site disposal of hazardous substances. We believe that we have been and are in substantial compliance with the terms of all applicable environmental laws and regulations and that we have no liabilities under environmental requirements that we would expect to have a material adverse effect on our business, results of operations or financial condition (including our capital expenditures, earnings and competitive position).

Insurance

We maintain liability insurance in amounts that we believe are appropriate for our operations. Currently, we maintain professional liability insurance that provides coverage on a claims-made basis of \$1.0 million per occurrence with a retention of \$100,000 per occurrence and \$3.0 million in annual aggregate coverage per surgical facility, including the facility and employed staff. We maintain general liability insurance that provides coverage on an occurrence basis of \$1.0 million per occurrence with a retention of \$25,000 per occurrence and \$3.0 million in annual aggregate coverage per surgical facility. We also maintain business interruption insurance and property damage insurance. Coverage under certain of these policies is contingent upon the policy being in effect when a claim is made regardless of when the events which caused the claim occurred. The cost and availability of such coverage has varied widely in recent years.

In addition, physicians who provide professional services in our surgical facilities are required to maintain separate malpractice coverage with similar minimum coverage limits. While we believe that our insurance policies are adequate in amount and coverage for our anticipated operations, we cannot assure you that the insurance coverage is sufficient to cover all future claims or will continue to be available in adequate amounts or at a reasonable cost.

Private Third-Party Payors

Most third-party payors reimburse us for surgical and ancillary services pursuant to written contracts. These contracts generally require that we offer discounts from our established charges. Some of our payments come from third-party payors with which we do not have written contracts. In those situations, commonly known as “out-of-network” services, we generally charge the patients the same co-payment or other patient responsibility amounts that we would have charged had we had a contract with the third-party payor. We also submit a claim for the services to the third-party payor along with full disclosure that we have charged the patient an in-network patient responsibility amount.

Governmental Regulation

General

Our businesses are subject to federal, state and local laws dealing with issues such as occupational safety, employment, medical leave, insurance regulations, civil rights, discrimination, building codes and medical waste and other environmental issues. Federal, state and local governments are expanding the regulatory requirements on businesses like ours. The imposition of these regulatory requirements may have the effect of increasing operating costs and reducing the profitability of our operations.

Certificates of Need, Licensure and Accreditation

Capital expenditures for the construction of new healthcare facilities, the addition of beds or new healthcare services or the acquisition of existing healthcare facilities may be reviewable by state regulators under statutory schemes that are sometimes referred to as certificate of need laws. States with certificate of need laws place limits on the construction and acquisition of healthcare facilities and the expansion of existing facilities and services. In these states, approvals, generally known as certificates of need, are required for capital expenditures exceeding certain preset monetary thresholds for the development, acquisition and/or expansion of certain facilities or services, including, in certain of these states, surgical facilities. We currently operate in 20 states that have certificate of need laws.

Our healthcare facilities also are subject to state licensing requirements for medical providers. Our ASCs have licenses to operate in the states in which they operate and must meet all applicable requirements for ASCs. In addition, even though our surgical facilities that are licensed as hospitals primarily provide surgical services, they must meet all applicable requirements for general hospital licensure. To assure continued compliance with these regulations, governmental and other authorities periodically inspect our surgical facilities. The failure to comply with these regulations could result in the suspension or revocation of a facility's license. In addition, based on the specific operations

of our surgical facilities, some of these facilities maintain a pharmacy license, a controlled substance registration, a clinical laboratory certification waiver, and environmental protection permits for biohazards and/or radioactive materials, as required by applicable law.

As of December 31, 2017, the majority of our facilities were accredited by either The Joint Commission or the Accreditation Association for Ambulatory Health Care, two of the major national organizations that establish standards relating to the physical plant, administration, quality of patient care and operation of medical staffs of various types of healthcare facilities. The effect of accreditation by these organizations is to exempt the facilities from routine surveys by state agencies to determine compliance with Medicare conditions. These accredited facilities are subject to periodic surveys by the accrediting organization to ensure that they are in compliance with the applicable standards. Many commercial health plans require our facilities to be accredited in order to be participating providers. Failure to maintain accreditation would cause a facility to become subject to state survey agency oversight and potentially subject to increased scrutiny by CMS, and could result in a loss of payment from commercial health plans.

Affordable Care Act Repeal Efforts

Initiatives to repeal or modify the Affordable Care Act have been persistent and have increased as a result of the 2016 election. As of December 31, 2017, efforts to repeal and replace the Affordable Care Act in full have not been successful. However, as a result of the enactment of the Tax and Jobs Act of 2017, the so-called “individual mandate,” which requires most individuals to obtain qualifying health insurance coverage or pay a tax penalty, was repealed effective as of calendar year 2019. The repeal of the individual mandate and any other future repeal or replacement of the Affordable Care Act may have significant impact on the reimbursement for healthcare services generally, and may cause more individuals to become uninsured, rendering them unable to afford healthcare services offered by the Company. Accordingly, there can be no assurance that the adoption of any future federal or state healthcare reform legislation will not have a negative financial impact on the Company.

Medicare and Medicaid Private Contractor Audits

CMS has implemented a number of programs that use private contractors that contract with CMS to identify overpayments and underpayments and other potential sources of billing fraud. These contractors, known as Recovery Audit Contractors (“RACs”) and Zone Program Integrity Contractors (“ZPICs”) conduct both post-payment and pre-payment review of claims submitted by Medicare providers. In addition, CMS employs Medicaid Integrity Contractors (“MICs”) to perform post-payment audits of Medicaid claims and identify overpayments. Our facilities and providers continue to receive letters from auditors such as RACs and ZPICs requesting repayment of alleged overpayments for services and incur expenses associated with responding to and appealing these determinations, as well as the costs of repaying any overpayments. Moreover, in recent years, the increase in Medicare payment appeals has created a backlog such that resolving appeals often takes multiple years. For instance, we recently settled claims resulting from an audit for the period July 1, 2009 through May 31, 2012 in the second quarter of fiscal 2017. See Note 15 to our audited financial statements included elsewhere in this report.

Although all other repayments requested to date as a result of RAC, MIC and ZPIC audits have not been material to our Company, we are unable to quantify the aggregate financial impact of these audits on our facilities given the pending appeals and uncertainty about the extent of future audits.

Medicare and Medicaid Participation

The majority of our revenue is expected to continue to be received from third-party payors, including federal and state programs, such as Medicare and Medicaid, and commercial payors. To participate in the Medicare program and receive Medicare payment, our surgical facilities must comply with regulations promulgated by HHS. Among other things, these regulations, known as “conditions for coverage” or “conditions of participation,” impose numerous requirements on our facilities, their equipment, their personnel and their standards of medical care, as well as compliance with all applicable state and local laws and regulations. On April 26, 2007, CMS issued a policy memorandum that reaffirmed its prior interpretation of its conditions of participation that all hospitals (other than critical access hospitals) participating in the Medicare program are required to provide basic emergency care interventions regardless of whether or not the hospital maintains an emergency department. Our facilities licensed as hospitals are required to meet this requirement to maintain their participating provider status in the Medicare program. As of December 31, 2017, seven of our hospitals, which do not have an emergency room, maintain a protocol for the transfer of patients requiring emergency treatment. While we believe such protocols satisfy CMS requirements, CMS could interpret such protocols to be inconsistent with the 2007 CMS policy memorandum, which could jeopardize each facility's participation in the Medicare program. Our surgical facilities must also satisfy the conditions of participation to be eligible to participate in the various state Medicaid programs. The requirements for certification under Medicare and Medicaid are subject to change and, in order to remain qualified for these programs, we may have to make changes from time to time in our facilities, equipment, personnel or services. Although we intend to continue to participate in these reimbursement programs, we cannot assure you that our surgical facilities will continue to qualify for participation.

The Affordable Care Act and its implementing regulations require a hospital to provide written disclosure of physician ownership interests to the hospital's patients and on the hospital's website and in any advertising, along with annual reports to the government detailing such interests. Additionally, hospitals that do not have 24/7 physician coverage are required to inform patients of this fact and receive signed acknowledgment from the patients of the disclosure. A hospital's provider agreement may be terminated if it fails to provide the required notices.

Utilization Review

Federal law contains numerous provisions designed to ensure that services rendered by hospitals to Medicare and Medicaid patients meet professionally recognized standards and are medically necessary and that claims for reimbursement are properly filed. These provisions include a requirement that a sampling of admissions of Medicare and Medicaid patients must be reviewed by quality improvement organizations, which review the appropriateness of Medicare and Medicaid patient admissions and discharges, the quality of care provided, the validity of MS-DRG classifications and the appropriateness of cases of extraordinary length of stay or cost. Quality improvement organizations may deny payment for services provided or assess fines and also have the authority to recommend to HHS that a provider which is in substantial noncompliance with the standards of the quality improvement organization be excluded from participation in the Medicare program. Utilization review is also a requirement of most non-governmental managed care organizations.

Federal Anti-Kickback Statute and Medicare Fraud and Abuse Laws

The Social Security Act includes provisions addressing false statements, illegal remuneration and other instances of fraud and abuse in federal health care programs. These provisions include the statute commonly known as the federal Anti-Kickback statute (the "Anti-Kickback Statute"). The Anti-Kickback Statute prohibits providers and others from, among other things, soliciting, receiving, offering or paying, directly or indirectly, any remuneration in return for either making a referral for, or ordering or arranging for, or recommending the order of, any item or service covered by a federal healthcare program, including, but not limited to, the Medicare and Medicaid programs. Violations of the Anti-Kickback Statute are criminal offenses punishable by imprisonment and fines of up to \$25,000 for each violation. Civil violations are punishable by fines of up to \$50,000 for each violation, as well as damages of up to three times the total amount of remuneration received from the government for healthcare claims.

Because physician-investors in our surgical facilities are in a position to generate referrals to the facilities, the distribution of available cash to those investors could come under scrutiny under the Anti-Kickback Statute. Some courts have held that the Anti-Kickback Statute is violated if one purpose (as opposed to a primary or the sole purpose) of a payment to a provider is to induce referrals. Further, Section 6402(f)(2) of the Affordable Care Act amends the Anti-Kickback Statute by adding a provision to clarify that a person need not have actual knowledge of such section or specific intent to commit a violation of the Anti-Kickback Statute. Because none of these cases involved a joint venture such as those owning and operating our surgical facilities, it is not clear how a court would apply these holdings to our activities. It is clear, however, that a physician's investment income from a surgical facility may not vary with the number of his or her referrals to the surgical facility.

Under regulations issued by the Office of the Inspector General of the U.S. Department of Health and Human Services (the "OIG"), certain categories of activities are deemed not to violate the Anti-Kickback Statute (commonly referred to as the safe harbors). According to the preamble to these safe harbor regulations, the failure of a particular business arrangement to comply with the regulations does not determine whether the arrangement violates the Anti-Kickback Statute. The safe harbor regulations do not make conduct illegal, but instead outline standards that, if complied with, protect conduct that might otherwise be deemed in violation of the Anti-Kickback Statute. When a transaction or relationship does not fit within a safe harbor, it does not mean that an Anti-Kickback Statute violation has occurred; rather, it means that the facts and circumstances as well as the intent of the parties related to a specific transaction or relationship must be examined to determine whether or not any illegal conduct has occurred.

We believe the ownership and operations of our surgery centers and hospitals do not fit wholly within any of the safe harbors, but we attempt to structure our ASCs to fit as closely as possible within the safe harbor designed to protect distributions to physician-investors in ASCs who directly refer patients to the ASC and personally perform the procedures at the center as an extension of their practice (the "ASC Safe Harbor"). The ASC Safe Harbor protects four categories of investors, including ASCs owned by (1) general surgeons, (2) single-specialty physicians, (3) multi-specialty physicians and (4) hospital/physician joint ventures, provided that certain requirements are satisfied. These requirements include the following:

- The ASC must be certified to participate in the Medicare program, and its operating and recovery room space must be dedicated exclusively to the center and not a part of a hospital (although such space may be leased from a hospital if such lease meets the requirements of the safe harbor for space rental).
- Each investor must be either (a) a physician who derived at least one-third of his or her medical practice income for the previous fiscal year or 12-month period from performing procedures on the list of Medicare-covered procedures for ASCs, (b) a hospital, or (c) a person or entity not in a position to make or influence referrals to the center, nor to provide items or services to the center, nor employed by the center or any investor.
- Unless all physician-investors are members of a single specialty, each physician-investor must perform at least one-third of his or her procedures at the ASC each year. This requirement is in addition to the requirement that the physician-investor has derived at least one-third of his or her medical practice income for the past year from performing procedures.
- Physician-investors must have fully informed their referred patients of the physician's investment.

- The terms on which an investment interest is offered to an investor are not related to the previous or expected volume of referrals, services furnished or the amount of business otherwise generated from that investor to the entity.
- Neither the ASC nor any other investor nor any person acting on their behalf may loan funds to or guarantee a loan for an investor if the investor uses any part of such loan to obtain the investment interest.

- The amount of payment to an investor in return for the investment interest is directly proportional to the amount of the capital investment (including the fair market value of any pre-operational services rendered) of that investor.
- All physician-investors, any hospital-investor and the center agree to treat patients receiving benefits or assistance under a federal healthcare program in a non-discriminatory manner.
- All ancillary services performed at the ASC for beneficiaries of federal healthcare programs must be directly and integrally related to primary procedures performed at the center and may not be billed separately.
- No hospital-investor may include on its cost report or any claim for payment from a federal healthcare program any costs associated with the ASC.
- The ASC may not use equipment owned by or services provided by a hospital-investor unless such equipment is leased in accordance with a lease that complies with the Anti-Kickback Statute equipment rental safe harbor and such services are provided in accordance with a contract that complies with the Anti-Kickback Statute personal services and management contract safe harbor.
- No hospital-investor may be in a position to make or influence referrals directly or indirectly to any other investor or the center.

We believe that the ownership and operations of our surgical centers will not fully satisfy the ASC Safe Harbor requirements for investment interests in ASCs because, among other things, we or one of our subsidiaries will generally be an investor in and provide management services to each ASC. While we believe our ASCs would nonetheless be found to be compliant with the Anti-Kickback Statute, we cannot assure you that the OIG would view our activities favorably even though we strive to achieve compliance with the remaining elements of this safe harbor.

In addition, although we expect each physician-investor to utilize the ASCs as an extension of his or her practice and ask each physician-investor to certify this practice, we cannot assure you that all physician-investors will derive at least one-third of their medical practice income from performing Medicare-covered ASC procedures, perform one-third of their procedures at the centers or inform their referred patients of their investment interests. Interests in our ASC joint ventures are purchased at what we believe to be fair market value. Investors who purchase at a later time generally pay more for a given percentage interest than founding investors. The result is that while all investors are paid distributions in accordance with their ownership interests, for ASCs where there are later purchases, we cannot meet the safe harbor requirement that return on investment is directly proportional to the amount of capital investment. The OIG has on several occasions reviewed investments relating to ASCs, and in Advisory Opinion No. 07-05, raised concerns that (a) purchases of interests from physicians might yield gains on investment rather than capital infusion to the ASCs, (b) such purchases could be meant to reward or influence the selling physicians' referrals to the ASC or the hospital, and (c) such returns might not be directly proportional to the amount of capital invested.

In OIG Advisory Opinion No. 09-09 (July 29, 2009), the OIG concluded that an arrangement involving an ASC joint venture between a hospital and physicians involving the combination of their two ASCs into a single, larger ASC presented minimal risk of fraud or abuse, despite the fact that it did not fit within any applicable Anti-Kickback safe harbors. Additionally, the OIG stated that fair market value should be determined based only on the tangible assets of each ASC since the physician investors are referral sources for the ASC. The OIG stated that a cash flow-based valuation of the business contributed by the physician investors potentially would include the value of the physician investors' referrals over the time that their ASC was in existence prior to the merger with the hospital's ASC. The OIG went on to note that a valuation involving intangible assets would not necessarily result in a violation of the Anti-Kickback Statute, but would require a review of all the facts and circumstances. It is not clear whether the OIG is concerned about using a cash flow-based valuation in most healthcare transactions involving referral sources, or just transactions where the parties' contributions would be valued differently for contributing the same assets if only one party's contribution is valued as a going concern based on cash flow. Also, the OIG appears to be focused on historical cash flow rather than a projected, discounted cash flow, which is a commonly used valuation methodology.

Our hospital investments do not fit wholly within the safe harbor for investments in small entities because more than 40.0% of the investment interests are held by investors who are either in a position to refer to the hospital or who provide services to the hospital and more than 40.0% of the hospital's gross revenue last year were derived from referrals generated by investors. However, we believe we comply with the remaining elements of the safe harbor.

In addition to the physician ownership in our surgical facilities, other financial relationships of ours with potential referral sources could potentially be scrutinized under the Anti-Kickback Statute. We have entered into management agreements to manage the majority of our surgical facilities and physician practices. Most of these agreements call for our subsidiary to be paid a percentage-based management fee. Although there is a safe harbor for personal services and management contracts (the "Personal Services and Management Safe Harbor"), the Personal Services and Management Safe Harbor requires, among other things, that the amount of the aggregate compensation paid to the manager over the term of the agreement be set in advance. Because our management fees are generally based on a percentage of revenue, our management agreements do not typically meet this requirement. We do, however, believe that our management arrangements satisfy the other requirements of the Personal Services and Management Safe Harbor for personal services and management contracts. The OIG has taken the position in several advisory opinions that percentage-based management agreements

are not protected by a safe harbor, and consequently, may violate the Anti-Kickback Statute. We have implemented formal compliance programs designed to safeguard against overbilling and believe that our management agreements comply with the requirements of the Anti-Kickback Statute. However, we cannot assure you that the OIG would find our compliance programs to be adequate or that our management agreements would be found to comply with the Anti-Kickback Statute.

Certain of our ASCs have entered into arrangements for professional services, including arrangements for anesthesia services. In a Special Advisory Bulletin issued in April 2003, the OIG focused on “questionable” contractual arrangements where a health care provider in one line of business (the “Owner”) expands into a related health care business by contracting with an existing provider of a related item or service (the “Manager/Supplier”) to provide the new item or service to the Owner’s existing patient population, including federal health care program patients (so called “suspect Contractual Joint Ventures”). The Manager/Supplier not only manages the new line of business, but may also supply it with inventory, employees, space, billing, and other services. In other words, the Owner contracts out substantially the entire operation of the related line of business to the Manager/Supplier-otherwise a potential competitor-receiving in return the profits of the business as remuneration for its referrals. Through an Advisory Opinion, the OIG extended this suspect contractual joint venture analysis to arrangements between anesthesiologists and physician owners of ASCs. In Advisory Opinion 12-06, the OIG concluded that certain proposed arrangements between anesthesia groups and physician-owned ASCs could result in prohibited remuneration under the federal Anti-Kickback Statute. We believe our arrangements for anesthesia services are distinguishable from those described in Advisory Opinion 12-06 (May 25, 2012) and are in compliance with the requirements of the federal Anti-Kickback Statute. However, we cannot assure you that regulatory authorities would agree with that position.

We also may guarantee a surgical facility’s third-party debt financing and certain lease obligations as part of our obligations under a management agreement. Physician investors are generally not required to enter into similar guarantees. The OIG might take the position that the failure of the physician investors to enter into similar guarantees represents a special benefit to the physician investors given to induce patient referrals and that such failure constitutes a violation of the Anti-Kickback Statute. We believe that the management fees (and in some cases guarantee fees) are adequate compensation to us for the credit risk associated with the guarantees and that the failure of the physician investors to enter into similar guarantees does not create a material risk of violating the Anti-Kickback Statute. However, the OIG has not issued any guidance in this regard.

The OIG is authorized to issue advisory opinions regarding the interpretation and applicability of the Anti-Kickback Statute, including whether an activity constitutes grounds for the imposition of civil or criminal sanctions. We have not, however, sought such an opinion regarding any of our arrangements. If it were determined that our activities, or those of our surgical facilities or hospitals, violate the Anti-Kickback Statute, we, our subsidiaries, our officers, our directors and each surgical facility and hospital investor could be subject, individually, to substantial monetary liability, prison sentences and/or exclusion from participation in any healthcare program funded in whole or in part by the U.S. government, including Medicare, Medicaid, TRICARE or state healthcare programs.

Evolving interpretations of current, or the adoption of new, federal or state laws or regulations could affect many of our arrangements. Law enforcement authorities, including the OIG, the courts and Congress, are increasing their scrutiny of arrangements between healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to exchange remuneration for patient care referrals or opportunities. Investigators have also demonstrated a willingness to look behind the formalities of a business transaction to determine the underlying purposes of payments between healthcare providers and potential referral sources.

Federal Physician Self-Referral Law

The federal physician self-referral law, or Stark Law, prohibits certain self-referrals for healthcare services. The Stark Law prohibits a practitioner, including a physician, dentist or podiatrist, from referring patients to an entity with which the practitioner or a member of his or her immediate family has a “financial relationship” for the provision of certain “designated health services” that are paid for in whole or in part by Medicare or Medicaid unless an exception applies. “Designated health services” include inpatient and outpatient hospital services, clinical laboratory services and radiology services. The term “financial relationship” is broadly defined and includes most types of ownership and compensation relationships. The Stark Law also prohibits the entity from seeking payment from Medicare or Medicaid for services that are rendered through a prohibited referral. If an entity is paid for services provided through a prohibited referral, it may be required to refund the payments. Violations of the Stark Law may also result in the imposition of damages equal to three times the amount improperly claimed and civil monetary penalties of up to \$15,000 per prohibited claim and \$100,000 per prohibited circumvention scheme and exclusion from participation in the Medicare and Medicaid programs.

Notably, “designated health services” does not include surgical services that are provided in an ASC. Furthermore, Stark Law regulations specifically define the term “designated health services” to not include services that are reimbursed by Medicare as part of a composite rate, such as services that are provided in an ASC. However, if designated health services are provided by an ASC and separately billed, referrals to the ASC by a physician-investor would be prohibited by the Stark Law. Because our facilities that are licensed as ASCs do not have independent laboratories and do not provide designated health services apart from surgical services, we do not believe referrals to these facilities by physician-investors are prohibited. If legislation or regulations are implemented that prohibit physicians from referring patients to surgical facilities in which the physician has a beneficial interest, our business and financial results would be materially adversely affected.

The Stark Law currently includes the Whole Hospital Exception, which applies to physician ownership of a hospital, provided such ownership is in the whole hospital and the physician is authorized to perform services at the hospital. We believe that physician investments in our facilities licensed as hospitals meet this requirement. However, certain changes to the Whole Hospital Exception were made by the Affordable Care Act including:

- a prohibition on hospitals from having any physician ownership unless the hospital already had physician ownership and a Medicare provider agreement in effect as of December 31, 2010;

[Table of Contents](#)

- a limitation on the percentage of total physician ownership or investment interests in the hospital or entity whose assets include the hospital to the percentage of physician ownership or investment as of March 23, 2010;
- a prohibition from expanding the number of beds, operating rooms, and procedure rooms for which it is licensed after March 23, 2010, unless the hospital obtains an exception from the Secretary;
- a requirement that return on investment be proportionate to the investment by each investor;
- restrictions on preferential treatment of physician versus non-physician investors;
- a requirement for written disclosures of physician ownership interests to the hospital's patients and on the hospital's website and in any advertising, along with annual reports to the government detailing such interests;
- a prohibition on the hospital or other investors from providing financing to physician investors;
- a requirement that any hospital that does not have 24/7 physician coverage inform patients of this fact and receive signed acknowledgments from the patients of the disclosure; and
- a prohibition on "grandfathered" status for any physician owned hospital that converted from an ASC to a hospital on or after March 23, 2010.

We cannot predict whether other proposed amendments to the Whole Hospital Exception will be included in any future legislation, including a repeal of the Affordable Care Act, or if Congress will adopt any similar provisions that would prohibit or otherwise restrict physicians from holding ownership interests in hospitals. Any such changes could have an adverse effect on our financial condition and results of operations.

In 2010, CMS issued a "self-referral disclosure protocol" for hospitals and other providers that wish to self-disclose potential violations of the Stark Law to CMS and to attempt to resolve those potential violations and any related overpayment liabilities at levels below the maximum penalties and amounts set forth in the statute.

In addition to the physician ownership in our surgical facilities, we have other financial relationships with potential referral sources that potentially could be scrutinized under the Stark Law. We have entered into personal service agreements, such as medical director agreements, with physicians at our hospitals and physician owners within our physician practices may make referrals for certain designated health services within their physician practices. We believe that our agreements with referral sources satisfy the requirements of the personal service arrangements exception and that our physician practices satisfy the physician services and in-office ancillary services exceptions to the Stark Law and have implemented formal compliance programs designed to ensure continued compliance. However, we cannot assure you that the OIG or CMS would find our compliance programs to be adequate or that our agreements with referral sources would be found to comply with the Stark Law.

Other Fraud and Abuse Laws

The Medicare Patient and Program Protection Act of 1987, as amended by the Health Insurance Portability and Accountability Act of 1996, ("HIPAA"), and the Balanced Budget Act of 1997, impose civil monetary penalties and exclusion from state and federal healthcare programs on providers who commit violations of fraud and abuse laws. HIPAA authorizes the Secretary of the Department of Health & Human Services ("Secretary"), and in some cases requires the Secretary, to exclude individuals and entities that the Secretary determines have "committed an act" in violation of applicable fraud and abuse laws or improperly filed claims in violation of such laws from participating in any federal healthcare program. HIPAA also expanded the Secretary's authority to exclude a person involved in fraudulent activity from participating in a program providing health benefits, whether directly or indirectly, in whole or in part, by the U.S. government. Additionally, under HIPAA, individuals who hold a direct or indirect ownership or controlling interest in an entity that is found to violate these laws may also be excluded from Medicare and Medicaid and other federal and state healthcare programs if the individual knew or should have known, or acted with deliberate ignorance or reckless disregard of, the truth or falsity of the information of the activity leading to the conviction or exclusion of the entity, or where the individual is an officer or managing employee of such entity. This standard does not require that specific intent to defraud be proven by OIG. Under HIPAA it is also a crime to defraud any commercial healthcare benefit program.

Federal and State Privacy and Security Requirements

We are subject to HIPAA, including The HITECH Act, which was enacted as part of The American Recovery and Reinvestment Act of 2009. The HITECH Act strengthened the requirements and significantly increased the penalties for violations of the HIPAA privacy and security regulations. On January 25, 2013, HHS issued the HIPAA Omnibus Rule, which became effective on March 26, 2013. The HIPAA Omnibus Rule requires us to notify patients of any unauthorized access, acquisition, or disclosure of their unsecured protected health information in all situations except those in which we

can demonstrate that there is a low probability that the protected health information has been compromised. We now have the burden of demonstrating through a risk assessment that a breach of protected health information has not occurred. This new more objective standard may lead to an increased number of occurrences that require breach notifications.

The HIPAA privacy standards apply to individually identifiable information held or disclosed by a covered entity in any form, whether communicated electronically, on paper or orally. These standards impose extensive administrative requirements on us. These standards require our compliance with rules governing the use and disclosure of this health information. They create rights for patients in their health information, such as the right to amend their health information, and they require us to impose these rules, by contract, on any business associate to whom we disclose such information in order to perform functions on our behalf.

The HIPAA security standards require us to establish and maintain reasonable and appropriate administrative, technical and physical safeguards to ensure the integrity, confidentiality and the availability of electronic protected health and related financial information. Although the security standards do not reference or advocate a specific technology, and covered healthcare providers, plans and clearinghouses have the flexibility to choose their own technical solutions, the security standards have required us to implement significant new systems, business procedures and training programs.

Violations of the HIPAA privacy and security regulations may result in civil and criminal penalties. The HITECH Act strengthened the requirements of the HIPAA privacy and security regulations and significantly increased the penalties for violations by introducing a tiered penalty system, with penalties of up to \$50,000 per violation with a maximum civil penalty of \$1.5 million in a calendar year for violations of the same requirement. However, a single breach incident can result in violations of multiple requirements, resulting in possible penalties well in excess of \$1.5 million. Under the HITECH Act, HHS is required to conduct periodic compliance audits of covered entities and their business associates. The HITECH Act and the HIPAA Omnibus Rule also extend the application of certain provisions of the security and privacy regulations to business associates and subjects business associates to civil and criminal penalties for violation of the regulations.

The HITECH Act authorizes State Attorneys General to bring civil actions seeking either an injunction or damages in response to violations of HIPAA privacy and security regulations or the new data breach law that affects the privacy of their state residents. We expect vigorous enforcement of the HITECH Act's requirements by HHS and State Attorneys General. HHS has allocated increased funding towards HIPAA enforcement activity and such enforcement activity has seen a marked increase over recent years. We cannot predict whether our surgical facilities will be able to comply with the final rules and the financial impact to our surgical facilities in implementing the requirements under the final rules when they take effect, or whether our hospitals will be selected for an audit, or the results of such an audit.

Our facilities also remain subject to any state laws that relate to privacy or the reporting of data breaches that are more restrictive than the regulations issued under HIPAA and the requirements of the HITECH Act. For example, various state laws and regulations may require us to notify affected individuals in the event of a data breach involving certain personal information, such as social security numbers, dates of birth and credit card information.

Adoption of Electronic Health Records

The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning in 2011 and extending through 2016, eligible hospitals may receive incentive payments based upon successfully demonstrating meaningful use of its certified EHR technology. Beginning in 2015, those hospitals that did not successfully demonstrate meaningful use of EHR technology were subject to reduced payments from Medicare. EHR meaningful use objectives and measures that hospitals and physicians must meet in order to qualify for incentive payments were implemented in three stages taking full effect in 2018. Our facilities licensed as hospitals began the implementation of EHR initiatives in 2012. We strive to comply with the EHR meaningful use requirements of the HITECH Act so as to qualify for incentive payments. Continued implementation of EHR and compliance with the HITECH Act may result in significant costs.

HIPAA Administrative Simplification Requirements

The HIPAA transaction regulations were issued to encourage electronic commerce in the healthcare industry. These regulations include standards that healthcare providers must follow when electronically transmitting certain healthcare transactions, such as healthcare claims.

Emergency Medical Treatment and Active Labor Act

Our hospitals are subject to the Emergency Medical Treatment and Active Labor Act ("EMTALA"). This federal law requires any hospital that participates in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital's emergency department for treatment and, if the patient is suffering from an emergency medical condition, to either stabilize that condition or make an appropriate transfer of the patient to a facility that can handle the condition. The obligation to screen and stabilize emergency medical conditions or transfer exists regardless of a patient's ability to pay for treatment. Off-campus facilities such as surgery centers that lack emergency departments or otherwise do not treat emergency medical conditions generally are not subject to EMTALA. They must, however, have policies in place that explain how the location should proceed in an emergency situation, such as transferring the patient to the closest hospital with an emergency department. There are severe penalties under EMTALA if a hospital fails to screen or appropriately stabilize or transfer a patient or if the hospital delays appropriate treatment in order to first inquire about the patient's ability to pay, including civil monetary penalties and exclusion from participation in the government health care programs. In addition, an injured patient, the patient's family or a medical facility that suffers a financial loss as a direct result of another hospital's violation of the law can bring a civil suit against that other hospital. CMS has actively enforced EMTALA and has indicated that it will continue to do so in the future. We believe that our hospitals comply with EMTALA.

State Regulation

Many of the states in which our surgical facilities operate have adopted statutes and/or regulations that prohibit the payment of kickbacks or any type of remuneration in exchange for patient referrals and that prohibit healthcare providers from, in certain circumstances, referring a patient to a healthcare facility in which the provider has an ownership or investment interest. While these statutes generally mirror the federal Anti-Kickback Statute and Stark Law, they vary widely in their scope and application. Some are specifically limited to healthcare services that are paid for in whole or in part by the Medicaid program; others apply to all healthcare services regardless of payor; and others apply only to state-defined designated services, which may differ from the designated health services under the Stark Law. In addition, many states have adopted statutes that mirror the False Claims Act and that prohibit the filing of a false or fraudulent claim with a state governmental agency. We intend to comply with all applicable state healthcare laws, rules and regulations. However, these laws, rules and regulations have typically been the subject of limited judicial and regulatory interpretation. As a result, we cannot assure you that our surgical facilities will not be investigated or scrutinized by the governmental authorities empowered to do so or, if challenged, that their activities would be found to be lawful. A determination of non-compliance with the applicable state healthcare laws, rules, and regulations could subject our surgical facilities to civil and criminal penalties and could have a material adverse effect on our operations.

We are also subject to various state insurance statutes and regulations that prohibit us from submitting inaccurate, incorrect or misleading claims. Many state insurance laws and regulations are broadly worded and could be implicated, for example, if our surgical facilities were to adjust an out-of-network co-payment or other patient responsibility amounts without fully disclosing the adjustment on the claim submitted to the payor. While some of our surgical facilities adjust the out-of-network costs of patient co-payment and deductible amounts to reflect in-network co-payment costs when providing services to patients whose health insurance is covered by a payor with which the surgical facilities are not contracted, our policy is to fully disclose adjustments in the claims submitted to the payors. We believe that our surgical facilities are in compliance with all applicable state insurance laws and regulations regarding the submission of claims. We cannot assure you, however, that none of our surgical facilities' insurance claims will ever be challenged. If we were found to be in violation of a state's insurance laws or regulations, we could be forced to discontinue the violative practice, which could have an adverse effect on our financial position and results of operations, and we could be subject to fines and criminal penalties.

Fee Splitting; Corporate Practice of Medicine

The laws of many states prohibit physicians from splitting fees with non-physicians (i.e., sharing in a percentage of professional fees), prohibit non-physician entities (such as us) from practicing medicine and exercising control over or employing physicians and prohibit referrals to facilities in which physicians have a financial interest. The existence, interpretation and enforcement of these laws vary significantly from state to state. In light of these restrictions, in certain states we facilitate the provision of physician services by maintaining long-term management services agreements through our subsidiaries with affiliated professional contractors, which employ or contract with physicians and other healthcare professionals to provide physician professional services. Under these arrangements, our subsidiaries perform only non-medical administrative services, do not represent that they offer medical services and do not exercise influence or control over the practice of medicine by the physicians employed by the affiliated professional contractors. Although we believe that the fees we receive from affiliated professional contractors have been structured in a manner that is compliant with applicable fee-splitting laws, it is possible that a government regulator could interpret such fee arrangements to be in violation of certain fee-splitting laws. Future interpretations of, or changes in, these laws might require structural and organizational modifications of our existing relationships, and we cannot assure you that we would be able to appropriately modify such relationships. In addition, statutes in some states could restrict our expansion into those states.

Clinical Laboratory Regulation

Our clinical laboratories are subject to federal oversight under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") which extends federal oversight to virtually all clinical laboratories by requiring that they be certified by the federal government or by a federally-approved accreditation agency. CLIA requires that all clinical laboratories meet quality assurance, quality control and personnel standards. Laboratories also must undergo proficiency testing and are subject to inspections. Standards for testing under CLIA are based on the complexity of the tests performed by the laboratory, with tests classified as "high complexity," "moderate complexity," or "waived." Laboratories performing high complexity testing are required to meet more stringent requirements than moderate complexity laboratories. Laboratories performing only waived tests, which are tests determined by the Food and Drug Administration to have a low potential for error and requiring little oversight, may apply for a certificate of waiver exempting them from most of the requirements of CLIA. Our operations also subject to state and local laboratory regulation. CLIA provides that a state may adopt laboratory regulations different from or more stringent than those under federal law, and a number of states have implemented their own laboratory regulatory requirements. State laws may require that laboratory personnel meet certain qualifications, specify certain quality controls, or require maintenance of certain records. We believe that we are in material compliance with all applicable laboratory requirements, but no assurances can be given that our laboratories will pass all future licensure or certification inspections.

Regulatory Compliance Program

We have in place and continue to enhance a company-wide compliance program that focuses on all areas of regulatory compliance including billing, reimbursement, cost reporting practices and contractual arrangements with referral sources.

This regulatory compliance program is intended to help ensure that high standards of conduct are maintained in the operation of our business and that policies and procedures are implemented so that employees act in compliance with applicable laws, regulations and company policies. Under the regulatory compliance program, every employee and certain contractors involved in patient care, and coding and billing,

receive initial and periodic legal compliance and ethics training. In addition, we regularly monitor our ongoing compliance efforts and develop and implement policies and procedures designed to foster compliance with the law. The program also includes a mechanism for employees to report, without fear of retaliation, any suspected legal or ethical violations to their supervisors, designated compliance officers in our facilities, our compliance hotline or directly to our corporate compliance office. We believe our compliance program is consistent with standard industry practices. However, we cannot provide any assurances that our compliance program will detect all violations of law or protect against qui tam suits or government enforcement actions.

Where You Can Find More Information

We file reports and other information with the SEC, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We make available on or through the “Investors-SEC Filings” page of our website at www.surgerypartners.com, free of charge, copies of such reports and amendments to those reports (along with certain other Company filings with the SEC), as soon as reasonably practicable after electronically filing such material with, or furnishing it to, the SEC. The information found on, or otherwise accessible through, our website is not incorporated by reference into, nor does it form a part of, this Annual Report on Form 10-K or any other document that we file with the SEC.

Such reports (and amendments to those reports), along with certain other Company filings and information, can also be inspected and copied at the Public Reference Room of the SEC located at 100 F Street, N.E., Washington, D.C. 20549. Copies of such materials can be obtained from the Public Reference Room of the SEC at prescribed rates. You can call the SEC at 1-800-SEC-0330 to obtain information on the operation of the Public Reference Room. Such materials may also be accessed electronically by means of the SEC’s website at www.sec.gov.

Item 1A. Risk Factors

We are subject to risks and uncertainties that could cause our actual financial condition, results of operations, business and prospects to differ materially from those described in the forward-looking statements contained in this report or in our other filings with the SEC. Some of these risks and uncertainties are discussed below. If any of the following risks, or other risks and uncertainties, actually occurred, our business, financial condition and operating results could suffer.

Risks Related to Our Business and Industry

We depend on payments from third-party payors, including government healthcare programs and managed care organizations. If these payments are reduced or eliminated, our revenue and profitability could be materially and adversely affected.

We depend upon private and governmental third-party sources of payment for the services provided by physicians in our physician network, to patients in our surgical facilities and by our laboratory and diagnostic services. The amount that we receive in payment for our services may be adversely affected by market and cost factors that we do not control, including Medicare, Medicaid and state regulation changes, cost containment decisions and changes in reimbursement schedules of payors, legislative changes, refinements to the Medicare Ambulatory Surgery Center payment system and refinements made by CMS to Medicare's reimbursement policies. For instance, cuts to the federal budget caused a 2.0% reduction in Medicare provider payments starting in 2013. Similarly, third-party payors may be successful in negotiating reduced reimbursement schedules with our facilities. Fixed fee schedules, capitation payment arrangements, exclusion from participation in or inability to reach agreements with managed care programs, reduction or elimination of payments or an increase in the payments at a rate that is less than the increase in our costs, or other factors affecting payments for healthcare services over which we have no control could have a material adverse effect on our business, prospects, results of operations and financial condition.

If we are unable to negotiate and enter into favorable contracts or maintain satisfactory relationships and renew existing contracts on favorable terms with managed care organizations or other private third-party payors, our revenue and profitability may decrease.

Payments from private third-party payors, including state workers' compensation programs and managed care organizations, represented approximately 54%, 52% and 55% of our patient service revenue for the years ended December 31, 2017, 2016 and 2015, respectively. Most of these payments came from third-party payors with which our facilities have contracts. Managed care companies such as HMOs and PPOs, which offer prepaid and discounted medical service packages, represent a growing segment of private third-party payors. If we fail to enter into favorable contracts or maintain satisfactory relationships with managed care organizations, our revenue may decrease. Our competitive position has been, and will continue to be, affected by initiatives undertaken during the past several years by major purchasers of healthcare services, including insurance companies and employers, to revise payment methods and monitor healthcare expenditures in an effort to contain healthcare costs. For instance, managed care payors may lower reimbursement rates in response to increased obligations on payors imposed by the Affordable Care Act or future reductions in Medicare reimbursement rates. Further, managed care payors may narrow their provider networks in response to the need to negotiate lower reimbursement rates with providers. If we are unable to maintain strong relationships with payors, we may not be able to ensure participation in these narrow provider networks. Cost containment measures, such as fixed fee schedules, capitation payment arrangements, reductions in reimbursement schedules by third-party payors and closed provider networks, could also cause a reduction of our revenue in the future.

Some of our payments from third-party payors come from third-party payors with which our surgical facilities, physicians or subsidiaries that provide diagnostic services do not have a contract. In those cases where we provide services to a patient that does not use a third-party payor with which we have contracted, commonly known as "out-of-network" services, we generally charge the patients the same co-payment or other patient responsibility amounts that we would have charged had our surgical facilities had a contract with the payor. In accordance with insurance laws and regulations, we submit a claim for the services to the payor along with full disclosure that our surgical facility has charged the patient an in-network patient responsibility amount. Historically, those third-party payors who do not have contracts with our surgical facilities typically have paid our claims at higher than comparable contracted rates. However, over the past five years we have observed an increase in third-party payors adopting out-of-network fee schedules that are more comparable to our contracted rates or to take other steps to discourage their enrollees from seeking treatment at out-of-network surgical facilities. We are not always successful in securing contracts with payors. If the proportion of our services subject to out-of-network fee schedules increases, we may experience a decrease in volume at our ASCs due to fewer referrals of out-of-network patients.

Payments from workers' compensation payors represented approximately 5% of our patient service revenue for the fiscal year ended December 31, 2017. A majority of states have implemented workers' compensation provider fee schedules. In some cases, the fee schedule rates contain lower rates than the rates our surgical facilities have historically been paid for the same services. If states reduce the amounts paid to providers under the workers' compensation fee schedules, it could have an adverse impact on our operating results.

Significant changes in our payor mix or surgical case mix resulting from fluctuations in the types of cases performed at our facilities could have a material adverse effect on our business, prospects, results of operations and financial condition.

Our results may change from period to period due to fluctuations in payor mix or surgical case mix or other factors relating to the type of cases performed by physicians at our facilities. Payor mix refers to the relative share of total cases provided to patients with no insurance, commercial insurance, Medicare coverage, Medicaid coverage and workers' compensation insurance, respectively. Since, generally speaking, we receive relatively higher payment rates from commercial and workers' compensation insurers than Medicare, Medicaid and other

government-funded programs, a significant shift in our payor mix toward a higher percentage of Medicare and Medicaid cases, which could occur for reasons beyond our control, could have an adverse effect on our business, prospects, results of operations and financial condition.

Surgical case mix refers to the relative share of total cases performed by specialty, such as GI, general surgery, ophthalmology, orthopedic and pain management. Generally speaking, certain types of our cases, such as orthopedic cases, generate relatively higher revenue than other types of cases, such as pain management and GI cases. Therefore, a significant shift in our surgical case mix toward a higher percentage of lower revenue cases, which could occur for reasons beyond our control, could result in a material adverse effect on our business, prospects, results of operations and financial condition.

As we operate in multiple markets, each with a different competitive landscape, shifts within our payor mix or surgical case mix may not be uniform across all of our affiliated facilities. Rather, these shifts may be concentrated within certain markets due to local competitive factors. Therefore, the results of our individual affiliated facilities, including facilities that are material to our results, may be volatile, which could result in a material adverse effect on our business, prospects, results of operations and financial condition.

We have a history of net losses and may not achieve or sustain profitability in the future.

We had a net loss attributable to Surgery Partners, Inc. of \$53.0 million and had net income of \$9.5 million and \$1.4 million, for the years ended December 31, 2017, 2016 and 2015, respectively. We cannot assure you that our revenue will grow or that we will achieve or maintain profitability in the future. Growth of our revenue may slow or revenue may decline and expenses may increase for a number of possible reasons, including reduced demand for our services, regulatory shifts, failure to successfully continue to integrate the operations of Surgery Partners and NSH and other risks and uncertainties. Even though we have achieved profitability during 2016 and 2015, we may not achieve, sustain or increase profitability on a quarterly or annual basis in the future. Our ability to achieve profitability will be affected by the other risks and uncertainties described in this section and in “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All of these factors could contribute to future net losses and, if we are unable to meet these risks and challenges as we encounter them, our business may suffer. If we are not able to achieve, sustain or increase profitability, our business will be adversely affected and our stock price may decline.

We may be unable to fully realize the anticipated benefits of the NSH Merger if we do not successfully integrate our operations with those of NSH and we may not realize the anticipated synergies and cost savings from our combination. If the NSH Merger does not achieve its intended results, our business, financial condition and results of operations could be materially and adversely affected.

The integration of NSH into our operations is a significant undertaking requiring significant attention from our management team. It is possible that the integration process could take longer than anticipated and could result in the loss of valuable employees and customer relationships, the disruption of each company’s ongoing businesses, processes, and systems, additional operating expenses as a result of the integration of operations, potential impairment of intangible assets and goodwill acquired in the NSH Merger, or inconsistencies in standards, controls, procedures, practices, policies, and compensation arrangements, any of which could adversely affect our ability to achieve the anticipated benefits of the NSH Merger. The integration process is subject to a number of uncertainties, and no assurance can be given that the anticipated benefits will be realized or, if realized, the timing of their realization. Actual synergies may be lower than we currently expect, or may take longer to achieve than anticipated. In addition, we must achieve the anticipated savings, synergies and benefits without adversely affecting current revenues, earnings and investments in future growth. An inability to realize the full extent of the anticipated benefits of the NSH Merger, as well as any delays encountered in the integration process, could have an adverse effect upon our revenues, earnings, level of expenses and operating results, which may adversely affect the value of our common and preferred stock.

The integration may be complex and time consuming, and could require substantial resources and effort by management and others. The ongoing integration process may also disrupt our business or cause inconsistencies in standards, controls, procedures and policies that adversely affect our relationships with employees, business partners, customers and others with whom we have business or other dealings, or limit our ability to achieve the anticipated benefits of the NSH Merger. In addition, any difficulties in integrating the businesses could harm our reputation. If we are unable to successfully combine our business with that of NSH in an efficient, effective and timely manner, the anticipated benefits and cost savings of the NSH Merger may not be realized fully, or at all, or may take longer to realize than expected.

We depend on physician utilization of our surgical facilities, which could decrease if we fail to maintain good relationships with affiliated physicians. Our ability to provide medical services at our facilities would be impaired and our revenue reduced if we are not able to maintain these relationships.

Our business depends, among other things, upon the efforts and success of affiliated physicians who provide medical services at our surgical facilities and the strength of our relationships with these physicians. Most physicians are not employees of our surgical facilities and are not contractually required to use our facilities. We generally do not enter into contracts with physicians who use our surgical facilities, other than partnership and operating agreements with physicians who own interests in our surgical facilities, provider agreements with anesthesiology groups that provide anesthesiology services in our surgical facilities, medical director agreements, among others. Physicians who use our surgical facilities also use other facilities or hospitals and may choose to perform procedures in an office-based setting that might otherwise be performed at our surgical facilities. In recent years, pain management and gastrointestinal procedures have been performed increasingly in an office-based setting because of potential cost savings or better

access. Although physicians who own interests in our surgical facilities are subject to agreements restricting ownership of competing facilities, these agreements may not restrict procedures performed in a physician office or in other unrelated facilities. Also, these agreements restricting ownership of competing facilities are difficult to enforce, and we may be unsuccessful in preventing physicians who own interests in our surgical facilities from acquiring interests in competing facilities.

The financial success of our facilities is in part dependent upon the volume of procedures performed by the physicians who use our facilities, which is affected by the economy, healthcare reform, increases in patient co-payments and deductibles and other factors outside our or their control. The physicians who use our surgical facilities may choose not to accept patients who pay for services through certain third-party payors, which could reduce our revenue. From time to time, we may have disputes with physicians who use our surgical facilities and/or own interests in our surgical facilities or our Company. Our revenue and profitability could be significantly reduced if we lost our relationship with one or more key physicians or groups of physicians, or if such physicians or groups reduce their use of any of our surgical facilities. In addition, any damage to the reputation of a key physician or group of physicians or the failure of these physicians to provide quality medical care or adhere to professional guidelines at our surgical facilities could damage our reputation, subject us to liability and significantly reduce our revenue.

Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, expose us to interest rate risk to the extent of our variable rate debt and prevent us from meeting our obligations under our outstanding indebtedness.

As of December 31, 2017, we and our subsidiaries had approximately \$2.2 billion aggregate principal amount of indebtedness outstanding, which includes \$1.3 billion principal amount of senior secured term loans (the "Term Loan") outstanding, \$400.0 million senior unsecured notes due 2021 (the "2021 Unsecured Notes") and \$370.0 million senior unsecured notes due 2025 (the "2025 Unsecured Notes"). As of December 31, 2017, we had no outstanding borrowings under our \$75.0 million senior secured revolving credit facility (the "Revolver" and, together with the Term Loan, the "Senior Secured Credit Facilities" and, together with the 2025 Unsecured Notes and the 2021 Unsecured Notes, the "Senior Indebtedness"). After giving effect to the \$3.1 million principal amount of outstanding letters of credit issued under our Revolver, we had \$71.9 million of unused commitments available to be borrowed under the Revolver. In addition to the Senior Indebtedness, our aggregate principal amount of indebtedness outstanding includes approximately \$129.5 million of notes payable and capital lease obligations primarily related to property and equipment for operations. Our substantial level of indebtedness increases the risk that we may be unable to generate cash sufficient to pay amounts due in respect of our indebtedness. In addition, subject to applicable restrictions under our Senior Indebtedness, we may incur significant additional indebtedness, which may be secured, from time to time, which could have important consequences, including:

- making it more difficult for us to satisfy our obligations with respect to our indebtedness;
- making us more vulnerable to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
- requiring us to dedicate a substantial portion of our cash flow to making payments on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes;
- limiting our flexibility in reacting to competitive and other changes in our industry and economic conditions generally; and
- limiting our ability to borrow additional funds for working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy or other general corporate purposes;

To service our indebtedness, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control, and any failure to meet our debt service obligations may adversely affect our business, financial condition and results of operations.

Our ability to pay or to refinance our indebtedness and to fund working capital needs and planned capital expenditures will depend upon our future operating performance and our ability to generate cash, which, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory, business and other factors that are beyond our control.

If our business does not generate sufficient cash flow or if future borrowings are not available to us in an amount sufficient to enable us to pay our indebtedness or to fund our other liquidity needs, we may need to refinance all or a portion of our indebtedness on or before the maturity thereof, sell assets, reduce or delay capital investments or seek to raise additional capital, any of which could have a material adverse effect on our operations. In addition, we may not be able to affect any of these actions, if necessary, on commercially reasonable terms or at all. Our history of net losses may impair our ability to service our indebtedness or repay outstanding amounts when they become due. In addition, our ability to restructure or refinance our indebtedness will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. The terms of existing or future debt instruments may limit or prevent us from taking any of these actions. In addition, any failure to make scheduled payments of interest and principal on our outstanding indebtedness would likely result in a reduction of our credit rating, which could harm our ability to incur additional indebtedness on commercially reasonable terms or at all. Our inability to generate sufficient cash flow to satisfy our debt service obligations, or to refinance or restructure our obligations on commercially reasonable terms or at all, may adversely affect our business, financial condition and results of operations.

Restrictive covenants in our debt instruments may adversely affect us.

The 2021 Unsecured Notes, 2025 Unsecured Notes and Senior Secured Credit Facilities impose significant operating and financial restrictions and limit the ability of us and our restricted subsidiaries to, among other things:

- incur additional indebtedness and guarantee indebtedness;

[Table of Contents](#)

- pay dividends or make other distributions in respect of, or repurchase or redeem, capital stock;
- prepay, redeem or repurchase certain debt;
- make loans and investments;
- sell or otherwise dispose of assets;
- sell stock of our subsidiaries;
- incur liens;
- enter into transactions with affiliates;
- enter into agreements restricting certain of our subsidiaries' ability to pay dividends; and
- consolidate, merge or sell all or substantially all of our assets

As a result of these and other covenants and restrictions, we are and will be limited in how we conduct our business, and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. In addition, we may be required to maintain specified financial maintenance ratios and satisfy other financial condition tests in connection with the Senior Indebtedness. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants. Our failure to comply with the restrictive covenants described above as well as others contained in our future debt instruments from time to time could result in an event of default, which, if not cured or waived, could result in our being required to repay these borrowings before their maturity. If we are forced to refinance these borrowings on less favorable terms, our results of operations and financial condition could be adversely affected.

We cannot assure you that our business will generate sufficient cash flow from operations, that currently anticipated revenue growth and operating improvements will be realized or that future borrowings will be available to us under the Term Loans and Revolving Facility in amounts sufficient to enable us to pay our indebtedness, or to fund our other liquidity needs. If we are unable to meet our debt service obligations or fund our other liquidity needs, we could attempt to restructure or refinance our indebtedness or seek additional equity capital. We cannot assure you that we will be able to accomplish those actions on satisfactory terms, if at all.

Despite our current indebtedness levels, we and our subsidiaries may still be able to incur substantially more debt, which could further exacerbate the risks associated with our substantial leverage.

We and our subsidiaries may be able to incur substantial additional indebtedness in the future, including secured indebtedness. Although the credit agreement governing the Senior Secured Credit Facilities and the indentures governing each of the 2021 Unsecured Notes and 2025 Unsecured Notes, respectively, contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of significant qualifications and exceptions, and the indebtedness incurred in compliance with these restrictions could be substantial.

In addition, as of December 31, 2017 we had approximately \$71.9 million available for additional borrowings under the Revolver (after giving effect to the \$3.1 million aggregate principal amount of outstanding letters of credit issued under our Revolver at such time). If new debt is added to our or our subsidiaries' current debt levels, the related risks that we face would be increased.

We are a holding company with no operations of our own.

We are a holding company, and our ability to service our debt is dependent upon the earnings from the business conducted by our subsidiaries that operate the surgical facilities. The effect of this structure is that we depend on the earnings of our subsidiaries, and the distribution or payment to us of a portion of these earnings to meet our obligations, including those under the Term Loans and Revolving Facility and any of our other debt obligations. The distributions of those earnings or advances or other distributions of funds by these entities to us, all of which are contingent upon our subsidiaries' earnings, are subject to various business considerations. In addition, distributions by our subsidiaries could be subject to statutory restrictions, including state laws requiring that such subsidiaries be solvent, or contractual restrictions. Some of our subsidiaries may become subject to agreements that restrict the sale of assets and significantly restrict or prohibit the payment of dividends or the making of distributions, loans or other payments to stockholders, partners or members.

We make significant loans to, and are generally liable for debts and other obligations of, the partnerships and limited liability companies that own and operate some of our surgical facilities.

We own and operate our surgical facilities through limited partnerships and limited liability companies. Local physicians, physician groups and healthcare systems also own an interest in all but three of these partnerships and limited liability companies. In the partnerships in which we are the general partner, we are liable for 100% of the debts and other obligations of the partnership, even if we do not own all of the partnership interests. For some of our surgical facilities, indebtedness at the partnership level is funded through intercompany loans that we provide. At December 31, 2017, our intercompany loans totaled \$39.0 million. Through these loans we may have a security interest in the partnership's or limited liability company's assets, depending upon the terms thereof in each instance. However, our financial condition and results of operations would be materially adversely affected if our surgical facilities are unable to repay these intercompany loans, or such loans are challenged under certain health care laws. Additionally, at December 31, 2017, our global intercompany note, which we use to transfer debt balances between our subsidiaries, had a \$3.0 million balance.

Although most of our intercompany loans are secured by the assets of the partnership or limited liability company, the physicians and physician groups that own an interest in these partnerships and limited liability companies generally do not guarantee a pro rata amount of this debt or the other obligations of these partnerships and limited liability companies.

From time to time, we may guarantee our pro-rata share of the third-party debts and other obligations of our non-wholly owned non-consolidated partnerships and limited liability companies in which we own an interest in an amount proportionate to our pro rata share of the equity interests issued by such entity. In such instances, the physicians and/or physician groups typically also guarantee their pro-rata share of such indebtedness.

Our variable rate indebtedness subjects us to interest rate risk, which could cause our indebtedness service obligations to increase significantly.

Borrowings under the Senior Secured Credit Facilities are at variable rates of interest and expose us to interest rate risk. If interest rates increase, our debt service obligations on variable rate indebtedness would increase even though the amount borrowed remained the same, and our net income and cash flows, including cash available for servicing our indebtedness, would correspondingly decrease.

Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations.

The Senior Secured Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors") and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors' assets (subject to certain exceptions).

The Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from 3.00% to 3.25% per annum, depending on the Company's first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.50% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, the Company is required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver. The 2021 Unsecured Notes bear interest at the rate of 8.875% per year. The 2025 Unsecured Notes bear interest at the rate of 6.750% per year.

Physician treatment methodologies and governmental or commercial health insurance controls designed to reduce the number of surgical procedures may reduce our revenue and profitability.

Controls imposed by Medicare and Medicaid, employer-sponsored healthcare plans and commercial health insurance payors designed to reduce surgical volumes, in some instances referred to as "utilization review," could adversely affect our facilities. Although we are unable to predict the effect these changes will have on our operations, significant limits on the scope of services reimbursed and on reimbursement rates and fees may reduce our revenue and profitability. Additionally, trends in physician treatment protocols and commercial health insurance plan design, such as plans that shift increased costs and accountability for care to patients, could reduce our surgical volumes in favor of lower intensity and lower cost treatment methodologies, each of which could, in turn, have a material adverse effect on our business, prospects, results of operations and financial condition.

Our growth strategy depends in part on our ability to integrate operations of acquired surgical facilities, attract new physician partners, and to acquire and develop additional surgical facilities, on favorable terms. If we are unable to achieve any of these goals, our future growth could be limited and our operating results could be adversely affected.

We believe that an important component of our financial performance and growth is our ability to provide physicians who use our facilities with the opportunity to purchase ownership interests in our facilities. We may not be successful in attracting new physician investment in our surgical facilities, and that failure could result in a reduction in the quality, efficiency and profitability of our facilities. Based on competitive factors and market conditions, physicians may be able to negotiate relatively higher levels of equity ownership in our facilities, consequently limiting or reducing our share of the profits from these facilities. In addition, physician ownership in our facilities is subject to certain regulatory restrictions.

In addition, our growth strategy includes the acquisition and development of existing surgical facilities and the development of new surgical facilities jointly with local physicians and, in some cases, healthcare systems and other strategic partners. We have acquired interests in or developed all of our surgical facilities since our inception and we expect to continue to expand our operations in the future. We are currently evaluating potential acquisitions and development projects and expect to continue to evaluate acquisitions and development projects in the foreseeable future. If we are unable to successfully execute on this strategy in the future, our future growth could be limited. We may be unable to identify suitable acquisition and development opportunities, or to complete acquisitions and new projects in a timely manner and on favorable terms. Further, the businesses or assets we acquire in the future may not ultimately produce returns that justify our related investment.

Our acquisition activities, and our limited development activities, require substantial capital resources, and we may need to obtain additional capital or financing, from time to time, to fund these activities. Historically, we have funded acquisition and development activities through our credit facilities. As a result, we may take actions that could have a material adverse effect on our business, prospects, results of operations and financial condition, including incurring substantial debt with certain restrictive terms. Further, sufficient capital or financing may not be available to us on satisfactory terms, if at all. In addition, our ability to acquire and develop additional surgical facilities may be

limited by state certificate of need programs, licensure requirements, antitrust laws, and other regulatory restrictions on expansion. We also face significant competition from local, regional and national health systems and other owners of surgical facilities in pursuing attractive acquisition candidates. The limited number of surgical facilities we develop typically incur losses in their early months of operation (more so in the case of surgical hospitals) and, until their case loads grow, they generally experience lower total revenue and operating margins than established surgical facilities, and we expect this trend to continue.

If we are not successful in integrating newly acquired surgical facilities, we may not realize the potential benefits of such acquisitions. Likewise, if we are not able to integrate acquired facilities' operations and personnel with ours in a timely and efficient manner, then the potential benefits of the transaction may not be realized. Further, any delays or unexpected costs incurred in connection with integration could have a material adverse effect on our operations and earnings. In particular, if we experience the loss of key personnel or if the effort devoted to the integration of acquired facilities diverts significant management or other resources from other operational activities, our operations could be impaired.

If we acquire or develop additional facilities, we may experience difficulty in retaining or integrating their operations, key physicians, systems and personnel. In some acquisitions, we may have to renegotiate, or risk losing, one or more of the facility's commercial payor contracts. We may also be unable to immediately collect the accounts receivable of an acquired facility while we align the payors' payment systems and accounts with our own systems. Certain transactions can require licensure changes which, in turn, result in disruptions in payment for services.

In addition, although we conduct extensive due diligence prior to the acquisition of surgical facilities and seek indemnification from prospective sellers covering unknown or contingent liabilities, we may acquire facilities with unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations. Although we maintain professional liability insurance that provides coverage on a claims-made basis of \$1.0 million per occurrence with a retention of \$100,000 per occurrence and \$3.0 million in annual aggregate coverage per surgical facility, as well as an additional umbrella liability insurance policy in the aggregate amount of \$33.0 million, we do not maintain insurance specifically covering all unknown or contingent liabilities that may have occurred prior to the acquisition of facilities. In some cases, our right to indemnification for these liabilities from the seller may be subject to negotiated limits or limits on our ability to enforce indemnification rights.

Our rapid growth has placed, and will continue to place, increased demands on our management, operational and financial information systems and other resources. Furthermore, expansions into new geographic markets and services may require us to comply with new and unfamiliar legal and regulatory requirements, which could impose substantial obligations on us and our management, cause us to expend additional time and resources, and increase our exposure to penalties or fines for non-compliance with such requirements. To accommodate our past and anticipated future growth, and to compete effectively, we will need to continue to improve our management, operational and financial information systems and to expand, train, manage and motivate our workforce. Our personnel, systems, procedures or controls may not be adequate to support our operations in the future. Further, focusing our financial resources and management attention on the expansion of our operations may negatively impact our financial results. Any failure to improve our management, operational and financial information systems, or to expand, train, manage or motivate our workforce, could reduce or prevent our growth.

Shortages of surgery-related products, equipment and medical supplies and quality control issues with such products, equipment and medical supplies could disrupt our operations and adversely affect our case volume, surgical case mix and profitability.

Our operations depend significantly upon our ability to obtain sufficient surgery-related products, drugs, equipment and medical supplies from suppliers on a timely basis. If we are unable to obtain such necessary products, or if we fail to properly manage existing inventory levels, the surgical facilities may be unable to perform certain surgeries, which could adversely affect case volume or result in a negative shift in surgical case mix. In addition, as a result of shortages, we could suffer, among other things, operational disruptions, disruptions in cash flows, increased costs and reductions in profitability. At times, supply shortages have occurred in our industry, and such shortages may be expected to recur from time to time.

Medical supplies and services can also be subject to supplier product quality control incidents and recalls. In addition to contributing to materials shortages, product quality can affect patient care and safety. Material quality control incidents have occurred in the past and may occur again in the future, for reasons beyond our control, and such incidents can negatively impact case volume, product costs and our reputation. In addition, we may have to incur costs to resolve quality control incidents related to medical supplies and services regardless of whether they were caused by us. Our inability to obtain the necessary amount and quality of surgery-related products, equipment and medical supplies due to a quality control incident or recall could have a material adverse effect on our business, prospects, results of operations and financial condition.

We face competition for patients, physicians and commercial payor contracts.

The healthcare business is highly competitive and each of the individual geographic areas in which we operate has a different competitive landscape. In each of our markets we compete with other healthcare providers for patients and in contracting with commercial payors. In addition, because the number of physicians available to utilize and invest in our facilities is finite, we face intense competition from other surgery centers, hospitals, health systems and other healthcare providers in recruiting physicians to utilize and invest in our facilities. We are in competition with other surgery centers, hospitals and healthcare systems in the communities we serve to attract patients and provide them with the care they need.

There are also unaffiliated hospitals in each market in which we operate. These hospitals have established relationships with physicians and payors. In addition, other companies either currently are in the same or similar business of developing, acquiring and operating surgical facilities or may decide to enter our business. Many of these companies have greater resources than we do, including financial, marketing, staff and capital resources. We also may compete with some of these companies for entry into strategic relationships with healthcare systems and healthcare professionals. In addition, many physician groups develop surgical facilities without a corporate partner. In recent years, more physicians are choosing to perform procedures, including pain management and gastrointestinal procedures, in an office-based setting rather than in a surgical facility. If we are unable to compete effectively with any of these entities or groups, we may be unable to implement our business strategies successfully and our financial position and results of operations could be adversely affected.

Competition for physicians and nurses, shortages of qualified personnel or other factors could increase our labor costs and adversely affect our revenue, profitability and cash flows.

Our operations are dependent on the efforts, abilities and experience of our physicians and clinical personnel. We compete with other healthcare providers, primarily hospitals and other surgical facilities, in attracting physicians to utilize our surgical facilities, nurses and medical staff to support our surgical facilities, recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our facilities and in contracting with managed care payors in each of our markets. In some markets, the lack of availability of clinical personnel, such as nurses, has become a significant operating issue facing all healthcare providers. This shortage may require us to continue to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel. For the year-ended December 31, 2017, our salary and benefit expenses represented approximately 31% of our revenue. We also depend on the available labor pool of semi-skilled and unskilled workers in each of the markets in which we operate.

If our labor costs increase, we may not be able to raise rates to offset these increased costs. Because a significant percentage of our revenue consists of fixed, prospective payments, our ability to pass along increased labor costs is limited. In particular, if labor costs rise at an annual rate greater than our net annual consumer price index basket update from Medicare, our results of operations and cash flows will likely be adversely affected. Any union activity at our facilities that may occur in the future could contribute to increased labor costs. Certain proposed changes in federal labor laws and the National Labor Relations Board's modification of its election procedures could increase the likelihood of employee unionization attempts. Although none of our employees are currently represented by a collective bargaining agreement, to the extent a significant portion of our employee base unionizes, it is possible our labor costs could increase materially. Our failure to recruit and retain qualified management and medical personnel, or to control our labor costs, could have a material adverse effect on our business, prospects, results of operations and financial condition.

Some jurisdictions preclude us from entering into non-compete agreements with our physicians, and other non-compete agreements and restrictive covenants applicable to certain physicians and other clinical employees may not be enforceable.

We have contracts with physicians and other health professionals in many states. Some of our physician services contracts, as well as many of our physician services contracts with hospitals, include provisions preventing these physicians and other health professionals from competing with us both during and after the term of our contract with them. The law governing non-compete agreements and other forms of restrictive covenants varies from state to state. Some jurisdictions prohibit us from entering into non-compete agreements with our professional staff. Other states are reluctant to strictly enforce non-compete agreements and restrictive covenants against physicians and other healthcare professionals. Therefore, there can be no assurance that our non-compete agreements related to employed or otherwise contracted physicians and other health professionals will be enforceable if challenged in certain states. In such event, we would be unable to prevent former employed or otherwise contracted physicians and other health professionals from competing with us, potentially resulting in the loss of some of our hospital contracts and other business. Additionally, certain facilities have the right to employ or engage our providers after the termination or expiration of our contract with those facilities and cause us not to enforce our non-compete provisions related to those providers.

We may become involved in litigation which could negatively impact the value of our business.

From time-to-time we are involved in lawsuits, claims, audits and investigations, including those arising out of services provided, personal injury claims, professional liability claims, billing and marketing practices, employment disputes and contractual claims. We may become subject to future lawsuits, claims, audits and investigations that could result in substantial costs and divert our attention and resources and adversely affect our business condition. In addition, since our current growth strategy includes acquisitions, among other things, we may become exposed to legal claims for the activities of an acquired business prior to the acquisition. These lawsuits, claims, audits or investigations, regardless of their merit or outcome, may also adversely affect our reputation and ability to expand our business.

In addition, from time to time we have received, and expect to continue to receive, correspondence from former employees terminated by us who threaten to bring claims against us alleging that we have violated one or more labor and employment regulations. In certain instances former employees have brought claims against us and we expect that we will encounter similar actions against us in the future. An adverse outcome in any such litigation could require us to pay contractual damages, compensatory damages, punitive damages, attorneys' fees and costs.

If we become subject to large malpractice or other legal claims, we could be required to pay significant damages, which may not be covered by insurance.

In recent years, physicians, hospitals and other healthcare providers have become subject to an increasing number of legal actions alleging malpractice, product liability or related legal theories. Many of these actions involve large monetary claims and significant defense costs. We also owe certain defense and indemnity obligations to our officers and directors.

We maintain liability insurance in amounts that we believe are customary for the industry. We maintain general liability insurance that provides coverage on an occurrence basis of \$1.0 million per occurrence with a retention of \$25,000 per occurrence and \$3.0 million in annual aggregate coverage per surgical facility. We also maintain business interruption insurance and property damage insurance, as well as an additional umbrella liability insurance policy in the aggregate amount of \$33.0 million. Coverage under certain of these policies is contingent upon the policy being in effect when a claim is made regardless of when the events which caused the claim occurred. In addition, physicians who provide professional services in our surgical facilities are required to maintain separate malpractice coverage with similar minimum coverage limits. We also maintain a directors' and officers' insurance policy, which insures our directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers.

This insurance coverage may not cover all claims against us. Insurance coverage may not continue to be available at a cost allowing us to maintain adequate levels of insurance. If one or more successful claims against us were not covered by or exceeded the coverage of our insurance, our financial condition and results of operations could be adversely affected. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including claims related to adverse patient events, contractual disputes, professional and general liability, and directors' and officers' duties.

In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our earnings and cash flows could be materially and adversely affected by any of the following:

- the collapse or insolvency of our insurance carriers;
- further increases in premiums and deductibles;
- increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; or
- an inability to obtain one or more types of insurance on acceptable terms, if at all.

Financial pressures on patients, and current and future economic condition, may adversely affect our volume and surgical case mix.

Even as the U.S. economy shows signs of sustained, if modest, growth, many individuals throughout the country continue to experience difficult financial conditions. Our case volume and surgical case mix may be adversely affected by patients' unwillingness to pay for procedures in our facilities. Higher numbers of unemployed individuals generally translates into more individuals without healthcare insurance to help pay for procedures, thereby increasing the potential for persons to elect not to have procedures performed. Even procedures normally thought to be non-elective may be delayed or may not be performed if the patient cannot afford the procedure due to a lack of insurance or money to pay their portion of our facilities' fee. Although we have taken steps to minimize the impact of these conditions, it is difficult to predict the degree to which our business will continue to be impacted by such conditions or the course of the economy in the future.

In addition, the difficult conditions of the U.S. economy have adversely affected and could continue to adversely affect the budgets of individual states and the federal government, which has resulted in and could continue to result in attempts to reduce payments made to us by federal and state government healthcare programs, including Medicare, military services, Medicaid and workers' compensation programs, a reduction in the scope of services covered by those programs and an increase in taxes and assessments on our activities. Additionally, there continues to be uncertainty regarding the Affordable Care Act, and any such result could adversely affect our business by exacerbating the financial pressures on patients, leading them to further delay or cancel non-emergency surgical procedures.

Our surgical facilities are sensitive to regulatory, economic and other conditions in the states where they are located. In addition, three of our surgical facilities account for a significant portion of our patient service revenue.

Our revenue is particularly sensitive to regulatory, economic and other conditions in the states of Florida and Texas. As of December 31, 2017, we owned and operated 9 consolidated surgical facilities in Texas and 23 consolidated surgical facilities in Florida. The Texas facilities represented approximately 14% of our revenue in fiscal 2017 and the Florida facilities represented approximately 12% of our revenue in fiscal 2017.

In addition, our surgical hospital in Idaho Falls, Idaho represented 19% of our revenue during fiscal 2017. This surgical hospital also provides ancillary services, including physician practices, radiation oncology and anesthesia services. If there were an adverse regulatory, economic or other development in any of the states in which we have a higher concentration of facilities, including Idaho, our case volumes could decline in such states or there could be other unanticipated adverse impacts on our business in those states, which could have a material adverse effect on our business, prospects, results of operations and financial condition.

If any of our existing healthcare facilities lose their accreditation status or any of our new facilities fail to receive accreditation, such facilities could become ineligible to receive reimbursement under Medicare or Medicaid or other third-party payors.

The construction and operation of healthcare facilities are subject to extensive federal, state and local regulation relating to, among other things, the adequacy of medical care, equipment, personnel, operating policies and procedures, fire prevention, rate-setting and compliance with building codes and environmental protection. Additionally, such facilities are subject to periodic inspection by government authorities and accreditation organizations to assure their continued compliance with these various standards.

All of our facilities are deemed certified, meaning that they are accredited, properly licensed under the relevant state laws and regulations and certified under the Medicare program or are in the process of applying for such accreditation, licensing or certification. The effect of maintaining certified facilities is to allow such facilities to participate in the Medicare and Medicaid programs. We believe that all of our facilities are in material compliance with applicable federal, state, local and other relevant accreditation and certification regulations and standards. However, should any of our healthcare facilities lose their deemed certified status and thereby lose certification under the Medicare or Medicaid programs, such facilities would be unable to receive reimbursement from either or both of those programs, and possibly from other third-party payors, and our business could be materially adversely affected.

Certain of our partnership and operating agreements contain provisions giving rights to our partners and other members that may be adverse to our interests.

Certain of the agreements governing the limited partnerships ("LPs"), general partnerships ("GP") and limited liability companies ("LLCs") through which we own and operate our facilities contain provisions that give our partners or other members rights that may, in certain circumstances, be adverse to our interests. These rights include, but are not limited to, rights to purchase our interest in the partnership or LLC, rights to require us to purchase the interests of our partners or other members, or rights requiring the consent of our partners and other members prior to our transferring our ownership interest in a facility or prior to a change in control of us or certain of our subsidiaries. With respect to these purchase rights, the agreements generally include a specified formula or methodology to determine the applicable purchase price, which may or may not reflect fair market value.

Additionally, many of our partnership and operating agreements contain restrictions on actions that we can take, even though we may be the general partner or the managing member. Examples of these restrictions include the rights of our partners and other members to approve the sale of substantially all of the assets of the partnership or LLC, to dissolve the partnership or LLC, to appoint a new or additional general partner or managing member and to amend the partnership or operating agreements. Many of our agreements also restrict our ability in certain instances to compete with our existing facilities or with our partners. Where we hold only a limited partner or a non-managing member interest, the general partner or managing member may take certain actions without our consent, although we typically have certain protective rights to approve major decisions such as the sale of substantially all of the assets of the entity, dissolution of the partnership or LLC and the amendment of the partnership or operating agreement. These management and governance rights held by our partners and other members limit and restrict our ability to make unilateral decisions about the management and operation of the facilities without the approval of our partners and other members.

We may have a special legal responsibility to the holders of ownership interests in the entities through which we own our facilities, which may conflict with, and prevent us from acting solely in, our own best interests or the interests of our stockholders.

We generally hold our ownership interests in facilities through limited or general partnerships, LLCs or limited liability partnerships ("LLPs") in which we maintain an ownership interest along with physicians and, in some cases, physicians and health systems. As general partner and manager of most of these entities, we may have a special responsibility, known as a fiduciary duty, to manage these entities in the best interests of the other owners. We also have a duty to operate our business for the benefit of our stockholders. As a result, we may encounter conflicts between our responsibility to the other owners and our responsibility to our stockholders. For example, we have entered into management agreements to provide management services to our surgical facilities in exchange for a fee. Disputes may arise as to the nature of the services to be provided or the amount of the fee to be paid. In these cases, we may be obligated to exercise reasonable, good faith judgment to resolve the disputes and may not be free to act solely in our own best interests or the stockholders best interest. Disputes may also arise between us and our physician investors with respect to a particular business decision or regarding the interpretation of the provisions of the applicable partnership or limited liability company agreement. We seek to avoid these disputes but have not implemented any measures to resolve these conflicts if they arise. If we are unable to resolve a dispute on terms favorable or satisfactory to us, it could have a material adverse effect on our business, prospects, results of operations and financial condition.

Growth of patient receivables or deterioration in the ability to collect on these accounts, due to changes in economic conditions or otherwise, could have a material adverse effect on our business, prospects, results of operations and financial condition.

The current practice of providing medical services in advance of payment or, in many cases, prior to assessment of ability to pay for such services, may have significant negative impact on our revenue, bad debt expense and cash flow. We bill numerous and varied payors, such as self-pay patients, managed care payors and Medicare and Medicaid. These different payors typically have different billing requirements that must be satisfied prior to receiving payment for services rendered. Reimbursement is typically conditioned on our documenting medical necessity and correctly applying diagnosis codes. Incorrect or incomplete documentation and billing information could result in non-payment for services rendered. The primary collection risks with respect to our patient receivables relate to patient accounts for which the primary third-party payor has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and co-payments) remain outstanding.

Additional factors that could complicate our billing include:

- disputes between payors as to which party is responsible for payment;

- failure of information systems and processes to submit and collect claims in a timely manner;
- variation in coverage for similar services among various payors;

- the difficulty of adherence to specific compliance requirements, diagnosis coding and other procedures mandated by various payors; and
- failure to obtain proper physician credentialing and documentation in order to bill various payors.

We provide for bad debts principally based upon the type of payor and the age of the receivables. Our allowance for doubtful accounts at December 31, 2017 represented 1% of our accounts receivable balance. Due to the difficulty in assessing future trends, including the effects of changes in economic conditions, we could be required to increase our provision for doubtful accounts. An increase in the amount of patient receivables or a deterioration in the collectability of these accounts could have a material adverse effect on our business, prospects, results of operations and financial condition.

The loss of certain physicians can have a disproportionate impact on certain of our facilities.

Generally, the top referring physicians within each of our facilities represent a large share of our revenue and admissions. The loss of one or more of these physicians, even if temporary, could cause a material reduction in our revenue, which could take significant time to replace given the difficulty and cost associated with recruiting and retaining physicians.

We may write-off intangible assets, such as goodwill.

As a result of purchase accounting for our various acquisition transactions, including the NSH Merger, our balance sheet at December 31, 2017 contained intangible assets designated as either goodwill or intangibles totaling approximately \$3.3 billion in goodwill and approximately \$58.9 million in intangibles. Any other additional acquisitions that result in the recognition of additional intangible assets would cause an increase in these intangible assets. On an ongoing basis, we evaluate whether facts and circumstances indicate any impairment of the value of intangible assets. As circumstances change, we cannot assure you that the value of these intangible assets will be realized by us. If we determine that a significant impairment has occurred, we will be required to write-off the impaired portion of intangible assets, which could have a material adverse effect on our results of operations in the period in which the write-off occurs.

We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability.

As of December 31, 2017, we had U.S. federal net operating loss ("NOL") carryforwards of approximately \$507.4 million and state NOL carryforwards of approximately \$619.6 million, which may be limited annually due to certain change in ownership provisions of Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"). In addition, as a result of the Symbion acquisition, approximately \$179 million in NOL carryforwards are subject to an annual Section 382 base limitation of \$4.9 million, and, as a result of the Novamed acquisition, approximately \$17 million in NOL carryforwards are subject to an annual Section 382 base limitation of \$4.9 million. As a result of the NSH acquisition, approximately \$20.5 million in NOL carryforwards are subject to an annual Section 382 base limitation of \$2.8 million. Further, the sale of H.I.G.'s shares to Bain Capital in connection with the Transactions resulted in an ownership change as defined in Section 382. As a result, we will not be able to use our pre-ownership-change NOLs in excess of the limitation imposed by Section 382. These limitations, when combined with amounts allowable due to net unrecognized built in gains, are not expected to impact the realization of the deferred tax assets associated with these NOLs. Our federal NOL carryforwards will begin to expire in 2025 and will completely expire in 2037, and our state NOL carryforwards will begin to expire in 2018 and will completely expire in 2037. Future ownership changes may subject our NOL carryforwards to further annual limitations, which could restrict our ability to use them to offset our taxable income in periods following the ownership changes.

We entered into a tax receivable agreement that will require us to make payments to the pre-IPO owners of Surgery Center Holdings, LLC (the "Pre-IPO Owners"), which amounts are expected to be material.

On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the "Reorganization"). We indirectly acquired favorable tax attributes in connection with the Reorganization. These tax attributes would not be available to us in the absence of the consummation of the Reorganization. As part of the Reorganization, we entered into a tax receivable agreement. In connection with the Transactions completed in August 2017, we entered into an agreement to amend the TRA (as amended, the "TRA"), which became effective on August 31, 2017.

Pursuant the TRA, we agreed to make annual payments to H.I.G. in its capacity as the stockholders representative on behalf of the other pre-Reorganization stockholders pursuant to a fixed payment schedule. The final payment is scheduled to be made in 2024. The amounts payable under the TRA are calculated to equal the product of (i) an annual base amount and (ii) the sum of (x) the maximum corporate federal income tax rate for the applicable year and (y) three percent. The amounts payable under the TRA are related to our projected realized tax savings over the next five years and are not dependent on our actual tax savings over the next five years. The calculations of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that we are unable to make payments under the TRA and such inability is a result of the terms of credit agreements and other debt documents that are materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 500 basis points until paid. If the terms of such credit agreements and other debt documents cause us to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015,

such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid. We estimate that the total remaining amounts payable under the TRA as of December 31, 2017 may be as high as \$65.1 million, but the ultimate amounts payable are likely to vary if there are further changes in law as to the income tax rates applicable to domestic corporations.

Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our financial condition and results of operations.

We are subject to income taxes in the United States, and our domestic tax liabilities are subject to the allocation of expenses in differing jurisdictions. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the Code, including:

- reducing the highest marginal U.S. federal corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017;
- limiting the extent to which net operating losses can be utilized against taxable income that would apply to losses created after December 31, 2017;
- changing rules related to the ability to apply net operating losses against later or earlier tax years that would apply to losses created after December 31, 2017;
- creating a new limitation on deductible interest expense for tax years beginning after December 31, 2017;
- eliminating the corporate alternative minimum tax (“AMT”) and changing how existing AMT credits can be realized for tax years beginning after December 31, 2017; and
- generally repealing the performance-based compensation exception to the Section 162(m) \$1.0 million deduction limitation and revising the definition of a covered employee for tax years beginning after December 31, 2017.

There are significant uncertainties regarding the interpretation and application of the Tax Act. Additional guidance on the Tax Act is expected; however, the timing, form, scope and content of such guidance is not known. In addition to the changes implemented by the Tax Act and associated regulations and guidance, our future effective tax rates could be subject to volatility or adversely affected by a number of other factors, including:

- changes in the valuation of our deferred tax assets and liabilities;
- expected timing and amount of the release of any tax valuation allowances;
- tax effects of equity-based compensation;
- costs related to intercompany restructurings;
- changes in tax laws, regulations or interpretations thereof; or
- lower than anticipated future earnings in jurisdictions where we have lower statutory tax rates and higher than anticipated future earnings in jurisdictions where we have higher statutory tax rates.

In addition, we may be subject to audits of our income, sales and other transaction taxes by U.S. federal, state and local authorities. Outcomes from these audits could have an adverse effect on our financial condition and results of operations.

Our facilities may be adversely impacted by weather and other factors beyond our control, and disruptions in our disaster recovery systems or management continuity planning could limit our ability to operate our business effectively.

The financial results of our facilities may be negatively impacted by adverse weather conditions, such as tornadoes, earthquakes and hurricanes, or other factors beyond our control, such as wildfires. These weather conditions or other factors could disrupt patient scheduling, displace our patients, employees and physician partners and force certain of our facilities to close temporarily or for an extended period of time. In certain markets, we have a large concentration of surgery centers that may be simultaneously affected by adverse weather condition or events beyond our control.

While we have disaster recovery systems and business continuity plans in place, any disruptions in our disaster recovery systems or the failure of these systems to operate as expected could, depending on the magnitude of the problem, adversely affect our operating results by limiting our capacity to effectively monitor and control our operations. Despite our implementation of a variety of security measures, our technology systems could be subject to physical or electronic break-ins, and similar disruptions from unauthorized tampering or weather related disruptions where our headquarters is located. In addition, in the event that a significant number of our management personnel were unavailable in the event of a disaster, our ability to effectively conduct business could be adversely affected.

Risks Related to Government Regulation

If we fail to comply with or otherwise incur liabilities under the numerous federal and state laws and regulations relating to the operation of our facilities, we could incur significant penalties or other costs or be required to make significant changes to our operations.

The healthcare industry is heavily regulated and we are subject to many laws and regulations at the federal, state and local government levels in the markets in which we operate. These laws and regulations require that our facilities meet various licensing, accreditation, certification and other requirements, including, but not limited to, those relating to:

- ownership and control of our facilities;

[Table of Contents](#)

- operating policies and procedures;
- qualification, training and supervision of medical and support persons;
- pricing of, billing for and coding of services and properly handling overpayments, debt collection practices and the submission of false statements or claims;
- the necessity, appropriateness and adequacy of medical care, equipment, personnel, operating policies and procedures; maintenance and preservation of medical records;
- financial arrangements between referral sources and our facilities;
- the protection of privacy, including patient and credit card information;
- screening, stabilization and transfer of individuals who have emergency medical conditions and provision of emergency services;
- antitrust;
- building codes;
- workplace health and safety;
- licensure, certification and accreditation;
- fee-splitting and the corporate practice of medicine;
- handling of medication;
- confidentiality, data breach, identity theft and maintenance and protection of health-related and other personal information and medical records; and
- environmental protection, health and safety.

If we fail to comply with applicable laws and regulations, we could subject ourselves to administrative, civil or criminal penalties, cease and desist orders, forfeiture of amounts owed and recoupment of amounts paid to us by governmental or commercial payors, loss of licenses necessary to operate and disqualification from Medicare, Medicaid and other government-sponsored healthcare programs.

Many of these laws and regulations have not been fully interpreted by regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. Different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or require us to make changes in our operations, facilities, equipment, personnel, services, capital expenditure programs or operating expenses to comply with the evolving rules. Any enforcement action against us, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business.

A number of initiatives have been proposed during the past several years to reform various aspects of the healthcare system in the United States. In the future, different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses. In addition, some of the governmental and regulatory bodies that regulate us are considering or may in the future consider enhanced or new regulatory requirements. These authorities may also seek to exercise their supervisory or enforcement authority in new or more robust ways. All of these possibilities, if they occurred, could detrimentally affect the way we conduct our business and manage our capital, either of which, in turn, could have a material adverse effect on our business, prospects, results of operations and financial condition.

We cannot predict the effect that healthcare reform and other changes in government programs may have on our business, financial condition or results of operations.

The Affordable Care Act has changed and continues to change how healthcare services are covered, delivered and reimbursed through, among other things, expanded coverage of uninsured individuals, reduced growth in Medicare program spending and the establishment and expansion of programs

tying reimbursement to quality and clinical integration. The Affordable Care Act also reforms certain aspects of health insurance, quality of care and fraud and abuse enforcement.

Substantial uncertainty remains regarding the net effect of the Affordable Care Act on our business because the long-term impact of a number of factors, including the following, remains unclear:

- the responses of individuals, businesses and other market participants to the evolving choices and obligations under the Affordable Care Act;
- the states' decisions whether to implement the Medicaid expansion provisions of the Affordable Care Act, and under what terms;
- the effect of value-based purchasing and other quality programs established under the Affordable Care Act;
- the scope and nature of changes to Medicare reimbursement methods and programs, including accountable care organizations, bundled payment programs and other coordinated care models;

- the financial sustainability of the Health Insurance Marketplace, which may be impacted by whether a sufficient number of payors participate;
- our ability to participate in health insurance plans offered through the Health Insurance Marketplaces and the terms of our participation;
- the net effect of reductions in federal healthcare program spending under the Affordable Care Act; and
- the resolution of new and ongoing legislative and legal challenges to the Affordable Care Act.

Initiatives to repeal the Affordable Care Act, in whole or in part, and to offer amendments or supplements to modify its provisions have been persistent and have increased as a result of the 2016 election. However, as a result of the enactment of the Tax and Jobs Act of 2017, the “individual mandate” was repealed effective as of calendar year 2019. The repeal of the individual mandate and any other future repeal or replacement of the Affordable Care Act may have significant impact on the reimbursement for healthcare services generally, and may cause more individuals to become uninsured, rendering them unable to afford healthcare services offered by the Company.

Because of the many variables involved, we are unable to predict the net effect of the Affordable Care Act and other associated changes within the healthcare industry on us or our operations. Depending on how the Affordable Care Act continues to be interpreted, implemented or changed, it could have a material adverse effect on our business, prospects, results of operations and financial condition.

If laws governing the corporate practice of medicine or fee-splitting change, we may be required to restructure some of our relationships, which may result in a significant loss of revenue and divert other resources.

The laws of various states in which we operate or may operate in the future do not permit business corporations to practice medicine, to exercise control over or employ physicians who practice medicine or to engage in various business practices, such as fee-splitting with physicians (i.e., sharing in a percentage of professional fees). The interpretation and enforcement of these laws vary significantly from state to state. We provide management services to a physician network. If our arrangements with this network were deemed to violate state corporate practice of medicine, fee-splitting or similar laws, or if new laws are enacted rendering our arrangements illegal, we may be subject to civil and/or criminal penalties and could be required to restructure or terminate these arrangements, any of which may result in a significant loss of revenue and divert management and business resources.

If regulations change, we may be obligated to purchase some or all of the ownership of our physician partners or renegotiate some of our partnership and operating agreements with our physician partners and management agreements with surgical facilities.

Upon the occurrence of various fundamental regulatory changes or changes in the interpretation of existing regulations, we may be obligated to purchase all of the ownership of the physician investors in most of the partnerships or limited liability companies that own and operate our surgical facilities. The purchase price that we would be required to pay for the ownership is specified in our partnership agreements and is typically based on either a multiple of the surgical facility’s EBITDA, as defined in our partnership and operating agreements with these surgical facilities, or the fair market value of the ownership as determined by a third-party appraisal. The physician investors in some of our surgical facilities can require us to purchase their interests in exchange for cash or shares of our common stock if these regulatory changes occur. In addition, some of our partnership agreements with our physician partners and management agreements with surgical facilities require us to attempt to renegotiate the agreements upon the occurrence of various fundamental regulatory changes or changes in the interpretation of existing regulations and provide for termination of the agreements if renegotiations are not successful.

Regulatory changes that could create purchase or renegotiation obligations include changes that:

- make illegal the referral of Medicare or other patients to our surgical facilities by physician investors;
- create a substantial likelihood that cash distributions to physician investors from the partnerships or limited liability companies through which we operate our surgical facilities would be illegal;
- make illegal the ownership by the physician investors of interests in the partnerships or limited liability companies through which we own and operate our surgical facilities; or
- require us to reduce the aggregate percentage of physician investor ownership in our hospitals.

We do not control whether or when any of these regulatory events might occur. In the event we are required to purchase all of the physicians’ ownership, our existing capital resources would not be sufficient for us to meet this obligation. These obligations and the possible termination of our partnership and management agreements would have a material adverse effect on our financial condition and results of operations.

Our revenue will decline if federal or state programs reduce our Medicare or Medicaid payments or if managed care companies reduce reimbursement amounts. In addition, the financial condition of payors and healthcare cost containment initiatives may limit our revenue and profitability.

For the years ended December 31, 2017, 2016 and 2015, we derived approximately 38%, 40% and 38% of our revenue, respectively, from government payors, including Medicare and Medicaid programs. The Medicare and Medicaid programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating payments or reimbursements, among other things; requirements for utilization review; and federal and state funding

restrictions, any of which could materially increase or decrease payments from these government programs in the future, as well as affect the timing of payments to our facilities.

We are unable to predict the effect of future government healthcare funding policy changes on our operations. If the rates paid by governmental payors are reduced, if the scope of services covered by governmental payors is limited or if we, or any of our surgical facilities, are excluded from participation in the Medicare, Medicaid or other government-sponsored healthcare programs, there could be a material adverse effect on our business, financial condition, results of operations or cash flows.

During the past several years, healthcare payors, such as federal and state governments, insurance companies and employers, have undertaken initiatives to revise payment methodologies and monitor healthcare costs. As part of their efforts to contain healthcare costs, payors increasingly are demanding discounted fee structures or the assumption by healthcare providers of all or a portion of the financial risk relating to paying for care provided, often in exchange for exclusive or preferred participation in their benefit plans. We expect efforts to impose greater discounts and more stringent cost controls by government and other payors to continue, thereby reducing the payments we receive for our services.

By way of example, under the Medicare program, physician payments were previously updated on an annual basis according to a statutory formula. Because application of the statutory formula for the update factor would result in a decrease in total physician payments, Congress would intervene with interim legislation on an annual basis to prevent the reductions. In April 2015, however, MACRA, was signed into law, which repealed and replaced the statutory formula for Medicare payment adjustments to physicians. MACRA provides a permanent end to the annual interim legislative updates that had previously been necessary to delay or prevent significant reductions to payments under the MPFS. MACRA extended previous payment rates through June 30, 2015, with a 0.5% update for each calendar year through 2018. In addition, MACRA requires the establishment of MIPS, beginning in 2019, under which physicians may receive performance-based payment incentives or payment reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities and meaningful use of electronic health records. For more information on the implementation of MACRA, see “Business - Sources of Revenue - Ancillary and Optical Services.”

The amount of our provision for doubtful accounts is based on our assessments of historical collection trends, business and economic conditions, trends in federal and state governmental and private employer health coverage and other collection indicators. A continuation in trends that results in increasing the proportion of accounts receivable being comprised of uninsured accounts and deterioration in the collectability of these accounts could adversely affect our collections of accounts receivable, results of operations and cash flows.

Our surgical facilities do not satisfy the requirements for any of the safe harbors under the federal Anti-Kickback Statute. If a federal or state agency asserts a different position or enacts new laws in this regard, we could be subject to criminal and civil penalties, loss of licenses and exclusion from governmental programs, which may result in a substantial loss of revenue.

The Anti-Kickback statute prohibits the offer, payment, solicitation or receipt of any form of remuneration in return for referrals for items or services payable by Medicare, Medicaid, or any other federally funded healthcare program. Additionally, the Anti-Kickback Statute prohibits any form of remuneration in return for purchasing, leasing or ordering, or arranging for or recommending the purchasing, leasing or ordering of items or services payable by Medicare, Medicaid or any other federally funded healthcare program. The Anti-Kickback Statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by existing case law or regulations. Moreover, several federal courts have held that the Anti-Kickback Statute can be violated if only one purpose (not necessarily the primary purpose) of a transaction is to induce or reward a referral of business, notwithstanding other legitimate purposes. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act (discussed below). Violations of the Anti-Kickback Statute may result in substantial civil or criminal penalties, including up to five years imprisonment and criminal fines of up to \$25,000 and civil penalties of up to \$50,000 for each violation, plus three times the remuneration involved or the amount claimed and exclusion from participation in all federally funded healthcare programs. Our exclusion from participation in such programs would have a material adverse effect on our business, prospects, results of operations and financial condition. In addition, many of the states in which we operate have also adopted laws, similar to the Anti-Kickback Statute, that prohibit payments to physicians in exchange for referrals, some of which apply regardless of the source of payment for care. These statutes typically impose criminal and civil penalties, including the loss of a license to do business in the state.

In July 1991, HHS, issued final regulations defining various “safe harbors” under the Anti-Kickback Statute. Business arrangements that meet the requirements of the safe harbors are not treated as criminal violations under the Anti-Kickback Statute. Business arrangements that do not meet the safe harbor requirements do not necessarily violate the Anti-Kickback Statute, but may be subject to scrutiny by the federal government to determine compliance. Two of the original safe harbors issued in 1991 apply to business arrangements similar to those used in connection with our surgical facilities: the “Investment Interest” safe harbor and the “Personal Services and Management Contracts” safe harbor. However, the structure of the partnerships and limited liability companies operating our surgery centers and surgical hospitals, as well as our various business arrangements involving physician group practices, do not satisfy all of the requirements of either safe harbor. We have entered into management agreements to manage the majority of our surgical facilities. Most of these agreements call for our subsidiary to be paid a percentage-based management fee. Because our management fees are generally based on a percentage of revenue, our management agreements do not typically meet the Personal Services and

Management Contracts safe harbor. We have implemented formal compliance programs designed to safeguard against overbilling and believe that our management agreements comply with the requirements of the Anti-Kickback Statute. However, we cannot assure you that the OIG would find our compliance programs to be adequate or that our management agreements would be found to comply with the Anti-Kickback Statute.

In November 1999, HHS promulgated final regulations creating additional safe harbor provisions, including a safe harbor that applies to physician ownership of or investment interests in surgery centers. The surgery center safe harbor protects four types of investment arrangements: (1) surgeon owned surgery centers; (2) single specialty surgery centers; (3) multi-specialty surgery centers; and (4) hospital/physician surgery centers. Each category has its own requirements with regard to what type of physician may be an investor in the surgery center. In addition to the physician investor, the categories permit an “unrelated” investor, who is a person or entity that is not in a position to provide items or services related to the surgery center or its investors. Our business arrangements with our surgical facilities typically consist of one of our subsidiaries being an investor in each partnership or limited liability company that owns the facility, in addition to providing management and other services to the facility. Therefore, our business arrangements with our surgery centers, surgical hospitals and physician groups do not qualify for the expanded safe harbor protection from government review or prosecution under the Anti-Kickback Statute. However, we believe that we are in compliance with the requirements of the Anti-Kickback Statute.

We employ dedicated marketing personnel whose job functions include the recruitment of physicians to perform surgery at our facilities. These employees are paid a base salary plus a productivity bonus. We believe our employment arrangements with these employees are consistent with a safe harbor provision designed to protect payments made to employees. However, a government agency or private party may assert a contrary position.

We also enter into lease agreements with physicians from time to time for the rental of space for our surgical facilities. We seek to structure these lease agreements so that they are in compliance with the Anti-Kickback Statute safe harbor provision regarding real estate leases. However, a government agency or private party may assert a contrary position.

If any of our business arrangements with physicians or sales and marketing personnel were alleged or deemed to violate the Anti-Kickback Statute or similar laws, or if new federal or state laws were enacted rendering these arrangements illegal, it could have a material adverse effect on our business, prospects, results of operations and financial condition.

In addition to the physician ownership in our surgical facilities, other financial relationships of ours with potential referral sources could potentially be scrutinized under the Anti-Kickback Statute.

Certain of our ASCs have entered into arrangements for professional services, including arrangements for anesthesia services. In a Special Advisory Bulletin issued in April 2003, the OIG focused on “questionable” contractual arrangements where a health care provider in one line of business (the “Owner”) expands into a related health care business by contracting with an existing provider of a related item or service (the “Manager/Supplier”) to provide the new item or service to the Owner’s existing patient population, including federal health care program patients (so called “suspect Contractual Joint Ventures”). The Manager/Supplier not only manages the new line of business, but may also supply it with inventory, employees, space, billing, and other services. In other words, the Owner contracts out substantially the entire operation of the related line of business to the Manager/Supplier—otherwise a potential competitor—receiving in return the profits of the business as remuneration for its referrals. Through an Advisory Opinion, the OIG extended this suspect contractual joint venture analysis to arrangements between anesthesiologists and physician owners of ASCs. In Advisory Opinion 12-06, the OIG concluded that certain proposed arrangements between anesthesia groups and physician-owned ASCs could result in prohibited remuneration under the federal Anti-Kickback Statute. We believe our arrangements for anesthesia services are distinguishable from those described in Advisory Opinion 12-06 (May 25, 2012) and are in compliance with the requirements of the federal Anti-Kickback Statute. However, we cannot assure you that regulatory authorities would agree with that position.

If we fail to comply with physician self-referral laws as they are currently interpreted or may be interpreted in the future, or if other legislative restrictions are issued, we could incur substantial monetary penalties and a significant loss of revenue.

The federal physician self-referral law, commonly referred to as the Stark Law, prohibits a physician from making a Medicare or Medicaid reimbursed referral for a “designated health service” to an entity if the physician or a member of the physician’s immediate family has a “financial relationship” with the entity unless an exception applies. The list of “designated health services” under the Stark Law does not generally include ambulatory surgery services, but it does include inpatient and outpatient hospital service and services such as clinical laboratory services, and certain imaging services that may be provided and separately billed by an ASC or other facility. Under the current Stark Law and related regulations, services provided at an ASC are not covered by the statute, even if those services include imaging, laboratory services or other Stark designated health services, provided that (i) the ASC does not bill for these services separately, or (ii) if the center is permitted to bill separately for these services, they are specifically exempted from Stark Law prohibitions. These are generally radiology and other imaging services integral to performance of surgical procedures that meet certain requirements and certain outpatient prescription drugs. Services provided at our facilities licensed as hospitals are covered by the Stark Law. We attempt to structure our relationship with physicians who refer to our hospitals to meet an exception to the Stark Law where required, but the regulations implementing the exceptions are detailed and complex, and we cannot guarantee that every relationship complies fully with the Stark Law. We also believe that certain services provided by our managed physician network are covered by the Stark Law, but referrals for those services are exempt from the Stark Law under its “in-office ancillary services exception,” among others. Our diagnostic laboratory is also subject to the Stark Law, but we believe that we have structured our agreements with physicians so as to not violate the Stark Law and related regulations.

The Stark Law and similar state statutes are subject to different interpretations with respect to many important provisions. Violations of these self-referral laws may result in substantial civil or criminal penalties, including treble damages for amounts improperly claimed, civil monetary penalties

of up to \$15,000 per prohibited service billed, up to \$100,000 per prohibited circumvention scheme and exclusion from participation in the Medicare and Medicaid and other federal and state healthcare programs. Violations of the Stark Law will also create liability under the federal False Claims Act. Exclusion of our ASCs or hospitals from these programs through judicial or agency interpretation of

existing laws or additional legislative restrictions on physician ownership or investments in healthcare entities could result in a significant loss of reimbursement revenue. We cannot provide assurances that CMS will not undertake other rulemaking to address additional revisions to or interpretations of the Stark Law regulations. If future rules modify the provisions of the Stark Law regulations that are applicable to our business, our revenue and profitability could be materially adversely affected and could require us to modify our relationships with our physician and healthcare system partners.

Federal law restricts the ability of our surgical hospitals to expand surgical capacity.

The Stark Law includes an exception that permits physicians to refer Medicare and Medicaid patients to hospitals in which they have an ownership interest if certain requirements are met. However, the Affordable Care Act dramatically curtailed this exception and prohibits physician ownership in hospitals that did not have a Medicare provider agreement by December 31, 2010. As a result, the law effectively prevents the formation of new physician-owned hospitals that participate in Medicare and Medicaid after December 31, 2010. Each of our surgical hospitals had a Medicare provider agreement in place prior to December 31, 2010 and is therefore able to continue operating with the ownership structure that was in place prior to December 30, 2010. However, the Affordable Care Act prohibits “grandfathered” hospitals from increasing their percentage of physician ownership, and it limits to a certain extent their ability to grow, because it prohibits such hospitals from increasing the aggregate number of inpatient beds, operating rooms and procedure rooms.

Companies within the healthcare industry continue to be the subject of federal and state audits and investigations, and we may be subject to such audits and investigations, including actions for false and other improper claims.

Federal and state government agencies, as well as commercial payors, have increased their auditing and administrative, civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare organizations. These audits and investigations relate to a wide variety of topics, including the following: cost reporting and billing practices; quality of care; financial reporting; financial relationships with referral sources; and medical necessity of services provided. In addition, the OIG and the U.S. Department of Justice (“DOJ”) have, from time to time, undertaken national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. In its 2013 Work Plan, the OIG stated its intention to review the safety and quality of care for Medicare beneficiaries having surgeries and procedures in ASCs and hospital outpatient departments.

The federal government may impose criminal, civil and administrative penalties on any person or entity that files a false claim for payment from the Medicare or Medicaid programs and other federal and state healthcare programs. Claims filed with private insurers can also lead to criminal and civil penalties, including, but not limited to, penalties relating to violations of federal mail and wire fraud statutes, as well as penalties under the anti-fraud provisions of the HIPAA. While the criminal statutes are generally reserved for instances of fraudulent intent, the federal government is applying its criminal, civil and administrative penalty statutes in an ever-expanding range of circumstances, including claiming payment for unnecessary services if the claimant merely should have known the services were unnecessary and claiming payment for low-quality services if the claimant should have known that the care was substandard. In addition, a violation of the Stark Law or the Anti-Kickback Statute can result in liability under the federal False Claims Act (“FCA”).

Over the past several years, the federal government has investigated an increasing number of healthcare providers for potential FCA violations, which, among other things, prohibits a person from knowingly presenting, or causing to be presented, a false or fraudulent claim to the federal government. The statute defines “knowingly” to include not only actual knowledge of a claim’s falsity, but also reckless disregard for or intentional ignorance of the truth or falsity of a claim. Violators of the FCA are subject to severe financial penalties, including treble damages and per claim penalties in excess of \$10,000. Because our facilities perform hundreds or thousands of similar procedures each year for which they are paid by Medicare, and since the statute of limitations for such claims extends for six years under normal circumstances (and possibly as long as ten years in the event of failure to discover material facts), a repetitive billing error or cost reporting error could result in significant, material repayments and civil or criminal penalties.

Moreover, another trend impacting healthcare providers is the increased use of the FCA, particularly by individuals who bring actions under that law. Under the “qui tam,” or whistleblower, provisions of the FCA, private parties may bring actions on behalf of the federal government. If the government intervenes and prevails in the action, the defendant may be required to pay three times the actual damages sustained by the government, plus mandatory civil monetary penalties of between \$5,500 and \$11,000 for each false claim submitted to the government. These private parties, often referred to as relators, are entitled to share in any amounts recovered by the government through trial or settlement. These qui tam cases are sealed by the court at the time of filing. The only parties privy to the information contained in the complaint are the relator, the federal government and the presiding court. It is possible that qui tam lawsuits have been filed against us and that we are unaware of such filings. Both direct enforcement activity by the government and whistleblower lawsuits under the FCA have increased significantly in recent years; thus, the risk that we will have to defend a false claims action, pay significant fines or be excluded from the Medicare and Medicaid programs has increased. For example, on October 23, 2017, the Company received a civil investigative demand (“CID”) from the federal government under the False Claims Act (“FCA”) for documents and information dating back to January 1, 2010 relating to the medical necessity of certain drug tests conducted by the Company’s physicians and submitted to laboratories owned and operated by the Company. The Company intends to respond to the CID and cooperate with the U.S. Attorney’s Office in connection with the FCA investigation.

In addition, the Fraud Enforcement and Recovery Act of 2009 (“FERA”) further expanded the scope of the FCA to create liability for knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government and FERA, along with statutory provisions found in the Acts, created federal False Claims Act liability for the knowing failure to report and return an overpayment within 60 days of the identification of the overpayment or, in certain cases, the date by which a corresponding cost report is due, whichever is later.

Governmental authorities may challenge or scrutinize our operations or we may be the subject of a whistleblower lawsuit at any time. A determination that we have violated these laws could have a material adverse effect on our business, prospects, results of operations and financial condition.

HIPAA also created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

In addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary's selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to \$10,000 for each wrongful act. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful act. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payors may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent our patient assistance programs or other discount policies are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties.

To enforce compliance with the federal laws, the DOJ has recently increased its scrutiny of interactions between health care companies and health care providers, which has led to a number of investigations, prosecutions, convictions and settlements in the health care industry. Dealing with investigations can be time and resource consuming and can divert management's attention from the business. In addition, settlements with the DOJ or other law enforcement agencies have forced healthcare providers to agree to additional compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.

We are also subject to various state laws and regulations, as well as contractual provisions with commercial payors that prohibit us from submitting inaccurate, incorrect or misleading claims. We cannot be sure that none of our surgical facilities' claims will ever be challenged. If we were found to be in violation of a state's laws or regulations, or of a commercial payor contract, we could be forced to discontinue the violative practice and be subject to recoupment actions, fines and criminal penalties, which could have a material adverse effect on our business, prospects, results of operations and financial condition.

All payors are increasingly conducting post-payment audits. For example, CMS has implemented the RAC program, involving Medicare claims audits nationwide. Under the program, CMS contracts with RACs on a contingency fee basis to conduct post-payment reviews to detect and correct improper payments in the fee-for-service Medicare program. The Affordable Care Act expanded the RAC program's scope to include managed Medicare plans and to include Medicaid claims. In addition, CMS employs MICs to perform post-payment audits of Medicaid claims and identify overpayments. The Affordable Care Act increases federal funding for the MIC program. In addition to RACs and MICs, the state Medicaid agencies and other contractors have increased their review activities. We are regularly subject to these external audits and we also perform both internal and third-party audits and monitoring.

Although all other repayments requested to date as a result of RAC, MIC and ZPIC audits have not been material to our Company, we are unable to quantify the suspended payments and aggregate financial impact of these audits on our facilities given the pending appeals and uncertainty about the extent of future audits and whether the underlying conduct could be considered systemic. As such, the resolution of these audits could have a material adverse effect on our business, prospects, results of operations and financial condition.

Failure to comply with Medicare's conditions for coverage and conditions of participation may result in loss of program payment or other governmental sanctions.

To participate in and receive payment from the Medicare program, our facilities must comply with regulations promulgated by CMS. These regulations, known as "conditions for coverage" for ASCs and "conditions of participation" for hospitals, set forth specific requirements with respect to, among other things, the facility's physical plant, equipment, personnel and standards of medical care. All of our surgery centers and surgical hospitals are certified to participate in the Medicare program. As such, these facilities are subject to on-site, unannounced surveys by state survey agencies working on behalf of CMS. Under the ASC survey process, the surveyors are becoming more familiar with expanded interpretive guidance and the updated ASC conditions for coverage, which may lead to an increased number of deficiency citations requiring remedy with appropriate action plans. Failure to comply with Medicare's conditions for coverage or conditions of participation may result in loss of payment or other governmental sanctions, including termination from participation in the Medicare program. We have established ongoing quality assurance activities to monitor our facilities' compliance with these conditions and respond to surveys, but we cannot be sure that our facilities are or will always remain in full compliance with the requirements.

In addition, pending a determination regarding our compliance with these conditions, payment to us may be suspended and we may be required to devote significant time, effort and expense to demonstrate satisfactory compliance.

Our facilities could face decreased Medicare payments if they fail to report and meet various quality metrics.

The Medicare program presently requires hospitals and ASCs to report performance data on a variety of quality metrics. Facilities that fail to report are penalized with reduced Medicare payments. Additionally, payments to hospitals are adjusted based on the hospital's performance on these quality measures. A substantial portion of hospital payment is at risk depending on its individual performance relative to benchmarks and other hospitals' performance. There is a substantial risk that our Medicare payments could be reduced if our hospitals fail to perform adequately on these measures. Additionally, there is a risk that Medicare payments could be reduced if our facilities-hospitals and ASCs fail to adequately report data as required by CMS. ASC payments are not yet adjusted based on performance against quality measures, but there is a substantial risk that Congress may soon link ASC Medicare payments to actual performance, in addition to reporting.

If the public performance data becomes a primary factor in determining where patients choose to receive care, and if competing hospitals and ASCs have better results than our facilities on those measures, our patient volumes could decline.

Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.

HIPAA as well as numerous other federal and state laws and regulations, govern the collection, dissemination, use, privacy, security, confidentiality, integrity and availability of personally identifiable information ("PII"), including protected health information ("PHI"). HIPAA applies national privacy and security standards for PHI to covered entities such as us. HIPAA requires covered entities to maintain policies and procedures governing PHI that is used or disclosed, and to implement administrative, physical and technical safeguards to protect PHI, including PHI maintained, used and disclosed in electronic form. These safeguards include team training, identifying "business associates" with whom we need to enter into HIPAA-compliant contractual arrangements and various other measures. Ongoing implementation and oversight of these measures involves significant time, effort and expense. While we undertake substantial efforts to secure the PHI we maintain, use and disclose in electronic form, a cyber-attack or other intrusion that bypasses our information security systems causing an information security breach, loss of protected health information or other data subject to privacy laws or a material disruption of our operational systems could result in a material adverse impact on our business, along with potentially substantial fines and penalties. Ongoing implementation and oversight of these security measures involves significant time, effort and expense.

HIPAA also requires our surgical facilities to use standard transaction code sets and identifiers for certain standardized healthcare transactions, including billing and other claim transactions. We have undertaken significant efforts involving substantial time and expense to implement these requirements, and we anticipate that continual time and expense will be required to submit standardized transactions and to ensure that any newly acquired facilities can submit HIPAA-compliant transactions.

HIPAA requires covered entities to report breaches of unsecured protected health information to affected individuals without unreasonable delay and in no case later than 60 days after the discovery of the breach by the covered entity or its agents. Notification must also be made to HHS and, in certain situations involving large breaches, to the media. The HIPAA rules created a presumption that all non-permitted uses or disclosures of unsecured protected health information are breaches unless the covered entity establishes that there is a low probability the information has been compromised. HIPAA imposes mandatory civil and criminal penalties for violations of its requirements ranging up to \$50,000 per violation, with a maximum civil penalty of \$1.5 million in a calendar year for violations of the same requirement. However, a single breach incident can result in violations of multiple requirements, resulting in possible penalties well in excess of \$1.5 million. In addition, the HITECH Act authorized state attorneys general to bring civil actions seeking either an injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents.

HIPAA also authorizes state attorneys general to bring civil actions seeking either an injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA's requirements, its standards have been used as a basis for the duty of care in state civil suits, such as those for negligence or recklessness in the handling of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities such as us.

In addition, many states in which we operate may impose laws that are more protective of the privacy and security of PII than HIPAA. Where these state laws are more protective than HIPAA, we have to comply with their stricter provisions. Only some of these state laws impose fines and penalties upon violators, but some may afford private rights of action to individuals who believe their PII has been misused. California's patient privacy laws, for example, provide for penalties of up to \$250,000 and permit injured parties to sue for damages. Both state and federal laws are subject to modification or enhancement of privacy protection at any time. Our facilities will continue to remain subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These statutes vary and could impose additional requirements on us and more severe penalties for disclosures of confidential health information. New health information standards could have a significant effect on the manner in which we do business, and the cost of complying with new standards could be significant. We may not remain in compliance with the diverse privacy requirements

in all of the jurisdictions in which we do business. If we fail to comply with HIPAA or similar state laws, we could incur substantial civil monetary or criminal penalties.

If we are unable to integrate and operate our information systems effectively or implement new systems and processes, our operations could be disrupted.

Our operations depend significantly on effective information systems, which require continual maintenance, upgrading and enhancement to meet our operational needs. Any system failure or integration delay that causes an interruption in service or availability of our systems could

adversely affect operations or delay the collection of revenue. Moreover, we use the development and implementation of sophisticated and specialized technology to improve our profitability, and our acquired surgical centers and hospitals will require frequent transitions and integration of various information systems. If we are unable to properly integrate other information systems or expand our current information systems it may have an adverse effect on our ability to obtain new business, retain existing business and maintain or increase our profit margins and we could suffer, among other things, operational disruptions, disruptions in cash flows and increases in administrative expenses.

Information security risks have generally increased in recent years because of threats from malicious persons and groups, new vulnerabilities, the proliferation of new technologies and the increased sophistication and activities of perpetrators of cyber-attacks. A failure in or breach of our operational or information security systems as a result of cyber-attacks or information security breaches could disrupt our business, result in the loss, disclosure or misuse of confidential or proprietary information, damage our reputation, increase our costs or lead to fines and financial losses. As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data and networks from attack, damage or unauthorized access remain a priority for us. As cyber threats continue to evolve, we will be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities.

State efforts to regulate the construction, acquisition or expansion of healthcare facilities could prevent us from acquiring additional surgical facilities, renovating our existing facilities or expanding the breadth of services we offer.

Some states require prior approval for the construction, acquisition or expansion of healthcare facilities or expansion of the services the facilities offer. In giving approval, these states consider the need for additional or expanded healthcare facilities or services, as well as the financial resources and operational experience of the potential new owners of existing healthcare facilities. In many of the states in which we currently operate, certificates of need must be obtained for capital expenditures exceeding a prescribed amount, changes in capacity or services offered and various other matters. The remaining states in which we now or may in the future operate may adopt similar legislation. Our costs of obtaining a certificate of need could be significant, and we cannot assure you that we will be able to obtain the certificates of need or other required approvals for additional or expanded surgical facilities or services in the future. In addition, at the time we acquire a surgical facility, we may agree to replace or expand the acquired facility. If we are unable to obtain required approvals, we may not be able to acquire additional surgical facilities, expand healthcare services we provide at these facilities or replace or expand acquired facilities.

If antitrust enforcement authorities conclude that our market share in any particular market is too concentrated, that our or our health system partners' commercial payor contract negotiating practices are illegal, or that we otherwise violate antitrust laws, we could be subject to enforcement actions that could have a material adverse effect on our business, prospects, results of operations and financial condition.

The federal government and most states have enacted antitrust laws that prohibit certain types of conduct deemed to be anti-competitive. These laws prohibit price fixing, concerted refusal to deal, market monopolization, price discrimination, tying arrangements, acquisitions of competitors and other practices that have, or may have, an adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties. Antitrust enforcement in the healthcare industry is currently a priority of the Federal Trade Commission (the "FTC"). We believe we are in compliance with federal and state antitrust laws, but courts or regulatory authorities may reach a determination in the future that could have a material adverse effect on our business, prospects, results of operations and financial condition.

The healthcare laws and regulation to which we are subject is constantly evolving and may change significantly in the future.

The regulation applicable to our business and to the healthcare industry generally to which we are subject is constantly in a state of flux. While we believe that we have structured our agreements and operations in material compliance with applicable healthcare laws and regulations, there can be no assurance that we will be able to successfully address changes in the current regulatory environment. We believe that our business operations materially comply with applicable healthcare laws and regulations. However, some of the healthcare laws and regulations applicable to us are subject to limited or evolving interpretations, and a review of our business or operations by a court, law enforcement or a regulatory authority might result in a determination that could have a material adverse effect on us. Furthermore, the healthcare laws and regulations applicable to us may be amended or interpreted in a manner that could have a material adverse effect on our business, prospects, results of operations and financial condition.

Risks Related to Our Common Stock

We are a "controlled company" within the meaning of NASDAQ rules and, therefore, we qualify for, and currently rely on, exemptions from certain corporate governance requirements. Our stockholders do not have the same protections afforded to stockholders of companies that are subject to such requirements.

As of December 31, 2017, Bain Capital controlled a majority of the voting power of our outstanding common stock. As a result, we are a "controlled company" within the meaning of the corporate governance standards of NASDAQ. Under these rules, a company of which more than a majority of the voting power is held by an individual, group or another company is a "controlled company" and may elect not to comply with certain corporate governance requirements including:

- the requirement that a majority of the board of directors consist of independent directors;
- the requirement that we have a nominating/corporate governance committee that is composed entirely of independent directors with

a written charter addressing the committee's purpose and responsibilities; and

- the requirement that we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee's purpose and responsibilities.

As of December 31, 2017, we have availed ourselves of certain of these exemptions. For example, as a result, we did not have a majority of independent directors for the entire period covered by this report (and may, in the future, have less than a majority of independent directors) and we do not have a nominating and corporate governance committee. Accordingly, our stockholders will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of NASDAQ.

There can be no assurance as to the period of time during which we will remain a "controlled company".

Our controlling stockholder has significant influence over us, including control over decisions that require the approval of stockholders, which could limit our stockholders' ability to influence the outcome of key transactions, including a change of control.

As of December 31, 2017, we were controlled by Bain Capital. As of that time, Bain Capital beneficially owned approximately 66% of our outstanding common stock. For as long as Bain Capital continues to control a majority of the voting power of our common stock, it will be able to direct the election of all of the members of our board of directors and could exercise a controlling influence over our business and affairs, including any determinations with respect to mergers or other business combinations, the acquisition or disposition of assets, the incurrence of indebtedness, the issuance of any additional common stock or other equity securities, the repurchase or redemption of common stock and the payment of dividends. Similarly, Bain Capital will have the power to determine matters submitted to a vote of our stockholders without the consent of our other stockholders, will have the power to prevent a change in our control and could take other actions that might be favorable to it. Even if Bain Capital ceases to beneficially own a majority of the voting power of our common stock, it will continue to be able to strongly influence or effectively control our decisions.

Our stock price could be extremely volatile, and, as a result, our stockholders may not be able to resell their shares at or above the price paid for them.

Since our initial public offering, the price of our common stock as reported on The NASDAQ Global Select Market has ranged from a low of \$7.10 on November 1, 2017 to a high of \$24.05 on June 28, 2017. The price of our common stock could be subject to wide fluctuations in response to a number of factors, including those described elsewhere in this report and others such as:

- variations in our operating performance and the performance of our competitors;
- actual or anticipated fluctuations in our quarterly or annual operating results;
- publication of research reports by securities analysts about us or our competitors or our industry;
- announcements by us, our competitors or our vendors of significant contracts, acquisitions, joint marketing relationships, joint ventures or capital commitments;
- our failure or the failure of our competitors to meet analysts' projections or guidance that we or our competitors may give to the market;
- strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;
- the passage of legislation or other regulatory developments affecting us or our industry;
- our limited public float;
- speculation in the press or investment community;
- changes in accounting principles;
- terrorist acts, acts of war or periods of widespread civil unrest;
- natural disasters and other calamities; and

- changes in general market and economic conditions.

Securities class action litigation is often initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation. For example, on December 4, 2017, we were named as one of the defendants, along with members of our board, and our current and former controlling shareholder and their respective affiliates in a suit filed in the Delaware Court of Chancery by a purported stockholder relating to the Transactions after a period of decline in our trading price. The plaintiff claims that the director defendants breached their fiduciary duties in connection with the Transactions, purporting to assert those claims on the Company's behalf. While we believe that there is no merit to the claims brought in this suit, litigation like this and others like it could result in diversion of resources including management's attention.

Provisions in the certificate of designation governing our preferred stock and in our charter documents and Delaware law may deter takeover efforts that could be beneficial to stockholder value.

Our certificate of incorporation and by-laws, the certificate of designation governing our preferred stock and Delaware law contain provisions that could make it harder for a third party to acquire us, even if doing so might be beneficial to our stockholders. The provisions in our organizational documents include a classified board of directors and limitations on actions by our stockholders. In addition, our board of directors has the right to issue additional preferred stock without stockholder approval that could be used to dilute a potential hostile acquiror. Our certificate of incorporation also imposes some restrictions on mergers and other business combinations between us and any holder of 15.0% or more of our outstanding common stock other than affiliates of Bain Capital. Finally, our 10% Series A Convertible Perpetual Participating Preferred Stock accrues conversion value for each quarter it is outstanding and is subject, under certain circumstances, to a redemption premium, which could significantly increase the cost to a potential acquirer of buying all of the outstanding securities of the Company. As a result of these features, our stockholders may lose their ability to sell their stock for a price in excess of the prevailing market price, and efforts by stockholders to change the direction or management of the Company may be unsuccessful.

Our amended and restated certificate of incorporation designates courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or (iv) any other action asserting a claim against us that is governed by the internal affairs doctrine (each, a "Covered Proceeding"). In addition, our amended and restated certificate of incorporation provides that if any action the subject matter of which is a Covered Proceeding is filed in a court other than the specified Delaware courts without the approval of our board of directors (each, a "Foreign Action"), the claiming party will be deemed to have consented to (i) the personal jurisdiction of the specified Delaware courts in connection with any action brought in any such courts to enforce the exclusive forum provision described above and (ii) having service of process made upon such claiming party in any such enforcement action by service upon such claiming party's counsel in the Foreign Action as agent for such claiming party. Any person or entity purchasing or otherwise acquiring any interest in shares of our stock shall be deemed to have notice of and to have consented to these provisions. These provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.

We have identified a material weakness in our internal control over financial reporting which could, if not remediated, result in material misstatements in our financial statements.

As a public company, we are required to evaluate our internal controls over financial reporting and to comply with Section 404 of the Sarbanes-Oxley Act. As disclosed in Item 9A. "Controls and Procedures", in connection with management's assessment of our internal control over financial reporting as of December 31, 2017, management recognized certain control deficiencies in our internal control over financial reporting pertaining to lack of documentation evidencing certain controls involving revenue, accounts receivable and related allowances and relating to the business combination accounting for the NSH acquisition and the application of pushdown accounting, which aggregates to a material weakness as of December 31, 2017. Certain of the control deficiencies identified as of December 31, 2017 were identified in connection with management's assessment of our internal control over financial reporting as of December 31, 2016, which management was unable to satisfactorily remediate during fiscal 2017. We have developed and are implementing a plan to remediate certain of these control deficiencies, against which we have made progress, and intend to design a plan to remediate the remainder, but there can be no assurance as to when we will be able to remediate our material weakness, if at all.

If our remediation measures prove to be insufficient to remediate the material weakness, or if additional material weaknesses or significant deficiencies in internal control are discovered or occur in the future, our consolidated financial statements may contain material misstatements and we could be required to restate our financial results, or the accuracy of our financial reporting could be adversely affected resulting in reputational harm, distractions to management and our board of directors, and disruptions to our business.

If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If securities or industry analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could

decrease, which could cause our stock price and trading volume to decline. If one or more of the analysts who covers us downgrades our common stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Our corporate headquarters is located in Brentwood, Tennessee, where we currently lease approximately 85,000 square feet of office space pursuant to an agreement with an initial term expiring December 31, 2027. In addition, certain of our corporate operational functions are located in Tampa, Florida and Chicago, Illinois. Our Tampa, Florida office contains approximately 31,000 square feet of leased office space, pursuant to an agreement which expires in April 2018. We have entered into a new lease agreement for our corporate functions in Tampa, which commences in May 2018. The new space will be approximately the same size. Our Chicago, Illinois office contains approximately 16,626 square feet of leased office space, pursuant to an agreement with an initial term expiring February 23, 2023. Our surgical facilities typically are located on real estate leased by the partnership or limited liability company that operates the facility. The average facility size is 8,000 to 12,000 square feet, and is specifically tailored to meet the needs of physician-partners and their specialties. Of our 124 surgical facilities, 117 utilize leased real property. These leases generally have initial terms of ten years, but range from 2 to 15 years. Most of the leases contain options to extend the lease period for up to ten additional years. We generally guarantee the lease obligations of the partnerships and limited liability companies that own our surgical facilities. We expect to be able to renew or replace a substantial majority of these leases on substantially similar terms as they come due. We believe these spaces are sufficient and adequate for our needs at this time.

Item 3. Legal Proceedings

Stockholder Litigation. On December 4, 2017, the Company, certain current and former members of the Company's board of directors, H.I.G. Capital LLC and certain of its affiliates and Bain Capital Private Equity, L.P. and certain of its affiliates and advised funds (collectively, the "Defendants") were named as defendants in a suit filed in the Delaware Court of Chancery (the "Delaware Action") by a purported Company stockholder relating to the Transactions. The plaintiff in the Delaware Action claims that the Defendants breached their fiduciary duties in connection with the Transactions, and that, in the alternative, Bain Capital aided and abetted those purported breaches. The plaintiff in the Delaware Action purports to assert those claims on the Company's behalf, as well as on behalf of a putative class of Company stockholders and requests that the Court award monetary damages to the purported class and/or the Company. On January 2, 2018 the defendants in the Delaware Action moved to dismiss all of the claims asserted in that suit. Briefing on that motion will conclude on or about May 21, 2018.

Other Litigation. In addition, we are, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, breach of management contracts and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages, which may not be covered by insurance.

In the opinion of management, we are not currently a party to any proceedings that would have a material adverse effect on our business, financial condition or results of operations.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information for Common Stock

Our common stock trades under the symbol “SGRY” on the NASDAQ Global Select Market. The following table presents the high and low sales prices per share for our common stock on the NASDAQ Global Select Market for the periods indicated:

	High	Low
2017		
First quarter	\$ 22.85	\$ 15.10
Second quarter	24.05	17.00
Third quarter	22.85	8.53
Fourth quarter	12.78	7.10
2016		
First quarter	\$ 20.40	\$ 11.97
Second quarter	18.45	11.76
Third quarter	20.78	15.94
Fourth quarter	20.93	13.60

Stockholders

As of March 14, 2018, there were 45 holders of record of our common stock. The actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividends

We have never declared or paid a cash dividend on our common stock, and have no current plans to declare or pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our Board of Directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our Board of Directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of our existing and future outstanding indebtedness we or our subsidiaries incur, including our credit facility. Additionally, because we are a holding company, we would depend on distributions from our subsidiaries to fund any potential dividends.

Equity Compensation Plans

See Item 12 for information with respect to the Company’s equity compensation plans.


Unregistered Sales of Equity Securities and Use of Proceeds

As previously reported in our Current Report on Form 8-K filed September 1, 2017, we issued 310,000 shares of the Company's preferred stock, par value \$0.01 per share, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock (the “Series A Preferred Stock”), to Bain Capital at a purchase price of \$1,000.00 per share for an aggregate purchase price of \$310.0 million on August 31, 2017 (the “Preferred Private Placement”). The net proceeds from the Preferred Private Placement were used to finance a portion of the Company’s acquisition of NSH Holdco, Inc. The issuance of the Series A Preferred Stock to Bain Capital was made in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) and Rule 506 promulgated thereunder. The issuance of Common Stock that may be issued upon the conversion of the Series A Preferred Stock will be issued in reliance upon an exemption from the registration requirements of the Securities Act pursuant to Section 4(a)(2) promulgated thereunder.

For further discussion of the Preferred Private Placement and the Series A Preferred Stock, see Note 1. “Organization” and Note 9, “Redeemable Preferred Stock” of our consolidated financial statements included elsewhere in this report and the disclosures set forth in Item 3.02 and Item 3.03 of our Current Report on Form 8-K filed September 1, 2017, which are incorporated by reference herein.

Stock Performance Graph

The following graph compares the cumulative total shareholder return on our common stock with the cumulative total returns of the NASDAQ Composite Index and the Dow Jones U.S. Health Care Providers Index. The graph begins on October 1, 2015, the day our shares were initially sold to the public. The comparison assumes \$100 was invested in our common stock and in each of the indices on October 1, 2015 and assumes the reinvestment of dividends, if any.



	10/1/2015	12/31/2015	6/30/2016	12/31/2016	6/30/2017	12/31/2017
Surgery Partners, Inc.	\$ 100.00	\$ 113.14	\$ 98.84	\$ 87.52	\$ 125.62	\$ 66.81
NASDAQ Composite Index	\$ 100.00	\$ 108.22	\$ 104.66	\$ 116.34	\$ 132.71	\$ 149.20
Dow Jones U.S. Health Care Providers Index	\$ 100.00	\$ 100.34	\$ 104.84	\$ 107.40	\$ 125.66	\$ 141.60

This graph is furnished and not filed with the SEC or soliciting material under the Exchange Act and shall not be incorporated by reference into any such filings, irrespective of any general incorporation contained in such filing. The stock performance shown on the graph represents historical stock performance and is not necessarily indicative of future stock price performance.

Recent Purchases of Equity Securities by the Issuer and Affiliated Purchasers

On December 15, 2017, our Board of Directors authorized a share repurchase program of up to \$50.0 million of our issued and outstanding common stock from time to time. The timing and size of repurchases will be determined based on market conditions and other factors. The authorization does not obligate us to repurchase any shares and we may repurchase shares of common stock at any time without prior notice. The share repurchases will be made in accordance with applicable securities laws in open market or privately negotiated transactions. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice.

The following table presents information related to our repurchases of common stock for the periods indicated:

	Total Number of Shares Purchased ⁽¹⁾	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
<i>(in thousands, except share and per share amounts)</i>				
October 1, 2017 to October 31, 2017	—	\$ —	—	\$ —
November 1, 2017 to November 30, 2017	—	\$ —	—	\$ —
December 1, 2017 to December 31, 2017	194,267	\$ 11.19	180,664	\$ 47,991
Total	<u>194,267</u>		<u>180,664</u>	

⁽¹⁾ Includes shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of stock awards.

Item 6. Selected Financial Data

The table below contains selected consolidated financial and other data that has been derived from our audited consolidated financial statements for each of the years in the five year period ended December 31, 2017. The timing of acquisitions and divestitures completed during the years presented affects the comparability of the selected financial data. The following table covers periods both prior to and subsequent to the Transactions (as defined in the Explanatory Note above). As discussed in the notes to the consolidated financial statements included in this report, in connection with the change of control effected by the Private Sale, we elected to apply “pushdown” accounting. We have presented the information for the year ended December 31, 2017 on a Predecessor period and Successor period combined basis (each as defined in Note 1. "Organization" of our consolidated financial statements) to facilitate meaningful comparisons of selected consolidated financial and other data to the prior year periods. The following selected consolidated financial and other data should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and our audited consolidated financial statements and the related notes included elsewhere in this report. The results presented below are not necessarily indicative of future results (dollars in thousands, except per share amounts):

	Year Ended December 31,				
	2017	2016	2015	2014	2013
Statements of Operations Data:					
Revenues	\$ 1,341,219	\$ 1,145,438	\$ 959,891	\$ 403,289	\$ 284,599
Net income (loss)	\$ 28,736	\$ 85,083	\$ 72,845	\$ (27,052)	\$ 17,727
Less: Net income attributable to non-controlling interests	(81,721)	(75,630)	(71,416)	(38,845)	(26,789)
Net (loss) income attributable to Surgery Partners, Inc.	(52,985)	9,453	1,429	(65,897)	(9,062)
Less: Amounts attributable to participating securities ⁽¹⁾	(26,047)	—	—	—	—
Net (loss) income attributable to common stockholders	<u>\$ (79,032)</u>	<u>\$ 9,453</u>	<u>\$ 1,429</u>	<u>\$ (65,897)</u>	<u>\$ (9,062)</u>
Per common share data:					
Basic	\$ (1.64)	\$ 0.20	\$ 0.04	\$ (2.04)	\$ (0.28)
Diluted ⁽²⁾	\$ (1.64)	\$ 0.20	\$ 0.04	\$ (2.04)	\$ (0.28)
Consolidated Balance Sheets Data:					
Working capital	\$ 260,220	\$ 175,230	\$ 129,668	\$ 127,258	\$ 40,056
Total assets	4,622,773	2,304,958	2,104,443	1,855,771	470,929
Long-term debt, less current maturities	2,130,556	1,414,421	1,228,112	1,336,243	414,787
Redeemable preferred stock	330,806	—	—	—	—
Total stockholders’ equity (deficit)	1,336,610	324,674	297,927	29,536	(14,375)
Statements of Cash Flows Data:					
Net cash provided by operating activities	\$ 120,943	\$ 125,239	\$ 84,481	\$ 21,949	\$ 49,078
Net cash used in investing activities	(783,449)	(184,749)	(134,842)	(271,106)	(3,622)
Net cash provided by (used in) financing activities	767,721	71,276	33,374	310,961	(37,662)
Other Data:					
Adjusted EBITDA ⁽³⁾	\$ 164,301	\$ 179,263	\$ 158,053	\$ 77,034	\$ 57,900
Adjusted EBITDA as a % of revenues	12.3%	15.7%	16.5%	19.1%	20.3%
Number of surgical facilities as of the end of period ⁽⁴⁾	124	104	101	103	47
Number of consolidated surgical facilities included as of the end of period	108	94	90	91	47

- ⁽¹⁾ Includes accrued dividends of \$10.4 million and a mark to redemption adjustment of \$15.6 million for the Series A Preferred Stock for the year ended December 31, 2017. There were no participating securities during the 2016, 2015, 2014 and 2013 periods.
- ⁽²⁾ The impact of potentially dilutive securities for the years ended December 31, 2017, 2014 and 2013 was not considered because the effect would be anti-dilutive in each of those periods.
- ⁽³⁾ See Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Certain non-GAAP Metrics" for a table showing the reconciliation of Adjusted EBITDA to income before income taxes.
- ⁽⁴⁾ Includes surgical facilities that we manage but in which we have no ownership interest.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with Item 6. "Selected Financial Data" and our audited consolidated financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements that involve risks and uncertainties. For additional information regarding certain of the risks and uncertainties that affect our business and the industry in which we operate, please see Item 1A. "Risk Factors" and Item 9A. "Controls and Procedures" found elsewhere in this report. Unless otherwise indicated or the context otherwise requires, references herein to the "Company", "Surgery Partners", "we", "us" and "our" refer: (i) immediately prior to the Reorganization, to Surgery Center Holdings, LLC and its consolidated subsidiaries, including Surgery Center Holdings, Inc., (ii) immediately following the Reorganization but immediately prior to the consummation of the NSH Merger, to Surgery Partners, Inc. and its consolidated subsidiaries, including Surgery Center Holdings, LLC and Surgery Center Holdings, Inc., and, (iii) immediately following the consummation of the NSH Merger, to Surgery Partners, Inc. and its consolidated subsidiaries, including Surgery Center Holdings, LLC, Surgery Center Holdings, Inc. and NSH. Unless the context implies otherwise, the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc., and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc.

The following discussion and analysis of our financial condition and results of operations covers periods both prior to and subsequent to the Transactions (as defined in the Explanatory Note above). Accordingly, the discussion and analysis of historical periods do not reflect the significant impact the Transactions had. As discussed in the notes to the consolidated financial statements included in this report, in connection with the change of control effected by the Private Sale, we elected to apply "pushdown" accounting. We have presented the information for the year ended December 31, 2017 on a Predecessor period and Successor period combined basis (each as defined in Note 1. "Organization" of our consolidated financial statements) to facilitate meaningful comparisons of operating results to the prior year period. You should read the following discussion together with our historical financial statements and related notes included elsewhere herein.

Executive Overview

As of December 31, 2017, we owned and operated a national network of surgical facilities, physician practices and a suite of ancillary services in 32 states. Our surgical facilities, which include ASCs and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology ("GI"), general surgery, ophthalmology, orthopedics and pain management. Our surgical hospitals provide services, such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Our portfolio of outpatient surgical facilities is complemented by our suite of ancillary services, which support our physicians in providing high quality and cost-efficient patient care. As a result, we believe we are well positioned to benefit from rising consumerism and payors' and patients' focus on the delivery of high quality care and superior clinical outcomes in the lowest cost and care setting.

As of December 31, 2017, we owned or operated, primarily in partnership with physicians, a portfolio of 124 surgical facilities comprised of 106 ASCs and 18 surgical hospitals across 32 states. We owned a majority interest in 84 of the surgical facilities and consolidated 108 of these facilities for financial reporting purposes. During the year ended December 31, 2017, approximately 468,000 surgical procedures were performed in our surgical facilities, generating approximately \$1.3 billion in revenue.

We continue to focus on improving our same-facility performance, selectively acquiring established facilities and developing new facilities. Excluding the acquisition of NSH, during the year ended December 31, 2017, we completed acquisitions of four physician practices and one surgical facility in existing markets for an aggregate investment of \$43.6 million.

Revenues

Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our surgical facility services and ancillary services segments. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues consist of product sales from our optical laboratories, as well as the discounts and handling charges billed to the members of our optical products purchasing organization. Other service revenues also include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest and management services we provide to physician practices for which we are not required to provide capital or additional assets.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

The following table summarizes our revenues by service type as a percentage of total revenues for the periods indicated:

	Year Ended December 31,		
	2017	2016	2015
Patient service revenues:			
Surgical facilities revenues	92.7%	90.3%	91.6%
Ancillary services revenues	5.7%	7.9%	6.4%
	98.4%	98.2%	98.0%
Other service revenues:			
Optical services revenues	0.8%	1.1%	1.5%
Other	0.8%	0.7%	0.5%
	1.6%	1.8%	2.0%
Total revenues	100.0%	100.0%	100.0%

During the third quarter of 2017, we experienced lower than expected revenue and incurred certain expenses related to Hurricanes Harvey and Irma, primarily driven by electrical outages at, and temporary closures of, certain of our facilities in affected areas. All affected facilities are currently open and our operations have returned to normal. We estimate the total impact from the hurricanes during the second half of 2017 to be approximately an \$8.0 million decrease in revenue.

Additionally, in the third quarter of 2017, we incurred a one-time adjustment to revenue of \$15.6 million that was attributable to an increase in reserves for certain accounts receivables. This increase in reserves resulted from certain known events and actions during the third quarter of 2017 related to select payors primarily in our ancillary services segment. Upon consideration of such additional information, related receivables were determined to have a low likelihood of collection. The majority of this adjustment relates to receivables with balances from the first quarter of 2016 and prior. We believe we have accounted for all necessary reserve adjustments at this time.

On a normalized basis, net revenues for the year ended December 31, 2017 were \$1.4 billion. Normalized revenue is not a financial measure prepared in accordance with GAAP. The following table reconciles normalized revenues to revenues, the most directly comparable GAAP financial measure:

	Year Ended December 31, 2017
Consolidated Statements of Operations Data:	
Revenues	\$ 1,341,219
Hurricane estimated impact	8,000
Reserve adjustment	15,572
Normalized Revenues	\$ 1,364,791

Payor Mix

The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities which we consolidate for financial reporting purposes in the periods indicated:

	Year Ended December 31,		
	2017	2016	2015
Private insurance payors	53.6%	51.5%	55.0%
Government payors	38.3%	39.9%	38.2%
Self-pay payors	2.4%	1.8%	1.7%

Other payors ⁽¹⁾	5.7%	6.8%	5.1%
Total	100.0%	100.0%	100.0%

⁽¹⁾ Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.

Surgical Case Mix

We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties, including GI, general surgery, ophthalmology, orthopedics and pain management, among others. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

The following table sets forth the percentage of cases in each specialty performed at the surgical facilities which we consolidate for financial reporting purposes for the periods indicated:

	Year Ended December 31,		
	2017	2016	2015
Gastrointestinal	22.3%	22.7%	22.2%
General surgery	2.7%	2.4%	2.9%
Ophthalmology	27.9%	29.4%	30.0%
Orthopedics and pain management	34.5%	32.4%	30.5%
Other	12.6%	13.1%	14.4%
Total	100.0%	100.0%	100.0%

Case Growth

Same-facility Information

Same-facility revenues include revenues from our consolidated and non-consolidated surgical facilities (excluding facilities acquired in new markets or divested during the current and prior periods) along with the revenues from our ancillary services. The below table reflects the pro forma effect of the NSH acquisition for a full period in both the years ended December 31, 2017 and 2016, and is normalized for the impact of the hurricanes and one-time adjustments to revenue described above.

	Year Ended December 31,	
	2017	2016
Cases ⁽¹⁾	550,405	545,718
Case growth	0.9%	N/A
Revenues per case ⁽¹⁾	\$ 3,309	\$ 3,189
Revenues per case growth	3.8%	N/A
Number of facilities	—	N/A

⁽¹⁾ The table above includes normalization impact of the hurricanes and the one-time adjustment to revenue on the same-facility information of \$23.6 million in revenues and 2,828 cases for year ended December 31, 2017.

Segment Information

Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or "CODM," in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet the criteria established by GAAP.

Our financial information by reporting segment is prepared on an internal management reporting basis that the CODM uses to allocate resources and assess the performance of the operating segments. Our operating segments have been defined based on the separate financial information that is regularly produced and reviewed by our CODM, which is our Chief Executive Officer. Adjusted EBITDA is the primary profit/loss metric reviewed by the CODM in making key business decisions and on allocation of resources.

Our business is comprised of the following three reportable segments:

Surgical Facility Services Segment: Our surgical facility services segment consists of the operation of ASCs and surgical hospitals, and includes our anesthesia services. Our surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, GI, general surgery, ophthalmology, orthopedics and pain management.

Ancillary Services Segment: Our ancillary services segment consists of a diagnostic laboratory and multi-specialty physician practices. These physician practices include our owned and operated physician practices pursuant to long-term management service agreements.

Optical Services Segment: Our optical services segment consists of an optical laboratory and an optical products group purchasing organization. Our optical laboratory manufactures eyewear, while our optical products purchasing organization negotiates volume buying discounts with optical product manufacturers.

"All other" primarily consists of the Company's corporate general and administrative functions. Prior to 2017, the all other component was disaggregated and presented below the reportable operating segments in the Adjusted EBITDA table. The Company has conformed the

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

prior periods to align to the current year presentation. These changes had no effect on the Company's reportable operating segments, which are presented consistent with prior periods.

The following tables present financial information for each reportable segment (in thousands):

	Year Ended December 31,		
	2017	2016	2015
Revenues:			
Surgical facility services	\$ 1,253,183	\$ 1,042,097	\$ 884,144
Ancillary services	76,921	90,836	61,175
Optical services	11,115	12,505	14,572
Total revenues	<u>\$ 1,341,219</u>	<u>\$ 1,145,438</u>	<u>\$ 959,891</u>

	Year Ended December 31,		
	2017	2016	2015
Adjusted EBITDA:			
Surgical facility services	\$ 229,672	\$ 214,218	\$ 180,113
Ancillary services	(8,781)	12,685	18,715
Optical services	2,950	3,308	3,905
All other	(59,540)	(50,948)	(44,680)
Total Adjusted EBITDA ⁽¹⁾	<u>\$ 164,301</u>	<u>\$ 179,263</u>	<u>\$ 158,053</u>

⁽¹⁾ For a reconciliation of Adjusted EBITDA to income before income taxes as reflected in the audited consolidated statements of operations see "--Certain Non-GAAP Metrics" below.

	December 31,	December 31,
	2017	2016
Assets:		
Surgical facility services	\$ 4,072,521	\$ 1,914,842
Ancillary services	104,274	184,002
Optical services	48,309	22,478
All other	397,669	183,636
Total assets	<u>\$ 4,622,773</u>	<u>\$ 2,304,958</u>

In connection with the application of pushdown accounting we reevaluated the relative fair value of our operating segments using a measurement date of October 1, 2017. As a result of this evaluation, we reallocated goodwill as of the measurement date to each reportable segment as follows: \$3.158 billion to surgical facilities services, \$74.3 million to ancillary services and \$38.4 million to optical services.

	Year Ended December 31,		
	2017	2016	2015
Supplemental Information:			
Cash purchases of property and equipment, net:			
Surgical facility services	\$ 23,916	\$ 29,157	26,723
Ancillary services	2,066	5,388	1,051
Optical services	156	351	128
All other	3,462	4,213	5,537

Total cash purchases of property and equipment, net	\$ 29,600	\$ 39,109	\$ 33,439
---	-----------	-----------	-----------

Critical Accounting Policies

Our significant accounting policies and practices are described in Note 2 of our consolidated financial statements included elsewhere in this report. In preparing our consolidated financial statements in conformity with Generally Accepted Accounting Principles ("GAAP"), our management must make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures at the date

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

of the financial statements and the reported amounts of revenue and expenses during the reporting period. Certain accounting estimates are particularly sensitive because of their complexity and the possibility that future events affecting them may differ materially from our current judgments and estimates. Our actual results could differ from those estimates. We believe that the following critical accounting policies are important to the portrayal of our financial condition and results of operations and require our management's subjective or complex judgment because of the sensitivity of the methods, assumptions and estimates used. This listing of critical accounting policies is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP, with no need for management's judgment regarding accounting policy.

Consolidation and Control

Our consolidated financial statements include the accounts of our Company, wholly-owned or controlled subsidiaries and variable interest entities in which we are the primary beneficiary. Our controlled subsidiaries consist of wholly-owned subsidiaries and other subsidiaries that we control through our ownership of a majority voting interest or other rights granted to us by contract to function as the sole general partner or managing member of the surgical facility. The rights of limited partners or minority members at our controlled subsidiaries are generally limited to those that protect their ownership interests, including the right to approve the issuance of new ownership interests, and those that protect their financial interests, including the right to approve the acquisition or divestiture of significant assets or the incurrence of debt that either physician limited partners or minority members are required to guarantee on a pro-rata basis based upon their respective ownership, or that exceeds 20.0% of the fair market value of the related surgical facility's assets. All significant intercompany balances and transactions, including management fees from consolidated surgical facilities, are eliminated in consolidation.

As of December 31, 2017 we held less than a majority economic interest in five surgical facilities, three anesthesia practices and three physician practices over which we exercise controlling influence. Controlling influence includes financial interests, duties, rights and responsibilities for the day-to-day management of the entity. We also consider the relevant sections of the Accounting Standard Codification ("ASC") 810, *Consolidation*, to determine if we have the power to direct the activities and are the primary beneficiary of (and therefore should consolidate) any entity whose operations we do not control with voting rights. As we were the primary beneficiary, we consolidated the above 11 entities at December 31, 2017.

Revenue Recognition

Our patient service revenues are derived from surgical procedures performed at our ASCs, patient visits to physician practices, anesthesia services provided to patients, pharmacy services and diagnostic screens ordered by our physicians. The fees for such services are billed either to the patient or a third-party payor, including Medicare and Medicaid. We recognize patient service revenues, net of contractual allowances, which we estimate based on the historical trend of our cash collections and contractual write-offs.

Our optical products purchasing organization negotiates volume buying discounts with optical product manufacturers. The buying discounts and any handling charges billed to the members of the purchasing organization represent the revenues recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. Product sale revenues from our optical laboratories and marketing products and services businesses, net of an allowance for returns and discounts, is recognized when the product is shipped or service is provided to the customer. We base our estimates for sales returns and discounts on historical experience and have not experienced significant fluctuations between estimated and actual return activity and discounts given.

Other service revenues consist of management and administrative service fees derived from non-consolidated surgical facilities that we account for under the equity method, management of surgical facilities in which we do not own an interest and management services we provide to physician networks for which we are not required to provide capital or additional assets. The fees we derive from these management arrangements are based on a predetermined percentage of the revenues of each surgical facility and physician network. We recognize other service revenues in the period in which services are rendered.

Allowance for Contractual Adjustments and Doubtful Accounts

Our patient service revenues and other receivables from third-party payors are recorded net of estimated contractual adjustments and allowances from third-party payors, which we estimate based on the historical trend of our surgical facilities' cash collections and contractual write-offs, accounts receivable agings, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, we expect that any such changes would be minimal and, therefore, would not have a material effect on our financial condition or results of operations.

We estimate our allowances for doubtful accounts using similar information and analysis. While we believe that our allowances for contractual adjustments and doubtful accounts are adequate, if the actual write-offs are significantly different from our estimates, it could have a material adverse effect on our financial condition and results of operations. Because in most cases we have the ability to verify a patient's insurance coverage before services are rendered, and because we have entered into contracts with third-party payors which account for a majority of our total revenues, the out-

of-period contractual adjustments have been minimal. Our net accounts receivable reflected allowances for doubtful accounts of \$2.0 million and \$29.9 million at December 31, 2017 and December 31, 2016, respectively. The decrease is due to the application of pushdown accounting.

Our collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The operating systems used to manage our patient accounts provide for an aging schedule in 30-day increments, by payor, physician and patient. We analyze accounts receivable at each of our surgical facilities to ensure the proper collection and aged category. The operating

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients, written correspondence and the use of legal or collection agency assistance, as required. Our days sales outstanding was 61 days for the year ended December 31, 2017 and 70 days for the year ended December 31, 2016.

At a consolidated level, we review the standard aging schedule, by facility, to determine the appropriate provision for doubtful accounts by monitoring changes in our consolidated accounts receivable by aging schedule, days sales outstanding and bad debt expense as a percentage of revenues. At a consolidated level, we do not review a consolidated aging by payor. Regional and local employees review each surgical facility's aged accounts receivable by payor schedule. These employees have a closer relationship with the payors and have a more thorough understanding of the collection process for that particular surgical facility. Furthermore, this review is supported by an analysis of the actual revenues, contractual adjustments and cash collections received. If our internal collection efforts are unsuccessful, we further review patient accounts with balances of \$25 or more. We then classify the accounts based on any external collection efforts we deem appropriate. An account is written-off only after we have pursued collection with legal or collection agency assistance or otherwise deemed an account to be uncollectible. Typically, accounts will be outstanding a minimum of 120 days before being written-off.

We recognize that final reimbursement of outstanding accounts receivable is subject to final approval by each third-party payor. However, because we have contracts with our third-party payors and we verify the insurance coverage of the patient before services are rendered, the amounts that are pending approval from third-party payors are minimal. Amounts are classified outside of self-pay if we have an agreement with the third-party payor or we have verified a patient's coverage prior to services rendered. It is our policy to collect co-payments and deductibles prior to providing services. It is also our policy to verify a patient's insurance 72 hours prior to the patient's procedure. Because our services are primarily non-emergency, our surgical facilities have the ability to control these procedures. Our patient service revenues from self-pay payors as a percentage of total revenues were approximately 2% for each of the years ended December 31, 2017, 2016 and 2015.

Income Taxes and Tax Receivable Agreement

We use the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. If a net operating loss ("NOL") carryforward exists, we make a determination as to whether that NOL carryforward will be utilized in the future. A valuation allowance will be established for certain NOL carryforwards and other deferred tax assets where their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets is based upon estimates and assumptions related to our ability to generate sufficient future taxable income in certain tax jurisdictions. If these estimates and related assumptions change in the future, we will be required to adjust our deferred tax valuation allowances.

As of December 31, 2017, we had unused federal net operating loss carryforwards ("NOLs") of approximately \$507.4 million. Such losses expire in various amounts at varying times beginning in 2025. Unless they expire, these NOLs may be used to offset future taxable income and thereby reduce our income taxes otherwise payable.

We recorded a valuation allowance against our deferred tax assets at December 31, 2017 and 2016 totaling \$11.0 million and \$7.4 million, respectively, which represents an increase of \$3.6 million. The valuation allowance continues to be provided for certain deferred tax assets for which we believe it is more likely than not that the tax benefits will not be realized, which are primarily certain state net operating losses and capital loss carryforwards. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.

Section 382 ("Section 382") of the Internal Revenue Code of 1986, as amended (the "Code") imposes an annual limit on the ability of a corporation that undergoes an "ownership change" to use its NOLs to reduce its tax liability. An "ownership change" is generally defined as any change in ownership of more than 50.0% of a corporation's "stock" by its "5-percent shareholders" (as defined in Section 382) over a rolling three-year period based upon each of those shareholder's lowest percentage of stock owned during such period. As a result of the Symbion acquisition, approximately \$179 million in NOL carryforwards are subject to an annual Section 382 base limitation of \$4.9 million, and, as a result of the NovaMed acquisition, approximately \$17 million in NOL carryforwards are subject to an annual Section 382 base limitation of \$4.9 million. As a result of the NSH acquisition, approximately \$20.5 million in NOL carryforwards are subject to an annual Section 382 base limitation of \$2.8 million. The Private Sale resulted in an ownership change as defined in Section 382. As a result, approximately \$449.7 million in NOL carryforwards are subject to an annual Section 382 base limitation of \$14.2 million. At this time, we do not believe this limitation, when combined with amounts allowable due to net unrecognized built in gains, will affect our ability to use any NOLs before they expire. However, no such assurances can be provided. If our ability to utilize our NOLs to offset taxable income generated in the future is subject to this limitation, it could have an adverse effect on our business, prospects, results of operations and financial condition.

The Tax Cuts and Jobs Act (the "Act") was enacted on December 22, 2017. The Act reduces the US federal corporate tax rate from 35% to 21%, allows for 100% expensing of certain capital expenditures, and will limit interest expense deductions beginning in 2018. As of December 31, 2017, we have not completed the accounting for the tax effects of enactment of the Act; however, in certain cases, as described below, we have made a reasonable estimate of the effects on existing deferred tax balances. In other cases, we have not been able to make a reasonable estimate and continue to account for those items based on existing accounting under ASC 740, and the provisions of the tax laws

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

that were in effect immediately prior to enactment. In all cases, we will continue to make and refine our calculations as additional analysis is completed. In addition, estimates may also be affected as we gain a more thorough understanding of the tax law.

We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. However, we are still analyzing certain aspects of the Act and refining our calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The most significant component of the uncertainty relates to the state tax impact of the federal changes and how the states will or will not adopt federal changes. The effect on the Company will primarily be related to our state net operating losses and related valuation allowances. The provisional amount recorded related to the remeasurement of our deferred tax balance was \$64.0 million, which is included as a component of income tax expense from operations.

We have not made sufficient progress on the analysis of the 100% expensing that may be claimed at certain partnership entities in their 2017 income tax returns for applicable capital expenditures, and the effects that would have on our deferred tax assets and liabilities. The temporary differences related to these amounts would adjust our deferred tax assets and liabilities related to partnership differences and net operating losses, but would likely have an immaterial net effect on the overall deferred tax asset recorded in the consolidated financial statements.

Tax Receivable Agreement

On May 9, 2017, we entered into an agreement to amend our Income Tax Receivable Agreement, dated September 30, 2015 (as amended, the "TRA"), between the Company, and the other parties referred to therein, which amendment became effective on August 31, 2017. Pursuant to the amendment to the TRA, we agreed to make payments to H.I.G., our former controlling shareholder, in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus three percent. The amounts payable under the TRA are related to our projected realized tax savings over the next five years and are not dependent on our actual tax savings. Amounts payable pursuant to the TRA will be adjusted downward in the event that the maximum corporate federal income tax rate is reduced. To the extent that we are unable to make payments under the TRA and such inability is a result of the terms of credit agreements and other debt documents that are materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 500 basis points until paid. If the terms of such credit agreements and other debt documents cause us to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid.

As a result of the amendment to the TRA, we were required to value the liability under the TRA by discounting the fixed payment schedule using our incremental borrowing rate. During the year ended December 31, 2017, we recognized a reduction in the carrying value of the TRA liability of \$43.9 million, with \$15.3 million of the reduction recorded to a gain on amendment to the TRA and \$28.6 million recorded as a reduction to the goodwill recorded in connection with the application of pushdown accounting related to the change of control (discussed in Note 1. "Organization" of our consolidated financial statements included elsewhere in this report).

As a result of the reduction in the corporate tax rate from the Tax Cuts and Jobs Act discussed above, we remeasured the value of the liability under the TRA pursuant to the calculation terms as described above. During the year ended December 31, 2017, we recognized a further reduction in the carrying value of the liability under the TRA of \$25.3 million, included as a tax receivable agreement benefit in the consolidated statement of operations. Assuming our tax rate is 24%, calculated as the maximum corporate federal tax rate plus three percent, throughout the remaining term of the TRA, we estimate the total remaining amounts payable under the TRA as of December 31, 2017 will be approximately \$65.1 million. The carrying value of the liability under the TRA, reflecting the discount as discussed above, was \$44.3 million as of December 31, 2017.

Prior to the remeasurement at the lower corporate tax rate, but subsequent to the effectiveness of the amendment discussed above, we estimated that the total amounts payable under the TRA would be approximately \$120.5 million. Prior to the effectiveness of the amendment to the TRA, the amounts payable under the TRA varied depending upon a number of factors, including the amount, character and timing of our taxable income. We estimated the total amounts payable would be approximately \$123.4 million, if the tax benefits of related deferred tax assets were ultimately realized. The amounts payable were recognized during 2015 in conjunction with the release of the valuation allowance recorded against the deferred tax assets.

On September 8, 2017, in connection with the resignation of our former Chief Executive Officer, Michael Doyle, Mr. Doyle entered into a TRA Waiver and Assignment Agreement (the "CEO TRA Assignment Agreement") with the Company, pursuant to which we accepted the assignment of 50% of Mr. Doyle's (and his affiliates') interest in future payments to which such parties were entitled pursuant to the TRA, in exchange for an upfront payment of approximately \$5.1 million, in the aggregate, as set forth in the CEO TRA Assignment Agreement. On September 15, 2017, certain of our employees entered into TRA Waiver and Assignment Agreements with the Company (collectively, the "Employee TRA Assignment Agreements" and together with the CEO TRA Assignment Agreement, the "TRA Assignment Agreements"), pursuant to which we made upfront payments of approximately \$4.8 million in the aggregate, in exchange for the assignment of 100% of each such employee's interest in future payments to which such employee was entitled pursuant to the TRA. During the year ended December 31, 2017, we recognized an aggregate gain of \$1.1 million as a result of the TRA Assignment Agreements.

Impairment of Long-Lived Assets, Goodwill and Intangible Assets

We evaluate the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. We perform an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value. The cash flow

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

projection and fair value represents management's best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation. No impairment losses on long-lived assets were recognized during the years ended December 31, 2017, 2016 and 2015.

We test goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. We test for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. We have identified five reporting units, which include the following: 1) Surgical Facilities 2) Ancillary Services, 3) Midwest Labs, 4) The Alliance, including Optical Synergies and 5) Family Vision Care. We compare the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. If the carrying value exceeds the estimated fair value, an impairment indicator exists and an estimate of the possible impairment loss is calculated. The fair value of the reporting units are estimated using a discounted cash flows approach and are corroborated using a market-based approach. The fair value calculation includes multiple assumptions and estimates, including the projected cash flows and discount rates applied.

In connection with the implementation of pushdown accounting, we performed our goodwill impairment test as of August 31, 2017, then re-evaluated for impairment at October 1, 2017. Both evaluations resulted in no impairment.

Off-Balance Sheet Arrangements

From time to time, we guarantee our pro-rata share of the third-party debts and other obligations of many of the non-consolidated partnerships and limited liability companies in which we own an interest. In most instances of these guarantees, the physicians and/or physician groups have also guaranteed their pro-rata share of the indebtedness to secure the financing. At December 31, 2017, we did not guarantee any debt of our non-consolidated surgical facilities.

Equity-Based Compensation

Transactions in which the Company receives employee and non-employee services in exchange for the Company's equity instruments or liabilities that are based on the fair value of the Company's equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The fair value of future stock options awarded will be based on the quoted market price of our common stock upon grant, as well as assumptions including expected stock price volatility, risk-free interest rate, expected dividends, and expected term.

Our policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. Our equity-based compensation expense can vary in the future depending on many factors, including levels of forfeitures and whether performance targets are met and whether a liquidity event occurs. In connection with the Reorganization, our board of directors and stockholders adopted the Surgery Partners, Inc. 2015 Omnibus Incentive Plan from which our future equity-based awards will be granted.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

Results of Operations

The following tables summarize certain results from the statements of operations for the years ended December 31, 2017, 2016 and 2015. The tables also show the percentage relationship to revenues for the periods indicated (dollars in thousands):

	Year Ended December 31,					
	2017		2016		2015	
	Amount	% of Revenues	Amount	% of Revenues	Amount	% of Revenues
Revenues	\$ 1,341,219	100.0 %	\$ 1,145,438	100.0 %	\$ 959,891	100.0 %
Operating expenses:						
Cost of revenues	1,013,800	75.6 %	821,196	71.7 %	669,326	69.7 %
General and administrative expenses ⁽¹⁾	75,950	5.7 %	60,246	5.3 %	55,992	5.8 %
Depreciation and amortization	51,928	3.9 %	39,551	3.5 %	34,545	3.6 %
Provision for doubtful accounts	28,752	2.1 %	24,212	2.1 %	23,578	2.5 %
Income from equity investments	(6,467)	(0.5)%	(4,764)	(0.4)%	(3,777)	(0.4)%
Loss (gain) on disposal or impairment of long-lived assets, net	1,720	0.1 %	2,355	0.2 %	(2,097)	(0.2)%
Merger transaction and integration costs	13,054	1.0 %	8,738	0.8 %	17,920	1.9 %
Loss on debt refinancing	18,211	1.4 %	11,876	1.0 %	16,102	1.7 %
Gain on litigation settlements	(12,534)	(0.9)%	(14,101)	(1.2)%	—	— %
Gain on acquisition escrow release	(1,167)	(0.1)%	—	— %	—	— %
Termination of management agreement and IPO costs	—	— %	—	— %	5,834	0.6 %
Electronic health records incentive income	(260)	— %	(408)	— %	(1,761)	(0.2)%
Other (income) expense	(2)	— %	55	— %	(525)	(0.1)%
Total operating expenses	1,182,985	88.2 %	948,956	82.8 %	815,137	84.9 %
Operating income	158,234	11.8 %	196,482	17.2 %	144,754	15.1 %
Gain on amendment to tax receivable agreement	16,392	1.2 %	—	— %	—	— %
Tax receivable agreement benefit (expense)	25,329	1.9 %	(3,733)	(0.3)%	(119,911)	(12.5)%
Interest expense, net	(117,669)	(8.8)%	(100,571)	(8.8)%	(100,980)	(10.5)%
Income (loss) before income taxes	82,286	6.1 %	92,178	8.0 %	(76,137)	(7.9)%
Income tax expense (benefit)	53,550	4.0 %	7,095	0.6 %	(148,982)	(15.5)%
Net income	28,736	2.1 %	85,083	7.4 %	72,845	7.6 %
Less: Net income attributable to non-controlling interests	(81,721)	(6.1)%	(75,630)	(6.6)%	(71,416)	(7.4)%
Net (loss) income attributable to Surgery Partners, Inc.	\$ (52,985)	(4.0)%	\$ 9,453	0.8 %	\$ 1,429	0.1 %

⁽¹⁾ Includes contingent acquisition compensation expense of \$7.0 million and \$5.1 million for the years ended December 31, 2017 and 2016, respectively.

Year Ended December 31, 2017 Compared to Year Ended December 31, 2016

Overview. During the year ended December 31, 2017, our revenues increased 17.1% to \$1.3 billion from \$1.1 billion for the year ended December 31, 2016. We incurred net loss attributable to Surgery Partners, Inc. for the 2017 period of \$53.0 million, compared to income of \$9.5 million for the 2016 period.

Revenues. Revenues for the year ended December 31, 2017 compared to the year ended December 31, 2016 were as follows (dollars in thousands):

Year Ended December 31,

	2017	2016	Dollar Variance	Percent Variance
Patient service revenues	\$ 1,320,211	\$ 1,124,604	\$ 195,607	17.4 %
Optical service revenues	11,115	12,505	(1,390)	(11.1)%
Other service revenues	9,893	8,329	1,564	18.8 %
Total revenues	<u>\$ 1,341,219</u>	<u>\$ 1,145,438</u>	<u>\$ 195,781</u>	17.1 %

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

Patient service revenues increased 17.4% to \$1.3 billion for the year ended December 31, 2017 compared to \$1.1 billion for the year ended December 31, 2016. This increase in patient service revenues was primarily attributable to the acquisition of NSH, which contributed \$202.6 million, during the four months of 2017 that was included in our operations. Excluding the impact of NSH, our patient service revenues decreased \$8.4 million or 0.7%, primarily due to the impact of the hurricanes and the one-time reserve adjustment as discussed previously under the heading "Revenues".

Cost of Revenues. Cost of revenues increased to \$1.0 billion for the year ended December 31, 2017 compared to \$821.2 million for the year ended December 31, 2016 primarily attributable to our 2017 and 2016 acquisitions. As a percentage of revenues, cost of revenues were 75.6% for the 2017 period and 71.7% for the 2016 period. The increase includes \$148.6 million related to the acquisition of NSH and their inclusion in our operations for four months of 2017. Excluding the impact of NSH, cost of revenues increased \$44.0 million primarily due to an increase in supply costs due to a higher acuity case mix.

General and Administrative Expenses. General and administrative expenses increased to \$76.0 million for the year ended December 31, 2017 compared to \$60.2 million for the year ended December 31, 2016. As a percentage of revenues, general and administrative expenses were 5.7% for the 2017 period compared to 5.3% for the 2016 period. General and administrative expenses as a percentage of revenues adjusted for contingent acquisition compensation expense and stock compensation expense would be 4.7% for the 2017 period and 4.6% for the 2016 period. This increase includes \$3.9 million attributable to the acquisition of NSH, which was included in our operations for four months of 2017. Excluding the impact of NSH, general and administrative expenses increased \$11.9 million. This includes an increase of \$3.6 million in equity-based compensation expense, \$2.1 million in rent expense for a period of overlap for the new corporate office building and the remaining term of our prior corporate office building and \$1.9 million of contingent acquisition compensation expense. The remaining increase is attributable to overall growth of the business.

Depreciation and Amortization. Depreciation and amortization increased to \$51.9 million for the year ended December 31, 2017 compared to \$39.6 million for the year ended December 31, 2016. As a percentage of revenues, depreciation and amortization expenses were 3.9% for the 2017 period and 3.5% for the 2016 period. The increase includes \$9.4 million attributable to the acquisition of NSH. Excluding the impact of NSH, depreciation and amortization increased \$2.9 million, primarily due to the remeasurement of assets at fair value in connection with the application of pushdown accounting.

Provision for Doubtful Accounts. The provision for doubtful accounts increased to \$28.8 million for the year ended December 31, 2017 compared to \$24.2 million for the year ended December 31, 2016. As a percentage of revenues, the provision for doubtful accounts was 2.1% for the 2017 period and 2.1% for the 2016 period. The increase includes \$5.8 million attributable to the acquisition of NSH. Excluding the impact of NSH, the provision for doubtful accounts decreased \$1.2 million as a result of favorable collection efforts.

Income from Equity Investments. Income from equity investments was \$6.5 million for the year ended December 31, 2017 compared to \$4.8 million for the year ended December 31, 2016. The increase includes \$1.3 million attributable to the acquisition of NSH which added four equity method investment entities to our structure. Excluding the impact of NSH, income from equity investments increased \$0.4 million.

Loss (Gain) on Disposal or Impairment of Long-Lived Assets, Net. The net loss on disposal of long-lived assets was \$1.7 million for the year ended December 31, 2017 compared to a net loss of \$2.4 million for the year ended December 31, 2016.

Merger Transaction and Integration Costs. We incurred \$13.1 million of merger transaction and integration costs for the year ended December 31, 2017 compared to \$8.7 million for the year ended December 31, 2016. The increase relates to the Transaction and the acquisition of NSH on August 31, 2017.

Loss on Debt Refinancing. We incurred \$18.2 million as a loss on debt refinancing for the year ended December 31, 2017 compared to \$11.9 million for the year ended December 31, 2016. The 2017 loss includes the partial write-off of unamortized debt issuance costs and discount related to the prepayment of the 2014 Revolver Loan and 2014 First Lien Credit Agreement and a portion of costs incurred with entering into the 2017 Senior Secured Credit Facilities.

Gain on Litigation Settlement. We recorded a gain of \$12.5 million year ended December 31, 2017 compared to \$14.1 million for the year ended December 31, 2016. These items related to a legal settlements for the year in which the settlements were reached.

Operating Income. Our operating income margin for the year ended December 31, 2017 decreased to 11.8% from 17.2% during the year ended December 31, 2016. During the year ended December 31, 2017, we recorded \$13.1 million of merger transaction and integration costs primarily related to the Transactions and acquisition of NSH, a loss on debt extinguishment of \$18.2 million, a gain on litigation settlement of \$12.5 million, contingent acquisition compensation expense of \$7.0 million and a loss on disposal of long-lived assets of \$1.7 million. Further, the 2017 period included the impact of hurricanes Irma and Harvey and the impact associated with an increase in reserves for certain accounts receivables, the combination of these items resulted in a one time reduction to operating income of \$23.2 million. Excluding the impact of these items, our operating income margin was 15.6% for the year ended December 31, 2017.

During the year ended December 31, 2016, we recorded \$8.7 million of merger transaction and integration costs related to acquisitions, a loss on debt refinancing of \$11.9 million, a gain on litigation settlement of \$14.1 million and a loss on disposal of long-lived assets of \$2.4 million. Excluding the impact of these items, our operating income margin was 18.5% for the year ended December 31, 2016. The decline was primarily related to an a greater number of higher acuity cases resulting in an increase in supply costs with lower reimbursement rates.

Gain on amendment to tax receivable agreement. During the year ended December 31, 2017, we recognized a tax receivable agreement gain of \$16.4 million. We recognized this gain as a result of the amendment of the TRA and the TRA Assignment Agreements.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

Tax Receivable Agreement Benefit (Expense). We incurred tax receivable agreement benefit of \$25.3 million for the year ended December 31, 2017 compared to expense of \$3.7 million for the year ended December 31, 2016. The 2017 benefit was related to a reduction in the corporate tax rate from the Tax Cuts and Jobs Act. The 2016 expense was recorded to update the initial estimated liability for the filed tax returns and final 2015 tax losses that are included in the amounts payable under the TRA.

Interest Expense, Net. Interest expense, net, increased to \$117.7 million for the year ended December 31, 2017 compared to \$100.6 million for the year ended December 31, 2016. The increase primarily relates to the issuance of our \$370 million Senior Unsecured Notes on June 30, 2017 due 2025 and the refinancing of our Senior Secured Credit Facility as of August 31, 2017.

Income Tax Expense (Benefit). The income tax expense was \$53.6 million for the year ended December 31, 2017 compared to an expense of \$7.1 million for the year ended December 31, 2016. The effective tax rate was 65.1% for the year ended December 31, 2017 compared to 7.7% for the year ended December 31, 2016. The change in effective tax rate was primarily attributable to the remeasurement of our deferred tax assets and liabilities due to the enactment of the 2017 Tax Cuts and Jobs Act.

Net Income Attributable to Non-Controlling Interests. Net income attributable to non-controlling interests increased to \$81.7 million for the year ended December 31, 2017 compared to \$75.6 million for the year ended December 31, 2016. As a percentage of revenues, net income attributable to non-controlling interests was 6.1% in the 2017 period and 6.6% for the 2016 period. The increase includes \$16.0 million attributable to the acquisition of NSH. Excluding the impact of NSH, net income attributable to non-controlling interests decreased \$9.9 million, primarily due to a decrease in operating income.

Year Ended December 31, 2016 Compared to Year Ended December 31, 2015

Overview. During the year ended December 31, 2016, our revenues increased 19.3% to \$1.1 billion from \$959.9 million for the year ended December 31, 2015. We incurred net income attributable to Surgery Partners, Inc. for the 2016 period of \$9.5 million, compared to \$1.4 million for the 2015 period.

Revenues. Revenues for the year ended December 31, 2016 compared to the year ended December 31, 2015 were as follows (dollars in thousands):

	<u>Year Ended December 31,</u>		<u>Dollar</u> <u>Variance</u>	<u>Percent</u> <u>Variance</u>
	<u>2016</u>	<u>2015</u>		
Patient service revenues	\$ 1,124,604	\$ 940,711	\$ 183,893	19.5 %
Optical service revenues	12,505	14,572	(2,067)	(14.2)%
Other service revenues	8,329	4,608	3,721	80.8 %
Total revenues	<u>\$ 1,145,438</u>	<u>\$ 959,891</u>	<u>\$ 185,547</u>	19.3 %

Patient service revenues increased 19.5% to \$1.1 billion for the year ended December 31, 2016 compared to \$940.7 million for the year ended December 31, 2015. This increase in patient service revenues was primarily attributable to the integration of our 2016 and 2015 acquisitions.

Cost of Revenues. Cost of revenues increased to \$821.2 million for the year ended December 31, 2016 compared to \$669.3 million for the year ended December 31, 2015 primarily attributable to our 2016 and 2015 acquisitions. As a percentage of revenues, cost of revenues were 71.7% for the 2016 period and 69.7% for the 2015 period.

General and Administrative Expenses. General and administrative expenses increased to \$60.2 million for the year ended December 31, 2016 compared to \$56.0 million for the year ended December 31, 2015. The 2016 period includes contingent acquisition compensation expense of \$5.1 million. As a percentage of revenues, general and administrative expenses were 5.3% for the 2016 period compared to 5.8% for the 2015 period. General and administrative expenses as a percentage of revenues adjusted for contingent acquisition compensation expense and stock compensation expense would be 4.6% for the 2016 period and 5.1% for the 2015 period.

Depreciation and Amortization. Depreciation and amortization increased to \$39.6 million for the year ended December 31, 2016 compared to \$34.5 million for the year ended December 31, 2015. As a percentage of revenues, depreciation and amortization expenses were 3.5% for the 2016 period and 3.6% for the 2015 period.

Provision for Doubtful Accounts. The provision for doubtful accounts increased to \$24.2 million for the year ended December 31, 2016 compared to \$23.6 million for the year ended December 31, 2015. As a percentage of revenues, the provision for doubtful accounts was 2.1% for the 2016 period and 2.5% for the 2015 period.

Income from Equity Investments. Income from equity investments was \$4.8 million for the year ended December 31, 2016 compared to \$3.8 million for the year ended December 31, 2015.

Loss (Gain) on Disposal or Impairment of Long-Lived Assets, Net. The net loss on disposal of long-lived assets was \$2.4 million for the year ended December 31, 2016 compared to a net gain of \$2.1 million for the year ended December 31, 2015. This difference is primarily

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

attributable to a gain on the sale of interests in a surgical facility in 2015 compared to a loss related to the disposition of equipment and leasehold improvements for 2016.

Merger Transaction and Integration Costs. We incurred \$8.7 million of merger transaction and integration costs for the year ended December 31, 2016 compared to \$17.9 million for the year ended December 31, 2015, related to the Merger and other acquisitions.

Loss on Debt Refinancing. We incurred \$11.9 million as a loss on debt refinancing for the year ended December 31, 2016 compared to \$16.1 million for the year ended December 31, 2015, related to the amendment of the 2014 First Lien, the paydown of the 2014 Second Lien, defined herein, and the write-off of the related debt issuance costs and discount in addition to a prepayment penalty in 2016 and the paydown of the Second Lien during 2015.

Gain on Litigation Settlement. We recorded a gain of \$14.1 million related to a legal settlement for the year ended December 31, 2016, the year in which the settlement was reached.

Electronic Health Records Incentives Income. Income from electronic health records incentives was \$0.4 million for the year ended December 31, 2016 compared to \$1.8 million for the year ended December 31, 2015.

Operating Income. Our operating income margin for the year ended December 31, 2016 increased to 17.2% from 15.1% during the year ended December 31, 2015. During the year ended December 31, 2016, we recorded \$8.7 million of merger transaction and integration costs related to the Merger and other acquisitions, a loss on debt extinguishment of \$11.9 million, a gain on litigation settlement of \$14.1 million, contingent acquisition compensation expense of \$5.1 million and a loss on disposal of long-lived assets of \$2.4 million. Excluding the impact of these items, our operating income margin was 18.4% for the year ended December 31, 2016.

During the year ended December 31, 2015, we recorded \$17.9 million of merger transaction and integration costs related to the Merger, a loss on debt extinguishment of \$16.1 million, IPO equity-based compensation expense of \$6.2 million, termination of management agreement and IPO costs of \$5.8 million and a gain on disposal of long-lived assets of \$2.1 million. Excluding the impact of these items, our operating income margin was 19.7% for the year ended December 31, 2015. The decrease in the operating income margin period over period is primarily related to the effects of the laboratory rate reductions from CMS, which accounted for approximately 0.9% of the decrease.

Tax Receivable Agreement Expense. We incurred tax receivable agreement expense of \$3.7 million for the year ended December 31, 2016 compared to \$119.9 million for the year ended December 31, 2015. The 2016 expense was recorded to update the initial estimated liability for the filed tax returns and final 2015 tax losses that are included in the amounts payable under the TRA.

Interest Expense, Net. Interest expense, net, decreased to \$100.6 million for the year ended December 31, 2016 compared to \$101.0 million for the year ended December 31, 2015.

Income Tax Expense (Benefit). The income tax expense was \$7.1 million for the year ended December 31, 2016 compared to a benefit of \$149.0 million for the year ended December 31, 2015. The effective tax rate was 7.7% for the year ended December 31, 2016 compared to 195.7% for the year ended December 31, 2015. The change in effective tax rate was primarily attributable to the tax-effect of the release of the valuation allowance during the year ended December 31, 2015. After considering the income attributable to noncontrolling interests, our tax rate was approximately 42.9% for the year ended December 31, 2016 compared to 101.0% for the year ended December 31, 2015.

Net Income Attributable to Non-Controlling Interests. Net income attributable to non-controlling interests increased to \$75.6 million for the year ended December 31, 2016 compared to \$71.4 million for the year ended December 31, 2015. As a percentage of revenues, net income attributable to non-controlling interests was 6.6% in the 2016 period and 7.4% for the 2015 period.

Liquidity and Capital Resources

Operating Activities

The primary source of our operating cash flow is the collection of accounts receivable from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and individuals. During the year ended December 31, 2017, our cash flow provided by operating activities decreased to \$120.9 million compared to \$125.2 million in the year ended December 31, 2016. This decrease was primarily related to the decline in performance of our ancillary business. At December 31, 2017, we had working capital of \$260.2 million compared to \$175.2 million at December 31, 2016.

During the year ended December 31, 2016, our cash flow provided by operating activities increased to \$125.2 million compared to \$84.5 million in the year ended December 31, 2015. This increase was primarily related to the growth from acquisition activity occurring subsequent to the 2015 period. At December 31, 2016, we had working capital of \$175.2 million compared to \$129.7 million at December 31, 2015.

Investing Activities

Net cash used in investing activities during the year ended December 31, 2017 was \$783.4 million, which included \$29.6 million related to purchases of property and equipment. Additionally, we paid \$755.1 million in cash for acquisitions (net of cash acquired), of which \$711.7 million related to the purchase of NSH. The remaining amount included the acquisitions of four physician practices and one surgical facility. Further, we received \$1.3 million in proceeds for the sale of our interests in a surgical facility.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

Net cash used in investing activities during the year ended December 31, 2016 was \$184.7 million, which included \$39.1 million related to purchases of property and equipment, including \$4.9 million related to the relocation of our hospital in Great Falls, Montana. Additionally, we paid \$146.4 million in cash for acquisitions (net of cash acquired), of which \$129.8 million, excluding the \$16.6 million of contingent acquisition consideration, related to the purchase of six surgical facilities, one of which was merged with an existing facility, three anesthesia practices, eleven physician practices, a lab and a pharmacy. The remaining amount included an additional payment of \$16.6 million to fund the final escrow payment related to the Merger. Further, we received \$0.8 million in proceeds for the sale of our interests in a surgical facility.

Net cash used in investing activities during the year ended December 31, 2015 was \$134.8 million, which included \$33.4 million related to purchases of property and equipment. Additionally, we purchased five surgical facilities, thirteen physician practices, four anesthesia practices and an urgent care facility for an aggregate purchase price of \$112.6 million (net of cash acquired). We received \$11.2 million in aggregate proceeds for the sale of our interests in three surgical facilities.

Financing Activities

Net cash provided by financing activities during the year ended December 31, 2017 was \$767.7 million. During this period, we made distributions to non-controlling interest holders of \$83.8 million and payments related to ownership transactions with consolidated affiliates of \$0.5 million. Further, we made repayments on our long-term debt of \$1.2 billion offset by borrowings of \$1.8 billion. Our repayments and borrowings include \$132.5 million in draws and \$217.5 million in repayments on our Revolver during the period. In addition, we made payments of debt issuance costs of \$58.6 million and received proceeds on the issuance of preferred stock of \$291.7 million, net of issuance costs, and repurchased \$2.0 million of our common stock pursuant to our \$50 million repurchase program announced on December 15, 2017.

Net cash provided by financing activities during the year ended December 31, 2016 was \$71.3 million. During this period, we made distributions to non-controlling interest holders of \$65.8 million and payments related to ownership transactions with consolidated affiliates of \$20.1 million. Further, we made repayments on our long-term debt of \$473.4 million offset by borrowings of \$650.7 million. Our repayments and borrowings include \$156.5 million draw down and subsequent repayments of \$196.8 million on our Revolver during the period. In addition, we made payments of debt issuance costs of \$14.3 million and a penalty on the prepayment of debt of \$4.9 million during the period.

Net cash provided by financing activities during the year ended December 31, 2015 was \$33.4 million. During this period, we received proceeds from our initial public offering, net of offering costs, of \$251.0 million, made distributions to non-controlling interest holders of \$69.7 million and payments related to ownership transactions with consolidated affiliates of \$12.2 million. We made repayments on our long-term debt of \$328.3 million. These were offset by cash inflows from debt borrowings of \$196.4 million.

Long-Term Debt

A summary of long-term debt follows (in thousands):

	December 31, 2017	December 31, 2016
2014 Revolver Loan	\$ —	\$ 85,000
2014 First Lien Credit Agreement	—	932,000
2017 Senior Secured Credit Facilities:		
Revolver	—	—
Term Loan ⁽¹⁾	1,280,532	—
Senior Unsecured Notes due 2021 ⁽²⁾	409,235	400,000
Senior Unsecured Notes due 2025	370,000	—
Subordinated Notes	—	1,000
Notes payable and secured loans	101,921	42,521
Capital lease obligations	27,594	13,996
Less: unamortized debt issuance costs and discount	—	(32,274)
Total debt	2,189,282	1,442,243
Less: Current maturities	58,726	27,822

Total long-term debt

\$	2,130,556	\$	1,414,421
----	-----------	----	-----------

⁽¹⁾ Includes unamortized fair value discount of \$6.2 million as of December 31, 2017. See further discussion below.

⁽²⁾ Includes unamortized fair value premium of \$9.2 million as of December 31, 2017. See further discussion below.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

2014 Revolver Loan & 2014 First Lien Credit Agreement

On August 31, 2017, we prepaid in full the outstanding principal of the 2014 Revolver Loan, a revolving credit facility entered into on November 3, 2014, and the 2014 First Lien Credit Agreement, a senior secured obligation of Surgery Center Holdings, Inc. entered into on November 3, 2014, with the proceeds from the 2017 Senior Secured Credit Facilities (as defined below). The total prepayment amount was \$1.030 billion, which included \$1.027 billion of outstanding principal and \$3.0 million of accrued and unpaid interest, other fees and expenses. In connection with the prepayment, we recorded a debt extinguishment loss of \$18.2 million, included in the loss on debt refinancing for the year ended December 31, 2017. The loss includes the partial write-off of unamortized debt issuance costs and discount related to the 2014 Revolver Loan and 2014 First Lien Credit Agreement and a portion of costs incurred with the 2017 Senior Secured Credit Facilities.

In September 2016, in connection with an amendment to the 2014 First Lien Credit Agreement, we recorded a loss on debt refinancing of \$3.6 million for the year ended December 31, 2016.

2014 Second Lien Credit Agreement

The 2014 Second Lien Credit Agreement, entered into on November 3, 2014, was a senior secured obligation of Surgery Center Holdings, Inc. In October 2015, we partially prepaid the outstanding principal of the 2014 Second Lien Credit Agreement, resulting in a debt extinguishment loss of \$16.1 million, included in the loss on debt refinancing for the year ended December 31, 2015. In March 2016, we prepaid in full the remaining outstanding principal of the 2014 Second Lien Credit Agreement, plus accrued and unpaid interest, with the proceeds of the issuance of the 2021 Unsecured Notes, defined below, resulting in a debt extinguishment loss of \$8.3 million, included in the loss on debt refinancing for the year ended December 31, 2016.

2017 Senior Secured Credit Facilities

On August 31, 2017, certain of our wholly owned subsidiaries entered into a credit agreement (the "Credit Agreement") providing for a \$1.290 billion senior secured term loan (the "Term Loan") and a \$75.0 million revolving credit facility (the "Revolver" and, together with the Term Loan, the "2017 Senior Secured Credit Facilities").

The Term Loan was fully drawn on August 31, 2017 and the proceeds thereof were used to finance the consideration paid in the NSH Merger, to repay amounts outstanding under our then-existing 2014 First Lien Credit Agreement and 2014 Revolver Loan and amounts outstanding under the existing senior secured credit facilities of NSH, and to pay fees and expenses in connection with the foregoing and transactions related to the Transaction Agreements. The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the Credit Agreement, we may request one or more additional incremental term loan facilities or one or more increases in the commitments under the Revolver. As of December 31, 2017, our availability on the Revolver was \$71.9 million (including outstanding letters of credit of \$3.1 million).

The Term Loan matures on August 31, 2024 (or, if at least 50.0% of the 2021 Unsecured Notes (as defined below) shall have not either been repaid or refinanced with permitted indebtedness having a maturity date not earlier than six months after the maturity date of the Term Loan by no later than October 15, 2020, then October 15, 2020). The Revolver will mature on August 31, 2022 (or, if at least 50.0% of the 2021 Notes have not either been repaid or refinanced with permitted indebtedness having a maturity date not earlier than six months after the maturity date of the Term Loan by no later than October 15, 2020, then October 15, 2020).

The 2017 Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from 3.00% to 3.25% per annum, depending on our first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, we are required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver.

The Term Loan amortizes in equal quarterly installments of 0.25% of the aggregate original principal amount of the Term Loan (such amortization payments commenced in December 2017). The Term Loan is subject to mandatory prepayments based on excess cash flow for the applicable fiscal year that will depend on the first lien net leverage ratio as of the last day of the applicable fiscal year, as well as upon the occurrence of certain other events, as described in the Credit Agreement. There were no excess cash flow payments required as of December 31, 2017.

With respect to the Revolver, we are required to comply with a maximum consolidated total net leverage ratio of 9.50:1.00, which covenant is tested quarterly on a trailing four quarter basis only if, as of the last day of the applicable fiscal quarter the Revolver is drawn in an aggregate amount greater than 35% of the total commitments under the Revolver. Such financial maintenance covenant is subject to an equity cure. The Credit Agreement includes customary negative covenants restricting or limiting the ability of the Company and our restricted subsidiaries, to, among other things, sell assets, alter our business, engage in mergers, acquisitions and other business combinations, declare dividends or redeem or repurchase equity interests, incur additional indebtedness or guarantees, make loans and investments, incur liens, enter into transactions with affiliates, prepay certain junior debt,

and modify or waive certain material agreements and organizational documents, in each case, subject to customary and other agreed upon exceptions. The Credit Agreement also contains customary affirmative covenants and events of default. As of December 31, 2017, we were in compliance with the covenants contained in the Credit Agreement.

The 2017 Senior Secured Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors")

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors' assets (subject to certain exceptions).

In connection with the Term Loan and Revolver, we incurred debt issuance costs and discount of \$18.8 million and \$9.4 million, respectively, which were eliminated with the application of pushdown accounting.

In connection with the application of pushdown accounting, we remeasured and recorded the Term Loan at fair value using a measurement date of August 31, 2017. The fair value was based on a Level 2 computation using quoted prices for identical liabilities in inactive markets. As a result, we recorded a fair value discount of \$6.5 million as of the measurement date, which is reported in the consolidated balance sheets as a direct deduction from the face amount the Term Loan. We amortize the fair value discount to interest expense over the life of the Term Loan.

Senior Unsecured Notes due 2021

On March 31, 2016, Surgery Center Holdings, Inc., our wholly owned subsidiary, issued \$400.0 million in gross proceeds of senior unsecured notes due April 15, 2021 (the "2021 Unsecured Notes"). The 2021 Unsecured Notes bear interest at the rate of 8.875% per year, payable semi-annually on April 15 and October 15 of each year. The 2021 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly owned restricted subsidiaries that guarantees the 2017 Senior Secured Credit Facilities (subject to certain exceptions).

We may redeem up to 35% of the aggregate principal amount of the 2021 Unsecured Notes, at any time before April 15, 2018, with the net cash proceeds of certain equity offerings at a redemption price equal to 108.875% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption, provided that at least 50% of the aggregate principal amount of the 2021 Unsecured Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

We may redeem the 2021 Unsecured Notes, in whole or in part, at any time prior to April 15, 2018 at a price equal to 100.000% of the principal amount to be redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. We may redeem the 2021 Unsecured Notes, in whole or in part, at any time on or after April 15, 2018, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, to the date of redemption:

April 15, 2018 to April 14, 2019	106.656%
April 15, 2019 to April 14, 2020	104.438%
April 15, 2020 and thereafter	100.000%

If Surgery Center Holdings, Inc., experiences a change in control under certain circumstances, we must offer to purchase the notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase. The change of control as discussed in Note 1. "Organization", did not trigger repurchase.

The 2021 Unsecured Notes contain customary affirmative and negative covenants, which among other things, limit our ability to incur additional debt, pay dividends, create or assume liens, effect transactions with affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.

In connection with the offering of the 2021 Unsecured Notes, we incurred debt issuance costs of \$8.4 million in the Predecessor period, which were eliminated with the application of pushdown accounting.

In connection with the application of pushdown accounting, we remeasured and recorded the 2021 Unsecured Notes at fair value using a measurement date of August 31, 2017. The fair value was based on a Level 2 computation using quoted prices for identical liabilities in inactive markets. As a result, we recorded a fair value premium of \$10.0 million as of the measurement date, which is reported in the consolidated balance sheets as a direct addition to the face amount the notes. We amortize the fair value premium to interest expense over the life of the 2021 Unsecured Notes.

Senior Unsecured Notes due 2025

On June 30, 2017, SP Finco, LLC, our wholly owned indirect subsidiary, issued \$370.0 million in gross proceeds of senior unsecured notes due July 1, 2025 (the "2025 Unsecured Notes"). In connection with the closing of the NSH Merger, Surgery Center Holdings Inc. assumed the obligations of SP Finco, LLC. As of such time, the 2025 Unsecured Notes became guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s domestic wholly owned restricted subsidiaries that guarantees Surgery Center Holdings, Inc.'s senior secured credit facilities (subject to certain

exceptions). The 2025 Unsecured Notes bear interest at the rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year, commencing on January 1, 2018.

We may redeem up to 40% of the aggregate principal amount of the 2025 Unsecured Notes at any time prior to July 1, 2020, with the net cash proceeds of certain equity issuances at a redemption price equal to 106.750% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption, provided that at least 50% of the aggregate principal amount of the 2025 Unsecured

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of the applicable equity offering.

We may redeem the 2025 Unsecured Notes, in whole or in part, at any time prior to July 1, 2020, at a price equal to 100.000% of the principal amount to be redeemed plus the applicable premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. We may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, to, but excluding, the date of redemption:

July 1, 2020 to June 30, 2021	103.375%
July 1, 2021 to June 30, 2022	101.688%
July 1, 2022 and thereafter	100.000%

If Surgery Center Holdings, Inc. experiences a change in control under certain circumstances, we must offer to purchase the 2025 Unsecured Notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase.

The 2025 Unsecured Notes contain customary affirmative and negative covenants, which, among other things, limit our ability to incur additional debt, pay dividends, create or assume liens, effect transactions with affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.

In connection with the offering of the 2025 Unsecured Notes, we incurred debt issuance costs of \$17.3 million, which were eliminated with the application of pushdown accounting.

Subordinated Notes

On August 3, 2017, we redeemed in whole a subordinated debt facility of \$1.0 million with a maturity date of August 4, 2017 and an interest rate of 17.00% per annum, at a price equal 100% of the \$1.0 million principal amount redeemed, plus accrued and unpaid interest.

Notes Payable and Secured Loans

Certain of our subsidiaries have outstanding bank indebtedness, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made. The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. At December 31, 2017, we were in compliance with the covenants contained in the credit agreements. We and our subsidiaries had notes payable to financial institutions of \$101.9 million and \$42.5 million as of December 31, 2017 and 2016, respectively. The increase is primarily due to the acquisition of NSH. We and our subsidiaries also provide a corporate guarantee of certain indebtedness of our subsidiaries.

Capital Lease Obligations

We are liable to various vendors for several property and equipment leases classified as capital leases. The carrying value of the leased assets was \$16.2 million and \$15.4 million as of December 31, 2017 and 2016, respectively.

Summary

We believe we have sufficient liquidity in the next 12 to 18 months as described above. Nevertheless, we continue to monitor the state of the financial and credit markets and our current and expected liquidity and capital resource needs, and intend to continue to explore various financing alternatives to improve our capital structure, including reducing debt, extending maturities or relaxing financial covenants. These may include new equity or debt financings or exchange offers with existing security holders (including exchanges of debt for debt or equity) and other transactions involving our outstanding securities, given their secondary market trading prices. We cannot assure you, if we pursue any of these transactions, that we will be successful in completing a transaction on attractive terms, or at all.

Certain Non-GAAP Metrics

EBITDA, Adjusted EBITDA and Normalized Adjusted EBITDA are not measurements of financial performance under GAAP. They should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from these non-GAAP metrics are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to

the assessment of normal operating performance. Our calculation of Adjusted EBITDA and Normalized Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

When we use the term “EBITDA,” we are referring to income before income taxes, net income attributable to non-controlling interests, interest expense, net and depreciation and amortization. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that we consolidate for financial reporting purposes. Our operating strategy is to apply a market-based approach in structuring our partnerships with individual market dynamics driving the structure. We believe that it is helpful to investors to present EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors our portion of EBITDA generated by our surgical facilities and other operations.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

When we use the term "Adjusted EBITDA", we are referring to EBITDA, as defined above, adjusted for non-cash stock compensation expense, contingent acquisition compensation expense, termination of management agreement and IPO costs, management fee, merger transaction, integration and practice acquisition costs, gain on litigation settlement, gain on acquisition escrow release, loss (gain) on disposal or impairment of long-lived assets, net, gain on amendment to tax receivable agreement, tax receivable agreement (benefit) expense and loss on debt refinancing. We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by our management to assess operating performance, make business decisions and allocate resources.

When we use the term "Normalized Adjusted EBITDA", we are referring to Adjusted EBITDA, as defined above, adjusted for the impact of the hurricanes and one-time adjustments to revenue described under the heading "Revenues" above.

The following table reconciles EBITDA, Adjusted EBITDA and Normalized Adjusted EBITDA to income before income taxes, the most directly comparable GAAP financial measure (in thousands and unaudited):

	Year Ended December 31,		
	2017	2016	2015
Consolidated Statements of Operations Data (in thousands):			
Income (loss) before income taxes	\$ 82,286	\$ 92,178	\$ (76,137)
<i>(Minus):</i>			
Net income attributable to non-controlling interests	81,721	75,630	71,416
<i>Plus:</i>			
Interest expense, net	117,669	100,571	100,980
Depreciation and amortization	51,928	39,551	34,545
EBITDA	170,162	156,670	(12,028)
<i>Plus (minus):</i>			
Non-cash stock compensation expense	5,584	2,021	7,502
Contingent acquisition compensation expense	7,039	5,092	—
Termination of management agreement and IPO costs	—	—	5,834
Management fee ⁽¹⁾	—	—	2,250
Merger transaction, integration and practice acquisition costs ⁽²⁾	17,007	11,617	20,579
Gain on litigation settlements	(12,534)	(14,101)	—
Gain on acquisition escrow release	(1,167)	—	—
Loss (gain) on disposal or impairment of long-lived assets, net	1,720	2,355	(2,097)
Gain on amendment to tax receivable agreement	(16,392)	—	—
Tax receivable agreement (benefit) expense	(25,329)	3,733	119,911
Loss on debt refinancing	18,211	11,876	16,102
Adjusted EBITDA	164,301	179,263	158,053
Hurricane estimated impact	5,000	—	—
Reserve adjustment	14,868	—	—
Normalized Adjusted EBITDA	\$ 184,169	\$ 179,263	\$ 158,053

⁽¹⁾ Fee payable pursuant the Management and Investment Advisory Services Agreement between the Company and Bayside Capital, Inc. which terminated in connection with our IPO.

⁽²⁾ This amount includes merger transaction and integration costs of \$13.1 million, \$8.7 million and \$17.9 million for the years ended December 31, 2017, 2016 and 2015, respectively, and practice acquisition costs of \$3.9 million, \$2.9 million and \$2.7 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Credit Agreement EBITDA is not a measurement of liquidity under GAAP, and should not be considered in isolation or as a substitute for any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Credit Agreement EBITDA are significant components in understanding and evaluating our liquidity. Our calculation of Credit Agreement EBITDA may not be comparable to similarly titled measures reported by other companies.

When we use the term “Credit Agreement EBITDA,” we are referring to Normalized Adjusted EBITDA, as defined above, further adjusted for acquisitions and non-cash expenses. These adjustments do not relate to our historical financial performance and instead relate to estimates compiled by our management and calculated in conformance with the definition of “Consolidated EBITDA” used in the credit agreements governing our credit facilities. We use Credit Agreement EBITDA as a measure of liquidity and to determine our compliance under certain covenants pursuant to our credit facilities. We have included it because we believe that it provides investors with additional information about our ability to incur and service debt and make capital expenditures.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

The following table reconciles Credit Agreement EBITDA to cash flows from operating activities, the most directly comparable GAAP financial measure (in thousands and unaudited):

	<u>Twelve Months Ended</u> <u>December 31, 2017</u>
Cash flows from operating activities	\$ 120,943
<i>Adjustments to reconcile cash flows from operating activities to income before income taxes:</i>	
Depreciation and amortization	(51,928)
Amortization of debt issuance costs, discounts and premium	(4,532)
Amortization of unfavorable lease liability	438
Equity-based compensation	(5,584)
Loss on disposal or impairment of long-lived assets, net	(1,720)
Gain on legal settlements	8,740
Loss on debt refinancing	(18,211)
Gain on amendment to tax receivable agreement	16,392
Tax receivable agreement benefit	25,329
Deferred income taxes	(52,328)
Provision for doubtful accounts	(28,752)
Income from equity investments, net of distributions received	(1,167)
Changes in operating assets and liabilities, net of acquisitions and divestitures	21,116
Income tax expense	53,550
Income before income taxes	82,286
<i>(Minus):</i>	
Net income attributable to non-controlling interests	81,721
<i>Plus (minus):</i>	
Interest expense, net	117,669
Depreciation and amortization	51,928
Non-cash stock compensation expense	5,584
Contingent acquisition compensation expense	7,039
Merger transaction, integration and practice acquisition costs	17,007
Gain on litigation settlements	(12,534)
Gain on acquisition escrow release	(1,167)
Loss on disposal or impairment of long-lived assets, net	1,720
Gain on amendment to tax receivable agreement	(16,392)
Tax receivable agreement benefit	(25,329)
Loss on debt refinancing	18,211
Hurricane estimated impact	5,000
Reserve impact	14,868
Normalized Adjusted EBITDA	184,169
<i>Plus:</i>	
Acquisitions ⁽¹⁾	94,650
Non-cash expenses	1,811
Credit Agreement EBITDA	\$ 280,630

⁽¹⁾ Represents impact of acquired anesthesia entities, physician practices and surgical facilities as if each acquisition had occurred on January 1, 2017, including cost savings from reductions in corporate overhead, supply chain rationalization, enhanced physician engagement, improved payor contracting and revenue synergies associated with the NSH acquisition. Further, this includes revenue synergies from other business initiatives as defined in the credit agreement.

SURGERY PARTNERS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (continued)

Contractual Obligations and Commercial Commitments

The following table summarizes our contractual obligations by period as of December 31, 2017 (in thousands):

	Payments Due by Period				
	Total	Less than 1 year	1-3 years	4-5 years	More than 5 years
Long-term debt obligations, including interest ⁽¹⁾	\$ 2,643,403	\$ 174,406	\$ 1,533,085	\$ 484,374	\$ 451,538
Capital lease obligations, including interest	33,314	9,100	12,424	5,491	6,299
Operating lease obligations ⁽²⁾	564,716	67,513	129,871	109,140	258,192
Other financing obligations, including interest ⁽³⁾	187,476	12,307	25,628	27,043	122,498
Tax receivable agreement	65,141	537	23,613	39,218	1,773
Total contractual obligations	<u>\$ 3,494,050</u>	<u>\$ 263,863</u>	<u>\$ 1,724,621</u>	<u>\$ 665,266</u>	<u>\$ 840,300</u>

⁽¹⁾ Included in long-term debt obligations are principal and interest owed on our outstanding debt obligations. These amounts exclude our unamortized fair value adjustments related non-cash amortization for the Term Loan and 2021 Unsecured Notes. These obligations are explained further in Note 7 to our consolidated financial statements included elsewhere in this report. We used the applicable annual interest rate as of December 31, 2017 of 4.6%, based on LIBOR plus the applicable margin, for our \$1.3 billion outstanding Term Loan to estimate interest payments on this variable rate debt instrument.

⁽²⁾ This reflects our future minimum operating lease payments. We enter into operating leases in the normal course of business. Substantially all of our operating lease agreements have fixed payment terms based on the passage of time. Some lease agreements provide us with the option to renew the lease. Our future operating lease obligations would change if we exercised these renewal options and if we entered into additional operating lease agreements. These obligations are explained further in Note 8 to our consolidated financial statements included elsewhere in this report. Operating lease obligations do not include common area maintenance, insurance or tax payments for which we are also obligated to pay.

⁽³⁾ Other financing obligations includes amounts due under our facility lease obligations at four of our surgical facilities as discussed further in Note 2 to our consolidated financial statements included elsewhere in this report.

Inflation

Inflation and changing prices have not significantly affected our operating results or the markets in which we operate.

Recent Accounting Pronouncements

Please refer to Note 2 to our consolidated financial statements included elsewhere in this report for a discussion of the impact of the adoption of recently issued accounting standards and accounting standards not yet adopted.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates, and do not hold or issue any derivative financial instruments for this purpose.

Our variable rate debt instruments are primarily indexed to the prime rate or LIBOR. Interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements. At December 31, 2017, we had outstanding principal amount of debt of \$1.3 billion in variable rate instruments. Assuming a hypothetical 100 basis points increase in LIBOR on our debt as of December 31, 2017, our annual interest expense would increase by approximately \$13.1 million. Although there can be no assurances that interest rates will not change significantly, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2018 based on our indebtedness at December 31, 2017.

Item 8. Financial Statements and Supplementary Data

Information with respect to this Item is contained in our consolidated financial statements beginning on Page F-1 of this report.

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Disclosure Controls and Procedures and Limitations on the Effectiveness of Controls

An evaluation was performed under the supervision and with the participation of our management, including the Chief Executive Officer and the Interim Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and the Interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on the evaluation of our disclosure controls and procedures conducted as of December 31, 2017, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective as a result of the material weakness that existed in our internal control over financial reporting, as described in Management's Report on Internal Control Over Financial Reporting below.

Management's Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate "internal control over financial reporting" (as such term is defined in Rule 13a-15(f) under the Exchange Act) for the Company. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions and disposition of assets; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures are made only in accordance with management and board authorizations; and providing reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with GAAP. Because of the inherent limitations in any internal control, no matter how well designed, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of management, including the Chief Executive Officer and Interim Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2017. The assessment was based on criteria established in the framework *Internal Control-Integrated Framework (2013)*, issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, management, including the Chief Executive Officer and Interim Chief Financial Officer, continues to believe that certain control deficiencies in our internal control over financial reporting pertaining to the design and operating effectiveness of certain

controls involving the initiation and recording of revenue and accounts receivable and the accurate estimation and recording of related allowances aggregate to a material weakness at December 31, 2017. Certain of these deficiencies existed as of December 31, 2016 and, though we believe we have made progress, we continue the process of implementing our plan for remediation with respect to these deficiencies.

In addition, management identified control deficiencies, which aggregate to a material weakness at December 31, 2017, relating to the lack of evidence to support the operating effectiveness of certain management review controls over the valuation inputs and assumptions of

assets acquired and non-controlling interests and purchase accounting adjustments recorded for business combination accounting, including the application of pushdown accounting.

A material weakness in internal control over financial reporting is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis by the company's internal controls. As a result of the identified material weakness, management, including the Chief Executive Officer and Interim Chief Financial Officer, concluded that internal control over financial reporting was not effective as of December 31, 2017. Ernst & Young LLP, the independent registered public accounting firm that audited our financial statements included in this Annual Report on Form 10-K, has issued an attestation report on the effectiveness of our internal control over financial reporting as of December 31, 2017. Their attestation report is included below in this Item 9A.

Notwithstanding the identified material weakness as of December 31, 2017, management, including the Chief Executive Officer and Interim Chief Financial Officer, believes that the audited consolidated financial statements contained in this Annual Report on Form 10-K fairly present, in all material respects, our financial condition, results of operations and cash flows for the fiscal years presented in conformity with GAAP. Additionally, this material weakness did not result in any restatements of our audited and unaudited consolidated financial statements or disclosures for any previously reported periods.

As permitted by SEC guidance, the Company excluded NSH from its assessment of and conclusion on the effectiveness of its internal control over financial reporting. As of and for the year ended December 31, 2017, these entities constituted 9.3% of consolidated total assets, and 15.3% of consolidated revenues.

Management's Plan for Remediation of the Material Weakness in Internal Control Over Financial Reporting

Our new management team is actively engaged in the implementation of a remediation plan to ensure that controls contributing to these material weaknesses are designed appropriately and will operate effectively. The remediation actions we are taking and expect to take include the following:

- We intend to enhance the design of our controls and implement policies setting forth specific requirements for documentation related to our controls with respect to revenue, accounts receivable and related allowances;
- We intend to implement additional review and analysis procedures to ensure that our policies are being followed; and
- We will evaluate whether additional internal resources are required to effectively implement additional review and analysis procedures over the assumptions, inputs and methodologies used by third-party valuation specialists.

Management believes that these efforts will effectively remediate the material weaknesses. However, the material weaknesses in our internal control over financial reporting will not be considered remediated until the new controls are fully implemented, in operation for a sufficient period of time and tested and concluded by management to be designed and operating effectively. In addition, as the Company continues to evaluate and work to improve its internal control over financial reporting, management may determine to take additional measures to address control deficiencies or determine to modify the remediation plan described above. Management will test and evaluate the implementation of these new processes and internal controls during 2018 to ascertain whether they are designed and operating effectively to provide reasonable assurance that they will prevent or detect a material error in the Company's financial statements. Although we believe our remediation efforts will be effective in remediating the material weaknesses, there can be no assurance as to when the remediation plan will be fully implemented.

Changes in Internal Control over Financial Reporting

Except for the material weaknesses and ongoing remediation efforts described above, there have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Attestation Report of the Registered Public Accounting Firm

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Surgery Partners, Inc.

Opinion on Internal Control over Financial Reporting

We have audited Surgery Partners, Inc.'s internal control over financial reporting as of December 31, 2017 (Successor), based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, because of the effect of the material weaknesses described below on the achievement of the objectives of the control criteria, Surgery Partners, Inc. (the Company) has not maintained effective internal control over financial reporting as of December 31, 2017, based on the COSO criteria.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses have been identified and included in management's assessment. Management has identified material weaknesses in controls pertaining to (i) the aggregation of design and operating deficiencies over revenue, accounts receivable and related allowances and (ii) the aggregation of design and operating deficiencies in management review controls over the valuation inputs and assumptions of assets and liabilities acquired and non-controlling interests and purchase accounting adjustments recorded for business combination accounting, including the application of pushdown accounting.

As indicated in the accompanying Management's Report on Internal Control Over Financial Reporting, management's assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of National Surgical Healthcare ("NSH"), which is included in the 2017 consolidated financial statements of the Company and constituted 9.3% of Total assets as of December 31, 2017 and 15.3% of Revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of NSH.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Surgery Partners, Inc. as of December 31, 2017 (Successor) and 2016 (Predecessor), and the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for the periods September 1, 2017 to December 31, 2017 (Successor) and January 1, 2017 to August 31, 2017 (Predecessor) and the years ended December 31, 2016 and 2015 (Predecessor), and the related notes. The material weaknesses were considered in determining the nature, timing and extent of audit tests applied in our audit of the 2017 consolidated financial statements, and this report does not affect our report dated March 16, 2018, which expressed an unqualified opinion thereon.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP
Nashville, Tennessee
March 16, 2018

Item 9B. Other Information

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information called for by Item 10 is incorporated herein by reference to the definitive Proxy Statement of the Company relating to the 2018 Annual Meeting of Stockholders (the “Definitive Proxy Statement”), which the Company intends to file within 120 days after the close of our fiscal year ended December 31, 2017.

Item 11. Executive Compensation

The information called for by Item 11 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information called for by Item 12 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information called for by Item 13 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.

Item 14. Principal Accounting Fees and Services

The information called for by Item 14 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.

PART IV

Item 15. Exhibits and Financial Statement Schedules

(a) Financial Statements, Financial Statement Schedules and Exhibits

(1) Financial Statements

Our Consolidated Financial Statements and Notes thereto are set forth starting on page F-1 of this Annual Report on Form 10-K.

(2) Financial Statement Schedules

All financial schedules have been omitted either because they are not applicable or because the required information is provided in our Consolidated Financial Statements and Notes thereto, starting on page F-1 of this Annual Report on Form 10-K.

(3) Exhibits:

No.	Description
2.1	Agreement and Plan of Merger by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of May 9, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed May 11, 2017).*
2.2	Letter Amendment to Merger Agreement, by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of July 7, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed July 11, 2017).*
3.1	Amended and Restated Certificate of Incorporation of Surgery Partners, Inc., dated October 30, 2017 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed November 3, 2017).
3.2	Amended and Restated Bylaws of Surgery Partners, Inc., dated August 31, 2017 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed September 1, 2017).
3.3	Certificate of Designations, Preferences, Rights and Limitations of the 10.00% Series A Convertible Perpetual Participating Preferred Stock of Surgery Partners, Inc., dated August 31, 2017 (incorporated herein by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed September 1, 2017).
4.1	Indenture, dated March 31, 2016, among Surgery Center Holdings, Inc., the Guarantors from time to time party thereto and Wilmington Trust, National Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed April 5, 2016).
4.2	Third Supplemental Indenture, dated as of May 25, 2017, by and among Surgery Center Holdings, Inc., the guarantors listed therein and Wilmington Trust, National Association, as trustee (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed May 26, 2017).
4.3	Fourth Supplemental Indenture, by and among Surgery Center Holdings, Inc., Wilmington Trust, National Association, as Trustee, and certain other parties thereto, dated August 31, 2017 (incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed September 1, 2017).
4.4	Indenture, dated June 30, 2017, among SP Finco, LLC and Wilmington Trust, National Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed July 6, 2017).
4.5	First Supplemental Indenture, by and among Surgery Center Holdings, Inc., Wilmington Trust, National Association, as Trustee, and certain other parties thereto, dated August 31, 2017 (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed September 1, 2017).
10.1	First Lien Incremental Term Loan Amendment and Consent, dated as of March 24, 2016, by and among SP Holdco I, Inc., Surgery Center (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed March 30, 2016).
10.2	Amendment No. 4 to Credit Agreement, dated as of September 26, 2016, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other guarantors and lenders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed September 27, 2016).
10.3	Office Lease Agreement dated November 17, 2015 between Highwoods Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed March 11, 2016).
10.4	Second Amendment to Lease Agreement, dated April 26, 2017, between Highwoods Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed May 10, 2017).
10.5	Securities Purchase Agreement by and among Surgery Partners, Inc. and BCPE Seminole Holdings LP, dated May 9, 2017 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed May 11, 2017).*
10.6	Stock Purchase Agreement by and between H.I.G. Surgery Centers, LLC, H.I.G. Bayside Debt & LBO Fund II L.P. (for the specific purposes stated therein), BCPE Seminole Holdings LP and Surgery Partners, Inc., dated May 9, 2017 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed May 11, 2017).*

- 10.7 [Amended and Restated Registration Rights Agreement by and among Surgery Partners, Inc., certain stockholders of Surgery Partners, Inc. and certain other parties thereto, dated August 31, 2017 \(incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed September 1, 2017\).](#)
- 10.8 [Credit Agreement, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other guarantors and lenders party thereto, dated August 31, 2017 \(incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed September 1, 2017\).*](#)

Table of Contents

10.9	Tax Receivable Agreement, dated as of September 30, 2015, among Surgery Partners, Inc., H.I.G. Surgery Centers, LLC and certain other stockholders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).
10.10	Amendment No. 1 to Income Tax Receivable Agreement, by and between Surgery Partners, Inc. and H.I.G. Surgery Centers, LLC (in its capacity as the Stockholders Representative), dated May 9, 2017 (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed May 11, 2017).
10.11	Form of TRA Waiver and Assignment Agreement.
10.12	Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.14 to Amendment No. 1 to the Company's Registration Statement on Form S-1, filed September 14, 2015).
10.13 (a)	2015 Omnibus Incentive Plan (incorporated herein by reference as Exhibit 4.3 to the Company's Registration Statement on Form S-8 filed October 6, 2015).
10.14 (a)	Cash Incentive Plan (incorporated herein by reference to Exhibit 10.8 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).
10.15 (a)	Symbion, Inc. Supplemental Executive Retirement Plan, Effective May 1, 2005 (incorporated herein by reference to Exhibit 10.17 to the Company's Registration Statement on Form S-1, Amended, filed September 21, 2015).
10.16 (a)	Form of Non-Statutory Stock Option Agreement under the 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).
10.17 (a)	Form of Director Option Award under the 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).
10.18 (a)	Form of Reorganization Restricted Stock Agreement under the 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).
10.19 (a)	Form of Restricted Stock Award Agreement under the 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed March 15, 2016).
10.20 (a)	Form of Performance Stock Unit Award Agreement under the 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed July 5, 2016).
10.21 (a)	Form of Director Restricted Stock Award Agreement (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed April 3, 2017).
10.22 (a)	Form of Leveraged Performance Unit Award Agreement (incorporated herein by reference to Exhibit 10.5 to the Company's Current Report on Form 8-K filed September 8, 2017).
10.23 (a)	Employment Agreement of Michael Doyle, as amended (incorporated herein by reference to Exhibit 10.10 to the Company's Registration Statement on Form S-1, Amended, filed September 21, 2015).
10.24 (a)	Employment Agreement of Teresa Sparks, as amended (incorporated herein by reference to Exhibit 10.11 to the Company's Registration Statement on Form S-1, Amended, filed September 21, 2015).
10.25 (a)	First Amendment to Amended and Restated Employment Agreement of Teresa Sparks, dated December 21, 2017.
10.26 (a)	Employment Agreement of John Crysel, as amended (incorporated herein by reference to Exhibit 10.12 to the Company's Registration Statement on Form S-1, Amended, filed September 21, 2015).
10.27 (a)	Letter Agreement to Employment Agreement of John Crysel, dated November 22, 2017.
10.28 (a)	Employment Agreement of Jennifer Baldock, as amended (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed April 17, 2017).
10.29 (a)	Employment Agreement of Dennis Dean, as amended (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed April 17, 2017).
10.30 (a)	Employment Agreement of Cliff Adlerz, dated September 7, 2017 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed September 8, 2017).
10.31 (a)	Employment Agreement of Wayne DeVeydt, dated January 4, 2018 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed January 8, 2018).
10.32 (a)	Employment Agreement of R. David Kretschmer, dated January 25, 2018 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed January 29, 2018).
10.33 (a)	Termination and Release Agreement, by and among Surgery Partners, Inc., Surgery Partners, LLC and Michael T. Doyle, dated September 7, 2017 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed September 8, 2017).
10.34 (a)	TRA Waiver and Assignment Agreement, by and among Surgery Partners, Inc., Michael T. Doyle, the Makayla Doyle 2012 Irrevocable Trust under agreement dated July 20, 2012, the Michael Doyle 2012 Irrevocable Trust under agreement dated July 20, 2012 and the Mason Doyle 2012 Irrevocable Trust under agreement dated July 20, 2012, dated September 8, 2017 (incorporated herein by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed September 8, 2017).
10.35 (a)	Consulting Services Agreement, by and between Surgery Partners, Inc. and Michael T. Doyle, dated September 7, 2017 (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed September 8, 2017).
10.36 (a)	Amendment No. 1 to Consulting Services Agreement, by and between Surgery Partners, Inc., Michael T. Doyle, and MD Healthcare Partners, LLC, dated December 21, 2017.

- 10.37 (a) [Separation and Consulting Services Agreement, by and between Surgery Partners, Inc. and Teresa Sparks, dated January 25, 2018 \(incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed January 29, 2018\).](#)
- 21.1 [List of Subsidiaries of the Registrant.](#)
- 23.1 [Consent of Independent Registered Public Accounting Firm.](#)

[Table of Contents](#)

31.1	Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

(a) Management Contract or Compensatory Plan or Arrangement.

* Schedules and/or Exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule or exhibit to the SEC upon request.

Item 16. Form 10-K Summary

None.

INDEX TO FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets - December 31, 2017 and 2016	F-3
Consolidated Statements of Operations - for the years ended December 31, 2017, 2016 and 2015	F-4
Consolidated Statements of Comprehensive Income (Loss) - for the years ended December 31, 2017, 2016 and 2015	F-5
Consolidated Statements of Stockholders' Equity - for the years ended December 31, 2017, 2016 and 2015	F-6
Consolidated Statements of Cash Flows - for the years ended December 31, 2017, 2016 and 2015	F-7
Notes to Consolidated Financial Statements	F-8

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Surgery Partners, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Surgery Partners, Inc. (the Company) as of December 31, 2017 (Successor) and 2016 (Predecessor), and the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for the periods September 1, 2017 to December 31, 2017 (Successor) and January 1, 2017 to August 31, 2017 (Predecessor) and the years ended December 31, 2016 and 2015 (Predecessor), and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company at December 31, 2017 (Successor) and 2016 (Predecessor), and the results of its operations and its cash flows for the periods September 1, 2017 to December 31, 2017 (Successor) and January 1, 2017 to August 31, 2017 (Predecessor) and the years ended December 31, 2016 and 2015 (Predecessor), in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2017 (Successor), based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 16, 2018 expressed an adverse opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company's auditor since 2014.

Nashville, Tennessee
March 16, 2018

SURGERY PARTNERS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except shares and per share amounts)

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 174,914	\$ 69,699
Accounts receivable, less allowance for doubtful accounts of \$2,026 and \$29,872, respectively	288,023	220,594
Inventories	44,951	28,777
Prepaid expenses and other current assets	55,337	42,885
Total current assets	563,225	361,955
Property and equipment, net	398,536	204,253
Intangible assets, net	58,908	48,023
Goodwill	3,346,838	1,555,204
Investments in and advances to affiliates	74,282	34,980
Restricted invested assets	315	315
Long-term deferred tax assets	132,319	83,793
Other long-term assets	48,350	16,435
Total assets	<u>\$ 4,622,773</u>	<u>\$ 2,304,958</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 84,710	\$ 49,766
Accrued payroll and benefits	49,625	29,273
Other current liabilities	109,944	79,864
Current maturities of long-term debt	58,726	27,822
Total current liabilities	303,005	186,725
Long-term debt, less current maturities	2,130,556	1,414,421
Long-term tax receivable agreement liability	43,791	122,351
Other long-term liabilities	178,689	76,266
Non-controlling interests—redeemable	299,316	180,521
Redeemable preferred stock - Series A, 310,000 shares authorized, issued and outstanding, redemption value of \$330,806 at December 31, 2017; no shares were authorized, issued or outstanding at December 31, 2016.	330,806	—
Stockholders' equity:		
Preferred stock, \$0.01 par value, 20,000,000 shares authorized, no shares issued or outstanding	—	—
Common stock, \$0.01 par value, 300,000,000 shares authorized, 48,687,136 shares issued and outstanding at December 31, 2017; 48,488,616 shares issued and outstanding at December 31, 2016.	487	485
Additional paid-in capital	695,560	320,543
Retained deficit	(41,316)	(311,351)
Total Surgery Partners, Inc. stockholders' equity	654,731	9,677
Non-controlling interests—non-redeemable	681,879	314,997
Total stockholders' equity	1,336,610	324,674
Total liabilities and stockholders' equity	<u>\$ 4,622,773</u>	<u>\$ 2,304,958</u>

See notes to consolidated financial statements.

SURGERY PARTNERS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except shares and per share amounts)

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Revenues	\$ 592,604	\$ 748,615	\$ 1,145,438	\$ 959,891
Operating expenses:				
Salaries and benefits	175,403	241,149	357,175	261,685
Supplies	161,015	193,322	269,239	242,083
Professional and medical fees	45,061	57,931	81,185	66,583
Lease expense	27,868	36,503	52,147	44,848
Other operating expenses	32,281	43,267	61,450	54,127
Cost of revenues	441,628	572,172	821,196	669,326
General and administrative expenses ⁽¹⁾	29,153	46,797	60,246	55,992
Depreciation and amortization	21,804	30,124	39,551	34,545
Provision for doubtful accounts	12,455	16,297	24,212	23,578
Income from equity investments	(3,319)	(3,148)	(4,764)	(3,777)
Loss (gain) on disposal or impairment of long-lived assets, net	5	1,715	2,355	(2,097)
Merger transaction and integration costs	7,470	5,584	8,738	17,920
Loss on debt refinancing	—	18,211	11,876	16,102
Gain on litigation settlements	(8,740)	(3,794)	(14,101)	—
Gain on acquisition escrow release	(167)	(1,000)	—	—
Termination of management agreement and IPO costs	—	—	—	5,834
Electronic health records incentive expense (income)	45	(305)	(408)	(1,761)
Other (income) expense	—	(2)	55	(525)
Total operating expenses	500,334	682,651	948,956	815,137
Operating income	92,270	65,964	196,482	144,754
Gain on amendment to tax receivable agreement	1,098	15,294	—	—
Tax receivable agreement benefit (expense)	25,329	—	(3,733)	(119,911)
Interest expense, net	(48,740)	(68,929)	(100,571)	(100,980)
Income (loss) before income taxes	69,957	12,329	92,178	(76,137)
Income tax expense (benefit)	71,639	(18,089)	7,095	(148,982)
Net (loss) income	(1,682)	30,418	85,083	72,845
Less: Net income attributable to non-controlling interests	(39,634)	(42,087)	(75,630)	(71,416)
Net (loss) income attributable to Surgery Partners, Inc.	(41,316)	(11,669)	9,453	1,429
Less: Amounts attributable to participating securities ⁽²⁾	(26,047)	—	—	—
Net (loss) income attributable to common stockholders	\$ (67,363)	\$ (11,669)	\$ 9,453	\$ 1,429
Net (loss) income per share attributable to common stockholders				
Basic	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04
Diluted ⁽³⁾	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04
Weighted average common shares outstanding				
Basic	48,319,193	48,121,404	48,018,944	36,066,233

Diluted ⁽³⁾	48,319,193	48,121,404	48,190,738	37,464,387
------------------------	------------	------------	------------	------------

⁽¹⁾ Includes contingent acquisition compensation expense of \$1.9 million for the four months ended December 31, 2017 (Successor), and \$5.1 million for both the eight months ended August 31, 2017 (Predecessor), and the year ended December 31, 2016 (Predecessor).

⁽²⁾ Includes accrued dividends and undistributed earnings allocated to participating securities and the mark to redemption adjustment for the Series A Preferred Stock. There were no participating securities during the Predecessor periods. See Note 10. "Earnings Per Share" for further discussion.

⁽³⁾ The impact of potentially dilutive securities for four months ended December 31, 2017 and the eight months ended August 31, 2017 were not considered because the effect would be anti-dilutive in those periods.

See notes to consolidated financial statements.

SURGERY PARTNERS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Net (loss) income	\$ (1,682)	\$ 30,418	\$ 85,083	\$ 72,845
Other comprehensive income	—	—	—	—
Comprehensive (loss) income	\$ (1,682)	\$ 30,418	\$ 85,083	\$ 72,845
Less: Comprehensive income attributable to non-controlling interests	(39,634)	(42,087)	(75,630)	(71,416)
Comprehensive (loss) income attributable to Surgery Partners, Inc.	\$ (41,316)	\$ (11,669)	\$ 9,453	\$ 1,429

See notes to consolidated financial statements.

SURGERY PARTNERS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(In thousands, except shares)

	Common Stock ⁽¹⁾		Additional Paid-in Capital	Retained Deficit	Non-Controlling Interests— Non-Redeemable	Total
	Shares	Amount				
<i>Predecessor</i>						
Balance as of December 31, 2014	1,000	\$ —	\$ 58,151	\$ (322,233)	\$ 293,618	\$ 29,536
Net income	—	—	—	1,429	53,800	55,229
Equity-based compensation	—	—	7,502	—	—	7,502
Acquisition and disposal of shares of non-controlling interests, net	—	—	(835)	—	4,321	3,486
Distributions to non-controlling interests—non-redeemable holders	—	—	—	—	(49,784)	(49,784)
Initial public offering	14,285,000	143	250,836	—	—	250,979
Effect of Reorganization ⁽²⁾	33,870,990	339	—	—	—	339
Other	—	—	640	—	—	640
Balance as of December 31, 2015	48,156,990	\$ 482	\$ 316,294	\$ (320,804)	\$ 301,955	\$ 297,927
Net income	—	—	—	9,453	57,607	67,060
Issuance of restricted stock, net of forfeitures	331,626	3	(3)	—	—	—
Equity-based compensation	—	—	2,021	—	—	2,021
Acquisition and disposal of shares of non-controlling interests, net	—	—	2,231	—	4,053	6,284
Distributions to non-controlling interests—non-redeemable holders	—	—	—	—	(48,618)	(48,618)
Balance as of December 31, 2016	48,488,616	\$ 485	\$ 320,543	\$ (311,351)	\$ 314,997	\$ 324,674
Net (loss) income	—	—	—	(11,669)	32,472	20,803
Issuance of restricted and unrestricted shares	355,607	3	(3)	—	—	—
Equity-based compensation	—	—	3,697	—	—	3,697
Cancellation of restricted shares	(33,908)	—	(790)	—	—	(790)
Acquisition of NSH	—	—	—	—	172,645	172,645
Acquisition and disposal of shares of non-controlling interests, net	—	—	3,483	—	(5,629)	(2,146)
Distributions to non-controlling interests—non-redeemable holders	—	—	—	—	(38,875)	(38,875)
Balance as of August 31, 2017	48,810,315	\$ 488	\$ 326,930	\$ (323,020)	\$ 475,610	\$ 480,008

	Common Stock ⁽¹⁾		Additional Paid-in Capital	Retained Deficit	Non-Controlling Interests— Non-Redeemable	Total
	Shares	Amount				
<i>Successor</i>						
Balance as of September 1, 2017	48,810,315	\$ 488	\$ 720,118	\$ —	\$ 684,480	\$ 1,405,086
Net (loss) income	—	—	—	(41,316)	26,703	(14,613)
Issuance of restricted and unrestricted shares	112,107	1	(1)	—	—	—
Equity-based compensation	—	—	1,887	—	—	1,887
Cancellation of restricted shares	(54,622)	—	(585)	—	—	(585)
Preferred dividends	—	—	(10,481)	—	—	(10,481)

Mark to redemption adjustment	—	—	(15,566)	—	—	(15,566)
Reallocation in application of pushdown accounting	—	—	—	—	(21,248)	(21,248)
Acquisition and disposal of shares of non-controlling interests, net	—	—	2,195	—	17,206	19,401
Distributions to non-controlling interests—non-redeemable holders	—	—	—	—	(25,262)	(25,262)
Repurchase of shares	(180,664)	(2)	(2,007)	—	—	(2,009)
Balance as of December 31, 2017	<u>48,687,136</u>	<u>\$ 487</u>	<u>\$ 695,560</u>	<u>\$ (41,316)</u>	<u>\$ 681,879</u>	<u>\$ 1,336,610</u>

⁽¹⁾ As described in Note 1 herein, the common stock of the Company is that of Surgery Partners, Inc. as of December 31, 2017, 2016 and 2015 and that of Surgery Center Holdings, Inc. as of December 31, 2014.

⁽²⁾ As a result of the Reorganization that occurred on September 30, 2015 (as further described in Note 1), Surgery Center Holdings, Inc. became an indirect wholly owned subsidiary of Surgery Partners, Inc. and the common stock of Surgery Center Holdings, Inc. is eliminated in consolidation.

See notes to consolidated financial statements.

SURGERY PARTNERS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Cash flows from operating activities:				
Net (loss) income	\$ (1,682)	\$ 30,418	\$ 85,083	\$ 72,845
Adjustments to reconcile net (loss) income to net cash provided by operating activities:				
Depreciation and amortization	21,804	30,124	39,551	34,545
Amortization of debt issuance costs, discounts and premium	(559)	5,091	7,199	6,263
Amortization of unfavorable lease liability	(221)	(217)	(431)	(431)
Equity-based compensation	1,887	3,697	2,021	7,502
Loss (gain) on disposal or impairment of long-lived assets, net	5	1,715	2,355	(2,097)
Gain on legal settlements	(8,740)	—	(14,101)	—
Loss on debt refinancing	—	18,211	11,876	16,102
Gain on amendment to tax receivable agreement	(1,098)	(15,294)	—	—
Tax receivable agreement (benefit) expense	(25,329)	—	3,733	119,911
Deferred income taxes	71,031	(18,703)	6,882	(149,891)
Interest on contingent consideration obligation	—	—	1,124	1,041
Provision for doubtful accounts	12,455	16,297	24,212	23,578
Income from equity investments, net of distributions received	678	489	(846)	(543)
Changes in operating assets and liabilities, net of acquisitions and divestitures:				
Accounts receivable	(31,500)	8,837	(60,622)	(48,783)
Other operating assets and liabilities	14,494	(12,947)	17,203	4,439
Net cash provided by operating activities	53,225	67,718	125,239	84,481
Cash flows from investing activities:				
Purchases of property and equipment, net	(10,827)	(18,773)	(39,109)	(33,439)
Payments for acquisitions, net of cash acquired	(29,249)	(725,853)	(146,405)	(112,596)
Proceeds from divestitures	1,183	70	765	11,193
Net cash used in investing activities	(38,893)	(744,556)	(184,749)	(134,842)
Cash flows from financing activities:				
Proceeds from initial public offering, net of offering costs	—	—	—	250,979
Principal payments on long-term debt	(18,629)	(1,164,237)	(473,437)	(328,329)
Borrowings of long-term debt	409	1,805,966	650,707	196,366
Payments of debt issuance costs	(4)	(58,591)	(14,296)	—
Penalty on prepayment of debt	—	—	(4,900)	—
Payment of premium of debt extinguishment	—	—	—	(7,305)
Proceeds from preferred stock issuance	—	310,000	—	—
Payments of stock issuance costs	—	(18,347)	—	—
Payments of preferred dividends	(1,316)	—	—	—
Distributions to non-controlling interest holders	(33,490)	(50,343)	(65,778)	(69,720)
Proceeds from (payments related to) ownership transactions with non-controlling interest holders	998	(1,518)	(20,096)	(12,175)

Repurchase of shares	(2,009)	—	—	—
Financing lease obligations	1,007	(796)	(924)	3,558
Other financing activities	(590)	(789)	—	—
Net cash (used in) provided by financing activities	(53,624)	821,345	71,276	33,374
Net (decrease) increase in cash and cash equivalents	(39,292)	144,507	11,766	(16,987)
Cash and cash equivalents at beginning of period	214,206	69,699	57,933	74,920
Cash and cash equivalents at end of period	\$ 174,914	\$ 214,206	\$ 69,699	\$ 57,933
Supplemental cash flow information:				
Interest paid, net of interest income received	40,872	68,646	79,262	96,799
Cash paid for income taxes	485	598	661	1,093
Non-cash purchases of property and equipment under capital leases and financing activities	14,872	8,469	9,226	5,443

See notes to consolidated financial statements.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization

Surgery Partners, Inc., a Delaware corporation (together with its subsidiaries, the "Company"), was formed April 2, 2015, as a holding company for the purpose of facilitating an initial public offering (the "IPO") of shares of common stock. Prior to September 30, 2015, the Company conducted business through Surgery Center Holdings, Inc. and its subsidiaries. Surgery Center Holdings, LLC was and is the sole indirect owner of the equity interests of Surgery Center Holdings, Inc. and had no other material assets.

On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the "Reorganization"). In the Reorganization, all of the equity interests held by the pre-IPO Owners of Surgery Center Holdings, LLC were contributed to Surgery Partners, Inc. in exchange for 33,871,990 shares of common stock of Surgery Partners, Inc. and certain rights to additional payments under a tax receivable agreement. After giving effect to the Reorganization, Surgery Partners, Inc. is a holding company, and its sole material asset is an equity interest in Surgery Center Holdings, LLC. The Company's consolidated financial statements for periods prior to the Reorganization represent the historical operating results and financial position of Surgery Center Holdings, Inc. and certain of its subsidiaries.

On October 1, 2015, the Company completed its IPO of 14,285,000 shares of common stock at an offering price of \$19.00 per share. On October 6, 2015, the Company received net proceeds from the sale of common stock in this offering of \$255.8 million, after deducting underwriting discounts and other fees of \$15.6 million. These net proceeds were used to repay a portion of the borrowings outstanding under the 2014 Second Lien and to pay fees associated with this offering. The Company also incurred an additional \$4.8 million in costs directly related to the IPO.

On August 31, 2017, the Company completed its acquisition of NSH Holdco, Inc. ("NSH"). Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 9, 2017, by and among the Company, SP Merger Sub, Inc., a wholly owned subsidiary of the Company, NSH, and IPC / NSH, L.P. (solely in its capacity as sellers' representative), as amended by that certain Letter Amendment, dated as of July 7, 2017 (as amended, the "NSH Merger Agreement"), SP Merger Sub, Inc. merged with and into NSH with NSH continuing as the surviving corporation and a wholly owned subsidiary of Surgery Center Holdings, Inc. (the "NSH Merger"). Also on August 31, 2017, (i) the Company completed the sale and issuance of 310,000 shares of the Company's preferred stock, par value \$0.01 per share, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") to BCPE Seminole Holdings LP ("Bain"), a fund advised by an affiliate of Bain Capital Private Equity, at a purchase price of \$1,000 per share in cash (the "Preferred Private Placement") pursuant to the Securities Purchase Agreement, dated as of May 9, 2017, by and between the Company and Bain (the "Preferred Stock Purchase Agreement"), and (ii) Bain completed its purchase of 26,455,651 shares (the "Purchased Shares") of the Company's common stock, par value \$0.01 per share (the "Common Stock") from H.I.G. Surgery Centers, LLC ("H.I.G.") at a purchase price of \$19.00 per share in cash (the "Private Sale") pursuant to the Stock Purchase Agreement, dated as of May 9, 2017, by and among the Company, Bain, H.I.G. and H.I.G. Bayside Debt & LBO Fund II L.P. (for the purposes stated therein) (the "Common Stock Purchase Agreement" and together with the NSH Merger Agreement, the Preferred Stock Purchase Agreement and the other agreements and documents executed in connection therewith, including the TRA (as defined in Note 2. "Significant Accounting Policies - Income Taxes and Tax Receivable Agreement"), the "Transaction Agreements"). As of August 31, 2017, the Purchased Shares represented approximately 54.2% of the Company's outstanding Common Stock. As a result of the Preferred Private Placement and the Private Sale, Bain became the controlling stockholder of the Company, holding Series A Preferred Stock and Common Stock that collectively represent approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017, and H.I.G. and its affiliated investment funds no longer own any capital stock of the Company.

In connection with the change of control effected by the Preferred Private Placement and the Private Sale, the Company elected to apply "pushdown" accounting by applying the guidance in Accounting Standards Codification Topic ("ASC") 805, *Business Combinations*, including the recognition of the Company's assets and liabilities at fair value as of August 31, 2017, and similarly recognizing goodwill calculated based on the terms of the transaction and the fair value of the new basis of net assets of the Company. Accordingly, the consolidated financial statements of the Company for periods before and after August 31, 2017 reflect different bases of accounting, and the financial positions and results of operations of those periods are not comparable. Throughout the Company's consolidated financial statements and the accompanying notes herein, periods prior to the change of control are identified as "Predecessor" and periods after the change of control are identified as "Successor."

As of December 31, 2017 (Successor), the Company owned and operated a national network of surgical facilities and ancillary services in 32 states. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology ("GI"), general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services and optical services.

As of December 31, 2017 (Successor), the Company owned or operated a portfolio of 124 surgical facilities, comprised of 106 ASCs and 18 surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, healthcare systems in the markets and communities it serves. The Company owned a majority interest in 84 of the surgical facilities and consolidated 108 of these facilities for financial reporting purposes.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.

Non-Controlling Interests

The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.

The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control.

Non-Controlling Interests — Redeemable. Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners' or physician minority members', as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. The non-controlling interests — redeemable are reported outside of stockholders' equity in the consolidated balance sheets.

A summary of activity related to the non-controlling interests—redeemable follows (in thousands):

<i>Predecessor</i>	
Balance at December 31, 2015	\$ 183,439
Net income attributable to non-controlling interests—redeemable	18,023
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(3,781)
Distributions to non-controlling interest —redeemable holders	(17,160)
Balance at December 31, 2016	180,521
Net income attributable to non-controlling interests—redeemable	9,615
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(3,323)
Distributions to non-controlling interest —redeemable holders	(11,468)
Acquisition of NSH	153,320
Balance at August 31, 2017	\$ 328,665
<i>Successor</i>	
Balance at September 1, 2017	\$ 271,001

Net income attributable to non-controlling interests—redeemable	12,931
Acquisition and disposal of shares of non-controlling interests, net—redeemable	819
Distributions to non-controlling interest —redeemable holders	(8,228)
Reallocation in application of pushdown accounting	21,248
Purchase price adjustments	1,545
Balance at December 31, 2017	<u>\$ 299,316</u>

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Variable Interest Entities

The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of ASC 810, *Consolidation*. At December 31, 2017 (Successor), the variable interest entities include five surgical facilities, three anesthesia practices and three physician practices. At December 31, 2016 (Predecessor), the variable interest entities included five surgical facilities, three anesthesia practices and two physician practice. The change is due to a physician practice acquired during the eight months ended August 31, 2017 (Predecessor). The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.

The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying consolidated balance sheets as of December 31, 2017 (Successor) and 2016 (Predecessor), were \$13.1 million and \$24.8 million, respectively, and the total liabilities of the consolidated VIEs were \$5.8 million and \$10.7 million, respectively. There are no assets that are restricted to use as of December 31, 2017 (Successor).

Equity Method Investments

The Company has non-consolidating investments in surgical facilities and management companies that own or manage surgical facilities. These investments are accounted for using the equity method of accounting. The total amount of these investments included in investments in and advances to affiliates in the consolidated balance sheets was \$74.3 million and \$35.0 million as of December 31, 2017 (Successor) and December 31, 2016 (Predecessor), respectively.

Use of Estimates

The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to the comparative periods' financial statements to conform to the current year presentation.

Fair Value of Financial Instruments

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), inputs other than quoted prices in active markets that are either directly or indirectly observable (Level 2), or unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions (Level 3), depending on the nature of the item being valued.

The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values.

A summary of the carrying amounts and fair values of the Company's long-term debt follows (in thousands):

	<i>Successor</i>				<i>Predecessor</i>			
	December 31, 2017				December 31, 2016			
	Carrying Amount		Fair Value		Carrying Amount		Fair Value	
2014 Revolver Loan	\$	—	\$	—	\$	85,000	\$	85,000
2014 First Lien Credit Agreement, net of debt issuance costs and discount	\$	—	\$	—	\$	911,784	\$	917,528
2017 Senior Secured Credit Facilities:								
Revolver	\$	—	\$	—	\$	—	\$	—
Term Loan	\$	1,280,532	\$	1,267,189	\$	—	\$	—

Senior Unsecured Notes due 2021 ⁽¹⁾	\$	409,235	\$	422,535	\$	387,942	\$	412,189
Senior Unsecured Notes due 2025	\$	370,000	\$	346,413	\$	—	\$	—

⁽¹⁾ The carrying amount in the Predecessor period is net of unamortized debt issuance costs and discount, which were eliminated with the application of pushdown accounting.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The fair values of the 2014 First Lien Credit Agreement, Term Loan, 2021 Unsecured Notes and the 2025 Unsecured Notes (in each case, as defined in Note 7. "Long-Term Debt") were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets at December 31, 2017 (Successor) and 2016 (Predecessor), as applicable. The carrying amounts related to the Company's other long-term debt obligations, including the 2014 Revolver Loan and the Revolver (in each case, as defined in Note 7. "Long-Term Debt"), approximate their fair values.

The Company maintains a supplemental executive retirement savings plan (the "SERP") for certain executive officers. The SERP is a non-qualified deferred compensation plan for eligible executive officers and other key employees of the Company that allows participants to defer portions of their compensation. The fair value of the SERP asset and liability was based on a quoted market price, or a Level 1 computation. As of December 31, 2017 (Successor) and 2016 (Predecessor), the fair value of the assets in the SERP were \$1.9 million and \$1.7 million, respectively, and were included in other long-term assets in the consolidated balance sheets. The Company had a liability related to the SERP of \$1.9 million and \$1.7 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively, which was included in other long-term liabilities in the consolidated balance sheets.

Revenues

The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.

A summary of revenues by service type as a percentage of total revenues follows:

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Patient service revenues:				
Surgical facilities revenues	94.3%	91.4%	90.3%	91.6%
Ancillary services revenues	4.2%	7.0%	7.9%	6.4%
	98.5%	98.4%	98.2%	98.0%
Other service revenues:				
Optical services revenues	0.6%	1.0%	1.1%	1.5%
Other	0.9%	0.6%	0.7%	0.5%
	1.5%	1.6%	1.8%	2.0%
Total revenues	100.0%	100.0%	100.0%	100.0%

Patient service revenues. The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid. Changes in estimated contractual adjustments and discounts are recorded in the period of change. There were no adjustments as a result of changes in estimates to third-party settlements related to prior years for the four months ended December 31, 2017 (Successor). During the eight months ended August 31, 2017 (Predecessor), the Company recognized an increase to patient service revenues as a result of changes in estimates to third-party settlements related to prior years of approximately \$1.1 million. During the years ended December 31, 2016 and 2015, the Company recognized an increase to patient service revenues of \$6.8 million and \$2.3 million, respectively, as a result of changes in estimates to third-party settlements related to prior years.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in thousands):

	<i>Successor</i>		<i>Predecessor</i>					
	September 1 to December 31,		January 1 to August 31,		Year Ended December 31,			
	2017		2017		2016		2015	
	Amount	%	Amount	%	Amount	%	Amount	%
Patient service revenues:								
Private insurance	\$ 347,801	59.6%	\$ 360,092	48.9%	\$ 579,662	51.5%	\$ 516,739	55.0%
Government	196,926	33.7%	308,993	42.0%	448,953	39.9%	359,471	38.2%
Self-pay	15,233	2.6%	15,949	2.2%	19,817	1.8%	16,190	1.7%
Other ⁽¹⁾	23,843	4.1%	51,374	6.9%	76,172	6.8%	48,311	5.1%
Total patient service revenues	\$ 583,803	100.0%	\$ 736,408	100.0%	\$ 1,124,604	100.0%	\$ 940,711	100.0%
Other service revenues:								
Optical service revenues	\$ 3,486		\$ 7,629		\$ 12,505		\$ 14,572	
Other revenues	5,315		4,578		8,329		4,608	
Total net revenues	\$ 592,604		\$ 748,615		\$ 1,145,438		\$ 959,891	

(1) Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.

Other service revenues. Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts.

Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered.

Subsequent to the Preferred Private Placement, the Company, as part of a review of operations undertaken to create a solid foundation to support the Company's long-term growth objectives, incurred a non-recurring adjustment to revenue of \$15.6 million, which was attributable to an increase in reserves for certain accounts receivable during the eight months ended August 31, 2017 (Predecessor). The increase in reserves resulted from certain known events and actions during the eight months ended August 31, 2017 (Predecessor) related to select payors primarily in the Company's ancillary services segment. Upon consideration of such additional information, related receivables were determined to have a low likelihood of collection. The majority of this adjustment related to receivables with balances from the first quarter of 2016 and prior. The Company believes it has accounted for all necessary reserve adjustments at this time.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.

Accounts Receivable and Allowances for Contractual Adjustments and Doubtful Accounts

Accounts receivable are recorded net of contractual adjustments and allowances for doubtful accounts to reflect accounts receivable at net realizable value. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. As of December 31, 2017, the Company

had a net third-party Medicaid settlements liability of \$1.0 million compared to a third-party Medicaid settlements receivable of \$0.5 million at December 31, 2016.

The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. The Company's policy is to collect co-payments and deductibles prior to providing medical services. It is also the Company's policy to verify a patient's insurance 72 hours prior

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

to the patient's procedure. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.

The Company analyzes accounts receivable at each of its facilities to ensure the proper aged category and collection assessment. At a consolidated level, the Company's policy is to review accounts receivable aging, by facility, to determine the appropriate allowance for doubtful accounts. Patient account balances are reviewed for delinquency based on contractual terms. This review is supported by an analysis of the actual revenues, contractual adjustments and cash collections received. An account balance is written off only after the Company has pursued collection with legal or collection agency assistance or otherwise has deemed an account to be uncollectible.

A summary of the changes in the allowance for doubtful accounts receivable follows (in thousands):

	Balance at Beginning of Period	Provision for Doubtful Accounts	Accounts Written off, Net of Recoveries	Balance at End of Period
<i>Predecessor</i>				
Year ended December 31, 2015	\$ 5,329	\$ 23,578	\$ (10,585)	\$ 18,322
Year ended December 31, 2016	18,322	24,212	(12,662)	29,872
Eight months ended August 31, 2017	29,872	16,297	(14,096)	32,073
Successor				
Four months ended December 31, 2017	—	12,455	(10,429)	2,026

The Company records an estimate for doubtful accounts based on the aging category and historical collection experience of each product sales or other business included in other service revenues, as discussed in the note above.

The receivables related to the Company's optical products purchasing organization are recognized separately from patient accounts receivable, as discussed above, and are included in other current assets in the consolidated balance sheets. Such receivables were \$7.6 million and \$7.0 million at December 31, 2017 (Successor) and 2016 (Predecessor), respectively.

Inventories

Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.

Prepaid Expenses and Other Current Assets

A summary of prepaid expenses and other current assets follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Prepaid expenses	\$ 16,835	\$ 11,158
Receivables - optical product purchasing organization	7,563	7,042
Acquisition escrow deposit	3,809	10,871
Insurance recoveries	2,828	2,476
Other	24,302	11,338
Total	\$ 55,337	\$ 42,885

Property and Equipment

Property and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings and building improvements, three to five years for computers and software and five to seven years for furniture and equipment. Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.

The Company also leases certain facilities and equipment under capital leases. Assets held under capital leases are stated at the present value of minimum lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset. The Company's property and equipment, as well as assets held under capital leases are further described in Note 5.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Goodwill and Intangible Assets

Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located and Medicare licenses. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally three to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from two to five years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from three to ten years. The Company's goodwill and intangible assets are further described in Note 6.

Impairment of Long-Lived Assets, Goodwill and Intangible Assets

The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value. The cash flow projection and fair value represents management's best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation. No impairment losses on long-lived assets were recognized during the four months ended December 31, 2017 (Successor), the eight months ended August 31, 2017 (Predecessor), and the years ended December 31, 2016 and 2015 (Predecessor).

The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. The Company has determined that it has five reporting units, which include the following: 1) Surgical Facilities 2) Ancillary Services, 3) Midwest Labs, 4) The Alliance, including Optical Synergies and 5) Family Vision Care. The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. If the carrying value exceeds the estimated fair value, an impairment indicator exists and an estimate of the possible impairment loss is calculated. The fair value of the reporting units are estimated using a discounted cash flows approach and are corroborated using a market-based approach. The fair value calculation includes multiple assumptions and estimates, including the projected cash flows and discount rates applied.

In connection with the implementation of pushdown accounting, the Company performed its goodwill impairment test as of August 31, 2017 (Predecessor), then re-evaluated for impairment at October 1, 2017 (Successor). Both evaluations resulted in no impairment. There were also no impairment charges recorded during the years ended December 31, 2016 and 2015 (Predecessor).

Restricted Invested Assets

Restricted invested assets of \$0.3 million as of both December 31, 2017 (Successor) and 2016 (Predecessor) were related to a requirement under the operating lease agreement at the Company's Chesterfield, Missouri facility. In accordance with the provisions of the lease agreement, the Company has a deposit with the landlord that shall be held as security for performance under the Company's covenants and obligations within the agreement through January 2024.

Other Long-Term Assets

A summary of other long-term assets follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Acquisition escrow deposit	\$ 19,600	\$ —
Insurance recoveries	10,018	6,835
Notes receivable	2,263	716
Deposits	3,151	4,196
Other	13,318	4,688
Total	<u>\$ 48,350</u>	<u>\$ 16,435</u>

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Other Current Liabilities

A summary of other current liabilities follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Interest payable	\$ 20,537	\$ 19,206
Amounts due to patients and payors	18,096	12,221
Insurance liabilities	9,873	6,625
Current taxes payable	4,912	2,622
Acquisition escrow liability	3,809	10,871
Accrued expenses and other	52,717	28,319
Total	<u>\$ 109,944</u>	<u>\$ 79,864</u>

Other Long-Term Liabilities

A summary of other long-term liabilities follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Facility lease obligations	\$ 121,627	\$ 52,653
Acquisition escrow liability	19,600	—
Medical malpractice liability	16,450	10,453
Unfavorable lease liability	11,889	1,671
Other	9,123	11,489
Total	<u>\$ 178,689</u>	<u>\$ 76,266</u>

At four of the Company's surgical facilities, the Company has facility lease obligations payable to the lessor of each facility. Payments are allocated to principal adjustments of the lease obligations and interest expense. The current portions of the lease obligations were \$6.3 million and \$1.3 million at December 31, 2017 (Successor) and 2016 (Predecessor), respectively, and were included in other current liabilities in the consolidated balance sheets. The long-term portions of the lease obligations, included in the table above, were \$121.6 million and \$52.7 million at December 31, 2017 (Successor) and 2016 (Predecessor), respectively. The increase is primarily due to two facility lease obligations assumed with the NSH Merger and the revaluation of the obligations with the application of pushdown accounting.

Equity-Based Compensation

Transactions in which the Company receives employee and non-employee services in exchange for the Company's equity instruments or liabilities that are based on the fair value of the Company's equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. Prior to the Reorganization, on the grant date, the Company employed a market approach to estimate the fair value of equity-based awards based on various considerations and assumptions, including implied earnings multiples and other metrics of relevant market participants, the Company's operating results and forecasted cash flows and the Company's capital structure. Such estimates require the input of highly subjective, complex assumptions. However, such assumptions are no longer required to determine fair value of shares of the Company's common stock as its underlying shares began trading publicly during the fourth quarter of 2015. The Company applies the Black-Scholes-Merton method of valuation in determining share-based compensation expense for option awards.

The Company's policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. Prior to the Reorganization, employees held membership units in Surgery Center Holdings, LLC, and the associated expense was referred

to as unit-based compensation; following the Reorganization, such expense is referred to as equity-based compensation. The Company's equity-based compensation is described further in Note 12.

Professional, General and Workers' Compensation Insurance

The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers compensation claims which relate to (i) claims made during the policy period, which are offset by insurance recoveries and (ii) an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets. Total professional, general and workers' compensation claim liabilities as of December 31, 2017 and 2016 are \$21.0 million and \$13.8 million, respectively. The balance includes expected insurance recoveries of \$12.8 million and \$9.3 million as of December 31, 2017 and 2016, respectively. The increase is primarily due to the acquisition of NSH.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, "*Revenue from Contracts with Customers*," along with subsequent amendments, updates and an extension of the effective date (collectively the "New Revenue Standard"), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This five-step process will require significant management judgment in addition to changing the way many companies recognize revenue in their financial statements. Additionally, and among other provisions, the New Revenue Standard requires expanded quantitative and qualitative disclosures, including disclosure about the nature, amount, timing and uncertainty of revenue. The provisions of the New Revenue Standard are effective for annual periods beginning after December 15, 2017, including interim periods within those years by applying either the full retrospective method or the modified retrospective approach upon adoption. The Company will adopt this ASU on January 1, 2018. The Company plans to adopt using the modified retrospective method, including providing all requisite disclosures under such method. The Company expects that the majority of its provision for doubtful accounts will continue to be recognized as an operating expense rather than as a direct reduction to revenues, given the Company's practice of assessing a patient's ability to pay prior to or on the date of providing healthcare services. The Company does not believe the adoption will have a significant impact on our recognition of net revenues for any period. The Company is still evaluating the impact that the adoption will have on its related disclosures.

In February 2016, the FASB issued ASU 2016-02, "*Leases*," which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. The Company believes the primary effect of adopting the new standard will be to record right-of-use assets and obligations for current operating leases.

In January 2017, the FASB issued ASU 2017-01, "*Business Combinations – Clarifying the Definition of a Business*," which narrows the definition of a business when evaluating whether transactions should be accounted for as asset acquisition or business combination. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those years. The adoption of this ASU will not have a material impact on the Company's condensed consolidated financial position, results of operations and cash flows.

3. Acquisitions and Developments

The Company accounts for its business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.

2017 Transactions

Acquisition of NSH

On August 31, 2017, the Company completed its acquisition of NSH through the NSH Merger, pursuant to the NSH Merger Agreement (as defined in Note 1. "Organization") for total cash consideration of \$711.7 million, net of cash acquired, including \$19.6 million funded to

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

an escrow account. The NSH Merger added to the Company's portfolio 22 owned or operated surgical facilities, including 7 ASCs and 15 surgical hospitals, as well as complementary ancillary services. The proceeds from the Preferred Private Placement (as defined in Note 1. "Organization"), the 2025 Unsecured Notes and the 2017 Senior Secured Credit Facilities (in each case, as defined in Note 7. "Long-Term Debt") were used to fund the acquisition.

Fees associated with the acquisition of NSH, which includes fees incurred related to the Company's preferred equity issuances and debt financings, was approximately \$82.6 million during the eight months ended August 31, 2017 (Predecessor). Approximately \$45.5 million was capitalized as deferred financing costs and discount, \$18.3 million was capitalized as deferred equity issuance costs, \$2.4 million was expensed as merger transaction and integration costs, and \$16.4 million was recorded as loss on debt refinancing costs. All capitalized costs were subsequently written off as a result of the application of pushdown accounting, further discussed below.

The total consideration related to the acquisition of NSH was allocated to the assets acquired and liabilities assumed based upon their respective acquisition date fair values. The aggregate amounts preliminarily recognized for each major class of assets and liabilities, including post acquisition date adjustments, are as follows (in thousands):

Cash consideration	\$ 762,850
Fair value of non-controlling interests	325,965
Aggregate fair value of acquisition	<u>1,088,815</u>
Net assets acquired:	
Cash and cash equivalents	51,159
Accounts receivable	71,901
Inventories	14,986
Prepaid expenses and other current assets	18,397
Property and equipment	174,499
Intangible assets	27,746
Goodwill	870,241
Investments in and advances to affiliates	29,737
Long-term deferred tax assets	17,279
Other long-term assets	27,229
Accounts payable	(29,652)
Accrued payroll and benefits	(28,755)
Other current liabilities	(21,287)
Current maturities of long-term debt	(16,416)
Long-term debt, less current maturities	(42,770)
Other long-term liabilities	(75,479)
Total fair value of net assets acquired	<u>\$ 1,088,815</u>

During the four months ended December 31, 2017, factors became known to the Company as part of its evaluation of the assets and liabilities existing at the date of acquisition. this resulted in a net increase to goodwill of \$25.1 million and corresponding changes to certain classes of assets and liabilities from the preliminary allocation recorded at August 31, 2017, that are reflected in the table above. The Company is still in the process of evaluating all major classes of assets acquired and liabilities assumed. As such, the fair values assigned are subject to change as new facts and circumstances emerge that were present at the date of acquisition.

A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the intangible assets recognized.

The preliminary estimated fair value assigned to goodwill is primarily attributable to synergies expected to arise as a result of the NSH Merger by enhancing the growth profile and diversity of the Company across the healthcare continuum. The entire amount of goodwill acquired in connection with the NSH Merger was allocated to the Company's surgical facility services operating segment. The total amount of the goodwill related to the NSH Merger that will be deductible for tax purposes is \$153.5 million.

The amounts of revenues and earnings of NSH for the four months ended December 31, 2017 (Successor) was \$205.2 million and \$20.4 million, respectively, and are included in revenues and net loss attributable to Surgery Partners, Inc., respectively, in the consolidated statement of operations.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The following unaudited pro forma combined summary of operations of the Company gives effect to using historical information of the operations of NSH as if the acquisition transaction had occurred as of January 1, 2016 (in thousands):

	<i>Successor</i>	<i>Predecessor</i>	
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,
	2017	2017	2016
Net revenues	\$ 592,604	\$ 1,122,326	\$ 1,679,254
Net income	4,477	63,269	132,699
Less: Net income attributable to non-controlling interests	(39,634)	(65,122)	(112,123)
Net (loss) income attributable to Surgery Partners, Inc.	<u>\$ (35,157)</u>	<u>\$ (1,853)</u>	<u>\$ 20,576</u>

These pro forma amounts exclude transaction related costs of \$7.3 million and the gain on amendment to the TRA of \$1.1 million for the four months ended December 31, 2017 (Successor), transaction related costs of \$11.3 million, loss on debt refinancing of \$18.2 million and the gain on amendment to the TRA of \$15.3 million for the eight months ended August 31, 2017 (Predecessor). The prior year pro forma amounts exclude the loss on debt refinancing of \$11.9 million for the year ended December 31, 2016 (Predecessor). Certain other adjustments, including those related to conforming accounting policies, have not been reflected in the supplemental pro forma operating results as estimating such impacts would be impracticable.

Change of Control - Pushdown Accounting

On August 31, 2017, H.I.G. sold the Purchased Shares (as defined in Note 1. "Organization") beneficially owned by H.I.G. to Bain at a purchase price per share of \$19.00 for an aggregate purchase price of \$502.7 million in cash pursuant to the Common Stock Purchase Agreement (as defined in Note 1. "Organization"). As of August 31, 2017 (Predecessor), prior to giving effect to the Preferred Private Placement (as defined in Note 1. "Organization"), the Purchased Shares represented approximately 54.2% of the Company's outstanding Common Stock. As a result of the Private Sale and the Preferred Private Placement, Bain holds Series A Preferred Stock and Common Stock that collectively represented approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017 (Predecessor), and H.I.G. and its affiliated investment funds no longer own any capital stock of the Company.

Fees associated with the change of control include fees incurred related to the Preferred Private Placement. Refer to Note 9. "Redeemable Preferred Stock", for the amount and accounting treatment of these costs.

In connection with the change of control, the Company elected to apply "pushdown" accounting by applying the guidance in ASC 805, *Business Combinations*. In accordance with ASC 805, all identifiable assets and liabilities of the Company were measured at and adjusted to fair value as of August 31, 2017, and similarly goodwill was recognized based on the terms of the transaction and the fair value of the new basis of the net assets of the Company.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The aggregate amounts preliminarily recognized in connection with the application of pushdown accounting for each major class of assets and liabilities as of August 31, 2017, including subsequent adjustments, are as follows (in thousands):

Equity attributable to Surgery Partners, Inc.	\$ 720,606
Redeemable preferred stock	310,000
Fair value of non-controlling interests	957,027
Aggregate fair value	<u>1,987,633</u>
Net assets:	
Cash and cash equivalents	214,206
Accounts receivable	253,173
Inventories	44,310
Prepaid expenses and other current assets	61,475
Property and equipment	380,085
Intangible assets	60,104
Goodwill	3,299,911
Investments in and advances to affiliates	74,722
Restricted invested assets	315
Long-term deferred tax asset	204,408
Other long-term assets	49,681
Accounts payable	(64,921)
Accrued payroll and benefits	(54,437)
Other current liabilities	(94,740)
Current maturities of long-term debt	(49,942)
Long-term debt, less current maturities	(2,142,375)
Long-term tax receivable agreement liability	(78,498)
Other long-term liabilities	(169,844)
Total fair value of net assets	<u>\$ 1,987,633</u>

During the four months ended December 31, 2017, factors became known to the Company as part of its evaluation of the assets and liabilities existing at August 31, 2017, resulting in a net increase to goodwill of \$30.7 million and corresponding changes to certain classes of assets and liabilities from the preliminary allocation recorded, that are reflected in the table above. The majority of the increase to goodwill for pushdown accounting relates to the acquisition of NSH discussed above. The Company is still in the process of evaluating all major classes of assets and liabilities. As such, the fair values assigned are subject to change as new facts and circumstances emerge that were present at August 31, 2017.

A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the intangible assets recognized.

Goodwill recognized in connection with the application of pushdown accounting was allocated to each reportable segment as follows: \$3.116 billion to surgical facilities services, \$151.9 million to ancillary services and \$32.5 million to optical services. The total amount of the goodwill related to the application of pushdown accounting that will be deductible for tax purposes is \$360.5 million.

Other 2017 Acquisitions

During the eight months ended August 31, 2017 (Predecessor), the Company completed acquisitions in existing markets of three physician practices for a combined cash purchase price of \$14.2 million. The acquisitions were funded through cash from operations and proceeds from the 2014 Revolver Loan (as defined in Note 7. "Long-Term Debt").

During the four months ended December 31, 2017 (Successor), the Company acquired a controlling interest in one surgical facility and one physician practice in existing markets for a combined cash purchase price of \$29.4 million. The acquisitions were funded through cash from operations.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The total consideration related to the other 2017 acquisitions was allocated to the assets acquired and liabilities assumed based upon their respective acquisition date fair values. The aggregate amounts preliminarily recognized for each major class of assets and liabilities assumed in the other acquisitions completed during 2017, including post acquisition date adjustments, are as follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	September 1 to December 31,	January 1 to August 31,
	2017	2017
Cash consideration	\$ 29,448	\$ 14,163
Fair value of non-controlling interests	21,893	105
Aggregate fair value of acquisitions	<u>51,341</u>	<u>14,268</u>
Net assets acquired:		
Current Assets	2,285	866
Property and equipment	248	696
Intangible assets	41	634
Goodwill	49,317	12,545
Current liabilities	(550)	(287)
Long-term debt	—	(186)
Total fair value of net assets acquired	<u>\$ 51,341</u>	<u>\$ 14,268</u>

The results of operations of the acquisitions are included in the Company's results of operations beginning on the date of acquisition. The fair values assigned to certain assets and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition.

2016 Transactions

During the year ended December 31, 2016, the Company acquired a controlling interest in two surgical facilities and two anesthesia practices in new markets and a surgical facility in an existing market which was merged into an existing facility and an anesthesia practice in an existing market for an aggregate purchase price of \$36.5 million. The Company additionally completed acquisitions in existing markets of an urgent care facility, nine physician practices and two integrated physician practices which includes three ASCs, a lab and a pharmacy for a combined purchase price of \$114.7 million, including \$16.6 million of contingent acquisition consideration. In addition, the Company purchased an additional 7.04% interest in its hospital in Idaho Falls, Idaho for \$20.3 million. The transactions were funded through cash from operations and proceeds from the 2014 First Lien Credit Agreement and 2014 Revolver Loan (in each case, as defined in Note 7. "Long-Term Debt").

The aggregate acquisition date fair value recognized for each major class of assets and liabilities assumed in the acquisitions completed during the year ended December 31, 2016, including post acquisition date adjustments, are as follows (in thousands):

Cash consideration	\$ 135,061
Fair value of non-controlling interests	27,164
Aggregate fair value of acquisitions	<u>162,225</u>
Net assets acquired:	
Current assets	11,383
Property and equipment	3,921
Intangible assets	4,475
Goodwill	148,181
Other long-term assets	56
Current liabilities	(5,422)
Long-term liabilities	<u>(369)</u>

Total fair value of net assets acquired

\$ 162,225

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

During 2017, no significant changes were made to the acquisition date purchase price allocation of assets and liabilities related to individual acquisitions completed in 2016. Approximately \$120.0 million of goodwill related to the 2016 acquisitions was deductible for tax purposes.

2015 Transactions

Surgical Facility Acquisitions

During the year ended December 31, 2015, the Company acquired a controlling interest in two surgical facilities located in new markets and three surgical facilities, four anesthesia practices and an urgent care facility in existing markets for an aggregate purchase price of \$84.2 million. The Company consolidates these facilities for financial reporting purposes. These transactions were funded with a combination of cash from operations, facility ownership, and proceeds from the refinancing of the Company's credit facilities in connection with the Symbion acquisition.

Ancillary Services

During the year ended December 31, 2015, through its recruiting efforts and capital-efficient acquisitions, the Company completed 13 in-market physician practice transactions through an aggregate investment of \$40.4 million. These transactions added a total of 17 physicians to the Company's physician network and were funded with a combination of cash from operations and revolver proceeds.

4. Divestitures

2017 Transactions

During the four months ended December 31, 2017 (Successor), the Company sold its interest in one surgical facility for \$1.3 million, resulting in a pre-tax gain of approximately \$0.8 million. During the eight months ended August 31, 2017 (Predecessor), the Company sold its interest in one surgical facility. The proceeds and pre-tax gain for the sale were not significant.

2016 Transactions

During the year ended December 31, 2016, the Company sold its interest in one surgical facility for \$0.8 million, resulting in a pre-tax gain of approximately \$0.8 million.

2015 Transactions

During the year ended December 31, 2015, the Company sold its interest in three surgical facilities and received aggregate proceeds of \$10.9 million, resulting in a pre-tax gain of approximately \$2.9 million.

5. Property and Equipment

A summary of property and equipment follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Land	\$ 19,561	\$ 8,082
Buildings and improvements	188,571	118,172
Furniture and equipment	20,813	14,670
Computer and software	28,578	29,902
Medical equipment	138,112	117,418
Construction in progress	22,581	2,396
Property and equipment, at cost	418,216	290,640
Less: Accumulated depreciation	(19,680)	(86,387)
Property and equipment, net	<u>\$ 398,536</u>	<u>\$ 204,253</u>

Depreciation expense was \$20.0 million for the four months ended December 31, 2017 (Successor) and \$24.1 million for the eight months ended August 31, 2017 (Predecessor). For the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), depreciation expense was \$30.0 million and \$25.5 million, respectively. Amortization expense related to assets under capital leases is included in depreciation expense. The carrying values of assets under capital lease were \$16.2 million and \$15.4 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively, net of accumulated depreciation of \$5.8 million and \$11.6 million, respectively.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. Goodwill and Intangible Assets

A summary of the changes in the carrying amount of goodwill for the years ended December 31, 2017 and 2016 follows (in thousands):

Predecessor

Balance at December 31, 2015	\$	1,407,927
Acquisitions		147,895
Divestitures		(552)
Purchase price adjustments		(66)
Balance at December 31, 2016	\$	1,555,204
Acquisitions		858,323
Divestitures		(175)
Purchase price adjustments		1,220
Balance at August 31, 2017	\$	2,414,572

Successor

Balance at September 1, 2017	\$	3,269,225
Acquisitions		49,317
Divestitures		(1,957)
Purchase price adjustments		30,253
Balance at December 31, 2017	\$	3,346,838

Additions to goodwill include new acquisitions and incremental ownership acquired in the Company's subsidiaries. A summary of the Company's acquisitions for the years ended December 31, 2017 and 2016 is included in Note 3, Acquisitions and Developments.

A summary of the components of intangible assets follows (in thousands):

	<i>Successor</i>			<i>Predecessor</i>		
	December 31, 2017			December 31, 2016		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Finite-lived intangible assets:						
Management rights agreements	\$ 42,600	\$ (1,058)	\$ 41,542	\$ 24,751	\$ (3,461)	\$ 21,290
Non-compete agreements	4,874	(715)	4,159	24,673	(8,216)	16,457
Physician income guarantees	878	(227)	651	1,901	(1,088)	813
Other	—	—	—	8,815	(3,374)	5,441
Total finite-lived intangible assets	48,352	(2,000)	46,352	60,140	(16,139)	44,001
Indefinite-lived intangible assets:						
Management rights agreements	5,900	—	5,900	—	—	—
Certificates of need	5,548	—	5,548	3,780	—	3,780
Medicare licenses	1,108	—	1,108	242	—	242
Total intangible assets	\$ 60,908	\$ (2,000)	\$ 58,908	\$ 64,162	\$ (16,139)	\$ 48,023

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

A summary of the aggregate activity related to intangible assets for the years ended December 31, 2017 and 2016 follows (in thousands):

Predecessor

Balance at December 31, 2015	\$	53,568
Additions		4,754
Disposals		(135)
Recruitment expense		(609)
Amortization		(9,555)
Balance at December 31, 2016	\$	48,023
Additions		28,312
Recruitment expense		(380)
Amortization		(6,040)
Balance at August 31, 2017	\$	69,915

Successor

Balance at September 1, 2017	\$	56,750
Additions		474
Disposals		(140)
Purchase price adjustments		3,873
Recruitment expense		(227)
Amortization		(1,822)
Balance at December 31, 2017	\$	58,908

Additions during the eight months ended August 31, 2017 (Predecessor) includes \$27.8 million from new acquisitions, primarily the acquisition of NSH. Approximately \$26.9 million was assigned to management rights agreements and \$0.1 million was assigned to non-compete agreements, with estimated weighted average amortization periods of 23 years and 3 years, respectively. Approximately \$0.7 million was assigned to certificates of need and \$0.1 million was assigned to Medicare licenses. Refer to Note 3. "Acquisitions and Developments" for a summary of acquisition activity.

Purchase price adjustments during the four months ended December 31, 2017 (Successor) includes net adjustments to preliminary amounts assigned as part of the acquisition of NSH, the application of pushdown accounting and other 2017 acquisitions. The adjustments included increases of \$6.9 million to management rights agreements and \$0.2 million to certificates of need, offset by a decrease of \$3.2 million to non-compete agreements. Refer to Note 3. "Acquisitions and Developments" for a summary of acquisition activity.

Amortization expense for intangible assets was \$1.8 million for the four months ended December 31, 2017 (Successor) and \$6.0 million for the eight months ended August 31, 2017 (Predecessor). For the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), amortization expense for intangible assets was \$9.6 million and \$9.1 million, respectively.

Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in thousands):

2018	\$	4,966
2019		4,576
2020		4,172
2021		3,730
2022		2,874
Thereafter		26,034
Total	\$	46,352

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. Long-Term Debt

A summary of long-term debt follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
2014 Revolver Loan	\$ —	\$ 85,000
2014 First Lien Credit Agreement	—	932,000
2017 Senior Secured Credit Facilities:		
Revolver	—	—
Term Loan ⁽¹⁾	1,280,532	—
Senior Unsecured Notes due 2021 ⁽²⁾	409,235	400,000
Senior Unsecured Notes due 2025	370,000	—
Subordinated Notes	—	1,000
Notes payable and secured loans	101,921	42,521
Capital lease obligations	27,594	13,996
Less: unamortized debt issuance costs and original issue discount	—	(32,274)
Total debt	2,189,282	1,442,243
Less: Current maturities	58,726	27,822
Total long-term debt	<u>\$ 2,130,556</u>	<u>\$ 1,414,421</u>

⁽¹⁾ Includes unamortized fair value discount of \$6.2 million as of December 31, 2017. See further discussion below.

⁽²⁾ Includes unamortized fair value premium of \$9.2 million as of December 31, 2017. See further discussion below.

2014 Revolver Loan & 2014 First Lien Credit Agreement

On August 31, 2017 (Predecessor), the Company prepaid in full the outstanding principal of the 2014 Revolver Loan, a revolving credit facility entered into on November 3, 2014, and the 2014 First Lien Credit Agreement, a senior secured obligation of Surgery Center Holdings, Inc. entered into on November 3, 2014, with the proceeds from the 2017 Senior Secured Credit Facilities (as defined below). The total prepayment amount was \$1.030 billion, which included \$1.027 billion of outstanding principal and \$3.0 million of accrued and unpaid interest, other fees and expenses. In connection with the prepayment, the Company recorded a debt extinguishment loss of \$18.2 million, included in the loss on debt refinancing in the consolidated statement of operations for the eight months ending August 31, 2017 (Predecessor). The loss includes the partial write-off of unamortized debt issuance costs and discount related to the 2014 Revolver Loan and 2014 First Lien Credit Agreement and a portion of costs incurred with the 2017 Senior Secured Credit Facilities.

In September 2016, in connection with an amendment to the 2014 First Lien Credit Agreement, the Company recorded a loss on debt refinancing of \$3.6 million, included in the accompanying consolidated statement of operations for the year ended December 31, 2016 (Predecessor).

2014 Second Lien Credit Agreement

The 2014 Second Lien Credit Agreement, entered into on November 3, 2014, was a senior secured obligation of Surgery Center Holdings, Inc.

In October 2015, the Company partially prepaid the outstanding principal of the 2014 Second Lien Credit Agreement. In connection with the partial prepayment, the Company recorded a debt extinguishment loss of \$16.1 million, included in the loss on debt refinancing in the accompanying consolidated statement of operations for the year ended December 31, 2015 (Predecessor).

In March 2016, the Company prepaid in full the remaining outstanding principal of the 2014 Second Lien Credit Agreement, plus accrued and unpaid interest, with the proceeds of the issuance of the 2021 Unsecured Notes, defined below. In connection with the prepayment, the Company

recorded a debt extinguishment loss of \$8.3 million, included in the loss on debt refinancing in the accompanying consolidated statement of operations for the year ended December 31, 2016 (Predecessor).

2017 Senior Secured Credit Facilities

On August 31, 2017 (Predecessor), SP Holdco I, Inc. and Surgery Center Holdings, Inc., each a wholly-owned subsidiary of the Company, entered into a credit agreement (the “Credit Agreement”) providing for a \$1.290 billion senior secured term loan (the “Term Loan”) and a \$75.0 million revolving credit facility (the “Revolver” and, together with the Term Loan, the “2017 Senior Secured Credit Facilities”).

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Term Loan was fully drawn on August 31, 2017 (Predecessor) and the proceeds thereof were used to finance the consideration paid in the NSH Merger, to repay amounts outstanding under the Company's then-existing 2014 First Lien Credit Agreement and 2014 Revolver Loan and amounts outstanding under the existing senior secured credit facilities of NSH, and to pay fees and expenses in connection with the foregoing and transactions related to the Transaction Agreements. The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the Credit Agreement, the Company may request one or more additional incremental term loan facilities or one or more increases in the commitments under the Revolver. As of December 31, 2017 (Successor), the Company's availability on the Revolver was \$71.9 million (including outstanding letters of credit of \$3.1 million).

The Term Loan will mature on August 31, 2024 (or, if at least 50.0% of the 2021 Unsecured Notes (as defined below) shall have not either been repaid or refinanced with permitted indebtedness having a maturity date not earlier than six months after the maturity date of the Term Loan by no later than October 15, 2020, then October 15, 2020). The Revolver will mature on August 31, 2022 (or, if at least 50.0% of the 2021 Notes have not either been repaid or refinanced with permitted indebtedness having a maturity date not earlier than six months after the maturity date of the Term Loan by no later than October 15, 2020, then October 15, 2020).

The 2017 Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from 3.00% to 3.25% per annum, depending on the Company's first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, the Company is required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver.

The Term Loan amortizes in equal quarterly installments of 0.25% of the aggregate original principal amount of the Term Loan (such amortization payments commenced in December 2017). The Term Loan is subject to mandatory prepayments based on excess cash flow for the applicable fiscal year that will depend on the first lien net leverage ratio as of the last day of the applicable fiscal year, as well as upon the occurrence of certain other events, as described in the Credit Agreement. There were no excess cash flow payments required as of December 31, 2017 (Successor).

With respect to the Revolver, the Company is required to comply with a maximum consolidated total net leverage ratio of 9.50:1.00, which covenant will be tested quarterly on a trailing four quarter basis only if, as of the last day of the applicable fiscal quarter the Revolver is drawn in an aggregate amount greater than 35% of the total commitments under the Revolver. Such financial maintenance covenant is subject to an equity cure. The Credit Agreement includes customary negative covenants restricting or limiting the ability of the Company and its restricted subsidiaries, to, among other things, sell assets, alter its business, engage in mergers, acquisitions and other business combinations, declare dividends or redeem or repurchase equity interests, incur additional indebtedness or guarantees, make loans and investments, incur liens, enter into transactions with affiliates, prepay certain junior debt, and modify or waive certain material agreements and organizational documents, in each case, subject to customary and other agreed upon exceptions. The Credit Agreement also contains customary affirmative covenants and events of default. As of December 31, 2017 (Successor), the Company was in compliance with the covenants contained in the Credit Agreement.

The 2017 Senior Secured Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors") and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors' assets (subject to certain exceptions).

In connection with the Term Loan and Revolver, the Company recorded debt issuance costs and discount of \$18.8 million and \$9.4 million, respectively, in the Predecessor period, which were eliminated with the application of pushdown accounting.

In connection with the application of pushdown accounting, the Company remeasured and recorded the Term Loan at fair value using a measurement date of August 31, 2017. The fair value was based on a Level 2 computation using quoted prices for identical liabilities in inactive markets. As a result, the Company recorded a fair value discount of \$6.5 million as of the measurement date, which is reported in the consolidated balance sheets as a direct deduction from the face amount the Term Loan. The Company amortizes the fair value discount to interest expense over the life of the Term Loan.

Senior Unsecured Notes due 2021

Effective March 31, 2016 (Predecessor), Surgery Center Holdings, Inc., issued \$400.0 million in gross proceeds of senior unsecured notes due April 15, 2021 (the "2021 Unsecured Notes"). The 2021 Unsecured Notes bear interest at the rate of 8.875% per year, payable semi-annually on April 15 and October 15 of each year. The 2021 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly owned restricted subsidiaries that guarantees the 2017 Senior Secured Credit Facilities (subject to certain exceptions).

The Company may redeem up to 35% of the aggregate principal amount of the 2021 Unsecured Notes, at any time before April 15, 2018, with the net cash proceeds of certain equity offerings at a redemption price equal to 108.875% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption, provided that at least 50% of the aggregate principal amount of the 2021 Unsecured Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company may redeem the 2021 Unsecured Notes, in whole or in part, at any time prior to April 15, 2018 at a price equal to 100.000% of the principal amount to be redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may redeem the 2021 Unsecured Notes, in whole or in part, at any time on or after April 15, 2018, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, to the date of redemption:

April 15, 2018 to April 14, 2019	106.656%
April 15, 2019 to April 14, 2020	104.438%
April 15, 2020 and thereafter	100.000%

If Surgery Center Holdings, Inc., experiences a change in control under certain circumstances, it must offer to purchase the notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase. The change of control as discussed in Note 1. "Organization", did not trigger repurchase.

The 2021 Unsecured Notes contain customary affirmative and negative covenants, which among other things, limit the Company's ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.

In connection with the offering of the 2021 Unsecured Notes, the Company recorded debt issuance costs of \$8.4 million in the Predecessor period, which were eliminated with the application of pushdown accounting.

In connection with the application of pushdown accounting, the Company remeasured and recorded the 2021 Unsecured Notes at fair value using a measurement date of August 31, 2017. The fair value was based on a Level 2 computation using quoted prices for identical liabilities in inactive markets. As a result, the Company recorded a fair value premium of \$10.0 million as of the measurement date, which is reported in the consolidated balance sheets as a direct addition to the face amount the notes. The Company amortizes the fair value premium to interest expense over the life of the 2021 Unsecured Notes.

Senior Unsecured Notes due 2025

Effective June 30, 2017 (Predecessor), SP Finco, LLC, a wholly owned subsidiary of Surgery Center Holdings, Inc., issued \$370.0 million in gross proceeds of senior unsecured notes due July 1, 2025 (the "2025 Unsecured Notes"), which gross proceeds were deposited in an escrow account (the "Escrow Account") established at Wilmington Trust, National Association (in such capacity, the "Escrow Agent") in the name of the trustee under the indenture governing the 2025 Unsecured Notes (the "2025 Unsecured Notes Indenture") on behalf of the holders of the 2025 Unsecured Notes. The 2025 Unsecured Notes bear interest at the rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year, commencing on January 1, 2018.

In connection with the closing of the NSH Merger and the release of the proceeds from the Escrow Account, both of which occurred on August 31, 2017 (Predecessor), SP Finco, LLC merged with and into Surgery Center Holdings, Inc., with Surgery Center Holdings, Inc. surviving such merger and assuming, by operation of law, the rights and obligations of SP Finco, LLC under the 2025 Unsecured Notes and the indenture governing such notes. As of such time, the 2025 Unsecured Notes became guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s domestic wholly owned restricted subsidiaries that guarantees Surgery Center Holdings, Inc.'s senior secured credit facilities (subject to certain exceptions).

The Company may redeem up to 40% of the aggregate principal amount of the 2025 Unsecured Notes at any time prior to July 1, 2020, with the net cash proceeds of certain equity issuances at a redemption price equal to 106.750% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption, provided that at least 50% of the aggregate principal amount of the 2025 Unsecured Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of the applicable equity offering.

The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time prior to July 1, 2020, at a price equal to 100.000% of the principal amount to be redeemed plus the applicable premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, to, but excluding, the date of redemption:

July 1, 2020 to June 30, 2021	103.375%
July 1, 2021 to June 30, 2022	101.688%
July 1, 2022 and thereafter	100.000%

If Surgery Center Holdings, Inc. experiences a change in control under certain circumstances, it must offer to purchase the 2025 Unsecured Notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The 2025 Unsecured Notes contain customary affirmative and negative covenants, which, among other things, limit the Company's ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.

In connection with the offering of the 2025 Unsecured Notes, the Company recorded debt issuance costs of \$17.3 million in the Predecessor period, which were eliminated with the application of pushdown accounting.

Subordinated Notes

On August 3, 2017 the Company redeemed in whole a subordinated debt facility of \$1.0 million with a maturity date of August 4, 2017 and an interest rate of 17.00% per annum, at a price equal 100% of the \$1.0 million principal amount redeemed, plus accrued and unpaid interest.

Notes Payable and Secured Loans

Certain of the Company's subsidiaries have outstanding bank indebtedness, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made. The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. At December 31, 2017 (Successor), the Company was in compliance with its covenants contained in the credit agreements. The Company and its subsidiaries had notes payable to financial institutions of \$101.9 million and \$42.5 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively. The increase is primarily due to the acquisition of NSH.

Capital Lease Obligations

The Company is liable to various vendors for several property and equipment leases classified as capital leases. The carrying value of the leased assets was \$16.2 million and \$15.4 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively.

Maturities

A summary of maturities for the Company's long-term debt, excluding unamortized fair value discount and premium discussed above, for the next five years and thereafter as of December 31, 2017 follows (in thousands):

2018	\$ 58,726
2019	36,857
2020	1,277,253
2021	411,748
2022	8,110
Thereafter	393,597
Total debt	<u>\$ 2,186,291</u>

8. Leases

The Company leases office space and equipment for its surgical facilities, including surgical facilities under development. The lease agreements generally require the lessee, or the Company, to pay all maintenance, property taxes, utilities and insurance costs. The Company accounts for operating lease obligations and sublease income on a straight-line basis. Lease obligations paid in advance are recorded as prepaid rent and included in prepaid expenses and other current assets on the consolidated balance sheets. The difference between actual lease payments and straight-line lease expense over the initial lease term, excluding optional renewal periods, is recorded as deferred rent and included in other current liabilities and other long-term liabilities on the consolidated balance sheets.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Future minimum lease payments for non-cancellable operating and capital leases for the next five years and thereafter at December 31, 2017 follows (in thousands):

	<u>Operating Leases</u>	<u>Capital Leases</u>
2018	\$ 67,513	\$ 9,100
2019	67,136	7,404
2020	62,735	5,020
2021	56,558	3,505
2022	52,582	1,986
Thereafter	258,192	6,299
Total minimum payments	<u>\$ 564,716</u>	<u>33,314</u>
Less: imputed interest		(5,720)
Capital lease obligations		<u>\$ 27,594</u>

The Company has various non-cancellable sub-lease arrangements. The total future minimum rentals to be received under these arrangements as of December 31, 2017 is \$4.2 million.

Rental expense for operating leases was \$27.8 million for the four months ended December 31, 2017 (Successor) and \$39.2 million for the eight months ended August 31, 2017 (Predecessor). For the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), rental expense for operating leases was \$47.3 million and \$40.1 million, respectively. Included in these amounts, the Company incurred lease expense under operating lease agreements with physician investors who are related parties of \$7.5 million for the four months ended December 31, 2017 (Successor), \$9.8 million for the eight months ended August 31, 2017 (Predecessor), \$14.4 million and \$12.9 million for years ended December 31, 2016 and 2015, respectively.

9. Redeemable Preferred Stock

On August 31, 2017, the Company issued 310,000 shares of Series A Preferred Stock to Bain at a purchase price of \$1,000 per share for an aggregate purchase price of \$310.0 million. The net proceeds from the Preferred Private Placement (as defined in Note 1. "Organization") were used to finance a portion of the NSH Merger.

The accrued value of the Series A Preferred Stock is convertible into shares of Common Stock at a price per share of Common Stock equal to \$19.00, subject to certain adjustments as provided in the Certificate of Designations, Preferences, Rights and Limitations of the 10.00% Series A Convertible Perpetual Participating Preferred Stock of Surgery Partners, Inc. (the "Series A Certificate of Designation"), at any time at the option of the holder. In addition, the Company may require the conversion of all, but not less than all, of the Series A Preferred Stock pursuant to the terms and conditions of the Series A Certificate of Designation, after the second anniversary of the date of issuance, if the volume weighted average closing price of the Common Stock for any 20 out of 30 consecutive trading days prior to such date, equals or exceeds \$42.00 per share.

The Company cannot redeem the Series A Preferred Stock prior to the fifth anniversary of its issuance and thereafter, may redeem all, but not less than all, of the Series A Preferred Stock for cash pursuant to and subject to the terms and conditions of the Series A Certificate of Designation. The holders of Series A Preferred Stock may cause the Company to redeem the Series A Preferred Stock upon the occurrence of certain change of control transactions of the Company or the Common Stock ceasing to be listed or quoted on a trading market. The Company adjusts the carrying amount of the Series A Preferred Stock to equal the redemption value at the end of each reporting period as if it were also the redemption date. Changes in the redemption value are recognized immediately as they occur.

The Series A Preferred Stock ranks senior to the Common Stock and any other capital stock of the Company with respect to dividends, redemption and any other rights upon the liquidation, dissolution or winding up of the Company, and the holders thereof are entitled to vote with the holders of Common Stock, together as a single class, on all matters submitted to a vote of the Company's stockholders. In addition to participating in any dividends that may be declared with respect to the Common Stock on an as-converted basis, each share of Series A Preferred Stock accrues dividends daily at a dividend rate of 10.00%, compounding quarterly, and in any given quarter, subject to certain conditions, the Board of Directors of the Company may declare a cash dividend in an amount up to 50% of the amount of the dividend that has accrued and accumulated during such quarter through the end of such quarter, and the amount of any quarterly dividend paid in cash shall not compound on the applicable date and shall not be included in the accrued value of the Series A Preferred Stock. In the event of the Company's liquidation, dissolution or winding-up (whether voluntary or involuntary), holders of Series A Preferred Stock will be entitled to receive out of the assets of the Company available for distribution to shareholders, after satisfaction of any

liabilities and obligations to creditors of the Company, with respect to each Series A Preferred Share, an amount equal to the greater of (i) \$1,000.00 per share, plus dividends compounded to date, plus dividends accrued but not yet compounded and (ii) the amount that a holder of one share of Common Stock would receive, assuming the Series A Preferred Stock had converted into shares of Common Stock.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

In connection with the issuance of Series A Preferred Stock in the Preferred Private Placement, the Company incurred issuance costs of \$18.3 million in the Predecessor period, which were eliminated with the application of pushdown accounting.

A summary of activity related to the redeemable preferred stock for the period from September 1, 2017 to December 31, 2017 (Successor) follows (in thousands):

Successor

Balance at September 1, 2017	\$ 310,000
Dividends accrued	10,481
Cash dividends declared	(5,241)
Mark to redemption adjustment	15,566
Balance at December 31, 2017	<u>\$ 330,806</u>

Cash dividends declared but unpaid at December 31, 2017 were \$3.9 million, and were included in other current liabilities in the consolidated balance sheet. The aggregate and per share amounts of unpaid cumulative preferred dividends as of December 31, 2017 were \$9.2 million and \$29.56, respectively.

10. Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with ASC 260, *Earnings Per Share*, based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. Beginning in the Successor period, in connection with the issuance of the Series A Preferred Stock, the Company began computing basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings. Refer to Note 9. "Redeemable Preferred Stock", for further disclosure of the terms and conditions, including the participation rights, of the Series A Preferred Stock.

A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (in thousands except share and per share amounts):

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Numerator:				
Net (loss) income attributable to Surgery Partners, Inc.	\$ (41,316)	\$ (11,669)	\$ 9,453	\$ 1,429
Less: amounts allocated to participating securities ⁽¹⁾	10,481	—	—	—
Less: mark to redemption adjustment	15,566	—	—	—
Net (loss) income attributable to common stockholders	<u>\$ (67,363)</u>	<u>\$ (11,669)</u>	<u>\$ 9,453</u>	<u>\$ 1,429</u>
Denominator:				
Weighted average shares outstanding- basic	48,319,193	48,121,404	48,018,944	36,066,233
Effect of dilutive securities ⁽²⁾	—	—	171,794	1,398,154
Weighted average shares outstanding- diluted	<u>48,319,193</u>	<u>48,121,404</u>	<u>48,190,738</u>	<u>37,464,387</u>
Earnings (loss) per share:				
Basic	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04
Diluted ⁽²⁾	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04

Securities outstanding not included in the computation of diluted (loss) earnings per share as their effect is antidilutive:

Stock options	—	—	—	—
Restricted shares	62,850	105,944	—	—
Convertible preferred stock	—	N/A	N/A	N/A

⁽¹⁾ Amounts allocated to participating securities includes dividends accrued during the Successor period for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses. There were no participating securities during the Predecessor periods.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

⁽²⁾ The impact of potentially dilutive securities for the four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), were not considered because the effect would be anti-dilutive in each of those periods.

Share Repurchase Transactions

On December 15, 2017, the Board of Directors authorized a share repurchase program of up to \$50.0 million of the Company's issued and outstanding common stock from time to time. The timing and size of repurchases will be determined based on market conditions and other factors. The authorization does not obligate the repurchase any shares and the Company may repurchase shares of common stock at any time without prior notice. The share repurchases will be made in accordance with applicable securities laws in open market or privately negotiated transactions. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice.

During December 2017, the Company repurchased 180,664 shares of its common stock at an average price of \$11.12 per share through market purchases. At December 31, 2017, the Company had \$48.0 million of repurchase authorization available under the December 2017 authorization.

During the first quarter of 2018, through the date of this report, the Company repurchased 156,818 shares of its common stock at an average price of \$12.64 per share through market purchases. At March 15, 2018, the Company had \$46.0 million of repurchase authorization available under the December 2017 authorization.

11. Income Taxes and Tax Receivable Agreement

Income Taxes

The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a net operating loss ("NOL") carryforward exists, the Company makes a determination as to whether that NOL carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances.

The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2014 or state income tax examinations for years prior to 2013.

The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.

The Company made income tax payments of \$0.5 million and \$0.6 million for the four months ended December 31, 2017 (Successor) and eight months ended August 31, 2017 (Predecessor), respectively. Income tax payments were \$0.7 million and \$1.1 million for the years ended December 31, 2016 and 2015, respectively.

Income tax expense (benefit) is comprised of the following (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	<u>September 1 to December 31,</u>	<u>January 1 to August 31,</u>	<u>Year Ended December 31,</u>	
	<u>2017</u>	<u>2017</u>	<u>2016</u>	<u>2015</u>
Current:				
Federal	\$ (111)	\$ —	\$ (31)	\$ —
State	990	614	244	909

Deferred:

Federal	77,472	(17,288)	7,326	(132,311)
State	(6,712)	(1,415)	(444)	(17,580)
Total income tax expense (benefit)	<u>\$ 71,639</u>	<u>\$ (18,089)</u>	<u>\$ 7,095</u>	<u>\$ (148,982)</u>

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax expense (benefit) computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 35% follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	<u>September 1 to December 31,</u>	<u>January 1 to August 31,</u>	<u>Year Ended December 31,</u>	
	<u>2017</u>	<u>2017</u>	<u>2016</u>	<u>2015</u>
Tax expense (benefit) at U.S. federal statutory rate	\$ 24,485	\$ 4,315	\$ 32,263	\$ (26,648)
State income tax, net of U.S. federal tax benefit	1,685	(456)	(86)	1,059
Change in valuation allowance	529	1,324	354	(137,721)
Net income attributable to non-controlling interests	(13,872)	(14,731)	(26,470)	(24,996)
Changes in measurement of uncertain tax positions	(191)	20	(262)	(10)
Stock option compensation	306	37	(200)	—
Differences related to divested facilities	(429)	(1,708)	—	—
Nondeductible transaction costs	2,058	(977)	—	3,442
Tax return reconciling differences	—	(316)	1,635	(1,574)
Change in effective tax rate	64,343	(825)	—	(2,143)
TRA liability	(7,404)	(4,782)	(327)	39,428
Other	129	10	188	181
Total income tax expense (benefit)	\$ 71,639	\$ (18,089)	\$ 7,095	\$ (148,982)

The components of temporary differences and the approximate tax effects that give rise to the Company's net deferred tax asset are as follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	<u>December 31, 2017</u>	<u>December 31, 2016</u>
Deferred tax assets:		
Medical malpractice liability	\$ 3,236	\$ 4,194
Accrued vacation and incentive compensation	2,125	1,112
Net operating loss carryforwards	137,794	158,796
Allowance for bad debts	2,545	8,343
Capital loss carryforwards	3,024	2,785
Deferred rent	—	1,371
Depreciation on property and equipment	—	530
Deferred financing costs	17,004	—
TRA liability	1,042	4,542
Other deferred assets	4,961	4,879
Total gross deferred tax assets	171,731	186,552
Less: Valuation allowance	(11,032)	(7,358)
Total deferred tax assets	160,699	179,194
Deferred tax liabilities:		
Deferred financing costs	—	(8,797)

Depreciation on property and equipment	(12,098)	—
Amortization of intangible assets	(12,441)	(15,241)
Basis differences of partnerships and joint ventures	(2,399)	(68,160)
Deferred rent	(717)	—
Other deferred liabilities	(725)	(3,203)
Total deferred tax liabilities	(28,380)	(95,401)
Net deferred tax assets	\$ 132,319	\$ 83,793

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company had federal net operating loss carryforwards of \$507.4 million as of December 31, 2017, which expire between 2025 and 2037 and state net operating loss carryforwards of \$619.6 million as of December 31, 2017, which expire between 2018 and 2037. The Company had capital loss carryforwards of \$12.6 million as of December 31, 2017, which expire between 2018 and 2022. The Company had federal and state credit carryforwards of \$1.1 million as of December 31, 2017. The federal credits do not expire, and the state credits expire between 2018 and 2029.

The Company has recorded a valuation allowance against deferred tax assets at December 31, 2017 and 2016 totaling \$11.0 million and \$7.4 million, respectively, which represents an increase of \$3.6 million. The valuation allowance continues to be provided for certain deferred tax assets for which the Company believes it is more likely than not that the tax benefits will not be realized, which are primarily certain state net operating losses and capital loss carryforwards.

Included in the increase in the valuation allowance for the year ended December 31, 2017 was an increase of approximately \$0.4 million that was recorded to additional-paid-in-capital as the result of the tax effect of the disposals of shares of non-controlling interests. Also included in the increase in the valuation allowance was an increase of approximately \$0.3 million that was recorded to goodwill related to certain deferred tax assets acquired during the year. Approximately \$1.8 million of the valuation allowance as of December 31, 2017 is recorded against deferred tax assets that, if subsequently recognized, will be credited directly to contributed capital.

A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December 31, 2017 and 2016 is as follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Unrecognized tax benefits at beginning of year	\$ 1,061	\$ 1,403
Additions for acquired positions	36	—
Additions for tax positions of prior years	—	60
Reductions for tax positions of prior year	(407)	(398)
Settlements	—	(4)
Unrecognized tax benefits at end of year	<u>\$ 690</u>	<u>\$ 1,061</u>

The Company recognizes interest and penalties related to uncertain tax positions in its provision for income taxes in the consolidated statements of operations. For the years ended December 31, 2017 and 2016, the Company had approximately \$0.1 million and \$0.2 million, respectively, of accrued interest and penalties related to uncertain tax positions. The total amount of accrued liabilities related to uncertain tax positions that would affect the Company's effective tax rate, if recognized, is \$0.2 million and \$0.3 million as of December 31, 2017 and 2016, respectively. The reserves are included in long-term taxes payable and long-term deferred tax assets in the consolidated balance sheet as of December 31, 2017.

The Tax Cuts and Jobs Act was enacted on December 22, 2017. The Act reduces the US federal corporate tax rate from 35% to 21%, allows for 100% expensing of certain capital expenditures, and will limit interest expense deductions beginning in 2018. As of December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Act; however, in certain cases, as described below, the Company has made a reasonable estimate of the effects on existing deferred tax balances. In other cases, the Company has not been able to make a reasonable estimate and continues to account for those items based on existing accounting under ASC 740, and the provisions of the tax laws that were in effect immediately prior to enactment. In all cases, the Company will continue to make and refine its calculations as additional analysis is completed. In addition, estimates may also be affected as the Company gains a more thorough understanding of the tax law.

The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. However, the Company is still analyzing certain aspects of the Act and refining its calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The most significant component of the uncertainty relates to the state tax impact of the federal changes and how the states will or will not adopt federal changes. The effect on the Company will primarily be related to its state net operating losses and related valuation allowances. The provisional amount recorded related to the remeasurement of the deferred tax balance was \$64.0 million, which is included as a component of income tax expense.

The Company has not made sufficient progress on the analysis of the 100% expensing that may be claimed at certain partnership entities in their 2017 income tax returns for applicable capital expenditures, and the effects that would have on the Company's deferred tax assets and liabilities. The temporary differences related to these amounts would adjust the Company's deferred tax assets and liabilities related to partnership differences and net operating losses, but would likely have an immaterial net effect on the overall deferred tax asset recorded in the financial statements.

Tax Receivable Agreement

On May 9, 2017, the Company and H.I.G., in its capacity as the stockholders representative, entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September 30, 2015 (as amended, the “TRA”), by and between the Company, H.I.G. (in its

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

capacity as the stockholders representative) and the other parties referred to therein, which amendment became effective on August 31, 2017. The TRA was initially entered into in connection with the reorganization undertaken to facilitate the Company's initial public offering. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G. in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus three percent. The amounts payable under the TRA are related to the Company's projected realized tax savings over the next six years and are not dependent on the Company's actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA and such inability is a result of the terms of credit agreements and other debt documents that are materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 500 basis points until paid. If the terms of such credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid.

As a result of the amendment to the TRA, the Company was required to value the liability under the TRA by discounting the fixed payment schedule using the Company's incremental borrowing rate. During the eight months ended August 31, 2017 (Predecessor), the Company recognized a reduction in the carrying value of the liability under the TRA of \$43.9 million, with \$15.3 million of the reduction recorded to a gain on amendment of TRA and \$28.6 million recorded as a reduction to the goodwill recorded in connection with the application of pushdown accounting related to the change of control (discussed in Note 1. "Organization").

As a result of the reduction in the corporate tax rate from the Tax Cuts and Jobs Act discussed above, the Company remeasured the value of the liability under the TRA pursuant to the calculation terms as described above. During the four months ended December 31, 2017 (Predecessor), the Company recognized a reduction in the carrying value of the liability under the TRA of \$25.3 million, included as a tax receivable agreement benefit in the consolidated statement of operations. Assuming the Company's tax rate is 24%, calculated as the maximum corporate federal tax rate plus three percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA as of December 31, 2017 will be approximately \$65.1 million. The carrying value of the liability under the TRA, reflecting the discount as discussed above, was \$44.3 million as of December 31, 2017.

Prior to the remeasurement at the lower corporate tax rate, but subsequent to the effectiveness of the amendment discussed above, the Company estimated that the total amounts payable under the TRA would be approximately \$120.5 million. Prior to the effectiveness of the amendment to the TRA, the amounts payable under the TRA varied depending upon a number of factors, including the amount, character and timing of the taxable income of Surgery Partners, Inc. The Company estimated the total amounts payable would be approximately \$123.4 million, if the tax benefits of related deferred tax assets were ultimately realized. The amounts payable were recognized during 2015 in conjunction with the release of the Company's valuation allowance recorded against the deferred tax assets.

On September 8, 2017 (Successor), in connection with the resignation of the Company's former Chief Executive Officer, Michael Doyle, Mr. Doyle entered into a TRA Waiver and Assignment Agreement (the "CEO TRA Assignment Agreement") with the Company, pursuant to which the Company accepted the assignment of 50% of Mr. Doyle's (and his affiliates') interest in future payments to which such parties were entitled pursuant to the TRA, in exchange for an upfront payment of approximately \$5.1 million, in the aggregate, as set forth in the CEO TRA Assignment Agreement. On September 15, 2017 (Successor), certain of the Company's employees entered into TRA Waiver and Assignment Agreements with the Company (collectively, the "Employee TRA Assignment Agreements" and together with the CEO TRA Assignment Agreement, the "TRA Assignment Agreements"), pursuant to which the Company made upfront payments of approximately \$4.8 million in the aggregate, in exchange for the assignment of 100% of each such employee's interest in future payments to which such employee was entitled pursuant to the TRA. During the four months ended December 31, 2017 (Successor), the Company recognized an aggregate gain of \$1.1 million as a result of the TRA Assignment Agreements.

12. Equity-Based Compensation

Prior to the Reorganization, the Surgery Center Holdings, LLC's ("Holdings LLC") Amended and Restated Limited Liability Company Agreement, dated December 24, 2009, provided, from time to time, as approved by the Holdings LLC's Board, for the issuance of a subordinate class of the Holdings LLC's nonvoting membership units to certain key persons, as defined, of the Company or its subsidiaries.

In April 2013, the Company modified the terms of the 2010 awards to allow for additional vesting in 2013 of its share-based awards with time-vesting conditions. In November 2014, the Holdings LLC issued to certain executives of Symbion who became employees of the Company following the Company's acquisition of Symbion an additional 1,300,000 unvested B-Units, which are subject to vesting conditions to occur through November 2019.

Prior to the Reorganization, in the event of employee termination, the B-Units were subject to a 90-day repurchase option. Upon termination, all unvested B-Units were effectively forfeited. If the employee was terminated for cause, as defined, or resigned prior to the expiration of certain tenure periods specified in such employee's agreement, the repurchase price for each vested B-Unit was zero, and was deemed automatically repurchased by the Company. The repurchase price for vested B-Units, should the Company elect to exercise the repurchase option, was at fair market value, as defined.

If the Company did not exercise the repurchase option, the employee owned the vested B-Units pursuant to the Holdings LLC's LLC Agreement, which included restrictions on transfer, among other provisions. The fair value of each Holdings LLC issued B-Unit was estimated on the date of grant.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

In September 2015, the Company adopted the Surgery Partners, Inc. 2015 Omnibus Incentive Plan ("2015 Omnibus Incentive Plan") from which all equity-based awards will be granted. Under this plan, the Company can grant stock options, SARs, restricted stock, unrestricted stock, stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of its common stock. As of December 31, 2017, 4,815,700 shares were authorized to be granted under the 2015 Omnibus Incentive Plan and 3,716,809 were available for future equity grants.

Restricted Share-Based Awards

During the four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), the Company granted 112,107 and 251,904 restricted stock awards, respectively, to certain officers, employees and non-employee directors in accordance with the 2015 Omnibus Incentive Plan. The Company granted 384,629 and 569,114 restricted stock awards during the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively. Vesting and payment of these restricted stock awards are generally subject to continuing service of the employee or non-employee director over the ratable vesting periods beginning one year from the date of grant to three or five years after the date of grant. The fair values of these restricted stock units were determined based on the closing price of the Company's common stock on the trading date immediately prior to the grant date.

During the eight months ended August 31, 2017 (Predecessor) and the year ended December 31, 2016 (Predecessor) the Company granted 232,242 and 292,147 performance-based restricted stock units, respectively, subject to the achievement of a combination of performance conditions. There were no grants during the four months ended December 31, 2017 (Successor) and the year ended December 31, 2015 (Predecessor). In addition to the achievement of the performance conditions, these performance-based restricted stock units are generally subject to the continuing service of the employee over the ratable vesting period from the earned date continuing for two years. The performance condition for the targeted performance-based restricted stock units granted during the eight months ended August 31, 2017 (Predecessor) is based on the Company's achievement of annually established targets for adjusted earnings per share for 2017. For these restricted stock units, the number of shares payable at the end of the performance periods ranges from 0% to 150% of the targeted units based on the Company's actual performance and/or market conditions results as compared to the targets. The performance condition for the targeted performance-based restricted stock units granted during the year ended December 31, 2016 (Predecessor) is based on the Company's actual adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"). These stock units are not considered outstanding until earned. During the eight months ended August 31, 2017 (Predecessor), 136,550 of the restricted stock units granted were deemed to have been earned. No additional units granted were deemed to have been earned during the four months ended December 31, 2017 (Successor).

Additionally, during the four months ended December 31, 2017 (Successor), the Company granted 215,823 leverage performance restricted stock units subject to the achievement of a combination of market conditions. There were no grants during the eight months ended August 31, 2017 (Predecessor) or the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor). In addition to the achievement of the market conditions, these leverage performance units are generally subject to the continuing service of the employee over the ratable vesting period from the performance period end date continuing for three years. The market condition for the leverage performance restricted stock units granted during the four months ended December 31, 2017 (Successor) is based on the Company's three-year annualized total shareholder return relative to the companies making up the S&P Composite 1500 Health Care Index as of the grant date. These stock units are not considered outstanding until earned. During the four months ended December 31, 2017 (Successor), none of the leverage performance restricted stock units granted were deemed to have been earned.

For these restricted stock units, the number of shares payable at the end of the vesting periods ranges from 0% to 500% of the targeted units based on the Company's actual performance and/or market conditions results as compared to the targets. The fair values of these restricted stock units were determined based on a combination, where applicable, of the closing price of the Company's common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions. The Company recognizes compensation expense for the portion of the targeted performance-based restricted stock units subject to market conditions even if the condition is never satisfied. However, if the performance conditions are not met for the portion of the targeted performance-based restricted stock units subject to such performance conditions, no compensation expense will be recognized, and any previously recognized compensation expense will be reversed. Forfeitures are recognized as incurred.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Restricted Share-Based Activity

All units and per unit amounts in these consolidated financial statements and notes to the consolidated financial statements reflect the Reorganization that occurred in September 2015 (see Note 1). A summary of non-vested restricted share-based activity for the years ended December 31, 2017, 2016, and 2015 follows:

	Unvested Shares	Weighted Average Grant Date Fair Value
<i>Predecessor</i>		
Outstanding at January 1, 2015	1,242,065	\$ 1.96
Granted/Earned	569,114	6.31
Vested	(1,643,525)	3.79
Outstanding at December 31, 2015	167,654	\$ 2.53
Granted/Earned	384,629	15.09
Forfeited/Canceled	(53,003)	11.85
Vested	(37,038)	6.31
Outstanding at December 31, 2016	462,242	\$ 3.72
Granted/Earned	388,454	18.40
Forfeited/Canceled	(67,771)	18.01
Vested	(169,881)	10.29
Outstanding at August 31, 2017	613,044	\$ 16.02

Successor

Outstanding at September 1, 2017	613,044	\$ 16.02
Granted/Earned	112,107	11.15
Forfeited/Canceled	(54,622)	10.94
Vested	(96,073)	17.03
Outstanding at December 31, 2017	574,456	\$ 15.95

Stock Options

The Company did not grant any stock options during the year ended December 31, 2017. During the years ended December 31, 2016 and 2015, the Company granted options to purchase shares of the Company's common stock to certain directors in accordance with the 2015 Omnibus Incentive Plan. Options to purchase shares are granted with an exercise price equal to the fair market value of the Company's common stock on the day of grant, based on the closing price of the Company's common stock on the trading date immediately prior to the grant date, and become ratably exercisable beginning one year from the date of grant to three years after the date of grant. Forfeitures are recognized as incurred.

Option Valuation

In applying the Black-Scholes-Merton option pricing model, the Company used the following assumptions:

- *Risk-free interest rate.* The risk-free interest rate is used as a component of the fair value of stock options to take into account the time value of money. For the risk-free interest rate, the Company uses the implied yield on United States Treasury zero-coupon issues with a remaining term equal to the expected life, in years, of the options granted.
- *Expected volatility.* Volatility, for the purpose of share-based compensation, is a measurement of the amount that a share price has fluctuated. Expected volatility involves reviewing historical volatility and determining what, if any, change the share price will have in the future. The Company used historical stock price information of certain peer group companies for a period of time equal to the expected option life period to determine estimated volatility.

- *Expected life, in years.* A clear distinction is made between the expected life of an option and the contractual term of the option. The expected life of an option is considered the amount of time, in years, that an option is expected to be outstanding before it is exercised. Whereas, the contractual term of the stock option is the term an option is valid before it expires.
- *Expected dividend yield.* Since issuing dividends will affect the fair value of a stock option, GAAP requires companies to estimate future dividend yields or payments. The Company has not historically issued dividends and does not intend to issue dividends in the future. As a result, the Company does not apply a dividend yield component to its valuation.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The following table sets forth the assumptions used by the Company to estimate the fair value of options granted in 2016 and 2015 under the 2015 Omnibus Incentive Plan:

Expected volatility	29% - 43%
Risk-free interest rate	0.54% - 1.36%
Expected dividends	—
Average expected term (years)	2.56
Fair value of stock options granted	\$2.64 - \$5.74

The estimated fair value of options is amortized to expense on a straight-line basis over the options' vesting period.

Stock Option Activity

A summary of stock option activity for the years ended December 31, 2017, 2016, and 2015 follows:

	<u>Options</u>	<u>Weighted Average Exercise Price</u>	<u>Weighted Average Remaining Contractual Term (years)</u>
<i>Predecessor</i>			
Outstanding at January 1, 2015	—		
Granted	8,488	\$ 20.03	3.0
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2015	8,488	\$ 20.03	3.0
Granted	7,779	17.99	1.6
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2016	16,267	\$ 19.05	1.8
Granted	—		
Exercised	(3,580)	15.36	
Forfeited	—		
Outstanding at August 31, 2017	12,687	\$ 20.10	1.5

Successor

Outstanding at September 1, 2017	12,687	\$ 20.10	1.5
Granted	—		
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2017 ⁽¹⁾	12,687	\$ 20.10	1.2

⁽¹⁾ Of the outstanding options, 7,058 were exercisable as of December 31, 2017 (Successor).

Other information pertaining to equity-based compensation

At December 31, 2017 (Successor), unrecognized compensation cost related to unvested shares was approximately \$6.6 million. Unrecognized compensation cost will be expensed annually based on the number of shares that vest during the year.

The Company records equity-based compensation expense to recognize the fair value of the restricted shares that vest and stock options granted. During the four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), the Company recorded equity-based compensation expense of \$1.9 million and \$3.7 million, respectively. The Company recorded equity-based compensation expense of \$2.0 million and \$7.5 million during the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively. In connection with the IPO, 1,632,626 restricted shares immediately vested which resulted in accelerated vesting of \$6.2 million which is included within the \$7.5 million of equity-based compensation expense for the year ended December 31, 2015 (Predecessor).

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

13. Employee Benefit Plans

Surgery Partners 401(k) Plan

The Surgery Partners 401(k) Plan is a defined contribution plan whereby certain employees who have completed at least one month of service, including at least one hour of service during that period of time, are eligible to participate. Employees may enroll in the plan immediately upon completion of the minimum service requirement. The Surgery Partners 401(k) Plan allows eligible employees to make contributions of varying percentages or flat dollar amounts of their annual compensation, up to the maximum allowable amounts by the Internal Revenue Service ("IRS"). Eligible employees may or may not receive a match by the Company of their contributions. Employer contributions vest incrementally over a period of five years. The Company's contributions were \$2.3 million for the four months ended December 31, 2017 (Successor), \$2.8 million for the eight months ended August 31, 2017 (Predecessor). For the years ended December 31, 2016 and 2015, contributions were \$5.1 million and \$2.2 million, respectively.

Supplemental Executive Retirement Savings Plan

In connection with the Symbion acquisition, the Company acquired and continues to maintain a supplemental executive retirement savings plan (the "SERP") for certain former Symbion executives. The SERP provides supplemental retirement savings alternatives to eligible officers and key employees of the Company by allowing participants to defer portions of their compensation. Under the SERP, eligible employees may enroll in the plan before December 31 to be entered in the plan the following year. Eligible employees may defer into the SERP up to 25% of their normal period payroll and up to 50% of their annual bonus. If the enrolled employee contributes a minimum of 2% of his or her base salary into the SERP, the Company will contribute 2% of the enrolled employee's base salary to the plan and has the option of contributing additional amounts. Periodically, the enrolled employee's deferred amounts are transferred to a plan administrator. The plan administrator maintains separate non-qualified accounts for each enrolled employee to track deferred amounts. On May 1 of each year, the Company is required to make its contribution to each enrolled employee's account. See Note 2. "Significant Accounting Policies" for information about the fair value of the assets and liabilities in the SERP.

14. Related Party Transactions

On December 24, 2009, the Company and Bayside Capital, Inc. (or "Bayside"), an affiliate of H.I.G. Capital, LLC (or "H.I.G."), entered into a Management and Investment Advisory Services Agreement ("Management Agreement") pursuant to which the Company received certain management, consulting and financial advisory services. The Management Agreement was terminated upon completion of the IPO in 2015. Prior to termination, fees related to the Management Agreement of \$3.0 million were included as general and administrative expense in the accompanying consolidated statements of operations for the year ended December 31, 2015. As a result of the IPO, the Company further paid Bayside a transaction fee pursuant to the Management Agreement of \$5.4 million during the year ended December 31, 2015.

15. Commitments and Contingencies

Professional, General and Workers' Compensation Liability Risks

The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. To cover these claims, the Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that would have a material adverse effect on the Company's business, financial position, results of operations or liquidity.

Laws and Regulations

Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory action including fines, penalties, and exclusion from the Medicare, Medicaid and other federal healthcare programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians. It is the Company's current practice and future intent to cooperate fully with such inquiries. The Company is not aware of any such inquiry that would have a material adverse effect on the Company's business, financial position, results of operations or liquidity. In addition, on October 23, 2017, the Company received a civil investigative demand ("CID") from the federal government under the False Claims Act ("FCA") for

documents and information dating back to January 1, 2010 relating to the medical necessity of certain drug tests conducted by the Company's physicians and submitted to laboratories owned and operated by the Company. The Company intends to respond to the CID and cooperate with the U.S. Attorney's Office in connection with the FCA investigation.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Acquired Facilities

The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations, such as billing and reimbursement, fraud and abuse and similar anti-referral laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.

The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other healthcare providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.

Potential Physician Investor Liability

A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.

Contingent Consideration

Pursuant to a purchase agreement dated December 24, 2009 ("the Purchase Agreement"), the Company acquired controlling interests in 36 business entities in various Florida locations which operate freestanding ASCs and provided anesthesia and pain management services ("the 2009 Acquisition"). The Purchase Agreement provided for maximum potential contingent consideration of up to \$10.0 million based on operating results subsequent to the acquisition for the period from January 1, 2010 to December 31, 2010. Pursuant to the Purchase Agreement, the contingent consideration was payable as principal under a Subordinated Promissory Note, the form of which was delivered concurrent with the Purchase Agreement. In December 2010, the Company filed an indemnification claim against the Seller alleging breaches of and inaccuracies in representations and warranties included in the Purchase Agreement. On June 10, 2013, the court issued a judgment in favor of the Company regarding its indemnification claim and its claim regarding the overstatement of accounts receivable by the seller. Following the judgment, an appeal was filed by the seller and a cross-appeal was filed by the Company. In December 2016, the appeals court found in favor of the Company as well as dismissing the arguments raised by the seller in its appeal as without merit. The parties subsequently agreed to mediate the dispute, which was scheduled to begin in 2017. Based on a court order in December 2016, the Company removed the contingent consideration liability on its consolidated balance sheets. For the year ended December 31, 2016 (Predecessor) the Company recorded a gain on litigation settlement of \$14.1 million related to this matter.

On April 20, 2017, a settlement was reached between the two parties resulting in the Company receiving \$3.9 million of which \$2.7 million was paid from the escrow funds set up by the seller at the time of purchase and \$1.2 million was paid by the seller. During the second quarter of 2017 (Predecessor) the Company recorded a gain on litigation settlement of \$3.8 million for the settlement amount, net of legal costs.

In connection with an acquisition during the three months ended June 30, 2016, the applicable purchase agreement provided for potential contingent consideration of up to \$16.6 million to be paid to the prior owners of the applicable facility should the requirements for continuing employment agreed to in the purchase agreement be met. In accordance with ASC 805, Business Combinations, contingent consideration with a continuing employment provision is recognized ratably over the defined performance period as compensation expense. In the fourth quarter of 2017, the Company reached a settlement for a dispute with the prior owners, providing relief to the Company of any unpaid current and future liability related to the contingent consideration. Based on the settlement, the Company removed its accrued contingent consideration liability, which was included in other current liabilities in the consolidated balance sheets and recorded a gain on litigation settlement of \$8.7 million during the four months ended December 31, 2017 (Successor).

As disclosed in the footnotes to the consolidated statement of operations, the Company recognized contingent acquisition compensation expense of \$1.9 million for the four months ended December 31, 2017 (Successor) and \$5.1 million for both the eight months ended August 31, 2017 (Predecessor) and the year ended December 31, 2016 (Predecessor).

Subsequent to December 31, 2017, the Company estimates contingent acquisition compensation expense of \$1.5 million for the year ended December 31, 2018 related to other acquisitions completed in 2016.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

16. Segment Reporting

A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or "CODM," in deciding how to allocate resources and in assessing performance.

The Company operates in three major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of optical services and the operation of ancillary services. "All other" primarily consists of the Company's corporate general and administrative functions. Prior to 2017, the all other component was disaggregated and presented below the reportable operating segments in the Adjusted EBITDA reconciliation table. The Company has conformed the prior periods to align to the current year presentation. These changes had no effect on the Company's reportable operating segments, which are presented consistent with prior periods.

Adjusted EBITDA is the primary profit/loss metric reviewed by the CODM in making key business decisions and on allocation of resources. The segment disclosures below provide a reconciliation from Adjusted EBITDA to income before income taxes, its most directly comparable GAAP financial measure, in the reported consolidated financial information.

The following tables present financial information for each reportable segment (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Revenues:				
Surgical facility services	\$ 564,458	\$ 688,725	\$ 1,042,097	\$ 884,144
Ancillary services	24,660	52,261	90,836	61,175
Optical services	3,486	7,629	12,505	14,572
Total revenues	<u>\$ 592,604</u>	<u>\$ 748,615</u>	<u>\$ 1,145,438</u>	<u>\$ 959,891</u>

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Adjusted EBITDA:				
Surgical facility services	\$ 103,760	\$ 125,912	\$ 214,218	\$ 180,113
Ancillary services	(2,255)	(6,526)	12,685	18,715
Optical services	736	2,214	3,308	3,905
All other	(23,504)	(36,036)	(50,948)	(44,680)
Total Adjusted EBITDA ⁽¹⁾	<u>78,737</u>	<u>85,564</u>	<u>179,263</u>	<u>158,053</u>
Net income attributable to non-controlling interests	39,634	42,087	75,630	71,416
Depreciation and amortization	(21,804)	(30,124)	(39,551)	(34,545)
Interest expense, net	(48,740)	(68,929)	(100,571)	(100,980)
Non-cash stock compensation expense	(1,887)	(3,697)	(2,021)	(7,502)
Contingent acquisition compensation expense	(1,982)	(5,057)	(5,092)	—
Termination of management agreement and IPO costs	—	—	—	(5,834)
Management fee ⁽²⁾	—	—	—	(2,250)
Merger transaction, integration and practice acquisition costs ⁽³⁾	(9,330)	(7,677)	(11,617)	(20,579)
Gain on litigation settlement	8,740	3,794	14,101	—

Gain on acquisition escrow release	167	1,000	—	—
Gain (loss) on disposal or impairment of long-lived assets, net	(5)	(1,715)	(2,355)	2,097
Gain on amendment to tax receivable agreement	1,098	15,294	—	—
Tax receivable agreement benefit (expense)	25,329	—	(3,733)	(119,911)
Loss on debt refinancing	—	(18,211)	(11,876)	(16,102)
Income (loss) before income taxes	<u>\$ 69,957</u>	<u>\$ 12,329</u>	<u>\$ 92,178</u>	<u>\$ (76,137)</u>

⁽¹⁾The above table reconciles Adjusted EBITDA to income before income taxes as reflected in the consolidated statements of operations.

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

When the Company uses the term “Adjusted EBITDA,” it is referring to income before income taxes minus (a) net income attributable to non-controlling interests plus (b) depreciation and amortization, (c) interest expense, net, (d) non-cash stock compensation expense, (e) contingent acquisition compensation expense, (f) termination of management agreement and IPO costs, (g) management fee, (h) merger transaction, integration and practice acquisition costs, minus (i) gain on litigation settlement, (j) gain on acquisition escrow release, (plus)/minus (k) (loss)/gain on disposal or impairment of long-lived assets, net, minus (l) gain on amendment to tax receivable agreement, (plus)/minus (m) tax receivable agreement (expense)/gain and plus (n) loss on debt refinancing. The Company uses Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by the Company’s management to assess operating performance, make business decisions and allocate resources. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that the Company consolidates for financial reporting purposes. The Company believes that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors the Company’s portion of Adjusted EBITDA generated by its surgical facilities and other operations.

Adjusted EBITDA is not a measurement of financial performance under GAAP, and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating the Company’s financial performance. The Company believes such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. The Company’s calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

- ⁽²⁾ Fee payable pursuant the Management and Investment Advisory Services Agreement between the Company and Bayside, which was terminated in connection with the Company’s IPO.
- ⁽³⁾ This amount includes merger transaction and integration costs of \$7.5 million for the four months ended December 31, 2017 (Successor), \$5.6 million for the eight months ended August 31, 2017 (Predecessor), and \$8.7 million and \$17.9 million for the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively.
- This amount includes practice acquisition costs of \$1.8 million for the four months ended December 31, 2017 (Successor), \$2.1 million for the eight months ended August 31, 2017 (Predecessor), and \$2.9 million and \$2.7 million for the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively.

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Assets:		
Surgical facility services	\$ 4,072,521	\$ 1,914,842
Ancillary services	104,274	184,002
Optical services	48,309	22,478
All other	397,669	183,636
Total assets	<u>\$ 4,622,773</u>	<u>\$ 2,304,958</u>

In connection with the application of pushdown accounting the Company reevaluated the relative fair value of its operating segments using a measurement date of October 1, 2017. As a result of its evaluation, the Company reallocated goodwill as of the measurement date to each reportable segment as follows: \$3.158 billion to surgical facilities services, \$74.3 million to ancillary services and \$38.4 million to optical services.

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31, 2017	January 1 to August 31, 2017	Year Ended December 31,	
		2016	2015	
Cash purchases of property and equipment, net:				
Surgical facility services	\$ 9,334	\$ 14,582	\$ 29,157	\$ 26,723
Ancillary services	191	1,875	5,388	1,051
Optical services	83	73	351	128
All other	1,219	2,243	4,213	5,537
Total cash purchases of property and equipment, net	<u>\$ 10,827</u>	<u>\$ 18,773</u>	<u>\$ 39,109</u>	<u>\$ 33,439</u>

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

17. Quarterly Financial Information (Unaudited)

The following tables include a summary of certain information related to the Company's quarterly consolidated results of operations for each of the four quarters in the years ended December 31, 2017 and 2016. The timing of acquisitions and divestitures completed during the years presented affects the comparability of the quarterly financial information. The following should be read in conjunction with the audited consolidated financial statements included herein. The amounts are as follows (in thousands except per share amounts):

	2017				
	<i>Predecessor</i>			<i>Successor</i>	
	Q1	Q2	Q3 ⁽¹⁾	Q3 ⁽¹⁾	Q4
Revenues	\$ 286,183	\$ 288,353	\$ 174,079	\$ 132,258	\$ 460,346
Cost of revenues	\$ 211,948	\$ 216,452	\$ 143,772	\$ 102,924	\$ 338,704
Net income (loss)	\$ 14,422	\$ 11,627	\$ 4,369	\$ (2,648)	\$ 966
Net income attributable to non-controlling interests	\$ (17,176)	\$ (16,098)	\$ (8,813)	\$ (6,492)	\$ (33,142)
Net loss attributable to Surgery Partners, Inc.	\$ (2,754)	\$ (4,471)	\$ (4,444)	\$ (9,140)	\$ (32,176)
Basic net loss per share attributable to common stockholders ⁽²⁾	\$ (0.06)	\$ (0.09)	\$ (0.09)	\$ (0.57)	\$ (0.83)
Diluted net loss per share attributable to common stockholders ⁽²⁾	\$ (0.06)	\$ (0.09)	\$ (0.09)	\$ (0.57)	\$ (0.83)

⁽¹⁾ The Predecessor period for Q3 includes the two months ended August 31, 2017. The Successor period for Q3 includes the one month ended September 30, 2017.

⁽²⁾ Beginning in the Successor period, per share amounts include the impact of amounts allocated to participating securities. Refer to Note 10. "Earnings Per Share" for further discussion.

	2016			
	<i>Predecessor</i>			
	Q1	Q2	Q3	Q4
Revenues	\$ 267,074	\$ 289,681	\$ 282,682	\$ 306,001
Cost of revenues	\$ 196,703	\$ 208,852	\$ 201,394	\$ 214,247
Net income	\$ 10,357	\$ 22,293	\$ 14,334	\$ 38,100
Net income attributable to non-controlling interests	\$ (17,547)	\$ (20,173)	\$ (16,672)	\$ (21,238)
Net (loss) income attributable to Surgery Partners, Inc.	\$ (7,190)	\$ 2,120	\$ (2,338)	\$ 16,862
Basic net (loss) income per share attributable to common stockholders	\$ (0.15)	\$ 0.04	\$ (0.05)	\$ 0.35
Diluted net (loss) income per share attributable to common stockholders	\$ (0.15)	\$ 0.04	\$ (0.05)	\$ 0.35

SURGERY PARTNERS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

17. Subsequent Events

On March 1, 2018, the Company acquired a controlling interest of a surgical facility in Omaha, Nebraska, for \$21.9 million. The acquisition was funded through cash from operations. As of the date of this filing, the Company has not completed its preliminary estimation of the fair values assigned to the assets acquired and liabilities assumed.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SURGERY PARTNERS, INC.

By: /s/ Wayne S. DeVeydt
Wayne S. DeVeydt
Chief Executive Officer
(Principal Executive Officer)

Date: March 16, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURES	TITLE	DATE
<u>/s/ Wayne S. DeVeydt</u> Wayne S. DeVeydt	Chief Executive Officer, Director (Principal Executive Officer)	March 16, 2018
<u>/s/ R. David Kretschmer</u> R. David Kretschmer	Interim Chief Financial Officer (Principal Financial Officer)	March 16, 2018
<u>/s/ Dennis Dean</u> Dennis Dean	Senior Vice President, Corporate Controller (Principal Accounting Officer)	March 16, 2018
<u>/s/ T. Devin O'Reilly</u> T. Devin O'Reilly	Chairman, Director	March 16, 2018
<u>/s/ Teresa DeLuca</u> Teresa DeLuca	Director	March 16, 2018
<u>/s/ Adam Feinstein</u> Adam Feinstein	Director	March 16, 2018
<u>/s/ Brent Turner</u> Brent Turner	Director	March 16, 2018
<u>/s/ Christopher Gordon</u> Christopher Gordon	Director	March 16, 2018
<u>/s/ Clifford G. Adlerz</u>	Director	March 16, 2018

TRA Waiver and Assignment Agreement

This TRA waiver and assignment agreement (this "Agreement"), dated as of September 15, 2017, is hereby entered into by and among Surgery Partners, Inc., a Delaware corporation (the "Corporation"), and [•] ("Employee"). Reference is hereby made to that certain Income Tax Receivable Agreement, by and among the Corporation, the Stockholders Representative, Employee and the other parties referred to therein, dated as of September 30, 2015 and amended by that certain Amendment No. 1 to Income Tax Receivable Agreement dated as of May 9, 2017 (as amended or otherwise modified, the "Tax Receivable Agreement"). All capitalized terms used and not otherwise defined herein shall have the meanings ascribed thereto in the Tax Receivable Agreement. In consideration of the respective covenants and agreements set forth herein, and intending to be legally bound hereby, the parties hereto agree as follows:

1. The Corporation hereby agrees to pay to Employee the amount set forth opposite Employee's name below on or before the date which is ten (10) days after the date of this Agreement, by wire transfer of immediately available funds to such account or accounts as may be designated in writing by Employee no later than two (2) Business Days prior to such date:

Employee	Amount
[•]	[•]

2. In consideration for the payments payable by the Corporation to Employee pursuant to Section 1 of this Agreement, Employee hereby agrees to assign and transfer to the Corporation, and otherwise hereby waives, one-hundred percent (100%) of Employee's right, title and interest in and to any ITR Payment payable pursuant to the Tax Receivable Agreement. The Corporation hereby accepts such assignment and transfer and hereby agrees to hold such right, title and interest in accordance with and subject to the terms of the Tax Receivable Agreement and accordingly to be bound by the terms thereof to the extent applicable to such right, title and interest. The Corporation hereby acknowledges that any and all requirements under Section 7.06(a) of the Tax Receivable Agreement with respect to such assignment and transfer are hereby satisfied. For the avoidance of doubt, pursuant to and in accordance with this Section 2, with respect to each ITR Payment payable after the date of this Agreement, Employee will be entitled to receive zero percent (0%) of Employee's share of such ITR Payment and the Corporation shall be entitled to receive or retain one-hundred percent (100%) of Employee's share of such ITR Payment.

3. The Corporation shall be entitled to deduct and withhold from any payment payable pursuant to this Agreement such amounts as the Corporation is required to deduct and withhold with respect to the making of such payment under the Code, or any applicable provision of state or local or foreign Tax law. To the extent that amounts are so withheld and paid over to the appropriate Taxing Authority by the Corporation, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to Employee.

4. The amount of all or any portion of any payment payable by the Corporation to Employee pursuant to Section 1 of this Agreement not made to Employee when due under the terms of this Agreement shall be payable together with any interest thereon, computed at the Default Rate and commencing from the date on which such payment was due and payable. Notwithstanding anything in this Agreement to the contrary, it shall not be a breach of this Agreement if the Corporation fails to make or cause to be made any payment payable by the Corporation to Employee pursuant to Section 1 of this Agreement when due to the extent that the Corporation determines in good faith that the Corporation has insufficient funds (taking into account funds of its wholly-owned Subsidiaries that are permitted to be distributed or loaned to the Corporation pursuant to the terms of any applicable credit agreements or other documents evidencing indebtedness (each as reasonably interpreted by the Corporation), but not taking into account funds of its

wholly-owned Subsidiaries that are not permitted to be distributed or loaned pursuant to the terms of such agreements or documents and not taking into account funds reasonably reserved for reasonably expected liabilities or expenses) to make such payment; provided that the interest provisions of the previous sentence shall apply to such late payment (unless the Corporation determines in good faith that (x) the Corporation does not have sufficient cash to make such payment as a result of limitations imposed by credit agreements or any other documents evidencing indebtedness to which the Corporation or its wholly-owned Subsidiaries is a party, guarantor or otherwise an obligor as of the date of this Agreement (the “Initial Debt Documents”) or any other document evidencing indebtedness to which the Corporation or its wholly-owned Subsidiaries becomes a party, guarantor or otherwise an obligor thereafter to the extent the terms of such other documents are not materially more restrictive in respect of the Corporation’s ability to receive from its direct or indirect Subsidiaries funds sufficient to make such payments compared to the terms of the Initial Debt Documents, as determined by the Corporation in good faith (any such document, collectively with the Initial Debt Documents, the “Permitted Debt Documents”), or (y) such payments could (I) be set aside as fraudulent transfers or conveyances or similar actions under fraudulent transfer laws or (II) could cause the Corporation and/or its wholly-owned Subsidiaries to be undercapitalized, in which case the interest provisions of the previous sentence shall apply, but the Default Rate shall be replaced by the Agreed Rate). The Corporation represents to Employee that it has sufficient funds to make the payments pursuant to Section 1, there are no limitations pursuant to any agreements, including any credit agreements or other documents evidencing indebtedness, which would prevent the Corporation from making such payments, and the making of the payments under Section 1 will not result in it and/or its wholly-owned Subsidiaries being undercapitalized or result in the payment potentially being set aside as a fraudulent transfer or conveyance under fraudulent transfer laws.

5. Sections 1.02, 7.02, 7.03, 7.04 and 7.05 of the Tax Receivable Agreement are hereby incorporated by reference into this Agreement and shall apply as if fully set forth herein *mutatis mutandis*. Employee may not assign any of Employee’s rights and obligations under this Agreement without the prior written consent of the Corporation. No provision of this Agreement may be amended unless such amendment is approved in writing by the Corporation and Employee. No provision of this Agreement may be waived unless such waiver is in writing and signed by the party against whom the waiver is to be effective. All of the terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of and shall be enforceable by the parties hereto and their respective successors, permitted assigns, heirs, executors, administrators and legal representatives.

6. All notices, requests, consents and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by courier service, by fax, by electronic mail (delivery receipt requested) or by certified or registered mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be as specified in a notice given in accordance with this Section 6):

If to the Corporation, to:

Surgery Partners, Inc.
40 Burton Hills Boulevard
Suite 500
Nashville, Tennessee 37215
Fax: (615) 234-5998
Attention: General Counsel
Email: jbaldock@surgerypartners.com

with a copy (which shall not constitute notice) to:

Ropes & Gray LLP
1211 Avenue of the Americas
New York, NY 10036
Attention: Carl Marcellino

Facsimile: (646) 728-1523

Email: Carl.Marcellino@ropesgray.com

If to Employee, to the address set forth under Employee's name on the signature page hereto.

7. Any and all disputes which cannot be settled amicably between the Corporation and any Employee, including any ancillary claims of any party, arising out of, relating to or in connection with the validity, negotiation, execution, interpretation, performance or non-performance of this Agreement (including the validity, scope and enforceability of this arbitration provision) shall be finally settled by arbitration conducted by a single arbitrator in accordance with the then existing Rules of Arbitration of the International Chamber of Commerce. The place of arbitration shall be New York, New York. The parties shall jointly select a single arbitrator who shall have the authority to hold hearings and to render a decision in accordance with the then existing Rules of Arbitration of the International Chamber of Commerce. If the Corporation and Employee fail to agree on the selection of an arbitrator within thirty (30) calendar days of the receipt of the request for arbitration, the arbitrator shall be selected by the International Chamber of Commerce. The arbitrator shall be a lawyer. The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. Section 1, et seq., and judgment on the award may be entered by any court having jurisdiction thereof. Performance under this Agreement shall continue if reasonably possible during any arbitration proceedings. Notwithstanding the foregoing, either the Corporation or Employee may bring an action or special proceeding in any court of competent jurisdiction for the purpose of compelling a party to arbitrate, seeking temporary or preliminary relief in aid of an arbitration hereunder, and/or enforcing an arbitration award and, for such purposes, Section 7.07(c) of the Tax Receivable Agreement is hereby incorporated by reference into this Agreement and shall apply to any such action or proceeding as if fully set forth herein *mutatis mutandis*.

[Signature pages follow]

IN WITNESS WHEREOF, the Corporation and Employee have duly executed this Agreement as of the date first written above.

Corporation:

SURGERY PARTNERS, INC.

By: _____

Name:

Title:

Employee:

Name:

Address:

[Signature Page to TRA Waiver and Assignment Agreement]

FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT

THIS FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Amendment") is hereby entered into on December 21, 2017, by and between Surgery Partners, Inc. ("Parent"), Symbion, Inc. ("Symbion"), and together with Parent, the "Company") and Teresa Sparks ("Executive").

RECITALS

A. The Company and the Executive entered into that certain Amended and Restated Employment Agreement dated September 17, 2015, as amended from time to time (the "Agreement").

B. The Company and the Executive desire to amend certain provisions of the Agreement pursuant to the terms and conditions set forth herein.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Section 3(a) of the Agreement is hereby amended to add the following provisions to the end thereof:

"Effective as of December 21, 2017, Executive's Base Salary shall be increased to \$475,000. Such increase shall be retroactive to August 31, 2017, and shall be reflected in the payroll period next following the effective date of such increase."

2. Section 3(d) of the Agreement is hereby deleted in its entirety and replaced with the following:

"(d) For the years beginning with 2018, in addition to Base Salary, Executive will be eligible to receive an annual bonus of sixty-five percent (65%) of Base Salary. Executive's annual bonus for the 2017 fiscal year will be determined based on the following: (i) the portion of Executive's annual bonus attributable to the period commencing on the first day of the 2017 fiscal year and ending on August 30, 2017 shall be determined based on a target of fifty percent (50%) of Base Salary as in effect during such portion of the 2017 fiscal year, and (ii) the portion of Executive's annual bonus attributable to the period commencing on August 31, 2017 and ending on the last day of the 2017 fiscal year shall be determined based on a target of sixty-five percent (65%) of Base Salary (of \$475,000) which, in each of subsections (i) and (ii) shall be pro-rated for the applicable partial fiscal year. The actual amount of any such bonus described hereunder shall be determined by the Board or the Committee, in either case, in its discretion, based on the achievement of performance goals established annually by the Board or the Committee, as applicable. Any annual bonus payable under this Section 3(d) will be paid no later than March 15th following the close of the year for which the bonus is earned."

3. The following new Section 3(f) is added immediately following Section 3(e) of the Agreement:

"(f) Prior to or during the Company's annual compensation review process for calendar year 2018, the Company shall review Executive's equity incentive award opportunity for calendar year 2018 and Executive's severance entitlement, in each case, in light of Executive's overall compensation package and the compensation packages of similarly situated executives at comparable companies (as determined by the Board or its designee in its sole discretion and consistent with the peer group selected by the Board as a benchmark for the compensation for the Company's NEOs in 2018 and the proxy to be filed for 2018). Adjustments to increase Executive's compensation, if any, in light of such review shall be determined by the Board or its designee in its sole discretion."

4. Section 4(g)(iii) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Compensation after Termination.

(iii) If the Employment Period has commenced and is terminated by the Company without Cause or by Executive for Good Reason or this Agreement is not renewed by the Company or is allowed to expire by the Company, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, “Severance Pay”): (A) an amount equal to the sum of Executive’s then-current annual Base Salary, payable in regular installments for 12 months beginning within 30 days following the Termination Date in accordance with the Company’s general payroll practices for salaried employees; (B) continuation of the welfare benefits described in Section 3(b) for 12 months (the “Severance Period”) to the extent permissible under the terms of the relevant benefit plans at no cost to Executive; (C) the Bonus payable to Executive within 2 and 1/2 months after the end of the applicable year; (D) with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the “Time-Based RSA”), accelerated vesting of the Time-Based RSA to the vesting event next following the date on which the Employment Period is terminated; and (E) with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into “earned shares” (the “Earned PSUs”), accelerated vesting of the Earned PSUs to the vesting event next following the date on which the Employment Period is terminated. For purposes of this Section 4(g)(iii), (x) “Bonus” shall mean an amount equal to Executive’s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof as in effect on the date of termination, and (y) if the Employment Period is terminated by the Executive by reason of Section 4(b)(ii), the term “Base Salary” and the bonus percentage described in Section 4(g)(iii)(x) shall be the Base Salary and bonus percentage, as applicable, as in effect immediately prior to the material reduction in such Base Salary or bonus percentage, as applicable, described in Section 4(b)(ii). For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D) and (E) herein and the acceleration provisions in any applicable equity award agreement or plan as well as the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect. For the avoidance of doubt, the accelerated vesting of Executive’s equity awards as set forth in subsections (D) and (E) are in addition to, and not in lieu of, any additional accelerated vesting under the applicable equity or long-term incentive award agreements and/or the applicable plan.

5. Section 4(g)(iv) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Compensation after Termination.

(iv) If, within 12 months following a Change in Control, either (A) the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B) Executive terminates her employment for Good Reason under Section 4(b) above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay. The Company will make any payment of the Severance Pay set forth in Section 4(g)(iii)(A) and (B) that is due under this clause (iv) in a single lump-sum payment not later than 30 days after termination. If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company’s obligation to make the payment(s) described in this paragraph.”

6. Section 4(g)(vi) of the Agreement is hereby amended to add the following provision to the end thereof:

“Notwithstanding anything to the contrary in this Agreement, except as otherwise provided in Section 4(g)(ii) and 4(g)(iii), Executive’s equity incentive awards shall be governed by the applicable award agreement and Plan.”

7. Executive expressly acknowledges and agrees that she shall not be entitled, and hereby waives her right (if any), to resign her employment with the Company for “Good Reason” pursuant to Section 4(b)(iv) of the Agreement in connection with any increase in Executive’s core functional responsibilities and/or change in Executive’s core functional role by reason of, or in connection with, the consummation of the transactions contemplated by the Agreement and Plan of Merger by and among Parent, SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH L.P. (solely in its capacity as Sellers’ Representative), dated as of March 9, 2017.

8. This Amendment may be executed in counterparts and by means of a facsimile machine or PDF, each of which shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

9. This Amendment shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflicts of law.

10. Except as set forth herein, the Agreement shall remain in full force and effect.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.

SURGERY PARTNERS, INC.

By: /s/ Jennifer Baldock
Jennifer Baldock
Senior Vice President, General Counsel and Secretary

SYMBION, INC.

By: /s/ Jennifer Baldock
Jennifer Baldock
Vice President and Secretary

Accepted and Agreed:

/s/ Teresa Sparks
Teresa Sparks

Date: December 21, 2017

November 22, 2017

Dear John:

This letter agreement amends the Employment Agreement among you, Surgery Partners, Inc. (“Parent”) and Symbion, Inc. (“Symbion” and, together with Parent, the “Company”), dated September 17, 2015 (the “Employment Agreement”). All capitalized terms used in this letter shall have the meaning ascribed to them in the Agreement unless otherwise expressly provided herein. This letter agreement shall be effective as of the date first written above.

In consideration of the promises, the mutual covenants of the parties hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, you hereby agree to amend the Employment Agreement, pursuant to Section 21 therein, as follows:

The closing paragraph of Section 4(b) of the Employment Agreement is hereby deleted in its entirety and replaced with the following, effective as of the date hereof:

“but only if (x) Executive notifies the Company in writing within 90 days of the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive’s belief that Good Reason exists and that Executive intends to resign for Good Reason and the Company, within 30 days after receipt of such notice, either fails to cure the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y) Executive actually resign prior to 15 days after the earlier to occur of either the end of such 30-day cure period or delivery of such written notice by the Company. Notwithstanding the foregoing, Executive shall have up to and through November 30, 2018 to notify the Company with respect to an event described in subsection (i) above that occurred, regardless of the initial existence or occurrence, as a result of any change in Executive’s title, reporting structure, duties and responsibilities by reason of, or relating to, the consummation of the transactions contemplated by the Agreement and Plan of Merger by and among Parent, SP Merger Sub., Inc. NSH Holdco, Inc. and IPC / NSH L.P. (solely in its capacity as the Sellers’ Representative), dated as of May 9, 2017 (the “NSH Transaction”).”

This letter agreement may only be amended by a writing signed by you and a duly authorized representative of the Company. Except as provided herein, all terms and conditions of the Employment Agreement, as set forth therein, remain in full force and effect. This letter agreement embodies the entire agreement between the parties with respect to amending the Employment Agreement and supersedes all prior communications, agreements and understandings, whether written or oral, with respect to the same. This letter agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same instrument.

If the foregoing is acceptable to you, please sign this letter in the space provided and return it to me. At the time you sign and return it, this letter will take effect as a binding agreement between you and the Company on the basis set forth above. The enclosed copy is for your records.

Very truly yours,

SURGERY PARTNERS, INC.

By: /s/ Jennifer Baldock
Jennifer Baldock
Senior Vice President and General Counsel

SYMBION, INC.

By: /s/ Jennifer Baldock
Jennifer Baldock
Senior Vice President and General Counsel

Accepted and Agreed:

/s/ John Crysel
John Crysel

Date: 11/28/17

AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT

This AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT (this "Amendment") is made as of the 21st day of December, 2017, by and among Surgery Partners, Inc., a Delaware corporation (the "Company"), Michael T. Doyle ("Doyle") and MD Healthcare Partners, LLC, a Florida limited liability company ("MDHC," and together with Doyle and the Company, the "Parties").

WHEREAS, the Company, Surgery Partners, LLC and Doyle are parties to that certain Termination and Release Agreement, dated as of September 7, 2017 (the "Termination Agreement"), pursuant to which such parties mutually agreed to terminate their employment relationship under the terms and conditions set forth therein;

WHEREAS, the Company and Doyle are parties to that certain Consulting Services Agreement, dated as of September 7, 2017 (the "Consulting Agreement"), pursuant to which Doyle agreed to provide certain consulting services to the Company for a period of six months following the cessation of Doyle's employment;

WHEREAS, Doyle desires to provide the Services through MDHC, Doyle's wholly-owned affiliate;

WHEREAS, the Consulting Agreement may be amended by the mutual written agreement of the Company and Doyle; and

WHEREAS, the Parties desire to amend the Consulting Agreement as set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties hereto agree as follows:

1. Definitions. Capitalized terms used herein but not otherwise defined shall have the meanings given to such terms in the Consulting Agreement. All references in this Amendment to definitions and sections shall be deemed references to definitions and sections in the Consulting Agreement, except as explicitly stated herein.

2. Addition of Parties. MDHC is hereby added a party to the Consulting Agreement, as set forth in this Amendment. For the avoidance of doubt, Doyle shall remain a party to the Consulting Agreement, as set forth herein.

3. Amendment to Definition of Consultant. The definition of "Consultant" in the Consulting Agreement is hereby amended by deleting the words "Michael T. Doyle" and replacing them with "MD Healthcare Partners, LLC, a Florida limited liability company." All references in the Consulting Agreement to "he," "him," "his," "himself" and words of similar import are hereby deleted and replaced with references to "the Consultant," "itself," and words of similar import, as appropriate.

4. Amendment to Definition of Termination Agreement. The reference to "the Consultant" in the definition of "Termination Agreement" in the Consulting Agreement is hereby replaced with a reference to "Michael T. Doyle ("MTD")", such that the first recital of the Consulting Agreement reads as follows:

"**WHEREAS**, the Company and Michael T. Doyle ("MTD"), an affiliate of the Consultant, are parties to that certain Termination and Release Agreement, dated as of September 7, 2017 (the "Termination Agreement");"

5. Amendment to Section 5 – Restrictive Covenants. Section 5 of the Consulting Agreement, "Restrictive Covenants," is hereby amended in its entirety to read as follows:

"MTD hereby reaffirms, and the Consultant hereby agrees to be bound by (*mutatis mutandis*), the rights and obligations contained within Sections 5 through 8 of that certain Employment Agreement (the "Employment Agreement"), dated September 17, 2015, by and among the Company, Surgery Partners, LLC and MTD, as

modified by Section 3 of the Termination Agreement. The Company acknowledges and agrees that the services to be provided hereunder are non-exclusive and, as such, as long as MTD and the Consultant comply with Section 7(a) of the Employment Agreement, as modified by Section 3 of the Termination Agreement, the Consultant and MTD are free to provide services to any other person or entity during the Term. For the avoidance of doubt, the Consultant agrees to be bound by Section 3 of the Termination Agreement mutatis mutandis.”

6. Insertion of New Section 6 – Certain Provisions Relating to the Consultant and MTD. A new Section 6, entitled “Certain Provisions Relating to the Consultant and MTD” is hereby added to the Consulting Agreement as set forth below, and the remaining sections, “Governing Law” and “Entire Agreement,” shall be deemed renumbered accordingly:

“The Consultant and MTD hereby jointly and severally represent, warrant, covenant and agree as follows: (i) MTD is the sole beneficial and record owner of 100% of the membership and voting interests of the Consultant, and the sole “manager” thereof, (ii) none of the Consultant or MTD shall transfer the membership or voting interests of the Consultant at any time that the Consulting Agreement remains in effect and (iii) MTD hereby guarantees to the Company the due and punctual performance by the Consultant of all of the obligations and liabilities of the Consultant under or in respect of the Consulting Agreement, including any obligations or liabilities of the Consultant arising from any breach of the Consulting Agreement by the Consultant, and warrants, covenants and agrees that such guarantee is absolute, unconditional, irrevocable and continuing and that his obligations hereunder shall not be released or discharged, in whole or in part, or otherwise affected by the failure or delay on the part of the Company to assert any claim or demand or to enforce any right or remedy hereunder or by any insolvency, bankruptcy, reorganization or other similar proceeding instituted by or against the Consultant.”

7. Miscellaneous.

(a) Continuation of Agreement. Except as amended hereby, all terms and conditions of the Consulting Agreement shall remain in full force and effect. Any reference to the Consulting Agreement, whether in the Consulting Agreement or in any other agreement, document or instrument, shall be a reference to the Consulting Agreement (including any schedules or exhibits attached thereto) as amended by this Amendment.

(b) Entire Agreement; No Waiver; Conflicts. The Consulting Agreement, as amended hereby, constitutes the entire agreement by and among the Parties with regard to the subject matter hereof, and supersedes any prior discussions hereon. Except as expressly provided herein, this Amendment shall not be deemed to be a waiver or modification of any term, condition or covenant of the Consulting Agreement. In the event of a conflict between the terms of the Consulting Agreement and this Amendment, the terms of this Amendment shall control.

(c) Incorporation by Reference. The provisions of Section 6 of the Consulting Agreement, “Governing Law,” are hereby incorporated by reference in and made applicable to this Amendment, *mutatis mutandis*.

(d) Counterparts. This Amendment may be executed in two or more counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together shall constitute one and the same agreement.

[Remainder of page intentionally left blank.]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first written above.

SURGERY PARTNERS, INC.

By: /s/ Teresa F. Sparks

Name: Teresa F. Sparks
Title: Executive Vice President,
Chief
Financial Officer

/s/ Michael T. Doyle

Michael T. Doyle

MD HEALTHCARE PARTNERS, LLC

By: /s/ Michael T. Doyle

Name: Michael T. Doyle
Title: Manager

[Signature Page to Amendment No. 1 to Consulting Services Agreement]

**Subsidiaries of
Surgery Partners, Inc.**

Entity Name	Jurisdiction of Organization	Doing Business As
Advanced Pain Institute Treatment Center, LLC	Louisiana	
Afshin Gerayli, MD	California	Pain Specialists of Orange County
AllCare Clinical Associates, P.A.	North Carolina	
Ambulatory Resource Centres Investment Company, LLC	Delaware	
Ambulatory Resource Centres of Washington, Inc.	Tennessee	
Ambulatory Resource Centres of Wilmington, Inc.	Tennessee	
Anesthesiology Professional Services, Inc.	Florida	
Animas Surgical Hospital, LLC	Delaware	
APS of Bradenton, LLC	Florida	
APS of Hammond, LLC	Delaware	
APS of Jonesboro, LLC	Delaware	
APS of Merritt Island, LLC	Florida	
APS of Suncoast, LLC	Florida	
ARC Development Corporation	Tennessee	
ARC Financial Services Corporation	Tennessee	
ARC Kentucky, LLC	Tennessee	ARC Kentucky/Louisville, LLC
ARC of Bellingham, L.P.	Tennessee	
ARC of Georgia, LLC	Tennessee	Premier Surgery Center
Arizona Spine & Joint Hospital, LLC	Arizona	
Armenia Ambulatory Surgery Center, LLC	Florida	
ASC Gamma Partners, Ltd.	Florida	West Kendall Surgical Center
ASC of New Albany, LLC	Indiana	
Asheville Pain Relief Center, P.C.	North Carolina	
ASJH Joint Venture, LLC	Arizona	
Aspen Surgery Center, LLC	California	
Baton Rouge Anesthesia Services, LLC	Delaware	
Bay Area Surgical Ventures, LLC	California	
Bayside Endoscopy Center, LLC	Rhode Island	
Birmingham Surgery Center, LLC	Delaware	
Blue Ridge NovaMed, Inc.	Missouri	
Blue Ridge Surgical Center, LLC	Delaware	
Boulder Spine Center, LLC	Delaware	Minimally Invasive Spine Institute
Bradenton Anesthesia Services, LLC	Florida	
Brazos Valley Physicians Alliance	Texas	
Brazos Valley Physicians Organization MSO, LLC	Texas	
Brentwood Surgery Center, LLC	California	
Bristol Spine Center, LLC	Delaware	Renaissance Surgery Center
Cache Valley Specialty Hospital, LLC	Utah	
Canyon Ambulatory Surgery Center, LLC	North Carolina	
Cape Coral Ambulatory Surgery Center, LLC	Florida	

Cape Coral Anesthesia Services, LLC

Florida

CBSH, LLC

Texas

CC Pocatello, LLC

Idaho

CCIF, LLC

Delaware

Chesterfield Spine Center, LLC

Delaware

St. Louis Spine and Orthopedic Surgery Center

CMMP Surgical Center, L.L.C.	Missouri	
CMSC, LLC	Montana	
Coastal Bend Medical Park, LLC	Texas	
Coastal Bend Surgery Center, Ltd	Texas	
Coastal Pain Center, LLC	Georgia	
Collier Anesthesia Pain, LLC	Florida	
Community Care Channing Way, LLC	Delaware	
Community Care Rexburg, LLC	Delaware	
Community Care West Side, LLC	Delaware	
Community Hospital Holding Company, LLC	Georgia	
Community Hospital Management Company, LLC	Georgia	
Complete Care Pharmacy, LLC	Florida	
Consultants in Pain Medicine, LLC	Georgia	
Cypress Surgery Center, LLC	Delaware	
Delaware Outpatient Center for Surgery, LLC	Delaware	
Dupont Anesthesia Services, P.S.C.	Kentucky	
El Paso Specialty Hospital, Ltd	Texas	
El Paso Specialty Physicians Group	Texas	
Epix Anesthesia of Houston, PLLC	Texas	
Fairfield Surgery Center, LLC	Connecticut	
Great Falls Clinic Surgery Center, L.L.C.	Montana	
Hammond Anesthesia Services, LLC	Louisiana	
Honolulu Spine Center, LLC	Delaware	Honolulu Sports and Spine Center
IFSC Acquisition, LLC	Delaware	
IPM Surgery Centers, LLC	California	SpinalCARE Surgicenter
Jacksonville Beach Surgery Center, LLC	Tennessee	Jacksonville Beach Surgery Center
Jenkins County Hospital, LLC	Georgia	
Jonesboro Anesthesia Services, LLC	Arkansas	
Kent, LLC	Rhode Island	
Lafayette Surgical Hospital, LLC	Louisiana	
Lake Mary Surgery Center, L.L.C.	Florida	
Largo Endoscopy Center, L.P.	Tennessee	Tampa Bay Regional Surgery Center
Largo Surgery, LLC	Florida	West Bay Surgery Center
Laser and Outpatient Surgery Center, LLC	Delaware	
Logan Laboratories, LLC	Delaware	
Lubbock Heart Hospital, LLC	Delaware	Lubbock Heart & Surgical Hospital
Lubbock Surgicenter, Inc.	Texas	
Medical Billing Solutions, LLC	Florida	
Medical Center Endoscopy, LLC	Texas	
Midwest Uncuts, Inc.	Iowa	Midwest Labs
Millenia Surgery Center, L.L.C.	Florida	
Minimally Invasive Surgical and Neuroscience Center, LLC	Delaware	
Mission Hills Surgicenter, LLC	California	Mission Hills Pain Treatment Center
Montana Health Partners, LLC	Montana	
Mountain View Hospital, LLC	Delaware	
MV Oncology, LLC	Delaware	

MVH Anesthesia, LLC
MVH BMC, LLC
MVH Idaho Falls Oncology, LLC
MVH SNF Holding, LLC

Idaho
Idaho
Delaware
Idaho

Eagle Rock Anesthesia

National Surgical Hospitals, Inc.	Delaware	
NeoSpine Puyallup Spine Center, LLC	Delaware	Microsurgical Spine Center
NeoSpine Surgery of Bristol, LLC	Delaware	
NeoSpine Surgery of Puyallup, LLC	Delaware	
NeoSpine Surgery, LLC	Delaware	
New Albany Outpatient Surgery, L.P.	Delaware	
New Tampa Surgery Center, Ltd.	Florida	
North Carolina Specialty Hospital, LLC	North Carolina	
North Dakota Surgery Center, LLC	Delaware	
North Idaho Day Surgery, LLC	Idaho	
Northwest Ambulatory Surgery Services, LLC	Washington	Bellingham Ambulatory Surgery Center
NovaMed Acquisition Company, Inc.	Delaware	
NovaMed Alliance, Inc.	Delaware	Optical Synergies Premier Vision Buying Group The Buyers Edge The Alliance
NovaMed Eye Surgery and Laser Center of St. Joseph, Inc.	Missouri	
NovaMed Eye Surgery Center of Maryville, LLC	Delaware	Eyes of Illinois Surgery Center
NovaMed Eye Surgery Center of New Albany, L.L.C.	Delaware	
NovaMed Eye Surgery Center of North County, LLC	Delaware	Woodcrest Surgery Center
NovaMed Eye Surgery Center of Overland Park, LLC	Delaware	
NovaMed Management of Kansas City, Inc.	Missouri	
NovaMed Management Services, LLC	Delaware	
NovaMed of Bethlehem, Inc.	Delaware	
NovaMed of Laredo, Inc.	Delaware	
NovaMed of Lebanon, Inc.	Delaware	
NovaMed of San Antonio, Inc.	Delaware	
NovaMed of Texas, Inc.	Delaware	
NovaMed of Wisconsin, Inc.	Delaware	
NovaMed Pain Management Center of New Albany, LLC	Delaware	
NovaMed Surgery Center of Baton Rouge, LLC	Delaware	Interventional Pain Management Center
NovaMed Surgery Center of Bedford, LLC	Delaware	NH Eye Surgicenter
NovaMed Surgery Center of Chattanooga, LLC	Delaware	
NovaMed Surgery Center of Chicago-Northshore, LLC	Delaware	NovaMed Eye Surgery Center – Northshore
NovaMed Surgery Center of Cleveland, LLC	Delaware	The Surgery Center of Cleveland
NovaMed Surgery Center of Colorado Springs, LLC	Delaware	United Ambulatory Surgery Center
NovaMed Surgery Center of Denver, LLC	Delaware	Colorado Outpatient Eye Surgery Center
NovaMed Surgery Center of Jonesboro, LLC	Delaware	Eye Surgery Center of Arkansas
NovaMed Surgery Center of Madison, Limited Partnership	Wisconsin	
NovaMed Surgery Center of Nashua, LLC	Delaware	Nashua Eye Surgery Center
NovaMed Surgery Center of Oak Lawn, LLC	Delaware	Center for Reconstructive Surgery
NovaMed Surgery Center of Orlando, LLC	Delaware	Downtown Surgery Center
NovaMed Surgery Center of San Antonio, L.P.	Delaware	American Surgery Centers of South Texas
NovaMed Surgery Center of Sandusky, LLC	Delaware	Surgery Center of Sandusky
NovaMed Surgery Center of St. Peters, LLC	Delaware	St. Peters Ambulatory Surgery Center
NovaMed Surgery Center of Tyler, L.P.	Delaware	The Cataract Center of East Texas

NovaMed Surgery Center of Warrensburg, LLC

Delaware

Surgery Center of Warrensburg

NovaMed Surgery Center of Whittier, LLC

Delaware

Eye Surgery Center of Warrensburg

NovaMed, Inc.

Delaware

Center for Outpatient Surgery

Surgery Partners

NSH Bryan Hospital, Inc.	Texas	
NSH California, Inc.	California	
NSH Connecticut, Inc.	Connecticut	
NSH Durham, Inc.	North Carolina	
NSH El Paso Specialty Hospital, Inc.	Texas	
NSH El Paso, Inc.	Texas	
NSH Georgia, Inc.	Delaware	
NSH Holdco, Inc.	Delaware	
NSH Indiana, Inc.	Indiana	
NSH LA GP Holdings, Inc.	Louisiana	
NSH Logan, Inc.	Utah	
NSH Louisiana, Inc.	Louisiana	
NSH Management of Arizona, Inc.	Arizona	
NSH Management of California, Inc.	California	
NSH Mesa Real Estate, LLC	Arizona	
NSH Mesa, Inc.	Arizona	
NSH Michigan Properties, LLC	Michigan	
NSH Michigan, Inc.	Michigan	
NSH North Idaho, Inc.	Idaho	
NSH Oklahoma, Inc.	Oklahoma	
NSH San Antonio Surgical Hospital, Inc.	Texas	
NSH Texas, Inc.	Illinois	
NSH Wisconsin, Inc.	Wisconsin	
Oak Leaf Surgical Hospital, LLC	Wisconsin	
Ocean State Endoscopy Holdings, LLC	Rhode Island	
Orange City Anesthesia Services, LLC	Florida	
Orange City Surgery Center, LLC	Florida	
Orthopaedic Surgery Center of Asheville, L.P.	Tennessee	Orthopaedic Surgery Center of Asheville, Limited
Orthopedic & Spine Surgical Hospital of South Texas, LP	Texas	
Park Place Surgery Center, L.L.C.	Florida	
Physicians Medical Center, L.L.C.	Louisiana	
Physicians Surgery Center, LLC	Delaware	Lee Island Coast Surgery Center
Physicians Surgical Care, Inc.	Delaware	
PMCROS, L.L.C.	Louisiana	
Portsmouth, LLC	Delaware	
PSC Development Company, LLC	Delaware	
PSC of New York, L.L.C.	Delaware	
PSC Operating Company, LLC	Delaware	
PSHS Alpha Partners, Ltd.	Florida	Lake Worth Surgery Center
PSHS Beta Partners, Ltd.	Florida	The Gables Surgical Center
Quahog Holding Company, LLC	Delaware	
Quantum Enterprises, PLLC	Colorado	
Riverside Anesthesia Services, LLC	Florida	
Riverside Billing & Management Company, LLC	Florida	
Riverside Spine & Pain Physicians, LLC	Florida	

Riverside Surgical Center, LLC	Florida
Saint Thomas Compounding LLC	Florida
Sarasota Ambulatory Surgery Center, Ltd.	Florida
Sarasota Anesthesia Services, LLC	Florida
SARC/Asheville, Inc.	Tennessee

SARC/Ft. Myers, Inc.	Tennessee
SARC/Georgia, Inc.	Tennessee
SARC/Kent, LLC	Tennessee
SARC/Largo Endoscopy, Inc.	Tennessee
SARC/Largo, Inc.	Tennessee
SARC/Providence, LLC	Tennessee
SARC/St. Charles, Inc.	Tennessee
SARC/Vincennes, Inc.	Tennessee
Sentry Anesthesia Management, LLC	Georgia
Sentry Medical Billing, LLC	Georgia
Screven County Family Health Center, LLC	Georgia
Screven County Hospital, LLC	Georgia
Sequoia Surgical Center Holding Company, LLC	California
Sequoia Surgical Center, LP	California
Sequoia Surgical Pavillion, LLC	California
Skyway Surgery Center, LLC	California
SMBI DOCS, LLC	Tennessee
SMBI Great Falls, LLC	Tennessee
SMBI Havertown, LLC	Tennessee
SMBI Idaho, LLC	Tennessee
SMBI Jackson, LLC	Delaware
SMBI LHH, LLC	Delaware
SMBI Portsmouth, LLC	Tennessee
SMBI STLWSC, LLC	Tennessee
SMBIMS Birmingham, Inc.	Tennessee
SMBIMS Durango, LLC	Tennessee
SMBIMS Florida I, LLC	Florida
SMBIMS Greenville, LLC	Tennessee
SMBIMS Kirkwood, LLC	Tennessee
SMBIMS Steubenville, Inc.	Tennessee
SMBIMS Wichita, LLC	Tennessee
SMBISS Beverly Hills, LLC	Tennessee
SMBISS Chesterfield, LLC	Tennessee
SMBISS Encino, LLC	Tennessee
SMBISS Irvine, LLC	Tennessee
SMBISS Thousand Oaks, LLC	Tennessee
Southeast Michigan Surgical Hospital, LLC	Michigan
Southern Crescent Anesthesiology, PC	Georgia
Southern Crescent Nurse Anesthesia, LLC	Georgia
SP California Management, LLC	Delaware
SP Holdco I, Inc.	Delaware
SP Louisiana, LLC	Louisiana
SP Management Services, Inc.	Tennessee

SymbionARC Management Services
Surgery Partners Management Services, Inc.
SGRY SP Management Services, Inc.

SGRY Surgery Partners Management Services, Inc.

SP North Dakota, LLC
SP Practice Management, LLC
Space Coast Anesthesia Services, LLC
Space Coast Surgery Center LLLP

Delaware
Delaware
Florida
Florida

Specialty Surgical Center of Beverly Hills, L.P.	California	
Specialty Surgical Center of Encino, L.P.	California	
Specialty Surgical Center of Encino, LLC	California	
Specialty Surgical Center of Irvine, L.P.	California	
Specialty Surgical Center of Irvine, LLC	California	
Specialty Surgical Center, LLC	California	
St. Louis Women's Surgery Center, LLC	Delaware	St. Louis Women's Multispecialty Surgery Center
STSSH Physicians Organization	Texas	
Suncoast Specialty Surgery Center, LLLP	Florida	
Surgery Center Holdings, Inc.	Delaware	
Surgery Center Holdings, LLC	Delaware	
Surgery Center of Fremont, LLC	Delaware	
Surgery Center of Kalamazoo, LLC	Michigan	
Surgery Center of Lebanon, LP	Pennsylvania	Physicians Surgical Center
Surgery Center of Pennsylvania, LLC	Pennsylvania	
Surgery Center Partners, LLC	Delaware	Timberlake Surgery Center
Surgery Partners Acquisition Company, Inc.	Florida	
Surgery Partners of Coral Gables, LLC	Florida	
Surgery Partners of Lake Mary, LLC	Florida	
Surgery Partners of Lake Worth, LLC	Florida	
Surgery Partners of Merritt Island, LLC	Florida	
Surgery Partners of Millenia, LLC	Florida	
Surgery Partners of New Tampa, LLC	Florida	
Surgery Partners of Park Place, LLC	Florida	
Surgery Partners of Sarasota, LLC	Florida	
Surgery Partners of Suncoast, LLC	Florida	
Surgery Partners of West Kendall, L.L.C.	Florida	
Surgery Partners of Westchase, LLC	Florida	
Surgery Partners, LLC	Florida	SGRY SP, LLC
Symbion Ambulatory Resource Centres, Inc.	Tennessee	
Symbion Anesthesia Services, LLC	Delaware	
Symbion Holdings Corporation	Delaware	
Symbion JV, LLC	Tennessee	
Symbion, Inc.	Delaware	
SymbionARC Support Services, LLC	Tennessee	
Tampa Pain Relief Center, Inc.	Florida	Central Florida Pain Relief Centers Florida Orthopedic Partners Florida Pain Institute - Melbourne Florida Pain Institute - Merritt Island Florida Pain Institute - Palm Bay Florinda Pain Institute - Pineda Florida Pain Institute - Titusville Florida Pain Institute - Viera Florida Pain Relief Centers Florida Spine Sports and Rehabilitation Center

Jacksonville Pain Relief Center
Kaizen Orthopedics
Medical Village Urgent Care
Orlando Pain Relief Center
Pain Institute Of Tampa

Tattnall Hospital Company, LLC
Texarkana Surgery Center GP, Inc.
Texarkana Surgery Center, L.P.
Texas Physician Group
The Center for Special Surgery, LLC
The Center for Specialized Surgery, LP
The Surgery Center of Ocala, LLC
The Surgery Center, L.L.C.
UniPhy Healthcare of Johnson City VI, LLC
UniPhy Healthcare of Maine I, Inc.
United ASC Holding Company, LLC
US Orthopedics, Inc.
Valley Ambulatory Surgery Center, L.P.
Valley Medical Inn, L.P.
Valley Surgical Center, Ltd.
VASC, Inc.
Village Surgicenter, Inc.
Village Surgicenter, Limited Partnership
West Bloomfield Surgery Center LLC
Westchase Surgery Center, Ltd.
Wilmington Surgery Center, L.P.

Georgia
Texas
Delaware
Texas
Delaware
Pennsylvania
Tennessee
Georgia
Tennessee
Tennessee
Delaware
North Carolina
Illinois
Illinois
Ohio
Illinois
Delaware
Delaware
Michigan
Florida
Tennessee

Pain Management of Brandon
Pain Medicine Institute
Palm Beach Pain Relief Center
Rehabilitation Medical Group
Sarasota Pain Relief Center - Bee Ridge
Sarasota Pain Relief Center - Bradenton
Sarasota Pain Relief Center - CPCS
Sarasota Pain Relief Center - Downtown
Sarasota Pain Relief Center - PMC
Sarasota Pain Relief Center - Venice
Sarasota Pain Relief Center
South Florida Pain Relief Center - Boynton Beach
South Florida Pain Relief Center
Tampa Pain Relief Center - Himes

Austin Wound Care and Hyperbaric Center

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-207298) pertaining to the Surgery Partners, Inc. 2015 Omnibus Incentive Plan, of our reports dated March 16, 2018, with respect to the consolidated financial statements of Surgery Partners, Inc. and the effectiveness of internal control over financial reporting of Surgery Partners, Inc., included in this Annual Report (Form 10-K) of Surgery Partners, Inc. for the year ended December 31, 2017.

/s/ Ernst & Young LLP

Nashville, Tennessee
March 16, 2018

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) OF
THE SECURITIES AND EXCHANGE ACT, AS AMENDED AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Wayne S. DeVeydt, certify that:

1. I have reviewed this annual report on Form 10-K of Surgery Partners, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By: /s/ Wayne S. DeVeydt
Wayne S. DeVeydt
Chief Executive Officer
(Principal Executive Officer)

Date: March 16, 2018

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) AND RULE 15d- 14(a) OF
THE SECURITIES AND EXCHANGE ACT, AS AMENDED AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, R. David Kretschmer, certify that:

1. I have reviewed this annual report on Form 10-K of Surgery Partners, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By: /s/ R. David Kretschmer
R. David Kretschmer
Interim Chief Financial Officer
(Principal Financial Officer)

Date: March 16, 2018

**CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the annual report on Form 10-K of Surgery Partners, Inc. (the "Company") for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Wayne S. DeVeydt, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

By: /s/ Wayne S. DeVeydt
Wayne S. DeVeydt
Chief Executive Officer
(Principal Executive Officer)

Date: March 16, 2018

**CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the annual report on Form 10-K of Surgery Partners, Inc. (the "Company") for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, R. David Kretschmer, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

By: /s/ R. David Kretschmer
R. David Kretschmer
Interim Chief Financial Officer
(Principal Financial Officer)

Date: March 16, 2018

**Document and Entity
Information - USD (\$)
\$ in Millions**

12 Months Ended

Dec. 31, 2017 Mar. 15, 2018 Jun. 30, 2017

Document and Entity Information [Abstract]

<u>Entity Registrant Name</u>	Surgery Partners, Inc.		
<u>Entity Central Index Key</u>	0001638833		
<u>Current Fiscal Year End Date</u>	--12-31		
<u>Entity Filer Category</u>	Accelerated Filer		
<u>Document Type</u>	10-K		
<u>Document Period End Date</u>	Dec. 31, 2017		
<u>Document Fiscal Year Focus</u>	2017		
<u>Document Fiscal Period Focus</u>	FY		
<u>Amendment Flag</u>	false		
<u>Entity Common Stock, Shares Outstanding</u>		48,611,578	
<u>Entity Well-known seasoned issuer</u>	No		
<u>Entity Voluntary Filers</u>	No		
<u>Entity Current Reporting Status</u>	Yes		
<u>Entity Public Float</u>			\$ 484.1

Consolidated Balance Sheets
- USD (\$)
\$ in Thousands

Dec. 31, Dec. 31,
2017 2016

Current assets:

<u>Cash and cash equivalents</u>	\$ 174,914	
<u>Accounts receivable, less allowance for doubtful accounts of \$2,026 and \$29,872, respectively</u>	288,023	
<u>Inventories</u>	44,951	
<u>Prepaid expenses and other current assets</u>	55,337	
<u>Total current assets</u>	563,225	
<u>Property and equipment, net</u>	398,536	\$ 204,253
<u>Intangible assets, net</u>	58,908	
<u>Goodwill</u>	3,346,838	
<u>Investments in and advances to affiliates</u>	74,282	
<u>Restricted invested assets</u>	315	
<u>Long-term deferred tax assets</u>	132,319	
<u>Other long-term assets</u>	48,350	
<u>Total assets</u>	4,622,773	

Current liabilities:

<u>Accounts payable</u>	84,710	
<u>Accrued payroll and benefits</u>	49,625	
<u>Other current liabilities</u>	109,944	
<u>Current maturities of long-term debt</u>	58,726	
<u>Total current liabilities</u>	303,005	
<u>Long-term debt, less current maturities</u>	2,130,556	
<u>Long-term tax receivable agreement liability</u>	43,791	
<u>Other long-term liabilities</u>	178,689	
<u>Non-controlling interests—redeemable</u>	299,316	
<u>Redeemable preferred stock - Series A, 310,000 shares authorized, issued and outstanding, redemption value of \$330,806 at December 31, 2017; no shares were authorized, issued or outstanding at December 31, 2016.</u>	330,806	

Stockholders' equity:

<u>Preferred stock, \$0.01 par value, 20,000,000 shares authorized, no shares issued or outstanding</u>	0	
<u>Common stock, \$0.01 par value, 300,000,000 shares authorized, 48,687,136 shares issued and outstanding at December 31, 2017; 48,488,616 shares issued and outstanding at December 31, 2016.</u>	487	
<u>Additional paid-in capital</u>	695,560	
<u>Retained deficit</u>	(41,316)	
<u>Total Surgery Partners, Inc. stockholders' equity</u>	654,731	
<u>Non-controlling interests—non-redeemable</u>	681,879	
<u>Total stockholders' equity</u>	1,336,610	
<u>Total liabilities and stockholders' equity</u>	4,622,773	
<u>Redeemable Preferred Stock</u>		

Current liabilities:

Redeemable preferred stock - Series A, 310,000 shares authorized, issued and outstanding, redemption value of \$330,806 at December 31, 2017; no shares were authorized, issued or outstanding at December 31, 2016. \$ 330,806

Predecessor**Current assets:**

<u>Cash and cash equivalents</u>	69,699
<u>Accounts receivable, less allowance for doubtful accounts of \$2,026 and \$29,872, respectively</u>	220,594
<u>Inventories</u>	28,777
<u>Prepaid expenses and other current assets</u>	42,885
<u>Total current assets</u>	361,955
<u>Property and equipment, net</u>	204,253
<u>Intangible assets, net</u>	48,023
<u>Goodwill</u>	1,555,204
<u>Investments in and advances to affiliates</u>	34,980
<u>Restricted invested assets</u>	315
<u>Long-term deferred tax assets</u>	83,793
<u>Other long-term assets</u>	16,435
<u>Total assets</u>	2,304,958

Current liabilities:

<u>Accounts payable</u>	49,766
<u>Accrued payroll and benefits</u>	29,273
<u>Other current liabilities</u>	79,864
<u>Current maturities of long-term debt</u>	27,822
<u>Total current liabilities</u>	186,725
<u>Long-term debt, less current maturities</u>	1,414,421
<u>Long-term tax receivable agreement liability</u>	122,351
<u>Other long-term liabilities</u>	76,266
<u>Non-controlling interests—redeemable</u>	180,521

Stockholders' equity:

<u>Preferred stock, \$0.01 par value, 20,000,000 shares authorized, no shares issued or outstanding</u>	0
<u>Common stock, \$0.01 par value, 300,000,000 shares authorized, 48,687,136 shares issued and outstanding at December 31, 2017; 48,488,616 shares issued and outstanding at December 31, 2016.</u>	485
<u>Additional paid-in capital</u>	320,543
<u>Retained deficit</u>	(311,351)
<u>Total Surgery Partners, Inc. stockholders' equity</u>	9,677
<u>Non-controlling interests—non-redeemable</u>	314,997
<u>Total stockholders' equity</u>	324,674
<u>Total liabilities and stockholders' equity</u>	2,304,958

Predecessor | Redeemable Preferred Stock**Current liabilities:**

Redeemable preferred stock - Series A, 310,000 shares authorized, issued and outstanding, redemption value of \$330,806 at December 31, 2017; no shares were authorized, issued or outstanding at December 31, 2016.

\$ 0

Consolidated Balance Sheets
(Parenthetical) - USD (\$)
\$ in Thousands

Dec. 31, 2017 **Dec. 31, 2016**

<u>Accounts receivable, allowance for doubtful accounts</u>	\$ 2,026	
<u>Redeemable preferred stock, shares authorized (in shares)</u>	310,000	
<u>Redeemable preferred stock, shares issued (in shares)</u>	310,000	
<u>Redeemable preferred stock, shares outstanding (in shares)</u>	310,000	
<u>Redeemable preferred stock, redemption value</u>	\$ 330,806	
<u>Preferred stock, par value (USD per share)</u>	\$ 0.01	
<u>Preferred stock, shares authorized (in shares)</u>	20,000,000	
<u>Preferred stock, shares issued (in shares)</u>	0	
<u>Preferred stock, shares outstanding (in shares)</u>	0	
<u>Common stock, par value (USD per share)</u>	\$ 0.01	
<u>Common stock, shares authorized (in shares)</u>	300,000,000	
<u>Common stock, shares issued (in shares)</u>	48,687,136	
<u>Common stock, shares outstanding (in shares)</u>	48,687,136	
<u>Predecessor</u>		
<u>Accounts receivable, allowance for doubtful accounts</u>		\$ 29,872
<u>Preferred stock, par value (USD per share)</u>		\$ 0.01
<u>Preferred stock, shares authorized (in shares)</u>		20,000,000
<u>Preferred stock, shares issued (in shares)</u>		0
<u>Preferred stock, shares outstanding (in shares)</u>		0
<u>Common stock, par value (USD per share)</u>		\$ 0.01
<u>Common stock, shares authorized (in shares)</u>		300,000,000
<u>Common stock, shares issued (in shares)</u>		48,488,616
<u>Common stock, shares outstanding (in shares)</u>		48,488,616
<u>Predecessor Redeemable Preferred Stock</u>		
<u>Redeemable preferred stock, shares authorized (in shares)</u>		0
<u>Redeemable preferred stock, shares issued (in shares)</u>		0
<u>Redeemable preferred stock, shares outstanding (in shares)</u>		0
<u>Redeemable preferred stock, redemption value</u>		\$ 0

Consolidated Statements of Operations - USD (\$) \$ in Thousands	4 Months	8 Months	12 Months Ended	
	Ended Dec. 31, 2017	Ended Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Revenues</u>	\$ 592,604			
<u>Operating expenses:</u>				
<u>Salaries and benefits</u>	175,403			
<u>Supplies</u>	161,015			
<u>Professional and medical fees</u>	45,061			
<u>Lease expense</u>	27,868			
<u>Other operating expenses</u>	32,281			
<u>Cost of revenues</u>	441,628			
<u>General and administrative expenses</u>	[1]29,153			
<u>Depreciation and amortization</u>	21,804			
<u>Provision for doubtful accounts</u>	12,455			
<u>Income from equity investments</u>	(3,319)			
<u>Loss (gain) on disposal or impairment of long-lived assets, net</u>	5			
<u>Merger transaction and integration costs</u>	7,470			
<u>Loss on debt refinancing</u>	0			
<u>Gain on litigation settlements</u>	(8,740)			
<u>Gain on acquisition escrow release</u>	(167)			
<u>Termination of management agreement and IPO costs</u>	0			
<u>Electronic health records incentive expense (income)</u>	45			
<u>Other (income) expense</u>	0			
<u>Total operating expenses</u>	500,334			
<u>Operating income</u>	92,270			
<u>Gain on amendment to tax receivable agreement</u>	1,098			
<u>Tax receivable agreement benefit (expense)</u>	25,329			
<u>Interest expense, net</u>	(48,740)			
<u>Income (loss) before income taxes</u>	69,957			
<u>Income tax expense (benefit)</u>	71,639			
<u>Net (loss) income</u>	(1,682)			
<u>Less: Net income attributable to non-controlling interests</u>	(39,634)			
<u>Net (loss) income attributable to Surgery Partners, Inc.</u>	(41,316)			
<u>Less: Amounts attributable to participating securities</u>	[2](26,047)			
<u>Net (loss) income attributable to common stockholders</u>	\$ (67,363)			
<u>Net (loss) income per share attributable to common stockholders</u>				
<u>Basic (in USD per share)</u>	\$ (1.39)			

<u>Diluted (in USD per share)</u>	\$ (1.39)		
<u>Weighted average common shares outstanding</u>			
<u>Basic (in shares)</u>	48,319,193		
<u>Diluted (in shares)</u>	48,319,193		
<u>Contingent acquisition compensation expense</u>	\$ 1,900		
<u>Predecessor</u>			
<u>Revenues</u>	\$ 748,615	\$ 1,145,438	\$ 959,891
<u>Operating expenses:</u>			
<u>Salaries and benefits</u>	241,149	357,175	261,685
<u>Supplies</u>	193,322	269,239	242,083
<u>Professional and medical fees</u>	57,931	81,185	66,583
<u>Lease expense</u>	36,503	52,147	44,848
<u>Other operating expenses</u>	43,267	61,450	54,127
<u>Cost of revenues</u>	572,172	821,196	669,326
<u>General and administrative expenses</u> [1]	46,797	60,246	55,992
<u>Depreciation and amortization</u>	30,124	39,551	34,545
<u>Provision for doubtful accounts</u>	16,297	24,212	23,578
<u>Income from equity investments</u>	(3,148)	(4,764)	(3,777)
<u>Loss (gain) on disposal or impairment of long-lived assets, net</u>	1,715	2,355	(2,097)
<u>Merger transaction and integration costs</u>	5,584	8,738	17,920
<u>Loss on debt refinancing</u>	18,211	11,876	16,102
<u>Gain on litigation settlements</u>	(3,794)	(14,101)	0
<u>Gain on acquisition escrow release</u>	(1,000)	0	0
<u>Termination of management agreement and IPO costs</u>	0	0	5,834
<u>Electronic health records incentive expense (income)</u>	(305)	(408)	(1,761)
<u>Other (income) expense</u>	(2)	55	(525)
<u>Total operating expenses</u>	682,651	948,956	815,137
<u>Operating income</u>	65,964	196,482	144,754
<u>Gain on amendment to tax receivable agreement</u>	15,294	0	0
<u>Tax receivable agreement benefit (expense)</u>	0	(3,733)	(119,911)
<u>Interest expense, net</u>	(68,929)	(100,571)	(100,980)
<u>Income (loss) before income taxes</u>	12,329	92,178	(76,137)
<u>Income tax expense (benefit)</u>	(18,089)	7,095	(148,982)
<u>Net (loss) income</u>	30,418	85,083	72,845
<u>Less: Net income attributable to non-controlling interests</u>	(42,087)	(75,630)	(71,416)
<u>Net (loss) income attributable to Surgery Partners, Inc.</u>	(11,669)	9,453	1,429
<u>Less: Amounts attributable to participating securities</u> [2]	0	0	0
<u>Net (loss) income attributable to common stockholders</u>	\$ (11,669)	\$ 9,453	\$ 1,429

Net (loss) income per share attributable to common stockholders

<u>Basic (in USD per share)</u>	\$ (0.24)	\$ 0.20	\$ 0.04
<u>Diluted (in USD per share)</u>	\$ (0.24)	\$ 0.20	\$ 0.04
<u>Weighted average common shares outstanding</u>			
<u>Basic (in shares)</u>	48,121,404	48,018,944	36,066,233
<u>Diluted (in shares)</u>	48,121,404	48,190,738 ^[3]	37,464,387 ^[3]
<u>Contingent acquisition compensation expense</u>	\$ 5,100	\$ 5,100	

[1] Includes contingent acquisition compensation expense of \$1.9 million for the four months ended December 31, 2017 (Successor), and \$5.1 million for both the eight months ended August 31, 2017 (Predecessor), and the year ended December 31, 2016 (Predecessor).

[2] Includes accrued dividends and undistributed earnings allocated to participating securities and the mark to redemption adjustment for the Series A Preferred Stock. There were no participating securities during the Predecessor periods. See Note 10. "Earnings Per Share" for further discussion.

[3] The impact of potentially dilutive securities for four months ended December 31, 2017 and the eight months ended August 31, 2017 were not considered because the effect would be anti-dilutive in those periods.

Consolidated Statements of Comprehensive Income (Loss) - USD (\$) \$ in Thousands	4 Months	8 Months	12 Months Ended	
	Ended Dec. 31, 2017	Ended Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Net (loss) income</u>	\$ (1,682)			
<u>Other comprehensive income</u>	0			
<u>Comprehensive (loss) income</u>	(1,682)			
<u>Less: Comprehensive income attributable to non-controlling interests</u>	(39,634)			
<u>Comprehensive (loss) income attributable to Surgery Partners, Inc. Predecessor</u>	\$ (41,316)			
<u>Net (loss) income</u>		\$ 30,418	\$ 85,083	\$ 72,845
<u>Other comprehensive income</u>		0	0	0
<u>Comprehensive (loss) income</u>		30,418	85,083	72,845
<u>Less: Comprehensive income attributable to non-controlling interests</u>		(42,087)	(75,630)	(71,416)
<u>Comprehensive (loss) income attributable to Surgery Partners, Inc.</u>		\$ (11,669)	\$ 9,453	\$ 1,429

Consolidated Statements of Stockholders' Equity (Deficit) - USD (\$) \$ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Deficit	Non-Controlling Interests— Non- Redeemable
<u>Beginning Balance, stockholders' equity (in shares) (Predecessor) at Dec. 31, 2014</u>	[1]	1,000			
<u>Beginning Balance, stockholders' equity (Predecessor) at Dec. 31, 2014</u>	\$ 29,536	\$ 0	[1] \$ 58,151	\$ (322,233)	\$ 293,618
<u>Increase (Decrease) in Stockholders' Equity [Roll Forward]</u>					
<u>Net (loss) income Predecessor</u>	55,229			1,429	53,800
<u>Equity-based compensation Predecessor</u>	7,502		7,502		
<u>Acquisition and disposal of shares of non-controlling interests, net Predecessor</u>	3,486		(835)		4,321
<u>Distributions to non-controlling interests—non-redeemable holders Predecessor</u>	(49,784)				(49,784)
<u>Initial public offering (in shares) Predecessor</u>	[1]	14,285,000			
<u>Initial public offering Predecessor</u>	250,979	\$ 143	[1] 250,836		
<u>Effect of Reorganization (in shares) Predecessor</u>	[1],[2]	33,870,990			
<u>Effect of Reorganization Predecessor</u>	[2]	339	\$ 339	[1]	
<u>Other Predecessor</u>	640		640		
<u>Ending Balance, stockholders' equity (in shares) (Predecessor) at Dec. 31, 2015</u>	[1]	48,156,990			
<u>Ending Balance, stockholders' equity (Predecessor) at Dec. 31, 2015</u>	297,927	\$ 482	[1] 316,294	(320,804)	301,955
<u>Increase (Decrease) in Stockholders' Equity [Roll Forward]</u>					
<u>Net (loss) income Predecessor</u>	67,060			9,453	57,607
<u>Issuance of restricted and unrestricted shares (in shares) Predecessor</u>	[1]	331,626			
<u>Issuance of restricted and unrestricted shares Predecessor</u>	0	\$ 3	[1] (3)		

Equity-based compensation Predecessor	2,021		2,021		
Acquisition and disposal of shares of non-controlling interests, net Predecessor	6,284		2,231		4,053
Distributions to non-controlling interests—non-redeemable holders Predecessor	\$ (48,618)				(48,618)
Ending Balance, stockholders' equity (in shares) (Predecessor) at Dec. 31, 2016	48,488,616		48,488,616	[1]	
Ending Balance, stockholders' equity (Predecessor) at Dec. 31, 2016	\$ 324,674	\$ 485	[1] 320,543	(311,351)	314,997
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Net (loss) income Predecessor	20,803			(11,669)	32,472
Issuance of restricted and unrestricted shares (in shares) Predecessor	[1]	355,607			
Issuance of restricted and unrestricted shares Predecessor	0	\$ 3	[1] (3)		
Equity-based compensation Predecessor	3,697		3,697		
Cancellation of restricted shares (in shares) Predecessor	[1]	(33,908)			
Cancellation of restricted shares Predecessor	(790)		(790)		
Acquisition of NSH Predecessor	172,645				172,645
Acquisition and disposal of shares of non-controlling interests, net Predecessor	(2,146)		3,483		(5,629)
Distributions to non-controlling interests—non-redeemable holders Predecessor	(38,875)				(38,875)
Ending Balance, stockholders' equity (in shares) (Predecessor) at Aug. 31, 2017	[1]	48,810,315			
Ending Balance, stockholders' equity (in shares) at Aug. 31, 2017	[1]	48,810,315			
Ending Balance, stockholders' equity (Predecessor) at Aug. 31, 2017	480,008	\$ 488	[1] 326,930	(323,020)	475,610
Ending Balance, stockholders' equity at Aug. 31, 2017	1,405,086	\$ 488	[1] 720,118	0	684,480

**Increase (Decrease) in
Stockholders' Equity [Roll
Forward]**

<u>Net (loss) income</u>	(14,613)			(41,316)	26,703
<u>Issuance of restricted and unrestricted shares (in shares)</u>	[1]	112,107			
<u>Issuance of restricted and unrestricted shares</u>	0	\$ 1	1		
<u>Equity-based compensation</u>	1,887		1,887		
<u>Cancellation of restricted shares (in shares)</u>	[1]	(54,622)			
<u>Cancellation of restricted shares</u>	(585)		(585)		
<u>Preferred dividends</u>	(10,481)		(10,481)		
<u>Mark to redemption adjustment</u>	(15,566)		(15,566)		
<u>Reallocation in application of pushdown accounting</u>	(21,248)				(21,248)
<u>Acquisition and disposal of shares of non-controlling interests, net</u>	19,401		2,195		17,206
<u>Distributions to non-controlling interests—non-redeemable holders</u>	(25,262)				(25,262)
<u>Repurchase of shares (in shares)</u>	[1]	(180,664)			
<u>Repurchase of shares</u>	\$ (2,009)	\$ (2)	[1](2,007)	0	0
<u>Ending Balance, stockholders' equity (in shares) at Dec. 31, 2017</u>	48,687,136	48,687,136	[1]		
<u>Ending Balance, stockholders' equity at Dec. 31, 2017</u>	\$ 1,336,610	\$ 487	[1]\$ 695,560	\$ (41,316)	\$ 681,879

[1] As described in Note 1 herein, the common stock of the Company is that of Surgery Partners, Inc. as of December 31, 2017, 2016 and 2015 and that of Surgery Center Holdings, Inc. as of December 31, 2014.

[2] As a result of the Reorganization that occurred on September 30, 2015 (as further described in Note 1), Surgery Center Holdings, Inc. became an indirect wholly owned subsidiary of Surgery Partners, Inc. and the common stock of Surgery Center Holdings, Inc. is eliminated in consolidation.

Consolidated Statements of Cash Flows - USD (\$) \$ in Thousands	4 Months Ended	8 Months Ended	12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Cash flows from operating activities:</u>				
<u>Net (loss) income</u>	\$ (1,682)			
<u>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</u>				
<u>Depreciation and amortization</u>	21,804			
<u>Amortization of debt issuance costs, discounts and premium</u>	(559)			
<u>Amortization of unfavorable lease liability</u>	(221)			
<u>Equity-based compensation</u>	1,887			
<u>Loss (gain) on disposal or impairment of long-lived assets, net</u>	5			
<u>Gain on legal settlements</u>	(8,740)			
<u>Loss on debt refinancing</u>	0			
<u>Gain on amendment to tax receivable agreement</u>	(1,098)			
<u>Tax receivable agreement (benefit) expense</u>	(25,329)			
<u>Deferred income taxes</u>	71,031			
<u>Interest on contingent consideration obligation</u>	0			
<u>Provision for doubtful accounts</u>	12,455			
<u>Income from equity investments, net of distributions received</u>	678			
<u>Changes in operating assets and liabilities, net of acquisitions and divestitures:</u>				
<u>Accounts receivable</u>	(31,500)			
<u>Other operating assets and liabilities</u>	14,494			
<u>Net cash provided by operating activities</u>	53,225			
<u>Cash flows from investing activities:</u>				
<u>Purchases of property and equipment, net</u>	(10,827)			
<u>Payments for acquisitions, net of cash acquired</u>	(29,249)			
<u>Proceeds from divestitures</u>	1,183			
<u>Net cash used in investing activities</u>	(38,893)			
<u>Cash flows from financing activities:</u>				
<u>Proceeds from initial public offering, net of offering costs</u>	0			
<u>Principal payments on long-term debt</u>	(18,629)			
<u>Borrowings of long-term debt</u>	409			
<u>Payments of debt issuance costs</u>	(4)			
<u>Penalty on prepayment of debt</u>	0			
<u>Payment of premium of debt extinguishment</u>	0			
<u>Proceeds from preferred stock issuance</u>	0			
<u>Payments of stock issuance costs</u>	0			
<u>Payments of preferred dividends</u>	(1,316)			
<u>Distributions to non-controlling interest holders</u>	(33,490)			
<u>Proceeds from (payments related to) ownership transactions with non-controlling interest holders</u>	998			

<u>Repurchase of shares</u>	(2,009)		
<u>Financing lease obligations</u>	1,007		
<u>Other financing activities</u>	(590)		
<u>Net cash (used in) provided by financing activities</u>	(53,624)		
<u>Net (decrease) increase in cash and cash equivalents</u>	(39,292)		
<u>Cash and cash equivalents at beginning of period</u>	214,206		
<u>Cash and cash equivalents at end of period</u>	174,914	\$ 214,206	
<u>Supplemental cash flow information:</u>			
<u>Interest paid, net of interest income received</u>	40,872		
<u>Cash paid for income taxes</u>	485		
<u>Non-cash purchases of property and equipment under capital leases and financing activities</u>	14,872		
<u>Predecessor</u>			
<u>Cash flows from operating activities:</u>			
<u>Net (loss) income</u>		30,418	\$ 85,083 \$ 72,845
<u>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</u>			
<u>Depreciation and amortization</u>	30,124	39,551	34,545
<u>Amortization of debt issuance costs, discounts and premium</u>	5,091	7,199	6,263
<u>Amortization of unfavorable lease liability</u>	(217)	(431)	(431)
<u>Equity-based compensation</u>	3,697	2,021	7,502
<u>Loss (gain) on disposal or impairment of long-lived assets, net</u>	1,715	2,355	(2,097)
<u>Gain on legal settlements</u>	0	(14,101)	0
<u>Loss on debt refinancing</u>	18,211	11,876	16,102
<u>Gain on amendment to tax receivable agreement</u>	(15,294)	0	0
<u>Tax receivable agreement (benefit) expense</u>	0	3,733	119,911
<u>Deferred income taxes</u>	(18,703)	6,882	(149,891)
<u>Interest on contingent consideration obligation</u>	0	1,124	1,041
<u>Provision for doubtful accounts</u>	16,297	24,212	23,578
<u>Income from equity investments, net of distributions received</u>	489	(846)	(543)
<u>Changes in operating assets and liabilities, net of acquisitions and divestitures:</u>			
<u>Accounts receivable</u>	8,837	(60,622)	(48,783)
<u>Other operating assets and liabilities</u>	(12,947)	17,203	4,439
<u>Net cash provided by operating activities</u>	67,718	125,239	84,481
<u>Cash flows from investing activities:</u>			
<u>Purchases of property and equipment, net</u>	(18,773)	(39,109)	(33,439)
<u>Payments for acquisitions, net of cash acquired</u>	(725,853)	(146,405)	(112,596)
<u>Proceeds from divestitures</u>	70	765	11,193
<u>Net cash used in investing activities</u>	(744,556)	(184,749)	(134,842)
<u>Cash flows from financing activities:</u>			
<u>Proceeds from initial public offering, net of offering costs</u>	0	0	250,979
<u>Principal payments on long-term debt</u>	(1,164,237)	(473,437)	(328,329)
<u>Borrowings of long-term debt</u>	1,805,966	650,707	196,366

<u>Payments of debt issuance costs</u>		(58,591)	(14,296)	0
<u>Penalty on prepayment of debt</u>		0	(4,900)	0
<u>Payment of premium of debt extinguishment</u>		0	0	(7,305)
<u>Proceeds from preferred stock issuance</u>		310,000	0	0
<u>Payments of stock issuance costs</u>		(18,347)	0	0
<u>Payments of preferred dividends</u>		0	0	0
<u>Distributions to non-controlling interest holders</u>		(50,343)	(65,778)	(69,720)
<u>Proceeds from (payments related to) ownership transactions with non-controlling interest holders</u>		(1,518)	(20,096)	(12,175)
<u>Repurchase of shares</u>		0	0	0
<u>Financing lease obligations</u>		(796)	(924)	3,558
<u>Other financing activities</u>		(789)	0	
<u>Net cash (used in) provided by financing activities</u>		821,345	71,276	33,374
<u>Net (decrease) increase in cash and cash equivalents</u>		144,507	11,766	(16,987)
<u>Cash and cash equivalents at beginning of period</u>	\$ 214,206	69,699	57,933	74,920
<u>Cash and cash equivalents at end of period</u>		214,206	69,699	57,933
<u>Supplemental cash flow information:</u>				
<u>Interest paid, net of interest income received</u>		68,646	79,262	96,799
<u>Cash paid for income taxes</u>		598	661	1,093
<u>Non-cash purchases of property and equipment under capital leases and financing activities</u>		\$ 8,469	\$ 9,226	\$ 5,443

Organization

**12 Months Ended
Dec. 31, 2017**

[Organization, Consolidation
and Presentation of
Financial Statements
\[Abstract\]
Organization](#)

Organization

Surgery Partners, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), was formed April 2, 2015, as a holding company for the purpose of facilitating an initial public offering (the “IPO”) of shares of common stock. Prior to September 30, 2015, the Company conducted business through Surgery Center Holdings, Inc. and its subsidiaries. Surgery Center Holdings, LLC was and is the sole indirect owner of the equity interests of Surgery Center Holdings, Inc. and had no other material assets.

On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the “Reorganization”). In the Reorganization, all of the equity interests held by the pre-IPO Owners of Surgery Center Holdings, LLC were contributed to Surgery Partners, Inc. in exchange for 33,871,990 shares of common stock of Surgery Partners, Inc. and certain rights to additional payments under a tax receivable agreement. After giving effect to the Reorganization, Surgery Partners, Inc. is a holding company, and its sole material asset is an equity interest in Surgery Center Holdings, LLC. The Company’s consolidated financial statements for periods prior to the Reorganization represent the historical operating results and financial position of Surgery Center Holdings, Inc. and certain of its subsidiaries.

On October 1, 2015, the Company completed its IPO of 14,285,000 shares of common stock at an offering price of \$19.00 per share. On October 6, 2015, the Company received net proceeds from the sale of common stock in this offering of \$255.8 million, after deducting underwriting discounts and other fees of \$15.6 million. These net proceeds were used to repay a portion of the borrowings outstanding under the 2014 Second Lien and to pay fees associated with this offering. The Company also incurred an additional \$4.8 million in costs directly related to the IPO.

On August 31, 2017, the Company completed its acquisition of NSH Holdco, Inc. (“NSH”). Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 9, 2017, by and among the Company, SP Merger Sub, Inc., a wholly owned subsidiary of the Company, NSH, and IPC / NSH, L.P. (solely in its capacity as sellers’ representative), as amended by that certain Letter Amendment, dated as of July 7, 2017 (as amended, the “NSH Merger Agreement”), SP Merger Sub, Inc. merged with and into NSH with NSH continuing as the surviving corporation and a wholly owned subsidiary of Surgery Center Holdings, Inc. (the “NSH Merger”). Also on August 31, 2017, (i) the Company completed the sale and issuance of 310,000 shares of the Company’s preferred stock, par value \$0.01 per share, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock (the “Series A Preferred Stock”) to BCPE Seminole Holdings LP (“Bain”), a fund advised by an affiliate of Bain Capital Private Equity, at a purchase price of \$1,000 per share in cash (the “Preferred Private Placement”) pursuant to the Securities Purchase Agreement, dated as of May 9, 2017, by and between the Company and Bain (the “Preferred Stock Purchase Agreement”), and (ii) Bain completed its purchase of 26,455,651 shares (the “Purchased Shares”) of the Company’s common stock, par value \$0.01 per share (the “Common Stock”) from H.I.G. Surgery Centers, LLC (“H.I.G.”) at a purchase price of \$19.00 per share in cash (the “Private Sale”) pursuant to the Stock Purchase Agreement, dated as of May 9, 2017, by and among the Company, Bain, H.I.G. and H.I.G. Bayside Debt & LBO Fund II L.P. (for the purposes stated therein) (the “Common Stock Purchase Agreement” and together with the NSH Merger Agreement, the Preferred Stock Purchase Agreement and the other agreements and documents executed in connection therewith, including the TRA (as defined in Note 2. “Significant Accounting Policies - Income Taxes and Tax Receivable Agreement”), the “Transaction Agreements”). As of August 31, 2017, the Purchased Shares represented approximately 54.2% of the Company’s outstanding Common Stock. As a result of the Preferred Private Placement and the Private Sale, Bain became the controlling stockholder of the Company, holding Series A Preferred Stock and Common Stock that collectively represent approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017, and H.I.G. and its affiliated investment funds no longer own any capital stock of the Company.

In connection with the change of control effected by the Preferred Private Placement and the Private Sale, the Company elected to apply “pushdown” accounting by applying the guidance in Accounting

Standards Codification Topic ("ASC") 805, *Business Combinations*, including the recognition of the Company's assets and liabilities at fair value as of August 31, 2017, and similarly recognizing goodwill calculated based on the terms of the transaction and the fair value of the new basis of net assets of the Company. Accordingly, the consolidated financial statements of the Company for periods before and after August 31, 2017 reflect different bases of accounting, and the financial positions and results of operations of those periods are not comparable. Throughout the Company's consolidated financial statements and the accompanying notes herein, periods prior to the change of control are identified as "Predecessor" and periods after the change of control are identified as "Successor."

As of December 31, 2017 (Successor), the Company owned and operated a national network of surgical facilities and ancillary services in 32 states. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology ("GI"), general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services and optical services.

As of December 31, 2017 (Successor), the Company owned or operated a portfolio of 124 surgical facilities, comprised of 106 ASCs and 18 surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, healthcare systems in the markets and communities it serves. The Company owned a majority interest in 84 of the surgical facilities and consolidated 108 of these facilities for financial reporting purposes.

Significant Accounting Policies

12 Months Ended
Dec. 31, 2017

[Organization, Consolidation and Presentation of](#)

[Financial Statements](#)

[\[Abstract\]](#)

[Significant Accounting Policies](#)

Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.

Non-Controlling Interests

The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.

The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control.

Non-Controlling Interests — Redeemable. Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners' or physician minority members', as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. The non-controlling interests — redeemable are reported outside of stockholders' equity in the consolidated balance sheets.

A summary of activity related to the non-controlling interests—redeemable follows (in thousands):

Predecessor

Balance at December 31, 2015	\$	183,439
Net income attributable to non-controlling interests—redeemable		18,023
Acquisition and disposal of shares of non-controlling interests, net—redeemable		(3,781)

Distributions to non-controlling interest —redeemable holders	(17,160)
Balance at December 31, 2016	180,521
Net income attributable to non-controlling interests—redeemable	9,615
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(3,323)
Distributions to non-controlling interest —redeemable holders	(11,468)
Acquisition of NSH	153,320
Balance at August 31, 2017	\$ 328,665

	<i>Successor</i>
Balance at September 1, 2017	\$ 271,001
Net income attributable to non-controlling interests—redeemable	12,931
Acquisition and disposal of shares of non-controlling interests, net—redeemable	819
Distributions to non-controlling interest —redeemable holders	(8,228)
Reallocation in application of pushdown accounting	21,248
Purchase price adjustments	1,545
Balance at December 31, 2017	\$ 299,316

Variable Interest Entities

The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of ASC 810, *Consolidation*. At December 31, 2017 (Successor), the variable interest entities include five surgical facilities, three anesthesia practices and three physician practices. At December 31, 2016 (Predecessor), the variable interest entities included five surgical facilities, three anesthesia practices and two physician practice. The change is due to a physician practice acquired during the eight months ended August 31, 2017 (Predecessor). The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.

The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying consolidated balance sheets as of December 31, 2017 (Successor) and 2016 (Predecessor), were \$13.1 million and \$24.8 million, respectively, and the total liabilities of the consolidated VIEs were \$5.8 million and \$10.7 million, respectively. There are no assets that are restricted to use as of December 31, 2017 (Successor).

Equity Method Investments

The Company has non-consolidating investments in surgical facilities and management companies that own or manage surgical facilities. These investments are accounted for using the equity method of accounting. The total amount of these investments included in investments in and advances to affiliates in the consolidated balance sheets was \$74.3 million and \$35.0 million as of December 31, 2017 (Successor) and December 31, 2016 (Predecessor), respectively.

Use of Estimates

The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to the comparative periods' financial statements to conform to the current year presentation.

Fair Value of Financial Instruments

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), inputs other than quoted prices in active markets that are either directly or indirectly observable (Level 2), or unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions (Level 3), depending on the nature of the item being valued.

The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values.

A summary of the carrying amounts and fair values of the Company's long-term debt follows (in thousands):

	<i>Successor</i>		<i>Predecessor</i>	
	December 31, 2017		December 31, 2016	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
2014 Revolver Loan	\$ —	\$ —	\$ 85,000	\$ 85,000
2014 First Lien Credit Agreement, net of debt issuance costs and discount	\$ —	\$ —	\$ 911,784	\$ 917,528
2017 Senior Secured Credit Facilities:				
Revolver	\$ —	\$ —	\$ —	\$ —
Term Loan	\$ 1,280,532	\$ 1,267,189	\$ —	\$ —
Senior Unsecured Notes due 2021 ⁽¹⁾	\$ 409,235	\$ 422,535	\$ 387,942	\$ 412,189
Senior Unsecured Notes due 2025	\$ 370,000	\$ 346,413	\$ —	\$ —

⁽¹⁾ The carrying amount in the Predecessor period is net of unamortized debt issuance costs and discount, which were eliminated with the application of pushdown accounting.

The fair values of the 2014 First Lien Credit Agreement, Term Loan, 2021 Unsecured Notes and the 2025 Unsecured Notes (in each case, as defined in Note 7. "Long-Term Debt") were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets at December 31, 2017 (Successor) and 2016 (Predecessor), as applicable. The carrying amounts related to the Company's other long-term debt obligations, including the 2014 Revolver Loan and the Revolver (in each case, as defined in Note 7. "Long-Term Debt"), approximate their fair values.

The Company maintains a supplemental executive retirement savings plan (the "SERP") for certain executive officers. The SERP is a non-qualified deferred compensation plan for eligible executive officers and other key employees of the Company that allows participants to defer portions of their compensation. The fair value of the SERP asset and liability was based on a quoted market price, or a Level 1 computation. As of December 31, 2017 (Successor) and 2016 (Predecessor), the fair value of the assets in the SERP were \$1.9 million and \$1.7 million, respectively, and were included in other long-term assets in the consolidated balance sheets. The Company had a liability related to the SERP of \$1.9 million and \$1.7 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively, which was included in other long-term liabilities in the consolidated balance sheets.

Revenues

The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.

A summary of revenues by service type as a percentage of total revenues follows:

	<i>Successor</i>		<i>Predecessor</i>		
	September 1 to December 31,		January 1 to August 31,	Year Ended December 31,	
	2017		2017	2016	2015
Patient service revenues:					
Surgical facilities revenues	94.3%	91.4%	90.3%	91.6%	
Ancillary services revenues	4.2%	7.0%	7.9%	6.4%	
	98.5%	98.4%	98.2%	98.0%	
Other service revenues:					
Optical services revenues	0.6%	1.0%	1.1%	1.5%	
Other	0.9%	0.6%	0.7%	0.5%	
	1.5%	1.6%	1.8%	2.0%	
Total revenues	100.0%	100.0%	100.0%	100.0%	

Patient service revenues. The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid. Changes in estimated contractual adjustments and discounts are recorded in the period of change. There were no adjustments as a result of changes in estimates to third-party settlements related to prior years for the four months ended December 31, 2017 (Successor). During the eight months ended August 31, 2017 (Predecessor), the Company recognized an increase to patient service revenues as a result of changes in estimates to third-party settlements related to prior years of approximately \$1.1 million. During the years ended December 31, 2016 and 2015, the Company recognized an increase to patient service revenues of \$6.8 million and \$2.3 million, respectively, as a result of changes in estimates to third-party settlements related to prior years.

The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in thousands):

	<i>Successor</i>		<i>Predecessor</i>					
	September 1 to December 31,		January 1 to August 31,		Year Ended December 31,			
	2017		2017		2016		2015	
	Amount	%	Amount	%	Amount	%	Amount	%
Patient service revenues:								
Private insurance	\$347,801	59.6%	\$360,092	48.9%	\$ 579,662	51.5%	\$516,739	55.0%
Government	196,926	33.7%	308,993	42.0%	448,953	39.9%	359,471	38.2%
Self-pay	15,233	2.6%	15,949	2.2%	19,817	1.8%	16,190	1.7%
Other ⁽¹⁾	23,843	4.1%	51,374	6.9%	76,172	6.8%	48,311	5.1%
Total patient service revenues	\$583,803	100.0%	\$736,408	100.0%	\$1,124,604	100.0%	\$940,711	100.0%
Other service revenues:								
Optical service revenues	\$ 3,486		\$ 7,629		\$ 12,505		\$ 14,572	

Other revenues	5,315	4,578	8,329	4,608
Total net revenues	<u>\$592,604</u>	<u>\$748,615</u>	<u>\$1,145,438</u>	<u>\$959,891</u>

(1) Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.

Other service revenues. Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts.

Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered.

Subsequent to the Preferred Private Placement, the Company, as part of a review of operations undertaken to create a solid foundation to support the Company's long-term growth objectives, incurred a non-recurring adjustment to revenue of \$15.6 million, which was attributable to an increase in reserves for certain accounts receivable during the eight months ended August 31, 2017 (Predecessor). The increase in reserves resulted from certain known events and actions during the eight months ended August 31, 2017 (Predecessor) related to select payors primarily in the Company's ancillary services segment. Upon consideration of such additional information, related receivables were determined to have a low likelihood of collection. The majority of this adjustment related to receivables with balances from the first quarter of 2016 and prior. The Company believes it has accounted for all necessary reserve adjustments at this time.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.

Accounts Receivable and Allowances for Contractual Adjustments and Doubtful Accounts

Accounts receivable are recorded net of contractual adjustments and allowances for doubtful accounts to reflect accounts receivable at net realizable value. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. As of December 31, 2017, the Company had a net third-party Medicaid settlements liability of \$1.0 million compared to a third-party Medicaid settlements receivable of \$0.5 million at December 31, 2016.

The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. The Company's policy is to collect co-payments and deductibles prior to providing medical services. It is also the Company's policy to verify a patient's insurance 72 hours prior to the patient's procedure. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.

The Company analyzes accounts receivable at each of its facilities to ensure the proper aged category and collection assessment. At a consolidated level, the Company's policy is to review accounts receivable aging, by facility, to determine the appropriate allowance for doubtful accounts. Patient account balances are reviewed for delinquency based on contractual terms. This review is supported by an analysis of the actual revenues, contractual adjustments and cash collections received. An account balance is written off only after the Company has pursued collection with legal or collection agency assistance or otherwise has deemed an account to be uncollectible.

A summary of the changes in the allowance for doubtful accounts receivable follows (in thousands):

	Balance at Beginning of Period	Provision for Doubtful Accounts	Accounts Written off, Net of Recoveries	Balance at End of Period
<i>Predecessor</i>				
Year ended December 31, 2015	\$ 5,329	\$ 23,578	\$ (10,585)	\$ 18,322
Year ended December 31, 2016	18,322	24,212	(12,662)	29,872
Eight months ended August 31, 2017	29,872	16,297	(14,096)	32,073
Successor				
Four months ended December 31, 2017	—	12,455	(10,429)	2,026

The Company records an estimate for doubtful accounts based on the aging category and historical collection experience of each product sales or other business included in other service revenues, as discussed in the note above.

The receivables related to the Company's optical products purchasing organization are recognized separately from patient accounts receivable, as discussed above, and are included in other current assets in the consolidated balance sheets. Such receivables were \$7.6 million and \$7.0 million at December 31, 2017 (Successor) and 2016 (Predecessor), respectively.

Inventories

Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.

Prepaid Expenses and Other Current Assets

A summary of prepaid expenses and other current assets follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Prepaid expenses	\$ 16,835	\$ 11,158
Receivables - optical product purchasing organization	7,563	7,042
Acquisition escrow deposit	3,809	10,871
Insurance recoveries	2,828	2,476
Other	24,302	11,338
Total	\$ 55,337	\$ 42,885

Property and Equipment

Property and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings and building improvements, three to five years for computers and software and five to seven years for furniture and equipment. Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.

The Company also leases certain facilities and equipment under capital leases. Assets held under capital leases are stated at the present value of minimum lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset. The Company's property and equipment, as well as assets held under capital leases are further described in Note 5.

Goodwill and Intangible Assets

Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located and Medicare licenses. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally three to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from two to five years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from three to ten years. The Company's goodwill and intangible assets are further described in Note 6.

Impairment of Long-Lived Assets, Goodwill and Intangible Assets

The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value. The cash flow projection and fair value represents management's best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation. No impairment losses on long-lived assets were recognized during the four months ended December 31, 2017 (Successor), the eight months ended August 31, 2017 (Predecessor), and the years ended December 31, 2016 and 2015 (Predecessor).

The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. The Company has determined that it has five reporting units, which include the following: 1) Surgical Facilities 2) Ancillary Services, 3) Midwest Labs, 4) The Alliance, including Optical Synergies and 5) Family Vision Care. The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. If the carrying value exceeds the estimated fair value, an impairment indicator exists and an estimate of the possible impairment loss is calculated. The fair value of the reporting units are estimated using a discounted cash flows approach and are corroborated using a market-based approach. The fair value calculation includes multiple assumptions and estimates, including the projected cash flows and discount rates applied.

In connection with the implementation of pushdown accounting, the Company performed its goodwill impairment test as of August 31, 2017 (Predecessor), then re-evaluated for impairment at October 1, 2017 (Successor). Both evaluations resulted in no impairment. There were also no impairment charges recorded during the years ended December 31, 2016 and 2015 (Predecessor).

Restricted Invested Assets

Restricted invested assets of \$0.3 million as of both December 31, 2017 (Successor) and 2016 (Predecessor) were related to a requirement under the operating lease agreement at the Company's

Chesterfield, Missouri facility. In accordance with the provisions of the lease agreement, the Company has a deposit with the landlord that shall be held as security for performance under the Company's covenants and obligations within the agreement through January 2024.

Other Long-Term Assets

A summary of other long-term assets follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Acquisition escrow deposit	\$ 19,600	\$ —
Insurance recoveries	10,018	6,835
Notes receivable	2,263	716
Deposits	3,151	4,196
Other	13,318	4,688
Total	<u>\$ 48,350</u>	<u>\$ 16,435</u>

Other Current Liabilities

A summary of other current liabilities follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Interest payable	\$ 20,537	\$ 19,206
Amounts due to patients and payors	18,096	12,221
Insurance liabilities	9,873	6,625
Current taxes payable	4,912	2,622
Acquisition escrow liability	3,809	10,871
Accrued expenses and other	52,717	28,319
Total	<u>\$ 109,944</u>	<u>\$ 79,864</u>

Other Long-Term Liabilities

A summary of other long-term liabilities follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Facility lease obligations	\$ 121,627	\$ 52,653
Acquisition escrow liability	19,600	—
Medical malpractice liability	16,450	10,453
Unfavorable lease liability	11,889	1,671
Other	9,123	11,489
Total	<u>\$ 178,689</u>	<u>\$ 76,266</u>

At four of the Company's surgical facilities, the Company has facility lease obligations payable to the lessor of each facility. Payments are allocated to principal adjustments of the lease obligations and interest expense. The current portions of the lease obligations were \$6.3 million and \$1.3 million at December 31, 2017 (Successor) and 2016 (Predecessor), respectively, and were included in other current liabilities in the consolidated balance sheets. The long-term portions of the lease obligations, included in the table above, were \$121.6 million and \$52.7 million at December 31, 2017 (Successor) and 2016 (Predecessor), respectively. The increase is primarily due to two facility lease obligations assumed with the NSH Merger and the revaluation of the obligations with the application of pushdown accounting.

Equity-Based Compensation

Transactions in which the Company receives employee and non-employee services in exchange for the Company's equity instruments or liabilities that are based on the fair value of the Company's equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. Prior to the Reorganization, on the grant date, the Company employed a market approach to estimate the fair value of equity-based awards based on various considerations and assumptions, including implied earnings multiples and other metrics of relevant market participants, the Company's operating results and forecasted cash flows and the Company's capital structure. Such estimates require the input of highly subjective, complex assumptions. However, such assumptions are no longer required to determine fair value of shares of the Company's common stock as its underlying shares began trading publicly during the fourth quarter of 2015. The Company applies the Black-Scholes-Merton method of valuation in determining share-based compensation expense for option awards.

The Company's policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. Prior to the Reorganization, employees held membership units in Surgery Center Holdings, LLC, and the associated expense was referred to as unit-based compensation; following the Reorganization, such expense is referred to as equity-based compensation. The Company's equity-based compensation is described further in Note 12.

Professional, General and Workers' Compensation Insurance

The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis.

The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers compensation claims which relate to (i) claims made during the policy period, which are offset by insurance recoveries and (ii) an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets. Total professional, general and workers' compensation claim liabilities as of December 31, 2017 and 2016 are \$21.0 million and \$13.8 million, respectively. The balance includes expected insurance recoveries of \$12.8 million and \$9.3 million as of December 31, 2017 and 2016, respectively. The increase is primarily due to the acquisition of NSH.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, "Revenue from Contracts with Customers," along with subsequent amendments, updates and an extension of the effective date (collectively the "New Revenue Standard"), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This five-step process will require significant management judgment in addition to changing the way many companies recognize revenue in their financial statements. Additionally, and among other provisions, the New Revenue Standard requires expanded quantitative and qualitative disclosures, including disclosure about the nature, amount, timing and uncertainty of revenue. The provisions of the New Revenue Standard are effective for annual periods beginning after December 15, 2017, including interim periods within those years by applying either the full retrospective method or the modified retrospective approach upon adoption. The Company will adopt this ASU on January

1, 2018. The Company plans to adopt using the modified retrospective method, including providing all requisite disclosures under such method. The Company expects that the majority of its provision for doubtful accounts will continue to be recognized as an operating expense rather than as a direct reduction to revenues, given the Company's practice of assessing a patient's ability to pay prior to or on the date of providing healthcare services. The Company does not believe the adoption will have a significant impact on our recognition of net revenues for any period. The Company is still evaluating the impact that the adoption will have on its related disclosures.

In February 2016, the FASB issued ASU 2016-02, "*Leases*," which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. The Company believes the primary effect of adopting the new standard will be to record right-of-use assets and obligations for current operating leases.

In January 2017, the FASB issued ASU 2017-01, "*Business Combinations – Clarifying the Definition of a Business*," which narrows the definition of a business when evaluating whether transactions should be accounted for as asset acquisition or business combination. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those years. The adoption of this ASU will not have a material impact on the Company's condensed consolidated financial position, results of operations and cash flows.

**Acquisitions and
Developments**
Business Combinations
[Abstract]
Acquisitions and
Developments

**12 Months Ended
Dec. 31, 2017**

Acquisitions and Developments

The Company accounts for its business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.

2017 Transactions

Acquisition of NSH

On August 31, 2017, the Company completed its acquisition of NSH through the NSH Merger, pursuant to the NSH Merger Agreement (as defined in Note 1. "Organization") for total cash consideration of \$711.7 million, net of cash acquired, including \$19.6 million funded to an escrow account. The NSH Merger added to the Company's portfolio 22 owned or operated surgical facilities, including 7 ASCs and 15 surgical hospitals, as well as complementary ancillary services. The proceeds from the Preferred Private Placement (as defined in Note 1. "Organization"), the 2025 Unsecured Notes and the 2017 Senior Secured Credit Facilities (in each case, as defined in Note 7. "Long-Term Debt") were used to fund the acquisition.

Fees associated with the acquisition of NSH, which includes fees incurred related to the Company's preferred equity issuances and debt financings, was approximately \$82.6 million during the eight months ended August 31, 2017 (Predecessor). Approximately \$45.5 million was capitalized as deferred financing costs and discount, \$18.3 million was capitalized as deferred equity issuance costs, \$2.4 million was expensed as merger transaction and integration costs, and \$16.4 million was recorded as loss on debt refinancing costs. All capitalized costs were subsequently written off as a result of the application of pushdown accounting, further discussed below.

The total consideration related to the acquisition of NSH was allocated to the assets acquired and liabilities assumed based upon their respective acquisition date fair values. The aggregate amounts preliminarily recognized for each major class of assets and liabilities, including post acquisition date adjustments, are as follows (in thousands):

Cash consideration	\$	762,850
Fair value of non-controlling interests		<u>325,965</u>

Aggregate fair value of acquisition	1,088,815
Net assets acquired:	
Cash and cash equivalents	51,159
Accounts receivable	71,901
Inventories	14,986
Prepaid expenses and other current assets	18,397
Property and equipment	174,499
Intangible assets	27,746
Goodwill	870,241
Investments in and advances to affiliates	29,737
Long-term deferred tax assets	17,279
Other long-term assets	27,229
Accounts payable	(29,652)
Accrued payroll and benefits	(28,755)
Other current liabilities	(21,287)
Current maturities of long-term debt	(16,416)
Long-term debt, less current maturities	(42,770)
Other long-term liabilities	(75,479)
Total fair value of net assets acquired	<u>\$ 1,088,815</u>

During the four months ended December 31, 2017, factors became known to the Company as part of its evaluation of the assets and liabilities existing at the date of acquisition. This resulted in a net increase to goodwill of \$25.1 million and corresponding changes to certain classes of assets and liabilities from the preliminary allocation recorded at August 31, 2017, that are reflected in the table above. The Company is still in the process of evaluating all major classes of assets acquired and liabilities assumed. As such, the fair values assigned are subject to change as new facts and circumstances emerge that were present at the date of acquisition.

A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the intangible assets recognized.

The preliminary estimated fair value assigned to goodwill is primarily attributable to synergies expected to arise as a result of the NSH Merger by enhancing the growth profile and diversity of the Company across the healthcare continuum. The entire amount of goodwill acquired in connection with the NSH Merger was allocated to the Company's surgical facility services operating segment. The total amount of the goodwill related to the NSH Merger that will be deductible for tax purposes is \$153.5 million.

The amounts of revenues and earnings of NSH for the four months ended December 31, 2017 (Successor) was \$205.2 million and \$20.4 million, respectively, and are included in revenues and net loss attributable to Surgery Partners, Inc., respectively, in the consolidated statement of operations.

The following unaudited pro forma combined summary of operations of the Company gives effect to using historical information of the operations of NSH as if the acquisition transaction had occurred as of January 1, 2016 (in thousands):

	<i>Successor</i>	<i>Predecessor</i>	
	September 1 to December 31, 2017	January 1 to August 31, 2017	Year Ended December 31, 2016
Net revenues	\$ 592,604	\$1,122,326	\$1,679,254

Net income	4,477	63,269	132,699
Less: Net income attributable to non-controlling interests	(39,634)	(65,122)	(112,123)
Net (loss) income attributable to Surgery Partners, Inc.	<u>\$ (35,157)</u>	<u>\$ (1,853)</u>	<u>\$ 20,576</u>

These pro forma amounts exclude transaction related costs of \$7.3 million and the gain on amendment to the TRA of \$1.1 million for the four months ended December 31, 2017 (Successor), transaction related costs of \$11.3 million, loss on debt refinancing of \$18.2 million and the gain on amendment to the TRA of \$15.3 million for the eight months ended August 31, 2017 (Predecessor). The prior year pro forma amounts exclude the loss on debt refinancing of \$11.9 million for the year ended December 31, 2016 (Predecessor). Certain other adjustments, including those related to conforming accounting policies, have not been reflected in the supplemental pro forma operating results as estimating such impacts would be impracticable.

Change of Control - Pushdown Accounting

On August 31, 2017, H.I.G. sold the Purchased Shares (as defined in Note 1. "Organization") beneficially owned by H.I.G. to Bain at a purchase price per share of \$19.00 for an aggregate purchase price of \$502.7 million in cash pursuant to the Common Stock Purchase Agreement (as defined in Note 1. "Organization"). As of August 31, 2017 (Predecessor), prior to giving effect to the Preferred Private Placement (as defined in Note 1. "Organization"), the Purchased Shares represented approximately 54.2% of the Company's outstanding Common Stock. As a result of the Private Sale and the Preferred Private Placement, Bain holds Series A Preferred Stock and Common Stock that collectively represented approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017 (Predecessor), and H.I.G. and its affiliated investment funds no longer own any capital stock of the Company.

Fees associated with the change of control include fees incurred related to the Preferred Private Placement. Refer to Note 9. "Redeemable Preferred Stock", for the amount and accounting treatment of these costs.

In connection with the change of control, the Company elected to apply "pushdown" accounting by applying the guidance in ASC 805, *Business Combinations*. In accordance with ASC 805, all identifiable assets and liabilities of the Company were measured at and adjusted to fair value as of August 31, 2017, and similarly goodwill was recognized based on the terms of the transaction and the fair value of the new basis of the net assets of the Company.

The aggregate amounts preliminarily recognized in connection with the application of pushdown accounting for each major class of assets and liabilities as of August 31, 2017, including subsequent adjustments, are as follows (in thousands):

Equity attributable to Surgery Partners, Inc.	\$ 720,606
Redeemable preferred stock	310,000
Fair value of non-controlling interests	957,027
Aggregate fair value	<u>1,987,633</u>
Net assets:	
Cash and cash equivalents	214,206
Accounts receivable	253,173
Inventories	44,310
Prepaid expenses and other current assets	61,475
Property and equipment	380,085
Intangible assets	60,104
Goodwill	3,299,911
Investments in and advances to affiliates	74,722
Restricted invested assets	315
Long-term deferred tax asset	204,408

Other long-term assets	49,681
Accounts payable	(64,921)
Accrued payroll and benefits	(54,437)
Other current liabilities	(94,740)
Current maturities of long-term debt	(49,942)
Long-term debt, less current maturities	(2,142,375)
Long-term tax receivable agreement liability	(78,498)
Other long-term liabilities	(169,844)
Total fair value of net assets	<u>\$ 1,987,633</u>

During the four months ended December 31, 2017, factors became known to the Company as part of its evaluation of the assets and liabilities existing at August 31, 2017, resulting in a net increase to goodwill of \$30.7 million and corresponding changes to certain classes of assets and liabilities from the preliminary allocation recorded, that are reflected in the table above. The majority of the increase to goodwill for pushdown accounting relates to the acquisition of NSH discussed above. The Company is still in the process of evaluating all major classes of assets and liabilities. As such, the fair values assigned are subject to change as new facts and circumstances emerge that were present at August 31, 2017.

A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the intangible assets recognized.

Goodwill recognized in connection with the application of pushdown accounting was allocated to each reportable segment as follows: \$3.116 billion to surgical facilities services, \$151.9 million to ancillary services and \$32.5 million to optical services. The total amount of the goodwill related to the application of pushdown accounting that will be deductible for tax purposes is \$360.5 million.

Other 2017 Acquisitions

During the eight months ended August 31, 2017 (Predecessor), the Company completed acquisitions in existing markets of three physician practices for a combined cash purchase price of \$14.2 million. The acquisitions were funded through cash from operations and proceeds from the 2014 Revolver Loan (as defined in Note 7. "Long-Term Debt").

During the four months ended December 31, 2017 (Successor), the Company acquired a controlling interest in one surgical facility and one physician practice in existing markets for a combined cash purchase price of \$29.4 million. The acquisitions were funded through cash from operations.

The total consideration related to the other 2017 acquisitions was allocated to the assets acquired and liabilities assumed based upon their respective acquisition date fair values. The aggregate amounts preliminarily recognized for each major class of assets and liabilities assumed in the other acquisitions completed during 2017, including post acquisition date adjustments, are as follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	September 1 to December 31,	January 1 to August 31,
	2017	2017
Cash consideration	\$ 29,448	\$ 14,163
Fair value of non-controlling interests	21,893	105
Aggregate fair value of acquisitions	<u>51,341</u>	<u>14,268</u>
Net assets acquired:		
Current Assets	2,285	866
Property and equipment	248	696

Intangible assets	41	634
Goodwill	49,317	12,545
Current liabilities	(550)	(287)
Long-term debt	—	(186)
Total fair value of net assets acquired	<u>\$ 51,341</u>	<u>\$ 14,268</u>

The results of operations of the acquisitions are included in the Company's results of operations beginning on the date of acquisition. The fair values assigned to certain assets and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition.

2016 Transactions

During the year ended December 31, 2016, the Company acquired a controlling interest in two surgical facilities and two anesthesia practices in new markets and a surgical facility in an existing market which was merged into an existing facility and an anesthesia practice in an existing market for an aggregate purchase price of \$36.5 million. The Company additionally completed acquisitions in existing markets of an urgent care facility, nine physician practices and two integrated physician practices which includes three ASCs, a lab and a pharmacy for a combined purchase price of \$114.7 million, including \$16.6 million of contingent acquisition consideration. In addition, the Company purchased an additional 7.04% interest in its hospital in Idaho Falls, Idaho for \$20.3 million. The transactions were funded through cash from operations and proceeds from the 2014 First Lien Credit Agreement and 2014 Revolver Loan (in each case, as defined in Note 7. "Long-Term Debt").

The aggregate acquisition date fair value recognized for each major class of assets and liabilities assumed in the acquisitions completed during the year ended December 31, 2016, including post acquisition date adjustments, are as follows (in thousands):

Cash consideration	\$ 135,061
Fair value of non-controlling interests	27,164
Aggregate fair value of acquisitions	<u>162,225</u>
Net assets acquired:	
Current assets	11,383
Property and equipment	3,921
Intangible assets	4,475
Goodwill	148,181
Other long-term assets	56
Current liabilities	(5,422)
Long-term liabilities	(369)
Total fair value of net assets acquired	<u>\$ 162,225</u>

During 2017, no significant changes were made to the acquisition date purchase price allocation of assets and liabilities related to individual acquisitions completed in 2016. Approximately \$120.0 million of goodwill related to the 2016 acquisitions was deductible for tax purposes.

2015 Transactions

Surgical Facility Acquisitions

During the year ended December 31, 2015, the Company acquired a controlling interest in two surgical facilities located in new markets and three surgical facilities, four anesthesia practices and an urgent care facility in existing markets for an aggregate purchase price of \$84.2 million. The Company consolidates these facilities for financial reporting purposes. These transactions were funded with a combination of cash

from operations, facility ownership, and proceeds from the refinancing of the Company's credit facilities in connection with the Symbion acquisition.

Ancillary Services

During the year ended December 31, 2015, through its recruiting efforts and capital-efficient acquisitions, the Company completed 13 in-market physician practice transactions through an aggregate investment of \$40.4 million. These transactions added a total of 17 physicians to the Company's physician network and were funded with a combination of cash from operations and revolver proceeds.

Divestitures

**12 Months Ended
Dec. 31, 2017**

Discontinued Operations and Disposal Groups

[Abstract]

Divestitures

Divestitures

2017 Transactions

During the four months ended December 31, 2017 (Successor), the Company sold its interest in one surgical facility for \$1.3 million, resulting in a pre-tax gain of approximately \$0.8 million. During the eight months ended August 31, 2017 (Predecessor), the Company sold its interest in one surgical facility. The proceeds and pre-tax gain for the sale were not significant.

2016 Transactions

During the year ended December 31, 2016, the Company sold its interest in one surgical facility for \$0.8 million, resulting in a pre-tax gain of approximately \$0.8 million.

2015 Transactions

During the year ended December 31, 2015, the Company sold its interest in three surgical facilities and received aggregate proceeds of \$10.9 million, resulting in a pre-tax gain of approximately \$2.9 million.

Property and Equipment

12 Months Ended
Dec. 31, 2017

[Property, Plant and
Equipment \[Abstract\]](#)
[Property and Equipment](#)

Property and Equipment

A summary of property and equipment follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Land	\$ 19,561	\$ 8,082
Buildings and improvements	188,571	118,172
Furniture and equipment	20,813	14,670
Computer and software	28,578	29,902
Medical equipment	138,112	117,418
Construction in progress	22,581	2,396
Property and equipment, at cost	418,216	290,640
Less: Accumulated depreciation	(19,680)	(86,387)
Property and equipment, net	<u>\$ 398,536</u>	<u>\$ 204,253</u>

Depreciation expense was \$20.0 million for the four months ended December 31, 2017 (Successor) and \$24.1 million for the eight months ended August 31, 2017 (Predecessor). For the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), depreciation expense was \$30.0 million and \$25.5 million, respectively. Amortization expense related to assets under capital leases is included in depreciation expense. The carrying values of assets under capital lease were \$16.2 million and \$15.4 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively, net of accumulated depreciation of \$5.8 million and \$11.6 million, respectively.

**Goodwill and Intangible
Assets**

**12 Months Ended
Dec. 31, 2017**

**Goodwill and Intangible
Assets Disclosure [Abstract]**

**Goodwill and Intangible
Assets**

Goodwill and Intangible Assets

A summary of the changes in the carrying amount of goodwill for the years ended December 31, 2017 and 2016 follows (in thousands):

<i>Predecessor</i>	
Balance at December 31, 2015	\$ 1,407,927
Acquisitions	147,895
Divestitures	(552)
Purchase price adjustments	(66)
Balance at December 31, 2016	\$ 1,555,204
Acquisitions	858,323
Divestitures	(175)
Purchase price adjustments	1,220
Balance at August 31, 2017	<u>\$ 2,414,572</u>

<i>Successor</i>	
Balance at September 1, 2017	\$ 3,269,225
Acquisitions	49,317
Divestitures	(1,957)
Purchase price adjustments	30,253
Balance at December 31, 2017	<u>\$ 3,346,838</u>

Additions to goodwill include new acquisitions and incremental ownership acquired in the Company's subsidiaries. A summary of the Company's acquisitions for the years ended December 31, 2017 and 2016 is included in Note 3, Acquisitions and Developments.

A summary of the components of intangible assets follows (in thousands):

	<i>Successor</i>			<i>Predecessor</i>		
	December 31, 2017			December 31, 2016		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Finite-lived intangible assets:						
Management rights agreements	\$ 42,600	\$ (1,058)	\$ 41,542	\$ 24,751	\$ (3,461)	\$ 21,290
Non-compete agreements	4,874	(715)	4,159	24,673	(8,216)	16,457
Physician income guarantees	878	(227)	651	1,901	(1,088)	813
Other	—	—	—	8,815	(3,374)	5,441

Total finite-lived intangible assets	48,352	(2,000)	46,352	60,140	(16,139)	44,001
Indefinite-lived intangible assets:						
Management rights agreements	5,900	—	5,900	—	—	—
Certificates of need	5,548	—	5,548	3,780	—	3,780
Medicare licenses	1,108	—	1,108	242	—	242
Total intangible assets	<u>\$ 60,908</u>	<u>\$ (2,000)</u>	<u>\$ 58,908</u>	<u>\$ 64,162</u>	<u>\$ (16,139)</u>	<u>\$ 48,023</u>

A summary of the aggregate activity related to intangible assets for the years ended December 31, 2017 and 2016 follows (in thousands):

Predecessor

Balance at December 31, 2015	\$ 53,568
Additions	4,754
Disposals	(135)
Recruitment expense	(609)
Amortization	(9,555)
Balance at December 31, 2016	\$ 48,023
Additions	28,312
Recruitment expense	(380)
Amortization	(6,040)
Balance at August 31, 2017	<u>\$ 69,915</u>

Successor

Balance at September 1, 2017	\$ 56,750
Additions	474
Disposals	(140)
Purchase price adjustments	3,873
Recruitment expense	(227)
Amortization	(1,822)
Balance at December 31, 2017	<u>\$ 58,908</u>

Additions during the eight months ended August 31, 2017 (Predecessor) includes \$27.8 million from new acquisitions, primarily the acquisition of NSH. Approximately \$26.9 million was assigned to management rights agreements and \$0.1 million was assigned to non-compete agreements, with estimated weighted average amortization periods of 23 years and 3 years, respectively. Approximately \$0.7 million was assigned to certificates of need and \$0.1 million was assigned to Medicare licenses. Refer to Note 3. "Acquisitions and Developments" for a summary of acquisition activity.

Purchase price adjustments during the four months ended December 31, 2017 (Successor) includes net adjustments to preliminary amounts assigned as part of the acquisition of NSH, the application of pushdown accounting and other 2017 acquisitions. The adjustments included increases of \$6.9 million to management rights agreements and \$0.2 million to certificates of need, offset by a decrease of \$3.2 million to non-compete agreements. Refer to Note 3. "Acquisitions and Developments" for a summary of acquisition activity.

Amortization expense for intangible assets was \$1.8 million for the four months ended December 31, 2017 (Successor) and \$6.0 million for the eight months ended August 31, 2017 (Predecessor). For the years

ended December 31, 2016 (Predecessor) and 2015 (Predecessor), amortization expense for intangible assets was \$9.6 million and \$9.1 million, respectively.

Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in thousands):

2018	\$	4,966
2019		4,576
2020		4,172
2021		3,730
2022		2,874
Thereafter		26,034
Total	\$	<u>46,352</u>

Long-Term Debt

12 Months Ended
Dec. 31, 2017

[Debt Disclosure \[Abstract\]](#)

[Long-Term Debt](#)

Long-Term Debt

A summary of long-term debt follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
2014 Revolver Loan	\$ —	\$ 85,000
2014 First Lien Credit Agreement	—	932,000
2017 Senior Secured Credit Facilities:		
Revolver	—	—
Term Loan ⁽¹⁾	1,280,532	—
Senior Unsecured Notes due 2021 ⁽²⁾	409,235	400,000
Senior Unsecured Notes due 2025	370,000	—
Subordinated Notes	—	1,000
Notes payable and secured loans	101,921	42,521
Capital lease obligations	27,594	13,996
Less: unamortized debt issuance costs and original issue discount	—	(32,274)
Total debt	2,189,282	1,442,243
Less: Current maturities	58,726	27,822
Total long-term debt	<u>\$ 2,130,556</u>	<u>\$ 1,414,421</u>

⁽¹⁾ Includes unamortized fair value discount of \$6.2 million as of December 31, 2017. See further discussion below.

⁽²⁾ Includes unamortized fair value premium of \$9.2 million as of December 31, 2017. See further discussion below.

2014 Revolver Loan & 2014 First Lien Credit Agreement

On August 31, 2017 (Predecessor), the Company prepaid in full the outstanding principal of the 2014 Revolver Loan, a revolving credit facility entered into on November 3, 2014, and the 2014 First Lien Credit Agreement, a senior secured obligation of Surgery Center Holdings, Inc. entered into on November 3, 2014, with the proceeds from the 2017 Senior Secured Credit Facilities (as defined below). The total prepayment amount was \$1.030 billion, which included \$1.027 billion of outstanding principal and \$3.0 million of accrued and unpaid interest, other fees and expenses. In connection with the prepayment, the Company recorded a debt extinguishment loss of \$18.2 million, included in the loss on debt refinancing in the consolidated statement of operations for the eight months ending August 31, 2017 (Predecessor). The loss includes the partial write-off of unamortized debt issuance costs and discount related to the 2014 Revolver Loan and 2014 First Lien Credit Agreement and a portion of costs incurred with the 2017 Senior Secured Credit Facilities.

In September 2016, in connection with an amendment to the 2014 First Lien Credit Agreement, the Company recorded a loss on debt refinancing of \$3.6 million, included in the accompanying consolidated statement of operations for the year ended December 31, 2016 (Predecessor).

2014 Second Lien Credit Agreement

The 2014 Second Lien Credit Agreement, entered into on November 3, 2014, was a senior secured obligation of Surgery Center Holdings, Inc.

In October 2015, the Company partially prepaid the outstanding principal of the 2014 Second Lien Credit Agreement. In connection with the partial prepayment, the Company recorded a debt extinguishment loss of \$16.1 million, included in the loss on debt refinancing in the accompanying consolidated statement of operations for the year ended December 31, 2015 (Predecessor).

In March 2016, the Company prepaid in full the remaining outstanding principal of the 2014 Second Lien Credit Agreement, plus accrued and unpaid interest, with the proceeds of the issuance of the 2021 Unsecured Notes, defined below. In connection with the prepayment, the Company recorded a debt extinguishment loss of \$8.3 million, included in the loss on debt refinancing in the accompanying consolidated statement of operations for the year ended December 31, 2016 (Predecessor).

2017 Senior Secured Credit Facilities

On August 31, 2017 (Predecessor), SP Holdco I, Inc. and Surgery Center Holdings, Inc., each a wholly-owned subsidiary of the Company, entered into a credit agreement (the "Credit Agreement") providing for a \$1.290 billion senior secured term loan (the "Term Loan") and a \$75.0 million revolving credit facility (the "Revolver" and, together with the Term Loan, the "2017 Senior Secured Credit Facilities").

The Term Loan was fully drawn on August 31, 2017 (Predecessor) and the proceeds thereof were used to finance the consideration paid in the NSH Merger, to repay amounts outstanding under the Company's then-existing 2014 First Lien Credit Agreement and 2014 Revolver Loan and amounts outstanding under the existing senior secured credit facilities of NSH, and to pay fees and expenses in connection with the foregoing and transactions related to the Transaction Agreements. The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the Credit Agreement, the Company may request one or more additional incremental term loan facilities or one or more increases in the commitments under the Revolver. As of December 31, 2017 (Successor), the Company's availability on the Revolver was \$71.9 million (including outstanding letters of credit of \$3.1 million).

The Term Loan will mature on August 31, 2024 (or, if at least 50.0% of the 2021 Unsecured Notes (as defined below) shall have not either been repaid or refinanced with permitted indebtedness having a maturity date not earlier than six months after the maturity date of the Term Loan by no later than October 15, 2020, then October 15, 2020). The Revolver will mature on August 31, 2022 (or, if at least 50.0% of the 2021 Notes have not either been repaid or refinanced with permitted indebtedness having a maturity date not earlier than six months after the maturity date of the Term Loan by no later than October 15, 2020, then October 15, 2020).

The 2017 Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from 3.00% to 3.25% per annum, depending on the Company's first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, the Company is required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver.

The Term Loan amortizes in equal quarterly installments of 0.25% of the aggregate original principal amount of the Term Loan (such amortization payments commenced in December 2017). The Term Loan is subject to mandatory prepayments based on excess cash flow for the applicable fiscal year that will depend on the first lien net leverage ratio as of the last day of the applicable fiscal year, as well as upon the occurrence of certain other events, as described in the Credit Agreement. There were no excess cash flow payments required as of December 31, 2017 (Successor).

With respect to the Revolver, the Company is required to comply with a maximum consolidated total net leverage ratio of 9.50:1.00, which covenant will be tested quarterly on a trailing four quarter basis only if, as of the last day of the applicable fiscal quarter the Revolver is drawn in an aggregate amount greater than 35% of the total commitments under the Revolver. Such financial maintenance covenant is subject to an equity cure. The Credit Agreement includes customary negative covenants restricting or limiting the ability of the Company and its restricted subsidiaries, to, among other things, sell assets, alter its business, engage in mergers, acquisitions and other business combinations, declare dividends or redeem or repurchase equity interests, incur additional indebtedness or guarantees, make loans and investments, incur liens, enter into transactions with affiliates, prepay certain junior debt, and modify or waive certain material agreements and organizational documents, in each case, subject to customary and other agreed upon exceptions. The Credit

Agreement also contains customary affirmative covenants and events of default. As of December 31, 2017 (Successor), the Company was in compliance with the covenants contained in the Credit Agreement.

The 2017 Senior Secured Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors") and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors' assets (subject to certain exceptions).

In connection with the Term Loan and Revolver, the Company recorded debt issuance costs and discount of \$18.8 million and \$9.4 million, respectively, in the Predecessor period, which were eliminated with the application of pushdown accounting.

In connection with the application of pushdown accounting, the Company remeasured and recorded the Term Loan at fair value using a measurement date of August 31, 2017. The fair value was based on a Level 2 computation using quoted prices for identical liabilities in inactive markets. As a result, the Company recorded a fair value discount of \$6.5 million as of the measurement date, which is reported in the consolidated balance sheets as a direct deduction from the face amount the Term Loan. The Company amortizes the fair value discount to interest expense over the life of the Term Loan.

Senior Unsecured Notes due 2021

Effective March 31, 2016 (Predecessor), Surgery Center Holdings, Inc., issued \$400.0 million in gross proceeds of senior unsecured notes due April 15, 2021 (the "2021 Unsecured Notes"). The 2021 Unsecured Notes bear interest at the rate of 8.875% per year, payable semi-annually on April 15 and October 15 of each year. The 2021 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly owned restricted subsidiaries that guarantees the 2017 Senior Secured Credit Facilities (subject to certain exceptions).

The Company may redeem up to 35% of the aggregate principal amount of the 2021 Unsecured Notes, at any time before April 15, 2018, with the net cash proceeds of certain equity offerings at a redemption price equal to 108.875% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption, provided that at least 50% of the aggregate principal amount of the 2021 Unsecured Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

The Company may redeem the 2021 Unsecured Notes, in whole or in part, at any time prior to April 15, 2018 at a price equal to 100.000% of the principal amount to be redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may redeem the 2021 Unsecured Notes, in whole or in part, at any time on or after April 15, 2018, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, to the date of redemption:

April 15, 2018 to April 14, 2019	106.656%
April 15, 2019 to April 14, 2020	104.438%
April 15, 2020 and thereafter	100.000%

If Surgery Center Holdings, Inc., experiences a change in control under certain circumstances, it must offer to purchase the notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase. The change of control as discussed in Note 1. "Organization", did not trigger repurchase.

The 2021 Unsecured Notes contain customary affirmative and negative covenants, which among other things, limit the Company's ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.

In connection with the offering of the 2021 Unsecured Notes, the Company recorded debt issuance costs of \$8.4 million in the Predecessor period, which were eliminated with the application of pushdown accounting.

In connection with the application of pushdown accounting, the Company remeasured and recorded the 2021 Unsecured Notes at fair value using a measurement date of August 31, 2017. The fair value was based on a Level 2 computation using quoted prices for identical liabilities in inactive markets. As a result, the Company recorded a fair value premium of \$10.0 million as of the measurement date, which is reported in the consolidated balance sheets as a direct addition to the face amount the notes. The Company amortizes the fair value premium to interest expense over the life of the 2021 Unsecured Notes.

Senior Unsecured Notes due 2025

Effective June 30, 2017 (Predecessor), SP Finco, LLC, a wholly owned subsidiary of Surgery Center Holdings, Inc., issued \$370.0 million in gross proceeds of senior unsecured notes due July 1, 2025 (the "2025 Unsecured Notes"), which gross proceeds were deposited in an escrow account (the "Escrow Account") established at Wilmington Trust, National Association (in such capacity, the "Escrow Agent") in the name of the trustee under the indenture governing the 2025 Unsecured Notes (the "2025 Unsecured Notes Indenture") on behalf of the holders of the 2025 Unsecured Notes. The 2025 Unsecured Notes bear interest at the rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year, commencing on January 1, 2018.

In connection with the closing of the NSH Merger and the release of the proceeds from the Escrow Account, both of which occurred on August 31, 2017 (Predecessor), SP Finco, LLC merged with and into Surgery Center Holdings, Inc., with Surgery Center Holdings, Inc. surviving such merger and assuming, by operation of law, the rights and obligations of SP Finco, LLC under the 2025 Unsecured Notes and the indenture governing such notes. As of such time, the 2025 Unsecured Notes became guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s domestic wholly owned restricted subsidiaries that guarantees Surgery Center Holdings, Inc.'s senior secured credit facilities (subject to certain exceptions).

The Company may redeem up to 40% of the aggregate principal amount of the 2025 Unsecured Notes at any time prior to July 1, 2020, with the net cash proceeds of certain equity issuances at a redemption price equal to 106.750% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption, provided that at least 50% of the aggregate principal amount of the 2025 Unsecured Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of the applicable equity offering.

The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time prior to July 1, 2020, at a price equal to 100.000% of the principal amount to be redeemed plus the applicable premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, to, but excluding, the date of redemption:

July 1, 2020 to June 30, 2021	103.375%
July 1, 2021 to June 30, 2022	101.688%
July 1, 2022 and thereafter	100.000%

If Surgery Center Holdings, Inc. experiences a change in control under certain circumstances, it must offer to purchase the 2025 Unsecured Notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase.

The 2025 Unsecured Notes contain customary affirmative and negative covenants, which, among other things, limit the Company's ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.

In connection with the offering of the 2025 Unsecured Notes, the Company recorded debt issuance costs of \$17.3 million in the Predecessor period, which were eliminated with the application of pushdown accounting.

Subordinated Notes

On August 3, 2017 the Company redeemed in whole a subordinated debt facility of \$1.0 million with a maturity date of August 4, 2017 and an interest rate of 17.00% per annum, at a price equal 100% of the \$1.0 million principal amount redeemed, plus accrued and unpaid interest.

Notes Payable and Secured Loans

Certain of the Company's subsidiaries have outstanding bank indebtedness, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made. The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. At December 31, 2017 (Successor), the Company was in compliance with its covenants contained in the credit agreements. The Company and its subsidiaries had notes payable to financial institutions of \$101.9 million and \$42.5 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively. The increase is primarily due to the acquisition of NSH.

Capital Lease Obligations

The Company is liable to various vendors for several property and equipment leases classified as capital leases. The carrying value of the leased assets was \$16.2 million and \$15.4 million as of December 31, 2017 (Successor) and 2016 (Predecessor), respectively.

Maturities

A summary of maturities for the Company's long-term debt, excluding unamortized fair value discount and premium discussed above, for the next five years and thereafter as of December 31, 2017 follows (in thousands):

2018	\$ 58,726
2019	36,857
2020	1,277,253
2021	411,748
2022	8,110
Thereafter	393,597
Total debt	<u>\$ 2,186,291</u>

Leases

**12 Months Ended
Dec. 31, 2017**

[Leases \[Abstract\]](#)

[Leases](#)

Leases

The Company leases office space and equipment for its surgical facilities, including surgical facilities under development. The lease agreements generally require the lessee, or the Company, to pay all maintenance, property taxes, utilities and insurance costs. The Company accounts for operating lease obligations and sublease income on a straight-line basis. Lease obligations paid in advance are recorded as prepaid rent and included in prepaid expenses and other current assets on the consolidated balance sheets. The difference between actual lease payments and straight-line lease expense over the initial lease term, excluding optional renewal periods, is recorded as deferred rent and included in other current liabilities and other long-term liabilities on the consolidated balance sheets.

Future minimum lease payments for non-cancellable operating and capital leases for the next five years and thereafter at December 31, 2017 follows (in thousands):

	<u>Operating Leases</u>	<u>Capital Leases</u>
2018	\$ 67,513	\$ 9,100
2019	67,136	7,404
2020	62,735	5,020
2021	56,558	3,505
2022	52,582	1,986
Thereafter	258,192	6,299
Total minimum payments	<u>\$ 564,716</u>	33,314
Less: imputed interest		(5,720)
Capital lease obligations		<u>\$ 27,594</u>

The Company has various non-cancellable sub-lease arrangements. The total future minimum rentals to be received under these arrangements as of December 31, 2017 is \$4.2 million.

Rental expense for operating leases was \$27.8 million for the four months ended December 31, 2017 (Successor) and \$39.2 million for the eight months ended August 31, 2017 (Predecessor). For the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), rental expense for operating leases was \$47.3 million and \$40.1 million, respectively. Included in these amounts, the Company incurred lease expense under operating lease agreements with physician investors who are related parties of \$7.5 million for the four months ended December 31, 2017 (Successor), \$9.8 million for the eight months ended August 31, 2017 (Predecessor), \$14.4 million and \$12.9 million for years ended December 31, 2016 and 2015, respectively.

Redeemable Preferred Stock

12 Months Ended
Dec. 31, 2017

[Temporary Equity
Disclosure \[Abstract\]
Redeemable Preferred Stock](#)

Redeemable Preferred Stock

On August 31, 2017, the Company issued 310,000 shares of Series A Preferred Stock to Bain at a purchase price of \$1,000 per share for an aggregate purchase price of \$310.0 million. The net proceeds from the Preferred Private Placement (as defined in Note 1. "Organization") were used to finance a portion of the NSH Merger.

The accrued value of the Series A Preferred Stock is convertible into shares of Common Stock at a price per share of Common Stock equal to \$19.00, subject to certain adjustments as provided in the Certificate of Designations, Preferences, Rights and Limitations of the 10.00% Series A Convertible Perpetual Participating Preferred Stock of Surgery Partners, Inc. (the "Series A Certificate of Designation"), at any time at the option of the holder. In addition, the Company may require the conversion of all, but not less than all, of the Series A Preferred Stock pursuant to the terms and conditions of the Series A Certificate of Designation, after the second anniversary of the date of issuance, if the volume weighted average closing price of the Common Stock for any 20 out of 30 consecutive trading days prior to such date, equals or exceeds \$42.00 per share.

The Company cannot redeem the Series A Preferred Stock prior to the fifth anniversary of its issuance and thereafter, may redeem all, but not less than all, of the Series A Preferred Stock for cash pursuant to and subject to the terms and conditions of the Series A Certificate of Designation. The holders of Series A Preferred Stock may cause the Company to redeem the Series A Preferred Stock upon the occurrence of certain change of control transactions of the Company or the Common Stock ceasing to be listed or quoted on a trading market. The Company adjusts the carrying amount of the Series A Preferred Stock to equal the redemption value at the end of each reporting period as if it were also the redemption date. Changes in the redemption value are recognized immediately as they occur.

The Series A Preferred Stock ranks senior to the Common Stock and any other capital stock of the Company with respect to dividends, redemption and any other rights upon the liquidation, dissolution or winding up of the Company, and the holders thereof are entitled to vote with the holders of Common Stock, together as a single class, on all matters submitted to a vote of the Company's stockholders. In addition to participating in any dividends that may be declared with respect to the Common Stock on an as-converted basis, each share of Series A Preferred Stock accrues dividends daily at a dividend rate of 10.00%, compounding quarterly, and in any given quarter, subject to certain conditions, the Board of Directors of the Company may declare a cash dividend in an amount up to 50% of the amount of the dividend that has accrued and accumulated during such quarter through the end of such quarter, and the amount of any quarterly dividend paid in cash shall not compound on the applicable date and shall not be included in the accrued value of the Series A Preferred Stock. In the event of the Company's liquidation, dissolution or winding-up (whether voluntary or involuntary), holders of Series A Preferred Stock will be entitled to receive out of the assets of the Company available for distribution to shareholders, after satisfaction of any liabilities and obligations to creditors of the Company, with respect to each Series A Preferred Share, an amount equal to the greater of (i) \$1,000.00 per share, plus dividends compounded to date, plus dividends accrued but not yet compounded and (ii) the amount that a holder of one share of Common Stock would receive, assuming the Series A Preferred Stock had converted into shares of Common Stock.

In connection with the issuance of Series A Preferred Stock in the Preferred Private Placement, the Company incurred issuance costs of \$18.3 million in the Predecessor period, which were eliminated with the application of pushdown accounting.

A summary of activity related to the redeemable preferred stock for the period from September 1, 2017 to December 31, 2017 (Successor) follows (in thousands):

<i>Successor</i>	
Balance at September 1, 2017	\$ 310,000
Dividends accrued	10,481

Cash dividends declared	(5,241)
Mark to redemption adjustment	15,566
Balance at December 31, 2017	<u>\$ 330,806</u>

Cash dividends declared but unpaid at December 31, 2017 were \$3.9 million, and were included in other current liabilities in the consolidated balance sheet. The aggregate and per share amounts of unpaid cumulative preferred dividends as of December 31, 2017 were \$9.2 million and \$29.56, respectively.

Earnings Per Share

12 Months Ended
Dec. 31, 2017

[Earnings Per Share](#)

[\[Abstract\]](#)

[Earnings Per Share](#)

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with ASC 260, *Earnings Per Share*, based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. Beginning in the Successor period, in connection with the issuance of the Series A Preferred Stock, the Company began computing basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings. Refer to Note 9. "Redeemable Preferred Stock", for further disclosure of the terms and conditions, including the participation rights, of the Series A Preferred Stock.

A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (in thousands except share and per share amounts):

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31, 2017	January 1 to August 31, 2017	Year Ended December 31, 2016	2015
Numerator:				
Net (loss) income attributable to Surgery Partners, Inc.	\$ (41,316)	\$ (11,669)	\$ 9,453	\$ 1,429
Less: amounts allocated to participating securities ⁽¹⁾	10,481	—	—	—
Less: mark to redemption adjustment	15,566	—	—	—
Net (loss) income attributable to common stockholders	\$ (67,363)	\$ (11,669)	\$ 9,453	\$ 1,429
Denominator:				
Weighted average shares outstanding- basic	48,319,193	48,121,404	48,018,944	36,066,233
Effect of dilutive securities ⁽²⁾	—	—	171,794	1,398,154
Weighted average shares outstanding- diluted	48,319,193	48,121,404	48,190,738	37,464,387
Earnings (loss) per share:				
Basic	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04
Diluted ⁽²⁾	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04
Securities outstanding not included in the computation of diluted (loss) earnings per share as their effect is antidilutive:				
Stock options	—	—	—	—
Restricted shares	62,850	105,944	—	—
Convertible preferred stock	—	N/A	N/A	N/A

⁽¹⁾ Amounts allocated to participating securities includes dividends accrued during the Successor period for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses. There were no participating securities during the Predecessor periods.

⁽²⁾ The impact of potentially dilutive securities for the four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), were not considered because the effect would be anti-dilutive in each of those periods.

Share Repurchase Transactions

On December 15, 2017, the Board of Directors authorized a share repurchase program of up to \$50.0 million of the Company's issued and outstanding common stock from time to time. The timing and size of repurchases will be determined based on market conditions and other factors. The authorization does not obligate the repurchase any shares and the Company may repurchase shares of common stock at any time without prior notice. The share repurchases will be made in accordance with applicable securities laws in open market or privately negotiated transactions. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice.

During December 2017, the Company repurchased 180,664 shares of its common stock at an average price of \$11.12 per share through market purchases. At December 31, 2017, the Company had \$48.0 million of repurchase authorization available under the December 2017 authorization.

During the first quarter of 2018, through the date of this report, the Company repurchased 156,818 shares of its common stock at an average price of \$12.64 per share through market purchases. At March 15, 2018, the Company had \$46.0 million of repurchase authorization available under the December 2017 authorization.

**Income Taxes and Tax
Receivable Agreement**

**12 Months Ended
Dec. 31, 2017**

Income Tax Disclosure
[Abstract]

Income Taxes and Tax
Receivable Agreement

Income Taxes and Tax Receivable Agreement

Income Taxes

The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a net operating loss ("NOL") carryforward exists, the Company makes a determination as to whether that NOL carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances.

The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2014 or state income tax examinations for years prior to 2013.

The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.

The Company made income tax payments of \$0.5 million and \$0.6 million for the four months ended December 31, 2017 (Successor) and eight months ended August 31, 2017 (Predecessor), respectively. Income tax payments were \$0.7 million and \$1.1 million for the years ended December 31, 2016 and 2015, respectively.

Income tax expense (benefit) is comprised of the following (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31, 2017	January 1 to August 31, 2017	Year Ended December 31, 2016	2015
Current:				
Federal	\$ (111)	\$ —	\$ (31)	\$ —
State	990	614	244	909
Deferred:				
Federal	77,472	(17,288)	7,326	(132,311)
State	(6,712)	(1,415)	(444)	(17,580)
Total income tax expense (benefit)	\$ 71,639	\$(18,089)	\$ 7,095	\$(148,982)

A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax expense (benefit) computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 35% follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Tax expense (benefit) at U.S.federal statutory rate	\$ 24,485	\$ 4,315	\$ 32,263	\$ (26,648)
State income tax, net of U.S. federal tax benefit	1,685	(456)	(86)	1,059
Change in valuation allowance	529	1,324	354	(137,721)
Net income attributable to non-controlling interests	(13,872)	(14,731)	(26,470)	(24,996)
Changes in measurement of uncertain tax positions	(191)	20	(262)	(10)
Stock option compensation	306	37	(200)	—
Differences related to divested facilities	(429)	(1,708)	—	—
Nondeductible transaction costs	2,058	(977)	—	3,442
Tax return reconciling differences	—	(316)	1,635	(1,574)
Change in effective tax rate	64,343	(825)	—	(2,143)
TRA liability	(7,404)	(4,782)	(327)	39,428
Other	129	10	188	181
Total income tax expense (benefit)	\$ 71,639	\$(18,089)	\$ 7,095	\$(148,982)

The components of temporary differences and the approximate tax effects that give rise to the Company's net deferred tax asset are as follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Deferred tax assets:		
Medical malpractice liability	\$ 3,236	\$ 4,194
Accrued vacation and incentive compensation	2,125	1,112
Net operating loss carryforwards	137,794	158,796
Allowance for bad debts	2,545	8,343
Capital loss carryforwards	3,024	2,785
Deferred rent	—	1,371
Depreciation on property and equipment	—	530
Deferred financing costs	17,004	—
TRA liability	1,042	4,542
Other deferred assets	4,961	4,879
Total gross deferred tax assets	171,731	186,552
Less: Valuation allowance	(11,032)	(7,358)
Total deferred tax assets	160,699	179,194
Deferred tax liabilities:		
Deferred financing costs	—	(8,797)

Depreciation on property and equipment	(12,098)	—
Amortization of intangible assets	(12,441)	(15,241)
Basis differences of partnerships and joint ventures	(2,399)	(68,160)
Deferred rent	(717)	—
Other deferred liabilities	(725)	(3,203)
Total deferred tax liabilities	(28,380)	(95,401)
Net deferred tax assets	\$ 132,319	\$ 83,793

The Company had federal net operating loss carryforwards of \$507.4 million as of December 31, 2017, which expire between 2025 and 2037 and state net operating loss carryforwards of \$619.6 million as of December 31, 2017, which expire between 2018 and 2037. The Company had capital loss carryforwards of \$12.6 million as of December 31, 2017, which expire between 2018 and 2022. The Company had federal and state credit carryforwards of \$1.1 million as of December 31, 2017. The federal credits do not expire, and the state credits expire between 2018 and 2029.

The Company has recorded a valuation allowance against deferred tax assets at December 31, 2017 and 2016 totaling \$11.0 million and \$7.4 million, respectively, which represents an increase of \$3.6 million. The valuation allowance continues to be provided for certain deferred tax assets for which the Company believes it is more likely than not that the tax benefits will not be realized, which are primarily certain state net operating losses and capital loss carryforwards.

Included in the increase in the valuation allowance for the year ended December 31, 2017 was an increase of approximately \$0.4 million that was recorded to additional-paid-in-capital as the result of the tax effect of the disposals of shares of non-controlling interests. Also included in the increase in the valuation allowance was an increase of approximately \$0.3 million that was recorded to goodwill related to certain deferred tax assets acquired during the year. Approximately \$1.8 million of the valuation allowance as of December 31, 2017 is recorded against deferred tax assets that, if subsequently recognized, will be credited directly to contributed capital.

A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December 31, 2017 and 2016 is as follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Unrecognized tax benefits at beginning of year	\$ 1,061	\$ 1,403
Additions for acquired positions	36	—
Additions for tax positions of prior years	—	60
Reductions for tax positions of prior year	(407)	(398)
Settlements	—	(4)
Unrecognized tax benefits at end of year	\$ 690	\$ 1,061

The Company recognizes interest and penalties related to uncertain tax positions in its provision for income taxes in the consolidated statements of operations. For the years ended December 31, 2017 and 2016, the Company had approximately \$0.1 million and \$0.2 million, respectively, of accrued interest and penalties related to uncertain tax positions. The total amount of accrued liabilities related to uncertain tax positions that would affect the Company's effective tax rate, if recognized, is \$0.2 million and \$0.3 million as of December 31, 2017 and 2016, respectively. The reserves are included in long-term taxes payable and long-term deferred tax assets in the consolidated balance sheet as of December 31, 2017.

The Tax Cuts and Jobs Act was enacted on December 22, 2017. The Act reduces the US federal corporate tax rate from 35% to 21%, allows for 100% expensing of certain capital expenditures, and will limit

interest expense deductions beginning in 2018. As of December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Act; however, in certain cases, as described below, the Company has made a reasonable estimate of the effects on existing deferred tax balances. In other cases, the Company has not been able to make a reasonable estimate and continues to account for those items based on existing accounting under ASC 740, and the provisions of the tax laws that were in effect immediately prior to enactment. In all cases, the Company will continue to make and refine its calculations as additional analysis is completed. In addition, estimates may also be affected as the Company gains a more thorough understanding of the tax law.

The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. However, the Company is still analyzing certain aspects of the Act and refining its calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The most significant component of the uncertainty relates to the state tax impact of the federal changes and how the states will or will not adopt federal changes. The effect on the Company will primarily be related to its state net operating losses and related valuation allowances. The provisional amount recorded related to the remeasurement of the deferred tax balance was \$64.0 million, which is included as a component of income tax expense.

The Company has not made sufficient progress on the analysis of the 100% expensing that may be claimed at certain partnership entities in their 2017 income tax returns for applicable capital expenditures, and the effects that would have on the Company's deferred tax assets and liabilities. The temporary differences related to these amounts would adjust the Company's deferred tax assets and liabilities related to partnership differences and net operating losses, but would likely have an immaterial net effect on the overall deferred tax asset recorded in the financial statements.

Tax Receivable Agreement

On May 9, 2017, the Company and H.I.G., in its capacity as the stockholders representative, entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September 30, 2015 (as amended, the "TRA"), by and between the Company, H.I.G. (in its capacity as the stockholders representative) and the other parties referred to therein, which amendment became effective on August 31, 2017. The TRA was initially entered into in connection with the reorganization undertaken to facilitate the Company's initial public offering. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G. in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus three percent. The amounts payable under the TRA are related to the Company's projected realized tax savings over the next six years and are not dependent on the Company's actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA and such inability is a result of the terms of credit agreements and other debt documents that are materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 500 basis points until paid. If the terms of such credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid.

As a result of the amendment to the TRA, the Company was required to value the liability under the TRA by discounting the fixed payment schedule using the Company's incremental borrowing rate. During the eight months ended August 31, 2017 (Predecessor), the Company recognized a reduction in the carrying value of the liability under the TRA of \$43.9 million, with \$15.3 million of the reduction recorded to a gain on amendment of TRA and \$28.6 million recorded as a reduction to the goodwill recorded in connection with the application of pushdown accounting related to the change of control (discussed in Note 1. "Organization").

As a result of the reduction in the corporate tax rate from the Tax Cuts and Jobs Act discussed above, the Company remeasured the value of the liability under the TRA pursuant to the calculation terms as described above. During the four months ended December 31, 2017 (Predecessor), the Company recognized a reduction in the carrying value of the liability under the TRA of \$25.3 million, included as a tax receivable agreement benefit in the consolidated statement of operations. Assuming the Company's tax rate is 24%, calculated as the maximum corporate federal tax rate plus three percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA as of December 31, 2017 will be approximately \$65.1 million. The carrying value of the liability under the TRA, reflecting the discount as discussed above, was \$44.3 million as of December 31, 2017.

Prior to the remeasurement at the lower corporate tax rate, but subsequent to the effectiveness of the amendment discussed above, the Company estimated that the total amounts payable under the TRA would be approximately \$120.5 million. Prior to the effectiveness of the amendment to the TRA, the amounts payable under the TRA varied depending upon a number of factors, including the amount, character and timing of the taxable income of Surgery Partners, Inc. The Company estimated the total amounts payable would be approximately \$123.4 million, if the tax benefits of related deferred tax assets were ultimately realized. The amounts payable were recognized during 2015 in conjunction with the release of the Company's valuation allowance recorded against the deferred tax assets.

On September 8, 2017 (Successor), in connection with the resignation of the Company's former Chief Executive Officer, Michael Doyle, Mr. Doyle entered into a TRA Waiver and Assignment Agreement (the "CEO TRA Assignment Agreement") with the Company, pursuant to which the Company accepted the assignment of 50% of Mr. Doyle's (and his affiliates') interest in future payments to which such parties were entitled pursuant to the TRA, in exchange for an upfront payment of approximately \$5.1 million, in the aggregate, as set forth in the CEO TRA Assignment Agreement. On September 15, 2017 (Successor), certain of the Company's employees entered into TRA Waiver and Assignment Agreements with the Company (collectively, the "Employee TRA Assignment Agreements" and together with the CEO TRA Assignment Agreement, the "TRA Assignment Agreements"), pursuant to which the Company made upfront payments of approximately \$4.8 million in the aggregate, in exchange for the assignment of 100% of each such employee's interest in future payments to which such employee was entitled pursuant to the TRA. During the four months ended December 31, 2017 (Successor), the Company recognized an aggregate gain of \$1.1 million as a result of the TRA Assignment Agreements.

Equity-Based Compensation

**12 Months Ended
Dec. 31, 2017**

[Disclosure of Compensation
Related Costs, Share-based
Payments \[Abstract\]
Equity-Based Compensation](#)

Equity-Based Compensation

Prior to the Reorganization, the Surgery Center Holdings, LLC's ("Holdings LLC") Amended and Restated Limited Liability Company Agreement, dated December 24, 2009, provided, from time to time, as approved by the Holdings LLC's Board, for the issuance of a subordinate class of the Holdings LLC's nonvoting membership units to certain key persons, as defined, of the Company or its subsidiaries.

In April 2013, the Company modified the terms of the 2010 awards to allow for additional vesting in 2013 of its share-based awards with time-vesting conditions. In November 2014, the Holdings LLC issued to certain executives of Symbion who became employees of the Company following the Company's acquisition of Symbion an additional 1,300,000 unvested B-Units, which are subject to vesting conditions to occur through November 2019.

Prior to the Reorganization, in the event of employee termination, the B-Units were subject to a 90-day repurchase option. Upon termination, all unvested B-Units were effectively forfeited. If the employee was terminated for cause, as defined, or resigned prior to the expiration of certain tenure periods specified in such employee's agreement, the repurchase price for each vested B-Unit was zero, and was deemed automatically repurchased by the Company. The repurchase price for vested B-Units, should the Company elect to exercise the repurchase option, was at fair market value, as defined. If the Company did not exercise the repurchase option, the employee owned the vested B-Units pursuant to the Holdings LLC's LLC Agreement, which included restrictions on transfer, among other provisions. The fair value of each Holdings LLC issued B-Unit was estimated on the date of grant.

In September 2015, the Company adopted the Surgery Partners, Inc. 2015 Omnibus Incentive Plan ("2015 Omnibus Incentive Plan") from which all equity-based awards will be granted. Under this plan, the Company can grant stock options, SARs, restricted stock, unrestricted stock, stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of its common stock. As of December 31, 2017, 4,815,700 shares were authorized to be granted under the 2015 Omnibus Incentive Plan and 3,716,809 were available for future equity grants.

Restricted Share-Based Awards

During the four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), the Company granted 112,107 and 251,904 restricted stock awards, respectively, to certain officers, employees and non-employee directors in accordance with the 2015 Omnibus Incentive Plan. The Company granted 384,629 and 569,114 restricted stock awards during the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively. Vesting and payment of these restricted stock awards are generally subject to continuing service of the employee or non-employee director over the ratable vesting periods beginning one year from the date of grant to three or five years after the date of grant. The fair values of these restricted stock units were determined based on the closing price of the Company's common stock on the trading date immediately prior to the grant date.

During the eight months ended August 31, 2017 (Predecessor) and the year ended December 31, 2016 (Predecessor) the Company granted 232,242 and 292,147 performance-based restricted stock units, respectively, subject to the achievement of a combination of performance conditions. There were no grants during the four months ended December 31, 2017 (Successor) and the year ended December 31, 2015 (Predecessor). In addition to the achievement of the performance conditions, these performance-based restricted stock units are generally subject to the continuing service of the employee over the ratable vesting period from the earned date continuing for two years. The performance condition for the targeted performance-based restricted stock units granted during the eight months ended August 31, 2017 (Predecessor) is based on the Company's achievement of annually established targets for adjusted earnings per share for 2017. For these restricted stock units, the number of shares payable at the end of the performance periods ranges from 0% to 150% of the targeted units based on the Company's actual performance and/or market conditions results as compared to the targets. The performance condition for the targeted performance-

based restricted stock units granted during the year ended December 31, 2016 (Predecessor) is based on the Company's actual adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"). These stock units are not considered outstanding until earned. During the eight months ended August 31, 2017 (Predecessor), 136,550 of the restricted stock units granted were deemed to have been earned. No additional units granted were deemed to have been earned during the four months ended December 31, 2017 (Successor).

Additionally, during the four months ended December 31, 2017 (Successor), the Company granted 215,823 leverage performance restricted stock units subject to the achievement of a combination of market conditions. There were no grants during the eight months ended August 31, 2017 (Predecessor) or the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor). In addition to the achievement of the market conditions, these leverage performance units are generally subject to the continuing service of the employee over the ratable vesting period from the performance period end date continuing for three years. The market condition for the leverage performance restricted stock units granted during the four months ended December 31, 2017 (Successor) is based on the Company's three-year annualized total shareholder return relative to the companies making up the S&P Composite 1500 Health Care Index as of the grant date. These stock units are not considered outstanding until earned. During the four months ended December 31, 2017 (Successor), none of the leverage performance restricted stock units granted were deemed to have been earned.

For these restricted stock units, the number of shares payable at the end of the vesting periods ranges from 0% to 500% of the targeted units based on the Company's actual performance and/or market conditions results as compared to the targets. The fair values of these restricted stock units were determined based on a combination, where applicable, of the closing price of the Company's common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions. The Company recognizes compensation expense for the portion of the targeted performance-based restricted stock units subject to market conditions even if the condition is never satisfied. However, if the performance conditions are not met for the portion of the targeted performance-based restricted stock units subject to such performance conditions, no compensation expense will be recognized, and any previously recognized compensation expense will be reversed. Forfeitures are recognized as incurred.

Restricted Share-Based Activity

All units and per unit amounts in these consolidated financial statements and notes to the consolidated financial statements reflect the Reorganization that occurred in September 2015 (see Note 1). A summary of non-vested restricted share-based activity for the years ended December 31, 2017, 2016, and 2015 follows:

	<u>Unvested Shares</u>	<u>Weighted Average Grant Date Fair Value</u>
<i>Predecessor</i>		
Outstanding at January 1, 2015	1,242,065	\$ 1.96
Granted/Earned	569,114	6.31
Vested	<u>(1,643,525)</u>	3.79
Outstanding at December 31, 2015	167,654	\$ 2.53
Granted/Earned	384,629	15.09
Forfeited/Canceled	(53,003)	11.85
Vested	<u>(37,038)</u>	6.31
Outstanding at December 31, 2016	462,242	\$ 3.72
Granted/Earned	388,454	18.40
Forfeited/Canceled	(67,771)	18.01
Vested	<u>(169,881)</u>	10.29
Outstanding at August 31, 2017	<u>613,044</u>	\$ 16.02
<i>Successor</i>		
Outstanding at September 1, 2017	613,044	\$ 16.02

Granted/Earned	112,107	11.15
Forfeited/Canceled	(54,622)	10.94
Vested	(96,073)	17.03
Outstanding at December 31, 2017	<u>574,456</u>	\$ 15.95

Stock Options

The Company did not grant any stock options during the year ended December 31, 2017. During the years ended December 31, 2016 and 2015, the Company granted options to purchase shares of the Company's common stock to certain directors in accordance with the 2015 Omnibus Incentive Plan. Options to purchase shares are granted with an exercise price equal to the fair market value of the Company's common stock on the day of grant, based on the closing price of the Company's common stock on the trading date immediately prior to the grant date, and become ratably exercisable beginning one year from the date of grant to three years after the date of grant. Forfeitures are recognized as incurred.

Option Valuation

In applying the Black-Scholes-Merton option pricing model, the Company used the following assumptions:

- *Risk-free interest rate.* The risk-free interest rate is used as a component of the fair value of stock options to take into account the time value of money. For the risk-free interest rate, the Company uses the implied yield on United States Treasury zero-coupon issues with a remaining term equal to the expected life, in years, of the options granted.
- *Expected volatility.* Volatility, for the purpose of share-based compensation, is a measurement of the amount that a share price has fluctuated. Expected volatility involves reviewing historical volatility and determining what, if any, change the share price will have in the future. The Company used historical stock price information of certain peer group companies for a period of time equal to the expected option life period to determine estimated volatility.
- *Expected life, in years.* A clear distinction is made between the expected life of an option and the contractual term of the option. The expected life of an option is considered the amount of time, in years, that an option is expected to be outstanding before it is exercised. Whereas, the contractual term of the stock option is the term an option is valid before it expires.
- *Expected dividend yield.* Since issuing dividends will affect the fair value of a stock option, GAAP requires companies to estimate future dividend yields or payments. The Company has not historically issued dividends and does not intend to issue dividends in the future. As a result, the Company does not apply a dividend yield component to its valuation.

The following table sets forth the assumptions used by the Company to estimate the fair value of options granted in 2016 and 2015 under the 2015 Omnibus Incentive Plan:

Expected volatility	29% - 43%
Risk-free interest rate	0.54% - 1.36%
Expected dividends	—
Average expected term (years)	2.56
Fair value of stock options granted	\$2.64 - \$5.74

The estimated fair value of options is amortized to expense on a straight-line basis over the options' vesting period.

Stock Option Activity

A summary of stock option activity for the years ended December 31, 2017, 2016, and 2015 follows:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (years)
<i>Predecessor</i>			
Outstanding at January 1, 2015	—		
Granted	8,488	\$ 20.03	3.0
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2015	8,488	\$ 20.03	3.0
Granted	7,779	17.99	1.6
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2016	16,267	\$ 19.05	1.8
Granted	—		
Exercised	(3,580)	15.36	
Forfeited	—		
Outstanding at August 31, 2017	<u>12,687</u>	\$ 20.10	1.5
<i>Successor</i>			
Outstanding at September 1, 2017	12,687	\$ 20.10	1.5
Granted	—		
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2017 ⁽¹⁾	<u>12,687</u>	\$ 20.10	1.2

⁽¹⁾ Of the outstanding options, 7,058 were exercisable as of December 31, 2017 (Successor).

Other information pertaining to equity-based compensation

At December 31, 2017 (Successor), unrecognized compensation cost related to unvested shares was approximately \$6.6 million. Unrecognized compensation cost will be expensed annually based on the number of shares that vest during the year.

The Company records equity-based compensation expense to recognize the fair value of the restricted shares that vest and stock options granted. During the four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), the Company recorded equity-based compensation expense of \$1.9 million and \$3.7 million, respectively. The Company recorded equity-based compensation expense of \$2.0 million and \$7.5 million during the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively. In connection with the IPO, 1,632,626 restricted shares immediately vested which resulted in accelerated vesting of \$6.2 million which is included within the \$7.5 million of equity-based compensation expense for the year ended December 31, 2015 (Predecessor).

Employee Benefit Plans

**12 Months Ended
Dec. 31, 2017**

[Retirement Benefits](#)

[\[Abstract\]](#)

[Employee Benefit Plans](#)

Employee Benefit Plans

Surgery Partners 401(k) Plan

The Surgery Partners 401(k) Plan is a defined contribution plan whereby certain employees who have completed at least one month of service, including at least one hour of service during that period of time, are eligible to participate. Employees may enroll in the plan immediately upon completion of the minimum service requirement. The Surgery Partners 401(k) Plan allows eligible employees to make contributions of varying percentages or flat dollar amounts of their annual compensation, up to the maximum allowable amounts by the Internal Revenue Service ("IRS"). Eligible employees may or may not receive a match by the Company of their contributions. Employer contributions vest incrementally over a period of five years. The Company's contributions were \$2.3 million for the four months ended December 31, 2017 (Successor), \$2.8 million for the eight months ended August 31, 2017 (Predecessor). For the years ended December 31, 2016 and 2015, contributions were \$5.1 million and \$2.2 million, respectively.

Supplemental Executive Retirement Savings Plan

In connection with the Symbion acquisition, the Company acquired and continues to maintain a supplemental executive retirement savings plan (the "SERP") for certain former Symbion executives. The SERP provides supplemental retirement savings alternatives to eligible officers and key employees of the Company by allowing participants to defer portions of their compensation. Under the SERP, eligible employees may enroll in the plan before December 31 to be entered in the plan the following year. Eligible employees may defer into the SERP up to 25% of their normal period payroll and up to 50% of their annual bonus. If the enrolled employee contributes a minimum of 2% of his or her base salary into the SERP, the Company will contribute 2% of the enrolled employee's base salary to the plan and has the option of contributing additional amounts. Periodically, the enrolled employee's deferred amounts are transferred to a plan administrator. The plan administrator maintains separate non-qualified accounts for each enrolled employee to track deferred amounts. On May 1 of each year, the Company is required to make its contribution to each enrolled employee's account. See Note 2. "Significant Accounting Policies" for information about the fair value of the assets and liabilities in the SERP.

Related Party Transactions

**12 Months Ended
Dec. 31, 2017**

[Related Party Transactions](#)

[\[Abstract\]](#)

[Related Party Transactions](#)

Related Party Transactions

On December 24, 2009, the Company and Bayside Capital, Inc. (or "Bayside"), an affiliate of H.I.G. Capital, LLC (or "H.I.G."), entered into a Management and Investment Advisory Services Agreement ("Management Agreement") pursuant to which the Company received certain management, consulting and financial advisory services. The Management Agreement was terminated upon completion of the IPO in 2015. Prior to termination, fees related to the Management Agreement of \$3.0 million were included as general and administrative expense in the accompanying consolidated statements of operations for the year ended December 31, 2015. As a result of the IPO, the Company further paid Bayside a transaction fee pursuant to the Management Agreement of \$5.4 million during the year ended December 31, 2015.

Commitments and Contingencies

12 Months Ended
Dec. 31, 2017

[Commitments and Contingencies Disclosure](#)

[\[Abstract\]](#)

[Commitments and Contingencies](#)

Commitments and Contingencies

Professional, General and Workers' Compensation Liability Risks

The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. To cover these claims, the Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that would have a material adverse effect on the Company's business, financial position, results of operations or liquidity.

Laws and Regulations

Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory action including fines, penalties, and exclusion from the Medicare, Medicaid and other federal healthcare programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians. It is the Company's current practice and future intent to cooperate fully with such inquiries. The Company is not aware of any such inquiry that would have a material adverse effect on the Company's business, financial position, results of operations or liquidity. In addition, on October 23, 2017, the Company received a civil investigative demand ("CID") from the federal government under the False Claims Act ("FCA") for documents and information dating back to January 1, 2010 relating to the medical necessity of certain drug tests conducted by the Company's physicians and submitted to laboratories owned and operated by the Company. The Company intends to respond to the CID and cooperate with the U.S. Attorney's Office in connection with the FCA investigation.

Acquired Facilities

The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations, such as billing and reimbursement, fraud and abuse and similar anti-referral laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.

The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other healthcare providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.

Potential Physician Investor Liability

A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.

Contingent Consideration

Pursuant to a purchase agreement dated December 24, 2009 ("the Purchase Agreement"), the Company acquired controlling interests in 36 business entities in various Florida locations which operate freestanding ASCs and provided anesthesia and pain management services ("the 2009 Acquisition"). The Purchase Agreement provided for maximum potential contingent consideration of up to \$10.0 million based on operating results subsequent to the acquisition for the period from January 1, 2010 to December 31, 2010. Pursuant to the Purchase Agreement, the contingent consideration was payable as principal under a Subordinated Promissory Note, the form of which was delivered concurrent with the Purchase Agreement. In December 2010, the Company filed an indemnification claim against the Seller alleging breaches of and inaccuracies in representations and warranties included in the Purchase Agreement. On June 10, 2013, the court issued a judgment in favor of the Company regarding its indemnification claim and its claim regarding the overstatement of accounts receivable by the seller. Following the judgment, an appeal was filed by the seller and a cross-appeal was filed by the Company. In December 2016, the appeals court found in favor of the Company as well as dismissing the arguments raised by the seller in its appeal as without merit. The parties subsequently agreed to mediate the dispute, which was scheduled to begin in 2017. Based on a court order in December 2016, the Company removed the contingent consideration liability on its consolidated balance sheets. For the year ended December 31, 2016 (Predecessor) the Company recorded a gain on litigation settlement of \$14.1 million related to this matter.

On April 20, 2017, a settlement was reached between the two parties resulting in the Company receiving \$3.9 million of which \$2.7 million was paid from the escrow funds set up by the seller at the time of purchase and \$1.2 million was paid by the seller. During the second quarter of 2017 (Predecessor) the Company recorded a gain on litigation settlement of \$3.8 million for the settlement amount, net of legal costs.

In connection with an acquisition during the three months ended June 30, 2016, the applicable purchase agreement provided for potential contingent consideration of up to \$16.6 million to be paid to the prior owners of the applicable facility should the requirements for continuing employment agreed to in the purchase agreement be met. In accordance with ASC 805, Business Combinations, contingent consideration with a continuing employment provision is recognized ratably over the defined performance period as compensation expense. In the fourth quarter of 2017, the Company reached a settlement for a dispute with the prior owners, providing relief to the Company of any unpaid current and future liability related to the contingent consideration. Based on the settlement, the Company removed its accrued contingent consideration liability, which was included in other current liabilities in the consolidated balance sheets and recorded a gain on litigation settlement of \$8.7 million during the four months ended December 31, 2017 (Successor).

As disclosed in the footnotes to the consolidated statement of operations, the Company recognized contingent acquisition compensation expense of \$1.9 million for the four months ended December 31, 2017 (Successor) and \$5.1 million for both the eight months ended August 31, 2017 (Predecessor) and the year ended December 31, 2016 (Predecessor).

Subsequent to December 31, 2017, the Company estimates contingent acquisition compensation expense of \$1.5 million for the year ended December 31, 2018 related to other acquisitions completed in 2016.

Segment Reporting

12 Months Ended
Dec. 31, 2017

[Segment Reporting](#)

[\[Abstract\]](#)

[Segment Reporting](#)

Segment Reporting

A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or "CODM," in deciding how to allocate resources and in assessing performance.

The Company operates in three major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of optical services and the operation of ancillary services. "All other" primarily consists of the Company's corporate general and administrative functions. Prior to 2017, the all other component was disaggregated and presented below the reportable operating segments in the Adjusted EBITDA reconciliation table. The Company has conformed the prior periods to align to the current year presentation. These changes had no effect on the Company's reportable operating segments, which are presented consistent with prior periods.

Adjusted EBITDA is the primary profit/loss metric reviewed by the CODM in making key business decisions and on allocation of resources. The segment disclosures below provide a reconciliation from Adjusted EBITDA to income before income taxes, its most directly comparable GAAP financial measure, in the reported consolidated financial information.

The following tables present financial information for each reportable segment (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Revenues:				
Surgical facility services	\$ 564,458	\$ 688,725	\$1,042,097	\$ 884,144
Ancillary services	24,660	52,261	90,836	61,175
Optical services	3,486	7,629	12,505	14,572
Total revenues	<u>\$ 592,604</u>	<u>\$ 748,615</u>	<u>\$1,145,438</u>	<u>\$ 959,891</u>

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Adjusted EBITDA:				
Surgical facility services	\$ 103,760	\$ 125,912	\$ 214,218	\$ 180,113
Ancillary services	(2,255)	(6,526)	12,685	18,715
Optical services	736	2,214	3,308	3,905
All other	(23,504)	(36,036)	(50,948)	(44,680)
Total Adjusted EBITDA ⁽¹⁾	<u>78,737</u>	<u>85,564</u>	<u>179,263</u>	<u>158,053</u>

Net income attributable to non-controlling interests	39,634	42,087	75,630	71,416
Depreciation and amortization	(21,804)	(30,124)	(39,551)	(34,545)
Interest expense, net	(48,740)	(68,929)	(100,571)	(100,980)
Non-cash stock compensation expense	(1,887)	(3,697)	(2,021)	(7,502)
Contingent acquisition compensation expense	(1,982)	(5,057)	(5,092)	—
Termination of management agreement and IPO costs	—	—	—	(5,834)
Management fee ⁽²⁾	—	—	—	(2,250)
Merger transaction, integration and practice acquisition costs ⁽³⁾	(9,330)	(7,677)	(11,617)	(20,579)
Gain on litigation settlement	8,740	3,794	14,101	—
Gain on acquisition escrow release	167	1,000	—	—
Gain (loss) on disposal or impairment of long-lived assets, net	(5)	(1,715)	(2,355)	2,097
Gain on amendment to tax receivable agreement	1,098	15,294	—	—
Tax receivable agreement benefit (expense)	25,329	—	(3,733)	(119,911)
Loss on debt refinancing	—	(18,211)	(11,876)	(16,102)
Income (loss) before income taxes	<u>\$ 69,957</u>	<u>\$ 12,329</u>	<u>\$ 92,178</u>	<u>\$ (76,137)</u>

(1) The above table reconciles Adjusted EBITDA to income before income taxes as reflected in the consolidated statements of operations.

When the Company uses the term "Adjusted EBITDA," it is referring to income before income taxes minus (a) net income attributable to non-controlling interests plus (b) depreciation and amortization, (c) interest expense, net, (d) non-cash stock compensation expense, (e) contingent acquisition compensation expense, (f) termination of management agreement and IPO costs, (g) management fee, (h) merger transaction, integration and practice acquisition costs, minus (i) gain on litigation settlement, (j) gain on acquisition escrow release, (plus)/minus (k) (loss)/gain on disposal or impairment of long-lived assets, net, minus (l) gain on amendment to tax receivable agreement, (plus)/minus (m) tax receivable agreement (expense)/gain and plus (n) loss on debt refinancing. The Company uses Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by the Company's management to assess operating performance, make business decisions and allocate resources. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that the Company consolidates for financial reporting purposes. The Company believes that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors the Company's portion of Adjusted EBITDA generated by its surgical facilities and other operations.

Adjusted EBITDA is not a measurement of financial performance under GAAP, and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating the Company's financial performance. The Company believes such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. The Company's calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

(2) Fee payable pursuant the Management and Investment Advisory Services Agreement between the Company and Bayside, which was terminated in connection with the Company's IPO.

(3) This amount includes merger transaction and integration costs of \$7.5 million for the four months ended December 31, 2017 (Successor), \$5.6 million for the eight months ended August 31, 2017 (Predecessor), and \$8.7 million and \$17.9 million for the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively.

This amount includes practice acquisition costs of \$1.8 million for the four months ended December 31, 2017 (Successor), \$2.1 million for the eight months ended August 31, 2017 (Predecessor), and \$2.9 million and \$2.7 million for the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively.

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Assets:		
Surgical facility services	\$ 4,072,521	\$ 1,914,842
Ancillary services	104,274	184,002
Optical services	48,309	22,478
All other	397,669	183,636
Total assets	<u>\$ 4,622,773</u>	<u>\$ 2,304,958</u>

In connection with the application of pushdown accounting the Company reevaluated the relative fair value of its operating segments using a measurement date of October 1, 2017. As a result of its evaluation, the Company reallocated goodwill as of the measurement date to each reportable segment as follows: \$3.158 billion to surgical facilities services, \$74.3 million to ancillary services and \$38.4 million to optical services.

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Cash purchases of property and equipment, net:				
Surgical facility services	\$ 9,334	\$ 14,582	\$ 29,157	\$ 26,723
Ancillary services	191	1,875	5,388	1,051
Optical services	83	73	351	128
All other	1,219	2,243	4,213	5,537
Total cash purchases of property and equipment, net	<u>\$ 10,827</u>	<u>\$ 18,773</u>	<u>\$ 39,109</u>	<u>\$ 33,439</u>

**Quarterly Financial
Information (Unaudited)**

**12 Months Ended
Dec. 31, 2017**

**Quarterly Financial
Information Disclosure**

[Abstract]

**Quarterly Financial
Information (Unaudited)**

Quarterly Financial Information (Unaudited)

The following tables include a summary of certain information related to the Company's quarterly consolidated results of operations for each of the four quarters in the years ended December 31, 2017 and 2016. The timing of acquisitions and divestitures completed during the years presented affects the comparability of the quarterly financial information. The following should be read in conjunction with the audited consolidated financial statements included herein. The amounts are as follows (in thousands except per share amounts):

	2017				
	<i>Predecessor</i>			<i>Successor</i>	
	Q1	Q2	Q3 ⁽¹⁾	Q3 ⁽¹⁾	Q4
Revenues	\$ 286,183	\$ 288,353	\$ 174,079	\$ 132,258	\$ 460,346
Cost of revenues	\$ 211,948	\$ 216,452	\$ 143,772	\$ 102,924	\$ 338,704
Net income (loss)	\$ 14,422	\$ 11,627	\$ 4,369	\$ (2,648)	\$ 966
Net income attributable to non-controlling interests	\$ (17,176)	\$ (16,098)	\$ (8,813)	\$ (6,492)	\$ (33,142)
Net loss attributable to Surgery Partners, Inc.	\$ (2,754)	\$ (4,471)	\$ (4,444)	\$ (9,140)	\$ (32,176)
Basic net loss per share attributable to common stockholders ⁽²⁾	\$ (0.06)	\$ (0.09)	\$ (0.09)	\$ (0.57)	\$ (0.83)
Diluted net loss per share attributable to common stockholders ⁽²⁾	\$ (0.06)	\$ (0.09)	\$ (0.09)	\$ (0.57)	\$ (0.83)

⁽¹⁾ The Predecessor period for Q3 includes the two months ended August 31, 2017. The Successor period for Q3 includes the one month ended September 30, 2017.

⁽²⁾ Beginning in the Successor period, per share amounts include the impact of amounts allocated to participating securities. Refer to Note 10. "Earnings Per Share" for further discussion.

	2016			
	<i>Predecessor</i>			
	Q1	Q2	Q3	Q4
Revenues	\$ 267,074	\$ 289,681	\$ 282,682	\$ 306,001
Cost of revenues	\$ 196,703	\$ 208,852	\$ 201,394	\$ 214,247
Net income	\$ 10,357	\$ 22,293	\$ 14,334	\$ 38,100
Net income attributable to non-controlling interests	\$ (17,547)	\$ (20,173)	\$ (16,672)	\$ (21,238)
Net (loss) income attributable to Surgery Partners, Inc.	\$ (7,190)	\$ 2,120	\$ (2,338)	\$ 16,862
Basic net (loss) income per share attributable to common stockholders	\$ (0.15)	\$ 0.04	\$ (0.05)	\$ 0.35
Diluted net (loss) income per share attributable to common stockholders	\$ (0.15)	\$ 0.04	\$ (0.05)	\$ 0.35

Subsequent Events

**12 Months Ended
Dec. 31, 2017**

[Subsequent Events](#)

[\[Abstract\]](#)

[Subsequent Events](#)

Subsequent Events

On March 1, 2018, the Company acquired a controlling interest of a surgical facility in Omaha, Nebraska, for \$21.9 million. The acquisition was funded through cash from operations. As of the date of this filing, the Company has not completed its preliminary estimation of the fair values assigned to the assets acquired and liabilities assumed.

Significant Accounting Policies (Policies)

12 Months Ended
Dec. 31, 2017

[Organization, Consolidation and Presentation of Financial Statements](#)

[\[Abstract\]](#)

[Principles of Consolidation](#)

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.

[Non-Controlling Interests](#)

Non-Controlling Interests

The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.

The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control.

Non-Controlling Interests — Redeemable. Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners' or physician minority members', as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. The non-controlling interests — redeemable are reported outside of stockholders' equity in the consolidated balance sheets.

[Variable Interest Entities](#)

Variable Interest Entities

The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of ASC 810, *Consolidation*. At December 31, 2017 (Successor), the variable interest entities include five surgical facilities, three anesthesia practices and three physician practices. At December 31, 2016 (Predecessor), the variable interest entities included five surgical facilities, three anesthesia practices and two physician practice. The change is due to a physician practice acquired during the eight months ended August 31, 2017 (Predecessor). The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance.

Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.

Equity Method Investments

Equity Method Investments

The Company has non-consolidating investments in surgical facilities and management companies that own or manage surgical facilities. These investments are accounted for using the equity method of accounting.

Use of Estimates

Use of Estimates

The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.

Reclassifications

Reclassifications

Certain reclassifications have been made to the comparative periods' financial statements to conform to the current year presentation.

Fair Value of Financial Instruments

were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets at December 31, 2017 (Successor) and 2016 (Predecessor), as applicable. The carrying amounts related to the Company's other long-term debt obligations, including the 2014 Revolver Loan and the Revolver (in each case, as defined in Note 7. "Long-Term Debt"), approximate their fair values.

The Company maintains a supplemental executive retirement savings plan (the "SERP") for certain executive officers. The SERP is a non-qualified deferred compensation plan for eligible executive officers and other key employees of the Company that allows participants to defer portions of their compensation. The fair value of the SERP asset and liability was based on a quoted market price, or a Level 1 computation

Fair Value of Financial Instruments

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), inputs other than quoted prices in active markets that are either directly or indirectly observable (Level 2), or unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions (Level 3), depending on the nature of the item being valued.

The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values.

Revenues

Revenues

The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.

Other service revenues. Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses

and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts.

Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered.

Patient service revenues. The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid. Changes in estimated contractual adjustments and discounts are recorded in the period of change.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.

Accounts Receivable and Allowances for Contractual Adjustments and Doubtful Accounts

The Company records an estimate for doubtful accounts based on the aging category and historical collection experience of each product sales or other business included in other service revenues, as discussed in the note above.

The receivables related to the Company's optical products purchasing organization are recognized separately from patient accounts receivable, as discussed above, and are included in other current assets in the consolidated balance sheets.

Accounts Receivable and Allowances for Contractual Adjustments and Doubtful Accounts

Accounts receivable are recorded net of contractual adjustments and allowances for doubtful accounts to reflect accounts receivable at net realizable value. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. As of December 31, 2017, the Company had a net third-party Medicaid settlements liability of \$1.0 million compared to a third-party Medicaid settlements receivable of \$0.5 million at December 31, 2016.

The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. The Company's policy is to collect co-payments and deductibles prior to providing medical services. It is also the Company's policy to verify a patient's insurance 72 hours prior to the patient's procedure. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.

The Company analyzes accounts receivable at each of its facilities to ensure the proper aged category and collection assessment. At a consolidated level, the Company's policy is to review accounts receivable aging, by facility, to determine the appropriate allowance for doubtful accounts. Patient account balances are reviewed for delinquency based on contractual terms. This review is supported by an analysis of the actual revenues, contractual adjustments and cash collections received. An account balance is written off only after

the Company has pursued collection with legal or collection agency assistance or otherwise has deemed an account to be uncollectible.

Inventories

Inventories

Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings and building improvements, three to five years for computers and software and five to seven years for furniture and equipment. Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.

The Company also leases certain facilities and equipment under capital leases. Assets held under capital leases are stated at the present value of minimum lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset.

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located and Medicare licenses. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally three to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from two to five years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from three to ten years.

Impairment of Long-Lived Assets, Goodwill and Intangible Assets

Impairment of Long-Lived Assets, Goodwill and Intangible Assets

The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value. The cash flow projection and fair value represents management's best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation. No impairment losses on long-lived assets were recognized during the four months ended December 31, 2017 (Successor), the eight months ended August 31, 2017 (Predecessor), and the years ended December 31, 2016 and 2015 (Predecessor).

The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. The Company has determined that it has five reporting units, which include the following: 1) Surgical Facilities 2) Ancillary Services, 3) Midwest Labs, 4) The Alliance, including Optical Synergies and 5) Family Vision Care. The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. If the carrying value exceeds the estimated fair value, an impairment indicator exists and an estimate of the possible impairment loss is calculated. The fair value of the reporting units are estimated using a discounted cash flows approach and are corroborated using a market-based approach. The fair value calculation includes multiple assumptions and estimates, including the projected cash flows and discount rates applied.

[Equity-Based Compensation](#)

Equity-Based Compensation

Transactions in which the Company receives employee and non-employee services in exchange for the Company's equity instruments or liabilities that are based on the fair value of the Company's equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. Prior to the Reorganization, on the grant date, the Company employed a market approach to estimate the fair value of equity-based awards based on various considerations and assumptions, including implied earnings multiples and other metrics of relevant market participants, the Company's operating results and forecasted cash flows and the Company's capital structure. Such estimates require the input of highly subjective, complex assumptions. However, such assumptions are no longer required to determine fair value of shares of the Company's common stock as its underlying shares began trading publicly during the fourth quarter of 2015. The Company applies the Black-Scholes-Merton method of valuation in determining share-based compensation expense for option awards.

The Company's policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. Prior to the Reorganization, employees held membership units in Surgery Center Holdings, LLC, and the associated expense was referred to as unit-based compensation; following the Reorganization, such expense is referred to as equity-based compensation. The Company's equity-based compensation is described further in Note 12.

[Professional, General and Workers' Compensation Insurance](#)

Professional, General and Workers' Compensation Insurance

The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis.

The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers compensation claims which relate to (i) claims made during the policy period, which are offset by insurance recoveries and (ii) an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets.

[Recent Accounting Pronouncements](#)

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, "*Revenue from Contracts with Customers*," along with subsequent amendments, updates and an extension of the effective date (collectively the "New Revenue Standard"), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This five-step process will require significant management judgment in addition to changing the way many companies recognize revenue in their financial statements. Additionally, and among other provisions, the New Revenue Standard requires expanded quantitative and qualitative disclosures, including disclosure about the nature, amount, timing and uncertainty of revenue. The provisions of the New Revenue Standard are effective for annual periods beginning after December 15, 2017, including interim periods within those years by applying either the full retrospective method or the modified retrospective approach upon adoption. The Company will adopt this ASU on January 1, 2018. The Company plans to adopt using the modified retrospective method, including providing all requisite disclosures under such method. The Company expects that the majority of its provision for doubtful accounts will continue to be recognized as an operating expense rather than as a direct reduction to revenues, given the Company's practice of assessing a patient's ability to pay prior to or on the date of providing healthcare services. The Company does not believe the adoption will have a significant impact on our recognition of net revenues for any period. The Company is still evaluating the impact that the adoption will have on its related disclosures.

In February 2016, the FASB issued ASU 2016-02, "*Leases*," which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. The

Company believes the primary effect of adopting the new standard will be to record right-of-use assets and obligations for current operating leases.

In January 2017, the FASB issued ASU 2017-01, “*Business Combinations – Clarifying the Definition of a Business*,” which narrows the definition of a business when evaluating whether transactions should be accounted for as asset acquisition or business combination. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those years. The adoption of this ASU will not have a material impact on the Company's condensed consolidated financial position, results of operations and cash flows.

Business Combinations

The Company accounts for its business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.

Significant Accounting
Policies (Tables)

12 Months Ended
Dec. 31, 2017

[Organization, Consolidation and
Presentation of Financial
Statements \[Abstract\]](#)

[Schedule of Rollforward of Non-
Controlling Interests - Redeemable](#)

A summary of activity related to the non-controlling interests—redeemable follows (in thousands):

Predecessor

Balance at December 31, 2015	\$ 183,439
Net income attributable to non-controlling interests—redeemable	18,023
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(3,781)
Distributions to non-controlling interest —redeemable holders	(17,160)
Balance at December 31, 2016	180,521
Net income attributable to non-controlling interests—redeemable	9,615
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(3,323)
Distributions to non-controlling interest —redeemable holders	(11,468)
Acquisition of NSH	153,320
Balance at August 31, 2017	<u>\$ 328,665</u>

Successor

Balance at September 1, 2017	\$ 271,001
Net income attributable to non-controlling interests—redeemable	12,931
Acquisition and disposal of shares of non-controlling interests, net—redeemable	819
Distributions to non-controlling interest —redeemable holders	(8,228)
Reallocation in application of pushdown accounting	21,248
Purchase price adjustments	1,545
Balance at December 31, 2017	<u>\$ 299,316</u>

[Schedule of Carrying Values and
Estimated Fair Values of Debt
Instruments](#)

A summary of the carrying amounts and fair values of the Company's long-term debt follows (in thousands):

	<i>Successor</i>		<i>Predecessor</i>	
	December 31, 2017		December 31, 2016	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
2014 Revolver Loan	\$ —	\$ —	\$ 85,000	\$ 85,000
2014 First Lien Credit Agreement, net of debt issuance costs and discount	\$ —	\$ —	\$ 911,784	\$ 917,528
2017 Senior Secured Credit Facilities:				
Revolver	\$ —	\$ —	\$ —	\$ —
Term Loan	\$ 1,280,532	\$ 1,267,189	\$ —	\$ —
Senior Unsecured Notes due 2021 ⁽¹⁾	\$ 409,235	\$ 422,535	\$ 387,942	\$ 412,189

Senior Unsecured Notes due 2025 \$ 370,000 \$ 346,413 \$ — \$ —

(1) The carrying amount in the Predecessor period is net of unamortized debt issuance costs and discount, which were eliminated with the application of pushdown accounting.

Schedule of Revenues by Service Type

A summary of revenues by service type as a percentage of total revenues follows:

	<i>Successor</i>		<i>Predecessor</i>		
	September 1 to December 31,		January 1 to August 31,	Year Ended December 31,	
	2017		2017	2016	2015
Patient service revenues:					
Surgical facilities revenues	94.3%	91.4%	90.3%	91.6%	
Ancillary services revenues	4.2%	7.0%	7.9%	6.4%	
	98.5%	98.4%	98.2%	98.0%	
Other service revenues:					
Optical services revenues	0.6%	1.0%	1.1%	1.5%	
Other	0.9%	0.6%	0.7%	0.5%	
	1.5%	1.6%	1.8%	2.0%	
Total revenues	100.0%	100.0%	100.0%	100.0%	100.0%

Schedule of Revenue Sources for Patient Service Revenues

The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in thousands):

	<i>Successor</i>		<i>Predecessor</i>					
	September 1 to December 31,		January 1 to August 31,		Year Ended December 31,			
	2017		2017		2016		2015	
	Amount	%	Amount	%	Amount	%	Amount	%
Patient service revenues:								
Private insurance	\$347,801	59.6%	\$360,092	48.9%	\$ 579,662	51.5%	\$516,739	55.0%
Government	196,926	33.7%	308,993	42.0%	448,953	39.9%	359,471	38.2%
Self-pay	15,233	2.6%	15,949	2.2%	19,817	1.8%	16,190	1.7%
Other ⁽¹⁾	23,843	4.1%	51,374	6.9%	76,172	6.8%	48,311	5.1%
Total patient service revenues	\$583,803	100.0%	\$736,408	100.0%	\$1,124,604	100.0%	\$940,711	100.0%
Other service revenues:								
Optical service revenues	\$ 3,486		\$ 7,629		\$ 12,505		\$ 14,572	
Other revenues	5,315		4,578		8,329		4,608	
Total net revenues	\$592,604		\$748,615		\$1,145,438		\$959,891	

(1) Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.

Schedules of Accounts Receivable

A summary of the changes in the allowance for doubtful accounts receivable follows (in thousands):

	Balance at Beginning of Period	Provision for Doubtful Accounts	Accounts Written off, Net of Recoveries	Balance at End of Period
<i>Predecessor</i>				
Year ended December 31, 2015	\$ 5,329	\$ 23,578	\$ (10,585)	\$ 18,322
Year ended December 31, 2016	18,322	24,212	(12,662)	29,872
Eight months ended August 31, 2017	29,872	16,297	(14,096)	32,073

Successor

Four months ended December 31, 2017	—	12,455	(10,429)	2,026
-------------------------------------	---	--------	----------	-------

Schedule of Prepaid Expenses and Other Current Assets

A summary of prepaid expenses and other current assets follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Prepaid expenses	\$ 16,835	\$ 11,158
Receivables - optical product purchasing organization	7,563	7,042
Acquisition escrow deposit	3,809	10,871
Insurance recoveries	2,828	2,476
Other	24,302	11,338
Total	\$ 55,337	\$ 42,885

Schedule of Other Long-Term Assets

A summary of other long-term assets follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Acquisition escrow deposit	\$ 19,600	\$ —
Insurance recoveries	10,018	6,835
Notes receivable	2,263	716
Deposits	3,151	4,196
Other	13,318	4,688
Total	\$ 48,350	\$ 16,435

Schedule of Other Current Liabilities

A summary of other current liabilities follows (in thousands):

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Interest payable	\$ 20,537	\$ 19,206

Amounts due to patients and payors	18,096	12,221
Insurance liabilities	9,873	6,625
Current taxes payable	4,912	2,622
Acquisition escrow liability	3,809	10,871
Accrued expenses and other	52,717	28,319
Total	<u>\$ 109,944</u>	<u>\$ 79,864</u>

Schedule of Other Long-Term
Liabilities

A summary of other long-term liabilities follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	<u>December 31, 2017</u>	<u>December 31, 2016</u>
Facility lease obligations	\$ 121,627	\$ 52,653
Acquisition escrow liability	19,600	—
Medical malpractice liability	16,450	10,453
Unfavorable lease liability	11,889	1,671
Other	9,123	11,489
Total	<u>\$ 178,689</u>	<u>\$ 76,266</u>

**Acquisitions and
Developments (Tables)**

**12 Months Ended
Dec. 31, 2017**

Business Combinations

[Abstract]

**Schedule of recognized
identified assets acquired and
liabilities assumed**

The aggregate amounts preliminarily recognized for each major class of assets and liabilities assumed in the other acquisitions completed during 2017, including post acquisition date adjustments, are as follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	September 1 to December 31,	January 1 to August 31,
	2017	2017
Cash consideration	\$ 29,448	\$ 14,163
Fair value of non-controlling interests	21,893	105
Aggregate fair value of acquisitions	<u>51,341</u>	<u>14,268</u>
Net assets acquired:		
Current Assets	2,285	866
Property and equipment	248	696
Intangible assets	41	634
Goodwill	49,317	12,545
Current liabilities	(550)	(287)
Long-term debt	—	(186)
Total fair value of net assets acquired	<u>\$ 51,341</u>	<u>\$ 14,268</u>

The aggregate amounts preliminarily recognized for each major class of assets and liabilities, including post acquisition date adjustments, are as follows (in thousands):

Cash consideration	\$ 762,850
Fair value of non-controlling interests	325,965
Aggregate fair value of acquisition	<u>1,088,815</u>
Net assets acquired:	
Cash and cash equivalents	51,159
Accounts receivable	71,901
Inventories	14,986
Prepaid expenses and other current assets	18,397
Property and equipment	174,499
Intangible assets	27,746
Goodwill	870,241
Investments in and advances to affiliates	29,737
Long-term deferred tax assets	17,279
Other long-term assets	27,229
Accounts payable	(29,652)
Accrued payroll and benefits	(28,755)
Other current liabilities	(21,287)
Current maturities of long-term debt	(16,416)
Long-term debt, less current maturities	(42,770)

Other long-term liabilities	(75,479)
Total fair value of net assets acquired	\$ 1,088,815

The aggregate acquisition date fair value recognized for each major class of assets and liabilities assumed in the acquisitions completed during the year ended December 31, 2016, including post acquisition date adjustments, are as follows (in thousands):

Cash consideration	\$ 135,061
Fair value of non-controlling interests	27,164
Aggregate fair value of acquisitions	162,225
Net assets acquired:	
Current assets	11,383
Property and equipment	3,921
Intangible assets	4,475
Goodwill	148,181
Other long-term assets	56
Current liabilities	(5,422)
Long-term liabilities	(369)
Total fair value of net assets acquired	\$ 162,225

The aggregate amounts preliminarily recognized in connection with the application of pushdown accounting for each major class of assets and liabilities as of August 31, 2017, including subsequent adjustments, are as follows (in thousands):

Equity attributable to Surgery Partners, Inc.	\$ 720,606
Redeemable preferred stock	310,000
Fair value of non-controlling interests	957,027
Aggregate fair value	1,987,633
Net assets:	
Cash and cash equivalents	214,206
Accounts receivable	253,173
Inventories	44,310
Prepaid expenses and other current assets	61,475
Property and equipment	380,085
Intangible assets	60,104
Goodwill	3,299,911
Investments in and advances to affiliates	74,722
Restricted invested assets	315
Long-term deferred tax asset	204,408
Other long-term assets	49,681
Accounts payable	(64,921)
Accrued payroll and benefits	(54,437)
Other current liabilities	(94,740)
Current maturities of long-term debt	(49,942)
Long-term debt, less current maturities	(2,142,375)
Long-term tax receivable agreement liability	(78,498)
Other long-term liabilities	(169,844)
Total fair value of net assets	\$ 1,987,633

[Schedule of unaudited consolidated pro forma results](#)

The following unaudited pro forma combined summary of operations of the Company gives effect to using historical information of the operations of NSH as if the acquisition transaction had occurred as of January 1, 2016 (in thousands):

	<i>Successor</i>	<i>Predecessor</i>	
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,
	2017	2017	2016
Net revenues	\$ 592,604	\$1,122,326	\$1,679,254
Net income	4,477	63,269	132,699
Less: Net income attributable to non-controlling interests	(39,634)	(65,122)	(112,123)
Net (loss) income attributable to Surgery Partners, Inc.	<u>\$ (35,157)</u>	<u>\$ (1,853)</u>	<u>\$ 20,576</u>

**Property and Equipment
(Tables)**

**12 Months Ended
Dec. 31, 2017**

[Property, Plant and Equipment \[Abstract\]](#)
[Schedule of Property and Equipment](#)

A summary of property and equipment follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Land	\$ 19,561	\$ 8,082
Buildings and improvements	188,571	118,172
Furniture and equipment	20,813	14,670
Computer and software	28,578	29,902
Medical equipment	138,112	117,418
Construction in progress	22,581	2,396
Property and equipment, at cost	418,216	290,640
Less: Accumulated depreciation	(19,680)	(86,387)
Property and equipment, net	<u>\$ 398,536</u>	<u>\$ 204,253</u>

**Goodwill and Intangible
Assets (Tables)**

**12 Months Ended
Dec. 31, 2017**

**Goodwill and Intangible Assets
Disclosure [Abstract]**

**Summary of activity related to
goodwill**

A summary of the changes in the carrying amount of goodwill for the years ended December 31, 2017 and 2016 follows (in thousands):

Predecessor

Balance at December 31, 2015	\$ 1,407,927
Acquisitions	147,895
Divestitures	(552)
Purchase price adjustments	(66)
Balance at December 31, 2016	\$ 1,555,204
Acquisitions	858,323
Divestitures	(175)
Purchase price adjustments	1,220
Balance at August 31, 2017	<u>\$ 2,414,572</u>

Successor

Balance at September 1, 2017	\$ 3,269,225
Acquisitions	49,317
Divestitures	(1,957)
Purchase price adjustments	30,253
Balance at December 31, 2017	<u>\$ 3,346,838</u>

**Summary of components of intangible
assets**

A summary of the components of intangible assets follows (in thousands):

	<i>Successor</i>			<i>Predecessor</i>		
	December 31, 2017			December 31, 2016		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Finite-lived intangible assets:						
Management rights agreements	\$42,600	\$ (1,058)	\$41,542	\$24,751	\$ (3,461)	\$21,290
Non-compete agreements	4,874	(715)	4,159	24,673	(8,216)	16,457
Physician income guarantees	878	(227)	651	1,901	(1,088)	813
Other	—	—	—	8,815	(3,374)	5,441
Total finite-lived intangible assets	48,352	(2,000)	46,352	60,140	(16,139)	44,001
Indefinite-lived intangible assets:						
Management rights agreements	5,900	—	5,900	—	—	—

Certificates of need	5,548	—	5,548	3,780	—	3,780
Medicare licenses	1,108	—	1,108	242	—	242
Total intangible assets	<u>\$60,908</u>	<u>\$ (2,000)</u>	<u>\$58,908</u>	<u>\$64,162</u>	<u>\$ (16,139)</u>	<u>\$48,023</u>

A summary of the aggregate activity related to intangible assets for the years ended December 31, 2017 and 2016 follows (in thousands):

Predecessor

Balance at December 31, 2015	\$ 53,568
Additions	4,754
Disposals	(135)
Recruitment expense	(609)
Amortization	(9,555)
Balance at December 31, 2016	\$ 48,023
Additions	28,312
Recruitment expense	(380)
Amortization	(6,040)
Balance at August 31, 2017	<u>\$ 69,915</u>

Successor

Balance at September 1, 2017	\$ 56,750
Additions	474
Disposals	(140)
Purchase price adjustments	3,873
Recruitment expense	(227)
Amortization	(1,822)
Balance at December 31, 2017	<u>\$ 58,908</u>

[Summary of components and activity related to intangible assets](#)

A summary of the components of intangible assets follows (in thousands):

	<i>Successor</i>			<i>Predecessor</i>		
	December 31, 2017			December 31, 2016		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Finite-lived intangible assets:						
Management rights agreements	\$42,600	\$ (1,058)	\$41,542	\$24,751	\$ (3,461)	\$21,290
Non-compete agreements	4,874	(715)	4,159	24,673	(8,216)	16,457
Physician income guarantees	878	(227)	651	1,901	(1,088)	813
Other	—	—	—	8,815	(3,374)	5,441
Total finite-lived intangible assets	48,352	(2,000)	46,352	60,140	(16,139)	44,001

Indefinite-lived intangible assets:						
Management rights agreements	5,900	—	5,900	—	—	—
Certificates of need	5,548	—	5,548	3,780	—	3,780
Medicare licenses	1,108	—	1,108	242	—	242
Total intangible assets	<u>\$60,908</u>	<u>\$ (2,000)</u>	<u>\$58,908</u>	<u>\$64,162</u>	<u>\$ (16,139)</u>	<u>\$48,023</u>

A summary of the aggregate activity related to intangible assets for the years ended December 31, 2017 and 2016 follows (in thousands):

Predecessor

Balance at December 31, 2015	\$ 53,568
Additions	4,754
Disposals	(135)
Recruitment expense	(609)
Amortization	(9,555)
Balance at December 31, 2016	\$ 48,023
Additions	28,312
Recruitment expense	(380)
Amortization	(6,040)
Balance at August 31, 2017	<u>\$ 69,915</u>

Successor

Balance at September 1, 2017	\$ 56,750
Additions	474
Disposals	(140)
Purchase price adjustments	3,873
Recruitment expense	(227)
Amortization	(1,822)
Balance at December 31, 2017	<u>\$ 58,908</u>

Summary of scheduled amortization

Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in thousands):

2018	\$ 4,966
2019	4,576
2020	4,172
2021	3,730
2022	2,874
Thereafter	26,034
Total	<u>\$ 46,352</u>

Long-Term Debt (Tables)

12 Months Ended
Dec. 31, 2017

[Debt Disclosure \[Abstract\]](#) [Schedule of long-term debt](#)

A summary of long-term debt follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
2014 Revolver Loan	\$ —	\$ 85,000
2014 First Lien Credit Agreement	—	932,000
2017 Senior Secured Credit Facilities:		
Revolver	—	—
Term Loan ⁽¹⁾	1,280,532	—
Senior Unsecured Notes due 2021 ⁽²⁾	409,235	400,000
Senior Unsecured Notes due 2025	370,000	—
Subordinated Notes	—	1,000
Notes payable and secured loans	101,921	42,521
Capital lease obligations	27,594	13,996
Less: unamortized debt issuance costs and original issue discount	—	(32,274)
Total debt	2,189,282	1,442,243
Less: Current maturities	58,726	27,822
Total long-term debt	<u>\$ 2,130,556</u>	<u>\$ 1,414,421</u>

⁽¹⁾ Includes unamortized fair value discount of \$6.2 million as of December 31, 2017. See further discussion below.

⁽²⁾ Includes unamortized fair value premium of \$9.2 million as of December 31, 2017. See further discussion below.

[Debt redemption percentages](#)

The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, to, but excluding, the date of redemption:

July 1, 2020 to June 30, 2021	103.375%
July 1, 2021 to June 30, 2022	101.688%
July 1, 2022 and thereafter	100.000%
April 15, 2018 to April 14, 2019	106.656%
April 15, 2019 to April 14, 2020	104.438%
April 15, 2020 and thereafter	100.000%

[Summary of scheduled maturities of debt](#)

A summary of maturities for the Company's long-term debt, excluding unamortized fair value discount and premium discussed above, for the next five years and thereafter as of December 31, 2017 follows (in thousands):

2018	\$ 58,726
2019	36,857
2020	1,277,253

2021	411,748
2022	8,110
Thereafter	393,597
Total debt	<u>\$ 2,186,291</u>

Leases (Tables)

**12 Months Ended
Dec. 31, 2017**

[Leases \[Abstract\]](#)

[Future minimum operating lease payments](#)

Future minimum lease payments for non-cancellable operating and capital leases for the next five years and thereafter at December 31, 2017 follows (in thousands):

	<u>Operating Leases</u>	<u>Capital Leases</u>
2018	\$ 67,513	\$ 9,100
2019	67,136	7,404
2020	62,735	5,020
2021	56,558	3,505
2022	52,582	1,986
Thereafter	258,192	6,299
Total minimum payments	<u>\$ 564,716</u>	<u>33,314</u>
Less: imputed interest		(5,720)
Capital lease obligations		<u>\$ 27,594</u>

[Future minimum capital lease payments](#)

Future minimum lease payments for non-cancellable operating and capital leases for the next five years and thereafter at December 31, 2017 follows (in thousands):

	<u>Operating Leases</u>	<u>Capital Leases</u>
2018	\$ 67,513	\$ 9,100
2019	67,136	7,404
2020	62,735	5,020
2021	56,558	3,505
2022	52,582	1,986
Thereafter	258,192	6,299
Total minimum payments	<u>\$ 564,716</u>	<u>33,314</u>
Less: imputed interest		(5,720)
Capital lease obligations		<u>\$ 27,594</u>

Redeemable Preferred Stock
(Tables)

12 Months Ended
Dec. 31, 2017

[Temporary Equity](#)
[Disclosure \[Abstract\]](#)

[Activity Related to](#)
[Redeemable Preferred Stock](#)

A summary of activity related to the redeemable preferred stock for the period from September 1, 2017 to December 31, 2017 (Successor) follows (in thousands):

Successor

Balance at September 1, 2017	\$	310,000
Dividends accrued		10,481
Cash dividends declared		(5,241)
Mark to redemption adjustment		15,566
Balance at December 31, 2017	\$	<u>330,806</u>

Earnings Per Share (Tables)

**12 Months Ended
Dec. 31, 2017**

[Earnings Per Share \[Abstract\]](#)
[Reconciliation of numerator and denominator of basic and diluted EPS](#)

A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (in thousands except share and per share amounts):

	<i>Successor</i>	<i>Predecessor</i>		
	<u>September 1 to December 31,</u>	<u>January 1 to August 31,</u>	<u>Year Ended December 31,</u>	
	<u>2017</u>	<u>2017</u>	<u>2016</u>	<u>2015</u>
Numerator:				
Net (loss) income attributable to Surgery Partners, Inc.	\$ (41,316)	\$ (11,669)	\$ 9,453	\$ 1,429
Less: amounts allocated to participating securities ⁽¹⁾	10,481	—	—	—
Less: mark to redemption adjustment	15,566	—	—	—
Net (loss) income attributable to common stockholders	<u>\$ (67,363)</u>	<u>\$ (11,669)</u>	<u>\$ 9,453</u>	<u>\$ 1,429</u>
Denominator:				
Weighted average shares outstanding- basic	48,319,193	48,121,404	48,018,944	36,066,233
Effect of dilutive securities ⁽²⁾	—	—	171,794	1,398,154
Weighted average shares outstanding- diluted	<u>48,319,193</u>	<u>48,121,404</u>	<u>48,190,738</u>	<u>37,464,387</u>
Earnings (loss) per share:				
Basic	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04
Diluted ⁽²⁾	\$ (1.39)	\$ (0.24)	\$ 0.20	\$ 0.04
Securities outstanding not included in the computation of diluted (loss) earnings per share as their effect is antidilutive:				
Stock options	—	—	—	—
Restricted shares	62,850	105,944	—	—
Convertible preferred stock	—	N/A	N/A	N/A

⁽¹⁾ Amounts allocated to participating securities includes dividends accrued during the Successor period for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses. There were no participating securities during the Predecessor periods.

⁽²⁾ The impact of potentially dilutive securities for the four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), were not considered because the effect would be anti-dilutive in each of those periods.

**Income Taxes and Tax
Receivable Agreement
(Tables)**

**12 Months Ended
Dec. 31, 2017**

[Income Tax Disclosure](#)

[\[Abstract\]](#)

[Schedule of Income Tax
Expense \(Benefit\)](#)

Income tax expense (benefit) is comprised of the following (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	<u>September 1 to December 31,</u> <u>2017</u>	<u>January 1 to August 31,</u> <u>2017</u>	<u>Year Ended December 31,</u> <u>2016</u> <u>2015</u>	
Current:				
Federal	\$ (111)	\$ —	\$ (31)	\$ —
State	990	614	244	909
Deferred:				
Federal	77,472	(17,288)	7,326	(132,311)
State	(6,712)	(1,415)	(444)	(17,580)
Total income tax expense (benefit)	<u>\$ 71,639</u>	<u>\$(18,089)</u>	<u>\$ 7,095</u>	<u>\$(148,982)</u>

[Schedule of Effective Income
Tax Rate Reconciliation](#)

A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax expense (benefit) computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 35% follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	<u>September 1 to December 31,</u> <u>2017</u>	<u>January 1 to August 31,</u> <u>2017</u>	<u>Year Ended December 31,</u> <u>2016</u> <u>2015</u>	
Tax expense (benefit) at U.S.federal statutory rate	\$ 24,485	\$ 4,315	\$ 32,263	\$ (26,648)
State income tax, net of U.S. federal tax benefit	1,685	(456)	(86)	1,059
Change in valuation allowance	529	1,324	354	(137,721)
Net income attributable to non-controlling interests	(13,872)	(14,731)	(26,470)	(24,996)
Changes in measurement of uncertain tax positions	(191)	20	(262)	(10)
Stock option compensation	306	37	(200)	—
Differences related to divested facilities	(429)	(1,708)	—	—
Nondeductible transaction costs	2,058	(977)	—	3,442
Tax return reconciling differences	—	(316)	1,635	(1,574)
Change in effective tax rate	64,343	(825)	—	(2,143)
TRA liability	(7,404)	(4,782)	(327)	39,428
Other	129	10	188	181
Total income tax expense (benefit)	<u>\$ 71,639</u>	<u>\$(18,089)</u>	<u>\$ 7,095</u>	<u>\$(148,982)</u>

[Schedule of Deferred Tax
Assets and Liabilities](#)

The components of temporary differences and the approximate tax effects that give rise to the Company's net deferred tax asset are as follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Deferred tax assets:		
Medical malpractice liability	\$ 3,236	\$ 4,194
Accrued vacation and incentive compensation	2,125	1,112
Net operating loss carryforwards	137,794	158,796
Allowance for bad debts	2,545	8,343
Capital loss carryforwards	3,024	2,785
Deferred rent	—	1,371
Depreciation on property and equipment	—	530
Deferred financing costs	17,004	—
TRA liability	1,042	4,542
Other deferred assets	4,961	4,879
Total gross deferred tax assets	171,731	186,552
Less: Valuation allowance	(11,032)	(7,358)
Total deferred tax assets	160,699	179,194
Deferred tax liabilities:		
Deferred financing costs	—	(8,797)
Depreciation on property and equipment	(12,098)	—
Amortization of intangible assets	(12,441)	(15,241)
Basis differences of partnerships and joint ventures	(2,399)	(68,160)
Deferred rent	(717)	—
Other deferred liabilities	(725)	(3,203)
Total deferred tax liabilities	(28,380)	(95,401)
Net deferred tax assets	\$ 132,319	\$ 83,793

Schedule of Unrecognized Tax Benefits Roll Forward

A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December 31, 2017 and 2016 is as follows (in thousands):

	<i>Successor</i>	<i>Predecessor</i>
	December 31, 2017	December 31, 2016
Unrecognized tax benefits at beginning of year	\$ 1,061	\$ 1,403
Additions for acquired positions	36	—
Additions for tax positions of prior years	—	60
Reductions for tax positions of prior year	(407)	(398)
Settlements	—	(4)
Unrecognized tax benefits at end of year	\$ 690	\$ 1,061

**Equity-Based Compensation
(Tables)**

**12 Months Ended
Dec. 31, 2017**

[Disclosure of Compensation Related
Costs, Share-based Payments \[Abstract\]
Schedule of Restricted Stock Activity](#)

A summary of non-vested restricted share-based activity for the years ended December 31, 2017, 2016, and 2015 follows:

	Unvested Shares	Weighted Average Grant Date Fair Value
<i>Predecessor</i>		
Outstanding at January 1, 2015	1,242,065	\$ 1.96
Granted/Earned	569,114	6.31
Vested	<u>(1,643,525)</u>	3.79
Outstanding at December 31, 2015	167,654	\$ 2.53
Granted/Earned	384,629	15.09
Forfeited/Canceled	(53,003)	11.85
Vested	<u>(37,038)</u>	6.31
Outstanding at December 31, 2016	462,242	\$ 3.72
Granted/Earned	388,454	18.40
Forfeited/Canceled	(67,771)	18.01
Vested	<u>(169,881)</u>	10.29
Outstanding at August 31, 2017	<u>613,044</u>	\$ 16.02
 		
<i>Successor</i>		
Outstanding at September 1, 2017	613,044	\$ 16.02
Granted/Earned	112,107	11.15
Forfeited/Canceled	(54,622)	10.94
Vested	<u>(96,073)</u>	17.03
Outstanding at December 31, 2017	<u>574,456</u>	\$ 15.95

[Schedule of Stock Options, Valuation
Assumptions](#)

The following table sets forth the assumptions used by the Company to estimate the fair value of options granted in 2016 and 2015 under the 2015 Omnibus Incentive Plan:

Expected volatility	29% - 43%
Risk-free interest rate	0.54% - 1.36%
Expected dividends	—
Average expected term (years)	2.56
Fair value of stock options granted	\$2.64 - \$5.74

[Schedule of Stock Options Activity](#)

A summary of stock option activity for the years ended December 31, 2017, 2016, and 2015 follows:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (years)
<i>Predecessor</i>			
Outstanding at January 1, 2015	—		
Granted	8,488	\$ 20.03	3.0
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2015	8,488	\$ 20.03	3.0
Granted	7,779	17.99	1.6
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2016	16,267	\$ 19.05	1.8
Granted	—		
Exercised	(3,580)	15.36	
Forfeited	—		
Outstanding at August 31, 2017	<u>12,687</u>	\$ 20.10	1.5

Successor

Outstanding at September 1, 2017	12,687	\$ 20.10	1.5
Granted	—		
Exercised	—		
Forfeited	—		
Outstanding at December 31, 2017 ⁽¹⁾	<u>12,687</u>	\$ 20.10	1.2

⁽¹⁾ Of the outstanding options, 7,058 were exercisable as of December 31, 2017 (Successor).

Segment Reporting (Tables)

12 Months Ended
Dec. 31, 2017

[Segment Reporting](#)

[\[Abstract\]](#)

[Schedule of Revenues by Reportable Segment](#)

The following tables present financial information for each reportable segment (in thousands):

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Revenues:				
Surgical facility services	\$ 564,458	\$ 688,725	\$1,042,097	\$ 884,144
Ancillary services	24,660	52,261	90,836	61,175
Optical services	3,486	7,629	12,505	14,572
Total revenues	<u>\$ 592,604</u>	<u>\$ 748,615</u>	<u>\$1,145,438</u>	<u>\$ 959,891</u>

[Schedule of Segment Operating Income](#)

	<i>Successor</i>	<i>Predecessor</i>		
	September 1 to December 31,	January 1 to August 31,	Year Ended December 31,	
	2017	2017	2016	2015
Adjusted EBITDA:				
Surgical facility services	\$ 103,760	\$ 125,912	\$ 214,218	\$ 180,113
Ancillary services	(2,255)	(6,526)	12,685	18,715
Optical services	736	2,214	3,308	3,905
All other	(23,504)	(36,036)	(50,948)	(44,680)
Total Adjusted EBITDA ⁽¹⁾	<u>78,737</u>	<u>85,564</u>	<u>179,263</u>	<u>158,053</u>
Net income attributable to non-controlling interests	39,634	42,087	75,630	71,416
Depreciation and amortization	(21,804)	(30,124)	(39,551)	(34,545)
Interest expense, net	(48,740)	(68,929)	(100,571)	(100,980)
Non-cash stock compensation expense	(1,887)	(3,697)	(2,021)	(7,502)
Contingent acquisition compensation expense	(1,982)	(5,057)	(5,092)	—
Termination of management agreement and IPO costs	—	—	—	(5,834)
Management fee ⁽²⁾	—	—	—	(2,250)
Merger transaction, integration and practice acquisition costs ⁽³⁾	(9,330)	(7,677)	(11,617)	(20,579)
Gain on litigation settlement	8,740	3,794	14,101	—
Gain on acquisition escrow release	167	1,000	—	—
Gain (loss) on disposal or impairment of long-lived assets, net	(5)	(1,715)	(2,355)	2,097
Gain on amendment to tax receivable agreement	1,098	15,294	—	—
Tax receivable agreement benefit (expense)	25,329	—	(3,733)	(119,911)
Loss on debt refinancing	—	(18,211)	(11,876)	(16,102)
Income (loss) before income taxes	<u>\$ 69,957</u>	<u>\$ 12,329</u>	<u>\$ 92,178</u>	<u>\$ (76,137)</u>

(1) The above table reconciles Adjusted EBITDA to income before income taxes as reflected in the consolidated statements of operations.

When the Company uses the term "Adjusted EBITDA," it is referring to income before income taxes minus (a) net income attributable to non-controlling interests plus (b) depreciation and amortization, (c) interest expense, net, (d) non-cash stock compensation expense, (e) contingent acquisition compensation expense, (f) termination of management agreement and IPO costs, (g) management fee, (h) merger transaction, integration and practice acquisition costs, minus (i) gain on litigation settlement, (j) gain on acquisition escrow release, (plus)/minus (k) (loss)/gain on disposal or impairment of long-lived assets, net, minus (l) gain on amendment to tax receivable agreement, (plus)/minus (m) tax receivable agreement (expense)/gain and plus (n) loss on debt refinancing. The Company uses Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by the Company's management to assess operating performance, make business decisions and allocate resources. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that the Company consolidates for financial reporting purposes. The Company believes that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors the Company's portion of Adjusted EBITDA generated by its surgical facilities and other operations.

Adjusted EBITDA is not a measurement of financial performance under GAAP, and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating the Company's financial performance. The Company believes such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. The Company's calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

(2) Fee payable pursuant the Management and Investment Advisory Services Agreement between the Company and Bayside, which was terminated in connection with the Company's IPO.

(3) This amount includes merger transaction and integration costs of \$7.5 million for the four months ended December 31, 2017 (Successor), \$5.6 million for the eight months ended August 31, 2017 (Predecessor), and \$8.7 million and \$17.9 million for the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively.

This amount includes practice acquisition costs of \$1.8 million for the four months ended December 31, 2017 (Successor), \$2.1 million for the eight months ended August 31, 2017 (Predecessor), and \$2.9 million and \$2.7 million for the years ended December 31, 2016 (Predecessor) and 2015 (Predecessor), respectively.

Reconciliation of Assets from Segment to Consolidated

	<i>Successor</i> December 31, 2017	<i>Predecessor</i> December 31, 2016
Assets:		
Surgical facility services	\$ 4,072,521	\$ 1,914,842
Ancillary services	104,274	184,002
Optical services	48,309	22,478
All other	397,669	183,636
Total assets	<u>\$ 4,622,773</u>	<u>\$ 2,304,958</u>

Schedule of Depreciation/ Amortization and Cash Purchases of PPE

	<i>Successor</i> September 1 to December 31, 2017	<i>Predecessor</i> January 1 to August 31, Year Ended December 31, 2017 2016 2015		
Cash purchases of property and equipment, net:				
Surgical facility services	\$ 9,334	\$ 14,582	\$ 29,157	\$ 26,723
Ancillary services	191	1,875	5,388	1,051
Optical services	83	73	351	128
All other	1,219	2,243	4,213	5,537
Total cash purchases of property and equipment, net	<u>\$ 10,827</u>	<u>\$ 18,773</u>	<u>\$ 39,109</u>	<u>\$ 33,439</u>

**Quarterly Financial
Information (Unaudited)
(Tables)**

[Quarterly Financial Information
Disclosure \[Abstract\]
Schedule of Quarterly Financial
Information](#)

**12 Months Ended
Dec. 31, 2017**

The amounts are as follows (in thousands except per share amounts):

	2017				
	<i>Predecessor</i>			<i>Successor</i>	
	Q1	Q2	Q3 ⁽¹⁾	Q3 ⁽¹⁾	Q4
Revenues	\$286,183	\$288,353	\$174,079	\$132,258	\$460,346
Cost of revenues	\$211,948	\$216,452	\$143,772	\$102,924	\$338,704
Net income (loss)	\$ 14,422	\$ 11,627	\$ 4,369	\$ (2,648)	\$ 966
Net income attributable to non-controlling interests	\$ (17,176)	\$ (16,098)	\$ (8,813)	\$ (6,492)	\$ (33,142)
Net loss attributable to Surgery Partners, Inc.	\$ (2,754)	\$ (4,471)	\$ (4,444)	\$ (9,140)	\$ (32,176)
Basic net loss per share attributable to common stockholders ⁽²⁾	\$ (0.06)	\$ (0.09)	\$ (0.09)	\$ (0.57)	\$ (0.83)
Diluted net loss per share attributable to common stockholders ⁽²⁾	\$ (0.06)	\$ (0.09)	\$ (0.09)	\$ (0.57)	\$ (0.83)

⁽¹⁾ The Predecessor period for Q3 includes the two months ended August 31, 2017. The Successor period for Q3 includes the one month ended September 30, 2017.

⁽²⁾ Beginning in the Successor period, per share amounts include the impact of amounts allocated to participating securities. Refer to Note 10. "Earnings Per Share" for further discussion.

	2016			
	<i>Predecessor</i>			
	Q1	Q2	Q3	Q4
Revenues	\$267,074	\$289,681	\$282,682	\$306,001
Cost of revenues	\$196,703	\$208,852	\$201,394	\$214,247
Net income	\$ 10,357	\$ 22,293	\$ 14,334	\$ 38,100
Net income attributable to non-controlling interests	\$ (17,547)	\$ (20,173)	\$ (16,672)	\$ (21,238)
Net (loss) income attributable to Surgery Partners, Inc.	\$ (7,190)	\$ 2,120	\$ (2,338)	\$ 16,862
Basic net (loss) income per share attributable to common stockholders	\$ (0.15)	\$ 0.04	\$ (0.05)	\$ 0.35
Diluted net (loss) income per share attributable to common stockholders	\$ (0.15)	\$ 0.04	\$ (0.05)	\$ 0.35

Organization (Details) \$/ shares in Units, \$ in Thousands	Aug. 31, 2017 \$/ shares shares	Oct. 06, 2015 USD (\$)	Oct. 01, 2015 \$/ shares shares	4 Months Ended	8 Months Ended	12 Months Ended			May 09, 2017 \$/ shares	Sep. 30, 2015 shares
				Dec. 31, 2017 USD (\$) surgical_facility state \$/ shares shares	Aug. 31, 2017 USD (\$) \$/ shares shares	Dec. 31, 2016 USD (\$) \$/ shares shares	Dec. 31, 2015 USD (\$) shares			
Product Information [Line Items]										
Common stock, shares issued (in shares) shares				48,687,136						
Proceeds from initial public offering, net of offering costs \$				\$ 0						
Preferred stock, par value (USD per share)				\$ 0.01						
Common stock, par value (USD per share)				\$ 0.01						
Number of States in which entity operates state				32						
Number of surgical facilities owned surgical_facility				124						
Number of surgical facilities owned, majority interest surgical_facility				84						
Number of surgical facilities owned, consolidated surgical_facility				108						
Facilities, Ambulatory Surgery Centers										
Product Information [Line Items]										
Number of surgical facilities owned surgical_facility				106						
Facilities, Surgical Hospitals										
Product Information [Line Items]										
Number of surgical facilities owned surgical_facility				18						
Predecessor										
Product Information [Line Items]										
Common stock, shares issued (in shares) shares						48,488,616				
Proceeds from initial public offering, net of offering costs \$					\$ 0	\$ 0	\$ 250,979			
Preferred stock, par value (USD per share)						\$ 0.01				
Common stock, par value (USD per share)						\$ 0.01				
Predecessor Common Stock										
Product Information [Line Items]										

Stock issued during period (in shares) shares	[1]		14,285,000
Predecessor IPO			
Product Information [Line Items]			
Stock issued during period (in shares) shares		14,285,000	
Fair value of stock options granted (in USD per share)		\$ 19.00	
Proceeds from initial public offering, net of offering costs \$		\$ 255,800	
Predecessor IPO, Underwriting Fees			
Product Information [Line Items]			
Issuance Costs \$		15,600	
Predecessor IPO, Directly Related Costs			
Product Information [Line Items]			
Issuance Costs \$		\$ 4,800	
Predecessor Surgery Center Holdings, LLC			
Product Information [Line Items]			
Common stock, shares issued (in shares) shares			33,871,990
Predecessor BCPE Seminole Holdings LP Majority Shareholder			
Product Information [Line Items]			
Shares expected to be sold by investor (in shares) shares	26,455,651		26,455,651
Common stock, par value (USD per share)	\$ 0.01		\$ 0.01
Stock expected to be sold by investor (USD per share)	\$ 19.00		\$ 19.00
Percentage of voting interest acquired	65.70%		65.70%
Predecessor BCPE Seminole Holdings LP Majority Shareholder Common Stock			
Product Information [Line Items]			
Percentage of voting interest acquired	54.20%		54.20%
Predecessor BCPE Seminole Holdings LP Preferred Class A Preferred Stock			
Product Information [Line Items]			
Stock issued during period (in shares) shares	310,000		

Preferred stock, par value (USD per share)			\$ 0.01
Preferred stock dividend	10.00%		
Purchase price (USD per share)	\$ 1,000	\$ 1,000	

[1] As described in Note 1 herein, the common stock of the Company is that of Surgery Partners, Inc. as of December 31, 2017, 2016 and 2015 and that of Surgery Center Holdings, Inc. as of December 31, 2014.

Significant Accounting Policies - Schedule of Non- Controlling Interests - Redeemable (Details) - USD (\$) \$ in Thousands	4 Months Ended Dec. 31, 2017	8 Months Ended Aug. 31, 2017	12 Months Ended Dec. 31, 2016
<u>Non-Controlling Interests - Redeemable [Roll Forward]</u>			
<u>Non-controlling interest, beginning balance</u>	\$ 271,001		
<u>Net income attributable to non-controlling interests—redeemable</u>	12,931		
<u>Acquisition and disposal of shares of non-controlling interests, net—redeemable</u>	819		
<u>Distributions to non-controlling interest —redeemable holders</u>	(8,228)		
<u>Reallocation in application of pushdown accounting</u>	21,248		
<u>Purchase price adjustments</u>	1,545		
<u>Non-controlling interest, ending balance</u>	299,316	\$ 271,001	
<u>Predecessor</u>			
<u>Non-Controlling Interests - Redeemable [Roll Forward]</u>			
<u>Non-controlling interest, beginning balance</u>	\$ 328,665	180,521	\$ 183,439
<u>Net income attributable to non-controlling interests—redeemable</u>		9,615	18,023
<u>Acquisition and disposal of shares of non-controlling interests, net—redeemable</u>		(3,323)	(3,781)
<u>Distributions to non-controlling interest —redeemable holders</u>		(11,468)	(17,160)
<u>Acquisition of NSH</u>		153,320	
<u>Non-controlling interest, ending balance</u>		\$ 328,665	\$ 180,521

Significant Accounting Policies - Variable Interest Entities (Details) \$ in Millions	12 Months Ended		8 Months Ended		12 Months Ended		Dec. 31, 2016 USD (\$) Practice
	Dec. 31, 2017 USD (\$) Anesthesia_Practice	Dec. 31, 2017 USD (\$) surgical_facility	Dec. 31, 2017 USD (\$) Practice	Aug. 31, 2017 Practice	Dec. 31, 2016 USD (\$) Anesthesia_Practice	Dec. 31, 2016 USD (\$) surgical_facility	
Variable Interest Entity [Line Items]							
Number of facilities included in VIE	3	5	3				
Predecessor							
Variable Interest Entity [Line Items]							
Number of facilities included in VIE					3	5	2
Number of business entities acquired Practice				1			
Variable Interest Entity Primary Beneficiary							
Variable Interest Entity [Line Items]							
Total assets related to VIE	\$ 13.1	\$ 13.1	\$ 13.1				
Total liabilities related to VIE	\$ 5.8	\$ 5.8	\$ 5.8				
Variable Interest Entity Primary Beneficiary Predecessor							
Variable Interest Entity [Line Items]							
Total assets related to VIE					\$ 24.8	\$ 24.8	\$ 24.8
Total liabilities related to VIE					\$ 10.7	\$ 10.7	\$ 10.7

**Significant Accounting
Policies - Equity Method
Investments (Details)
\$ in Thousands**

**Dec. 31, 2017
USD (\$)**

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Investments in and advances to affiliates

\$ 74,282

**Significant Accounting
Policies - Schedule of
Carrying Amount and Fair
Value of Financial
Instruments (Details) - USD
(\$)
\$ in Thousands**

**Dec. 31, Dec. 31,
2017 2016**

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt \$ 2,186,291

Line of Credit | Revolving Credit Facility

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 0

2014 Revolver Loan | Line of Credit | Revolving Credit Facility | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 0

2014 Revolver Loan | Line of Credit | Revolving Credit Facility | Fair Value | Fair Value, Inputs, Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 0

2014 First Lien Credit Agreement | Line of Credit | Revolving Credit Facility | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 0

2014 First Lien Credit Agreement | Line of Credit | Revolving Credit Facility | Fair Value | Fair Value, Inputs, Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 0

2017 Revolver Loan, Maturing 2022 | Senior Notes | Revolving Credit Facility | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 0

2017 Revolver Loan, Maturing 2022 | Senior Notes | Revolving Credit Facility | Fair Value | Fair Value, Inputs, Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 0

2017 Term Loan, Maturing 2024 | Senior Notes | Carrying Amount

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 1,280,532

2017 Term Loan, Maturing 2024 | Senior Notes | Fair Value | Fair Value, Inputs, Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt 1,267,189

Senior Unsecured Notes Due 2021 | Senior Notes

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term debt	409,235
Senior Unsecured Notes Due 2021 Senior Notes Carrying Amount	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	409,235
Senior Unsecured Notes Due 2021 Senior Notes Fair Value Fair Value, Inputs, Level 2	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	422,535
Senior Unsecured Notes Due 2025 Senior Notes	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	370,000
Senior Unsecured Notes Due 2025 Senior Notes Carrying Amount	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	370,000
Senior Unsecured Notes Due 2025 Senior Notes Fair Value Fair Value, Inputs, Level 2	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	\$ 346,413
Predecessor Line of Credit Revolving Credit Facility	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	\$ 85,000
Predecessor 2014 Revolver Loan Line of Credit Revolving Credit Facility Carrying Amount	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	85,000
Predecessor 2014 Revolver Loan Line of Credit Revolving Credit Facility Fair Value Fair Value, Inputs, Level 2	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	85,000
Predecessor 2014 First Lien Credit Agreement Line of Credit Revolving Credit Facility Carrying Amount	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	911,784
Predecessor 2014 First Lien Credit Agreement Line of Credit Revolving Credit Facility Fair Value Fair Value, Inputs, Level 2	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	917,528
Predecessor 2017 Revolver Loan, Maturing 2022 Senior Notes Revolving Credit Facility Carrying Amount	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	0
Predecessor 2017 Revolver Loan, Maturing 2022 Senior Notes Revolving Credit Facility Fair Value Fair Value, Inputs, Level 2	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	
Long-term debt	0
Predecessor 2017 Term Loan, Maturing 2024 Senior Notes Carrying Amount	
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	

<u>Long-term debt</u>	0
<u>Predecessor 2017 Term Loan, Maturing 2024 Senior Notes Fair Value Fair Value, Inputs, Level 2</u>	
<u>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</u>	
<u>Long-term debt</u>	0
<u>Predecessor Senior Unsecured Notes Due 2021 Senior Notes</u>	
<u>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</u>	
<u>Long-term debt</u>	400,000
<u>Predecessor Senior Unsecured Notes Due 2021 Senior Notes Carrying Amount</u>	
<u>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</u>	
<u>Long-term debt</u>	387,942
<u>Predecessor Senior Unsecured Notes Due 2021 Senior Notes Fair Value Fair Value, Inputs, Level 2</u>	
<u>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</u>	
<u>Long-term debt</u>	412,189
<u>Predecessor Senior Unsecured Notes Due 2025 Senior Notes</u>	
<u>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</u>	
<u>Long-term debt</u>	0
<u>Predecessor Senior Unsecured Notes Due 2025 Senior Notes Carrying Amount</u>	
<u>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</u>	
<u>Long-term debt</u>	0
<u>Predecessor Senior Unsecured Notes Due 2025 Senior Notes Fair Value Fair Value, Inputs, Level 2</u>	
<u>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</u>	
<u>Long-term debt</u>	\$ 0

**Significant Accounting
Policies - Fair Value of
Financial Instruments
(Details) - Fair Value, Inputs,
Level 1 - USD (\$)
\$ in Millions**

**Dec. 31,
2017**

**Dec. 31,
2016**

**Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line
Items]**

Deposits

\$ 1.9

Liability of SERP

\$ 1.9

Predecessor

**Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line
Items]**

Deposits

\$ 1.7

Liability of SERP

\$ 1.7

Significant Accounting Policies - Schedule of Revenues by Service Type (Details) - Revenue Source - Revenue	4 Months Ended	8 Months Ended	12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Healthcare Organization, Patient Service</u>	100.00%			
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Surgical facility services</u>	98.50%			
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Ancillary services</u>	94.30%			
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Healthcare Organization, Other Service</u>	4.20%			
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Optical services</u>	1.50%			
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Other</u>	0.60%			
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Predecessor</u>	0.90%			
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Predecessor Healthcare Organization, Patient Service</u>		100.00%	100.00%	100.00%
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u> <u>Predecessor Surgical facility services</u>		98.40%	98.20%	98.00%
<u>Revenue from External Customer [Line Items]</u> <u>Revenue by service type as a percentage of total revenues</u>		91.40%	90.30%	91.60%

Predecessor | Ancillary services

Revenue from External Customer [Line Items]

Revenue by service type as a percentage of total revenues

7.00%

7.90%

6.40%

Predecessor | Healthcare Organization, Other Service

Revenue from External Customer [Line Items]

Revenue by service type as a percentage of total revenues

1.60%

1.80%

2.00%

Predecessor | Optical services

Revenue from External Customer [Line Items]

Revenue by service type as a percentage of total revenues

1.00%

1.10%

1.50%

Predecessor | Other

Revenue from External Customer [Line Items]

Revenue by service type as a percentage of total revenues

0.60%

0.70%

0.50%

Significant Accounting Policies - Schedule of Revenues by Sources (Details) - USD (\$)	1 Months Ended	2 Months Ended	3 Months Ended						4 Months Ended	8 Months Ended	12 Months Ended		
	Sep. 30, 2017	Aug. 31, 2017	Dec. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Increase of revenue as result of changes in estimates to third-party settlements										\$ 0			
Total net revenues	\$ 132,258,000		\$ 460,346,000							592,604,000			
Healthcare Organization, Patient Service													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Patient service revenues										\$ 583,803,000			
Healthcare Organization, Patient Service Customer Revenue													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Revenue by service type as a percentage of total revenues										100.00%			
Optical services													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Other service revenues										\$ 3,486,000			
Other													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Other service revenues										5,315,000			
Private insurance Healthcare Organization, Patient Service													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Patient service revenues										\$ 347,801,000			
Private insurance Healthcare Organization, Patient Service Customer Revenue													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Revenue by service type as a percentage of total revenues										59.60%			
Government Healthcare Organization, Patient Service													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Patient service revenues										\$ 196,926,000			
Government Healthcare Organization, Patient Service Customer Revenue													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Revenue by service type as a percentage of total revenues										33.70%			
Self-pay Healthcare Organization, Patient Service													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Patient service revenues										\$ 15,233,000			
Self-pay Healthcare Organization, Patient Service Customer Revenue													
Health Care Organization, Receivable and Revenue Disclosures [Line Items]													
Revenue by service type as a percentage of total revenues										2.60%			

Other Healthcare Organization, Patient Service Health Care Organization, Receivable and Revenue Disclosures Line Items Patient service revenues									\$	23,843,000														
Other Healthcare Organization, Patient Service Customer Revenue Health Care Organization, Receivable and Revenue Disclosures Line Items Revenue by service type as a percentage of total revenues										4.10%														
Predecessor Health Care Organization, Receivable and Revenue Disclosures Line Items Increase of revenue as result of changes in estimates to third-party settlements									\$	1,100,000	\$ 6,800,000	\$ 2,300,000												
Total net revenues	\$	\$	\$	\$	\$	\$	\$	\$		174,079,000	288,353,000	286,183,000	306,001,000	282,682,000	289,681,000	267,074,000						748,615,000	1,145,438,000	959,891,000
Increase in reserves for accounts receivable																					15,600,000			
Predecessor Healthcare Organization, Patient Service Health Care Organization, Receivable and Revenue Disclosures Line Items Patient service revenues									\$		\$		\$											
										736,408,000	1,124,604,000	940,711,000												
Predecessor Healthcare Organization, Patient Service Customer Revenue Health Care Organization, Receivable and Revenue Disclosures Line Items Revenue by service type as a percentage of total revenues																								
										100.00%	100.00%	100.00%												
Predecessor Optical services Health Care Organization, Receivable and Revenue Disclosures Line Items Other service revenues																								
									\$	7,629,000	\$ 12,505,000	\$ 14,572,000												
Predecessor Other Health Care Organization, Receivable and Revenue Disclosures Line Items Other service revenues																								
										4,578,000	8,329,000	4,608,000												
Predecessor Private insurance Healthcare Organization, Patient Service Health Care Organization, Receivable and Revenue Disclosures Line Items Patient service revenues									\$		\$ 579,662,000	\$ 516,739,000												
										360,092,000														
Predecessor Private insurance Healthcare Organization, Patient Service Customer Revenue Health Care Organization, Receivable and Revenue Disclosures Line Items Revenue by service type as a percentage of total revenues																								
										48.90%	51.50%	55.00%												
Predecessor Government Healthcare Organization, Patient Service Health Care Organization, Receivable and Revenue Disclosures Line Items Patient service revenues									\$		\$ 448,953,000	\$ 359,471,000												
										308,993,000														
Predecessor Government Healthcare Organization, Patient Service Customer Revenue																								

[Health Care Organization,
Receivable and Revenue
Disclosures \[Line Items\]](#)

Revenue by service type as a
percentage of total revenues

42.00% 39.90% 38.20%

[Predecessor | Self-pay |
Healthcare Organization,
Patient Service](#)

[Health Care Organization,
Receivable and Revenue
Disclosures \[Line Items\]](#)

Patient service revenues

\$ 15,949,000 \$ 19,817,000 \$ 16,190,000

[Predecessor | Self-pay |
Healthcare Organization,
Patient Service | Customer |
Revenue](#)

[Health Care Organization,
Receivable and Revenue
Disclosures \[Line Items\]](#)

Revenue by service type as a
percentage of total revenues

2.20% 1.80% 1.70%

[Predecessor | Other |
Healthcare Organization,
Patient Service](#)

[Health Care Organization,
Receivable and Revenue
Disclosures \[Line Items\]](#)

Patient service revenues

\$ 51,374,000 \$ 76,172,000 \$ 48,311,000

[Predecessor | Other |
Healthcare Organization,
Patient Service | Customer |
Revenue](#)

[Health Care Organization,
Receivable and Revenue
Disclosures \[Line Items\]](#)

Revenue by service type as a
percentage of total revenues

6.90% 6.80% 5.10%

Significant Accounting Policies - Accounts Receivable (Details) - USD (\$) \$ in Thousands	4 Months Ended	8 Months Ended	12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Accounts, Notes, Loans and Financing Receivable [Line Items]</u>				
<u>Third-Party Medicaid settlements liability</u>	\$ 1,000			
<u>Allowance for Doubtful Accounts Receivable [Roll Forward]</u>				
<u>Allowance for doubtful accounts, beginning balance</u>	0			
<u>Provision for doubtful accounts</u>	12,455			
<u>Accounts written off, net of recoveries</u>	(10,429)			
<u>Allowance for doubtful accounts, ending balance</u>	2,026	\$ 0		
<u>Optical products receivable</u>	7,563			
<u>Predecessor</u>				
<u>Accounts, Notes, Loans and Financing Receivable [Line Items]</u>				
<u>Third-Party Medicaid settlements receivable</u>			\$ 500	
<u>Allowance for Doubtful Accounts Receivable [Roll Forward]</u>				
<u>Allowance for doubtful accounts, beginning balance</u>	\$ 32,073	29,872	18,322	\$ 5,329
<u>Provision for doubtful accounts</u>		16,297	24,212	23,578
<u>Accounts written off, net of recoveries</u>		(14,096)	(12,662)	(10,585)
<u>Allowance for doubtful accounts, ending balance</u>		\$ 32,073	29,872	\$ 18,322
<u>Optical products receivable</u>			\$ 7,042	

**Significant Accounting
Policies - Schedule of
Prepaid Expenses and Other
Current Assets (Details) -
USD (\$)
\$ in Thousands**

Dec. 31, 2017 Dec. 31, 2016

Schedule Of Prepaid Expenses And Other Current Assets [Line Items]

<u>Prepaid expenses</u>	\$ 16,835
<u>Receivables - optical product purchasing organization</u>	7,563
<u>Acquisition escrow deposit</u>	3,809
<u>Insurance recoveries</u>	2,828
<u>Other</u>	24,302
<u>Total</u>	\$ 55,337

Predecessor

Schedule Of Prepaid Expenses And Other Current Assets [Line Items]

<u>Prepaid expenses</u>	\$ 11,158
<u>Receivables - optical product purchasing organization</u>	7,042
<u>Acquisition escrow deposit</u>	10,871
<u>Insurance recoveries</u>	2,476
<u>Other</u>	11,338
<u>Total</u>	\$ 42,885

**Significant Accounting
Policies - Property and
Equipment (Details)**

**12 Months Ended
Dec. 31, 2017**

[Buildings and improvements | Minimum](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Property, and equipment useful life](#) 20 years

[Buildings and improvements | Maximum](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Property, and equipment useful life](#) 40 years

[Computer and software | Minimum](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Property, and equipment useful life](#) 3 years

[Computer and software | Maximum](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Property, and equipment useful life](#) 5 years

[Furniture and equipment | Minimum](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Property, and equipment useful life](#) 5 years

[Furniture and equipment | Maximum](#)

[Property, Plant and Equipment \[Line Items\]](#)

[Property, and equipment useful life](#) 7 years

**Significant Accounting
Policies - Goodwill and
Intangible Assets (Details) -
USD (\$)**

12 Months Ended

Oct. 01, 2017 Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015

Intangible Assets [Line Items]

Goodwill impairment \$ 0

Physician Income Guarantees | Minimum

Intangible Assets [Line Items]

Intangible asset useful life 3 years

Physician Income Guarantees | Maximum

Intangible Assets [Line Items]

Intangible asset useful life 4 years

Non-Compete Agreements | Minimum

Intangible Assets [Line Items]

Intangible asset useful life 2 years

Non-Compete Agreements | Maximum

Intangible Assets [Line Items]

Intangible asset useful life 5 years

Management Rights

Intangible Assets [Line Items]

Intangible asset useful life 15 years

Customer Relationships | Minimum

Intangible Assets [Line Items]

Intangible asset useful life 3 years

Customer Relationships | Maximum

Intangible Assets [Line Items]

Intangible asset useful life 10 years

Predecessor

Intangible Assets [Line Items]

Goodwill impairment \$ 0 \$ 0

**Significant Accounting
Policies - Restricted Invested
Assets (Details) - USD (\$)
\$ in Thousands**

Dec. 31, 2017 Dec. 31, 2016

Restricted Cash and Cash Equivalents Items [Line Items]

Restricted invested assets \$ 315

Chesterfield, Missouri facility

Restricted Cash and Cash Equivalents Items [Line Items]

Restricted invested assets 300

Predecessor

Restricted Cash and Cash Equivalents Items [Line Items]

Restricted invested assets \$ 315

Predecessor | Chesterfield, Missouri facility

Restricted Cash and Cash Equivalents Items [Line Items]

Restricted invested assets \$ 300

**Significant Accounting
Policies - Schedule of Other
Long-Term Assets (Details) - Dec. 31, 2017 Dec. 31, 2016
USD (\$)**

\$ in Thousands

Other Assets, Noncurrent [Line Items]

<u>Acquisition escrow deposit</u>	\$ 19,600
<u>Insurance recoveries</u>	10,018
<u>Notes receivable</u>	2,263
<u>Deposits</u>	3,151
<u>Other</u>	13,318
<u>Total</u>	\$ 48,350

Predecessor

Other Assets, Noncurrent [Line Items]

<u>Acquisition escrow deposit</u>	\$ 0
<u>Insurance recoveries</u>	6,835
<u>Notes receivable</u>	716
<u>Deposits</u>	4,196
<u>Other</u>	4,688
<u>Total</u>	\$ 16,435

**Significant Accounting
Policies - Schedule of Other
Current Liabilities (Details) -
USD (\$)**

Dec. 31, 2017 Dec. 31, 2016

\$ in Thousands

Other Liabilities, Current [Line Items]

<u>Interest payable</u>	\$ 20,537
<u>Amounts due to patients and payors</u>	18,096
<u>Insurance liabilities</u>	9,873
<u>Current taxes payable</u>	4,912
<u>Acquisition escrow liability</u>	3,809
<u>Accrued expenses and other</u>	52,717
<u>Total</u>	\$ 109,944

Predecessor

Other Liabilities, Current [Line Items]

<u>Interest payable</u>	\$ 19,206
<u>Amounts due to patients and payors</u>	12,221
<u>Insurance liabilities</u>	6,625
<u>Current taxes payable</u>	2,622
<u>Acquisition escrow liability</u>	10,871
<u>Accrued expenses and other</u>	28,319
<u>Total</u>	\$ 79,864

**Significant Accounting
Policies - Schedule of Other**

**Long-Term Liabilities
(Details) - USD (\$)**

Dec. 31, 2017 Dec. 31, 2016

\$ in Thousands

Capital Leased Assets [Line Items]

<u>Facility lease obligations</u>	\$ 121,627
<u>Acquisition escrow liability</u>	19,600
<u>Medical malpractice liability</u>	16,450
<u>Unfavorable lease liability</u>	11,889
<u>Other</u>	9,123
<u>Total</u>	178,689
<u>Capital lease obligations</u>	27,594

Surgical Facilities

Capital Leased Assets [Line Items]

<u>Current portion of lease obligation</u>	6,300
<u>Capital lease obligations</u>	\$ 121,600

Predecessor

Capital Leased Assets [Line Items]

<u>Facility lease obligations</u>	\$ 52,653
<u>Acquisition escrow liability</u>	0
<u>Medical malpractice liability</u>	10,453
<u>Unfavorable lease liability</u>	1,671
<u>Other</u>	11,489
<u>Total</u>	76,266
<u>Capital lease obligations</u>	13,996

Predecessor | Surgical Facilities

Capital Leased Assets [Line Items]

<u>Current portion of lease obligation</u>	1,300
<u>Capital lease obligations</u>	\$ 52,700

**Significant Accounting
Policies - Professional,
General and Workers'
Compensation Insurance
(Details) - USD (\$)
\$ in Millions**

Dec. 31, 2017 Dec. 31, 2016

Liability for Claims and Claims Adjustment Expense [Line Items]

Professional, general and workers' compensation insurance reserve \$ 21.0

Estimated insurance recoveries \$ 12.8

Predecessor

Liability for Claims and Claims Adjustment Expense [Line Items]

Professional, general and workers' compensation insurance reserve \$ 13.8

Estimated insurance recoveries \$ 9.3

Acquisitions and Developments - 2017 Transactions Narrative (Details) \$/shares in Units, \$ in Thousands	1		2		3 Months Ended				4 Months Ended				8 Months Ended				12 Months Ended			
	Aug. 31, 2017 USD (\$)	Aug. 31, 2017 USD (\$)	Aug. 31, 2017 USD (\$)	Aug. 31, 2017 USD (\$)	1 Months Ended Sep. 30, 2017 USD (\$)	2 Months Ended Aug. 31, 2017 USD (\$)	3 Months Ended Dec. 31, 2017 USD (\$)	4 Months Ended Jun. 30, 2017 USD (\$)	5 Months Ended Mar. 31, 2017 USD (\$)	6 Months Ended Dec. 31, 2016 USD (\$)	7 Months Ended Sep. 30, 2016 USD (\$)	8 Months Ended Jun. 30, 2016 USD (\$)	9 Months Ended Mar. 31, 2016 USD (\$)	10 Months Ended Dec. 31, 2015 USD (\$)	11 Months Ended Aug. 31, 2015 USD (\$)	12 Months Ended Dec. 31, 2015 USD (\$)	13 Months Ended Dec. 31, 2015 USD (\$)	14 Months Ended Dec. 31, 2015 USD (\$)		
Business Acquisition [Line Items]																				
Cash consideration																			\$ 29,249	
Merger transaction and integration costs																			7,470	
Merger transaction, integration and practice acquisition costs																			9,330	
Net (loss) income attributable to Surgery Partners, Inc.					\$ (9,140)		\$ (32,176)												(41,316)	
Gain on amendment to TRA																			1,100	
Loss on debt refinancing																			0	
Purchase price adjustments																			30,253	
Goodwill	\$ 3,269,225	\$ 3,269,225	\$ 3,269,225	\$ 3,269,225	\$ 3,269,225	\$ 3,269,225	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	\$ 3,346,838	
BCPE Seminole Holdings LP H.L.G Bayside Debt & LBO Fund II L.P.																				
Business Acquisition [Line Items]																				
Goodwill, expected tax deductible amount	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	\$ 360,500	
Purchase price per share (USD per share) \$ / shares	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	\$ 19.00	
Cash consideration																			\$ 502,700	
Equity interest in acquiree	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	54.20%	
Total interest in acquiree	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	65.70%	
Purchase price adjustments																			30,700	
Goodwill	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	\$ 3,299,911	
Surgical facility services BCPE Seminole Holdings LP H.L.G Bayside Debt & LBO Fund II L.P.																				
Business Acquisition [Line Items]																				
Goodwill	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	3,116,000	
Ancillary services BCPE Seminole Holdings LP H.L.G Bayside Debt & LBO Fund II L.P.																				
Business Acquisition [Line Items]																				
Goodwill	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	151,900	
Optical services BCPE Seminole Holdings LP H.L.G Bayside Debt & LBO Fund II L.P.																				
Business Acquisition [Line Items]																				
Goodwill	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	32,500	
NSH																				
Business Acquisition [Line Items]																				
Net increase in goodwill																			25,100	
Proforma revenue since date of acquisition																			205,200	
Net (loss) income attributable to Surgery Partners, Inc.																			20,400	
Transaction related costs																			7,300	
Gain on amendment to TRA 2017 Physician Practice Acquisitions																			\$ 1,100	
Business Acquisition [Line Items]																				
Number of business entities acquired Practice Acquisitions																			1	
Business Acquisition [Line Items]																				
Cash consideration																			\$ 29,448	
Goodwill																			\$ 49,317	
Surgical Facility Acquisitions																			\$ 49,317	
Business Acquisition [Line Items]																			\$ 49,317	
Number of business entities acquired surgical_facility																			1	
Number of businesses acquired in existing market																			1	
Predecessor																			4	
Business Acquisition [Line Items]																			3	
Cash consideration																			\$ 725,853	
Number of business entities acquired Practice																			1	
Merger transaction and integration costs																			\$ 5,584	
Merger transaction, integration and practice acquisition costs																			8,738	
Net (loss) income attributable to Surgery Partners, Inc.																			7,677	
Gain on amendment to TRA																			11,617	
Loss on debt refinancing																			20,579	
Purchase price adjustments																			11,876	
Goodwill	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	2,414,572	16,102	
Predecessor NSH																			66	
Business Acquisition [Line Items]																			1,220	
Cash consideration																			15,300	
Escrow account	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	\$ 19,600	18,211	
Number of business entities acquired	7	22	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15	11,876	
Merger transaction and integration costs																			11,876	
Deferred loan costs	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	\$ 45,500	66	

Issuance cost capitalized	18,300	18,300	18,300	18,300	18,300	18,300	
Merger transaction, integration and practice acquisition costs					2,400		
Loss on debt extinguishment					16,400		
Goodwill, expected tax deductible amount					\$ 153,500	\$ 153,500	\$ 153,500
Transaction related costs						11,300	
Gain on amendment to TRA						15,300	
Loss on debt refinancing						18,200	11,900
Cash consideration			762,850				
Goodwill	870,241	870,241	870,241	870,241	870,241	\$ 870,241	
Predecessor 2017 Physician Practice Acquisitions							
Business Acquisition [Line Items]							
Number of businesses acquired in existing market Practices						3	
Predecessor Acquisitions							
Business Acquisition [Line Items]							
Goodwill, expected tax deductible amount					120,000		120,000
Cash consideration						\$ 14,163	135,061
Goodwill	\$ 12,545	\$ 12,545	\$ 12,545	\$ 12,545	\$ 12,545	\$ 12,545	\$ 148,181

Acquisitions and Developments - Assets Acquired and Liabilities Assumed (Details) - USD (\$) \$ in Thousands	4 Months	8 Months	12 Months	
	Ended	Ended	Ended	
	Aug. 31, 2017	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016
				Dec. 31, 2015
Net assets acquired:				
<u>Goodwill</u>	\$ 3,269,225	\$ 3,346,838	\$ 3,269,225	
<u>Acquisitions</u>				
Business Acquisition [Line Items]				
<u>Cash consideration</u>		29,448		
<u>Fair value of non-controlling interests</u>		21,893		
<u>Aggregate fair value of acquisition</u>		51,341		
Net assets acquired:				
<u>Current assets</u>		2,285		
<u>Property and equipment</u>		248		
<u>Intangible assets</u>		41		
<u>Goodwill</u>		49,317		
<u>Current liabilities</u>		(550)		
<u>Long-term debt, less current maturities</u>		0		
<u>Total fair value of net assets acquired</u>		51,341		
<u>Predecessor</u>				
Net assets acquired:				
<u>Goodwill</u>	2,414,572		2,414,572	\$ 1,555,204
				\$ 1,407,927
<u>Predecessor NSH</u>				
Business Acquisition [Line Items]				
<u>Cash consideration</u>	762,850			
<u>Fair value of non-controlling interests</u>	325,965		325,965	
<u>Aggregate fair value of acquisition</u>	1,088,815		1,088,815	
Net assets acquired:				
<u>Cash and cash equivalents</u>	51,159		51,159	
<u>Accounts receivable</u>	71,901		71,901	
<u>Inventories</u>	14,986		14,986	
<u>Prepaid expenses and other current assets</u>	18,397		18,397	
<u>Property and equipment</u>	174,499		174,499	
<u>Intangible assets</u>	27,746		27,746	
<u>Goodwill</u>	870,241		870,241	
<u>Investments in and advances to affiliates</u>	29,737		29,737	
<u>Long-term deferred tax assets</u>	17,279		17,279	
<u>Other long-term assets</u>	27,229		27,229	
<u>Accounts payable</u>	(29,652)		(29,652)	
<u>Accrued payroll and benefits</u>	(28,755)		(28,755)	
<u>Other current liabilities</u>	(21,287)		(21,287)	

<u>Current maturities of long-term debt</u>	(16,416)	(16,416)	
<u>Long-term debt, less current maturities</u>	(42,770)	(42,770)	
<u>Other long-term liabilities</u>	(75,479)	(75,479)	
<u>Total fair value of net assets acquired</u>	1,088,815	1,088,815	
<u>Predecessor Acquisitions</u>			
<u>Business Acquisition [Line Items]</u>			
<u>Cash consideration</u>		14,163	135,061
<u>Fair value of non-controlling interests</u>	105	105	27,164
<u>Aggregate fair value of acquisition</u>	14,268	14,268	162,225
<u>Net assets acquired:</u>			
<u>Current assets</u>	866	866	11,383
<u>Property and equipment</u>	696	696	3,921
<u>Intangible assets</u>	634	634	4,475
<u>Goodwill</u>	12,545	12,545	148,181
<u>Other long-term assets</u>			56
<u>Current liabilities</u>	(287)	(287)	(5,422)
<u>Long-term debt, less current maturities</u>	(186)	(186)	
<u>Long-term liabilities</u>			(369)
<u>Total fair value of net assets acquired</u>	14,268	14,268	\$ 162,225
<u>H.I.G Bayside Debt & LBO Fund II L.P. BCPE</u>			
<u>Seminole Holdings LP</u>			
<u>Business Acquisition [Line Items]</u>			
<u>Cash consideration</u>	502,700		
<u>Equity attributable to Surgery Partners, Inc.</u>	720,606		
<u>Redeemable preferred stock</u>	310,000		
<u>Fair value of non-controlling interests</u>	957,027	957,027	
<u>Aggregate fair value of acquisition</u>		\$ 1,987,633	
<u>Net assets acquired:</u>			
<u>Cash and cash equivalents</u>	214,206	214,206	
<u>Accounts receivable</u>	253,173	253,173	
<u>Inventories</u>	44,310	44,310	
<u>Prepaid expenses and other current assets</u>	61,475	61,475	
<u>Property and equipment</u>	380,085	380,085	
<u>Intangible assets</u>	60,104	60,104	
<u>Goodwill</u>	3,299,911	3,299,911	
<u>Investments in and advances to affiliates</u>	74,722	74,722	
<u>Restricted invested assets</u>	315	315	
<u>Long-term deferred tax assets</u>	204,408	204,408	
<u>Other long-term assets</u>	49,681	49,681	
<u>Accounts payable</u>	(64,921)	(64,921)	
<u>Accrued payroll and benefits</u>	(54,437)	(54,437)	
<u>Other current liabilities</u>	(94,740)	(94,740)	
<u>Current maturities of long-term debt</u>	(49,942)	(49,942)	
<u>Long-term debt, less current maturities</u>	(2,142,375)	(2,142,375)	

<u>Long-term tax receivable agreement liability</u>	(78,498)	(78,498)
<u>Other long-term liabilities</u>	(169,844)	(169,844)
<u>Total fair value of net assets acquired</u>	\$ 1,987,633	\$ 1,987,633

**Acquisitions and
Developments - Pro Forma
Results (Details) - NSH -
USD (\$)
\$ in Thousands**

4 Months Ended 8 Months Ended 12 Months Ended

Dec. 31, 2017 Aug. 31, 2017 Dec. 31, 2016

Business Acquisition [Line Items]

<u>Net revenues</u>	\$ 592,604		
<u>Net income</u>	4,477		
<u>Less: Net income attributable to non-controlling interests</u>	(39,634)		
<u>Net income</u>	\$ (35,157)		

Predecessor

Business Acquisition [Line Items]

<u>Net revenues</u>		\$ 1,122,326	\$ 1,679,254
<u>Net income</u>		63,269	132,699
<u>Less: Net income attributable to non-controlling interests</u>		(65,122)	(112,123)
<u>Net income</u>		\$ (1,853)	\$ 20,576

Acquisitions and Developments - 2016 Transactions Narrative (Details) \$ in Millions	12 Months Ended				Dec. 31, 2015 USD (\$)
	Dec. 31, 2017 Anesthesia_Practice surgical_facility urgent_care_facility	Dec. 31, 2016 USD (\$) Anesthesia_Practice surgical_facility Practice	Dec. 31, 2015 Anesthesia_Practice	Dec. 31, 2015 surgical_facility	
Surgical Facility Acquisitions					
Business Acquisition [Line Items]					
Number of businesses acquired in new market surgical_facility				2	
Aggregate purchase price					\$ 84.2
Number of businesses acquired in existing market Anesthesia Practice	1		4	3	
Business Acquisition [Line Items]					
Number of businesses acquired in existing market Anesthesia_Practice Urgent Care Facility	1				
Business Acquisition [Line Items]					
Number of businesses acquired in existing market urgent_care_facility	1				
Ancillary Services Acquisition					
Business Acquisition [Line Items]					
Aggregate purchase price					\$ 40.4
Predecessor Idaho Falls, Idaho, Surgical Hospital					
Business Acquisition [Line Items]					
Amount of additional interest purchased, percentage		7.04%			
Amount of additional interest purchased, value		\$ 20.3			
Predecessor Surgical Facility Acquisitions					
Business Acquisition [Line Items]					
Number of businesses acquired in new market surgical_facility		2			

Predecessor | Anesthesia
Practice

**Business Acquisition [Line
Items]**

Number of businesses
acquired in new market | 2

Anesthesia Practice

Aggregate purchase price \$ 36.5

Predecessor | Physician
Practice

**Business Acquisition [Line
Items]**

Number of businesses
acquired in existing market | 9

Practice

Predecessor | Integrated
Physician Practice

**Business Acquisition [Line
Items]**

Number of businesses
acquired in existing market | 2

Practice

Predecessor | Ancillary
Services Acquisition

**Business Acquisition [Line
Items]**

Aggregate purchase price \$ 114.7

Fair value of contingent
consideration liability 16.6

Predecessor | Acquisitions

**Business Acquisition [Line
Items]**

Goodwill, expected tax
deductible amount \$ 120.0

Acquisitions and Developments - 2015 Transactions Narrative (Details) \$ in Millions	4 Months Ended		12 Months Ended		Dec.	
	Dec. 31, 2017 surgical_facility	Dec. 31, 2017 surgical_facility	Dec. 31, 2015 Anesthesia_Practice	Dec. 31, 2015 surgical_facility	Dec. 31, 2015 Practice USD	Dec. 31, 31, 2015 Physician (\$)
<u>Business Acquisition [Line Items]</u>						
<u>Number of physician practice transactions Physician Surgical Facility Acquisitions</u>						17
<u>Business Acquisition [Line Items]</u>						
<u>Number of businesses acquired in new market surgical_facility</u>				2		
<u>Number of businesses acquired in existing market</u>	1	4		3		
<u>Aggregate purchase price \$</u>						\$ 84.2
<u>Number of business entities acquired surgical_facility</u>	1					
<u>Ancillary Services Acquisition</u>						
<u>Business Acquisition [Line Items]</u>						
<u>Aggregate purchase price \$</u>						\$ 40.4
<u>Number of business entities acquired Practice</u>					13	

Divestitures (Details) \$ in Millions	4 Months Ended	12 Months Ended	
	Dec. 31, 2017 USD (\$)	Dec. 31, 2016 USD (\$)	Dec. 31, 2015 USD (\$)
<u>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</u>			
<u>Transaction value of business disposition</u>	\$ 1.3		
<u>Gain (loss) on disposition of business</u>	\$ 0.8		
<u>Disposed of by Sale</u>			
<u>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</u>			
<u>Number of surgical facilities sold surgical_facility</u>	1	1	3
<u>Transaction value of business disposition</u>		\$ 0.8	\$ 10.9
<u>Gain (loss) on disposition of business</u>		\$ 0.8	\$ 2.9

Property and Equipment (Details) - USD (\$) \$ in Thousands	4 Months Ended	8 Months Ended	12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, at cost</u>	\$ 418,216		\$ 290,640	
<u>Less: Accumulated depreciation</u>	(19,680)		(86,387)	
<u>Property and equipment, net</u>	398,536		204,253	
<u>Depreciation</u>	20,000			
<u>Carrying value of assets under capital lease</u>	16,200			
<u>Accumulated depreciation of assets under capital lease</u>	5,800			
<u>Land</u>				
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, at cost</u>	19,561		8,082	
<u>Buildings and improvements</u>				
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, at cost</u>	188,571		118,172	
<u>Furniture and equipment</u>				
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, at cost</u>	20,813		14,670	
<u>Computer and software</u>				
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, at cost</u>	28,578		29,902	
<u>Medical equipment</u>				
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, at cost</u>	138,112		117,418	
<u>Construction in progress</u>				
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, at cost</u>	\$ 22,581		2,396	
<u>Predecessor</u>				
<u>Property, Plant and Equipment [Line Items]</u>				
<u>Property and equipment, net</u>			204,253	
<u>Depreciation</u>		\$ 24,100	30,000	\$ 25,500
<u>Carrying value of assets under capital lease</u>			15,400	
<u>Accumulated depreciation of assets under capital lease</u>			\$ 11,600	

Goodwill and Intangible Assets - Goodwill (Details) - **4 Months Ended** **8 Months Ended** **12 Months Ended**
USD (\$) **Dec. 31, 2017** **Aug. 31, 2017** **Dec. 31, 2016**
\$ in Thousands

Goodwill [Roll Forward]

<u>Goodwill, beginning of period</u>	\$ 3,269,225		
<u>Acquisitions</u>	49,317		
<u>Divestitures</u>	(1,957)		
<u>Purchase price adjustments</u>	30,253		
<u>Goodwill, end of period</u>	3,346,838	\$ 3,269,225	

Predecessor

Goodwill [Roll Forward]

<u>Goodwill, beginning of period</u>	\$ 2,414,572	1,555,204	\$ 1,407,927
<u>Acquisitions</u>		858,323	147,895
<u>Divestitures</u>		(175)	(552)
<u>Purchase price adjustments</u>		1,220	(66)
<u>Goodwill, end of period</u>		\$ 2,414,572	\$ 1,555,204

Goodwill and Intangible Assets - Summary of Components of Intangible Assets (Details) - USD (\$) \$ in Thousands	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Finite-lived intangible assets, gross carrying amount</u>	\$ 48,352			
<u>Finite-lived intangible assets, accumulated amortization</u>	(2,000)			
<u>Total</u>	46,352			
<u>Total intangible assets, gross</u>	60,908			
<u>Total intangible assets, net</u>	58,908	\$ 56,750		
<u>Management Rights</u>				
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Indefinite-lived intangible assets</u>	5,900			
<u>Certificates of Need</u>				
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Indefinite-lived intangible assets</u>	5,548			
<u>Medicare licenses</u>				
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Indefinite-lived intangible assets</u>	1,108			
<u>Management Rights</u>				
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Finite-lived intangible assets, gross carrying amount</u>	42,600			
<u>Finite-lived intangible assets, accumulated amortization</u>	(1,058)			
<u>Total</u>	41,542			
<u>Non-Compete Agreements</u>				
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Finite-lived intangible assets, gross carrying amount</u>	4,874			
<u>Finite-lived intangible assets, accumulated amortization</u>	(715)			
<u>Total</u>	4,159			
<u>Physician income guarantees</u>				
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Finite-lived intangible assets, gross carrying amount</u>	878			
<u>Finite-lived intangible assets, accumulated amortization</u>	(227)			
<u>Total</u>	651			
<u>Other</u>				
<u>Finite-Lived Intangible Assets [Line Items]</u>				
<u>Finite-lived intangible assets, gross carrying amount</u>	0			
<u>Finite-lived intangible assets, accumulated amortization</u>	0			

<u>Total</u>	\$ 0		
<u>Predecessor</u>			
<u>Finite-Lived Intangible Assets [Line Items]</u>			
<u>Finite-lived intangible assets, gross carrying amount</u>		\$ 60,140	
<u>Finite-lived intangible assets, accumulated amortization</u>		(16,139)	
<u>Total</u>		44,001	
<u>Total intangible assets, gross</u>		64,162	
<u>Total intangible assets, net</u>	\$ 69,915	48,023	\$ 53,568
<u>Predecessor Certificates of Need</u>			
<u>Finite-Lived Intangible Assets [Line Items]</u>			
<u>Indefinite-lived intangible assets</u>		3,780	
<u>Predecessor Medicare licenses</u>			
<u>Finite-Lived Intangible Assets [Line Items]</u>			
<u>Indefinite-lived intangible assets</u>		242	
<u>Predecessor Management Rights</u>			
<u>Finite-Lived Intangible Assets [Line Items]</u>			
<u>Finite-lived intangible assets, gross carrying amount</u>		24,751	
<u>Finite-lived intangible assets, accumulated amortization</u>		(3,461)	
<u>Total</u>		21,290	
<u>Predecessor Non-Compete Agreements</u>			
<u>Finite-Lived Intangible Assets [Line Items]</u>			
<u>Finite-lived intangible assets, gross carrying amount</u>		24,673	
<u>Finite-lived intangible assets, accumulated amortization</u>		(8,216)	
<u>Total</u>		16,457	
<u>Predecessor Physician income guarantees</u>			
<u>Finite-Lived Intangible Assets [Line Items]</u>			
<u>Finite-lived intangible assets, gross carrying amount</u>		1,901	
<u>Finite-lived intangible assets, accumulated amortization</u>		(1,088)	
<u>Total</u>		813	
<u>Predecessor Other</u>			
<u>Finite-Lived Intangible Assets [Line Items]</u>			
<u>Finite-lived intangible assets, gross carrying amount</u>		8,815	
<u>Finite-lived intangible assets, accumulated amortization</u>		(3,374)	
<u>Total</u>		\$ 5,441	

Goodwill and Intangible Assets - Summary of Activity of Intangible Assets (Details)
- USD (\$)
\$ in Thousands

	4 Months Ended Dec. 31, 2017	8 Months Ended Aug. 31, 2017	12 Months Ended Dec. 31, 2016	12 Months Ended Dec. 31, 2015
--	---------------------------------	---------------------------------	----------------------------------	----------------------------------

Finite-lived assets:

<u>Intangible assets, beginning balance</u>	\$ 56,750			
<u>Additions</u>	474			
<u>Disposals</u>	(140)			
<u>Purchase price adjustments</u>	3,873			
<u>Recruitment expense</u>	(227)			
<u>Amortization</u>	(1,822)			
<u>Intangible assets, ending balance</u>	58,908	\$ 56,750		

Predecessor

Finite-lived assets:

<u>Intangible assets, beginning balance</u>	69,915	48,023	\$ 53,568	
<u>Additions</u>		28,312	4,754	
<u>Disposals</u>			(135)	
<u>Recruitment expense</u>		(380)	(609)	
<u>Amortization</u>		(6,040)	(9,555)	\$ (9,100)
<u>Intangible assets, ending balance</u>		69,915	\$ 48,023	\$ 53,568

NSH

Finite-lived assets:

<u>Additions</u>		27,800		
------------------	--	--------	--	--

Certificates of Need

Finite-lived assets:

<u>Purchase price adjustments</u>	200			
-----------------------------------	-----	--	--	--

Certificates of Need | NSH

Finite-lived assets:

<u>Additions</u>		700		
------------------	--	-----	--	--

Medicare licenses | NSH

Finite-lived assets:

<u>Additions</u>		100		
------------------	--	-----	--	--

Management Rights

Finite-lived assets:

<u>Purchase price adjustments</u>	6,900			
-----------------------------------	-------	--	--	--

Management Rights | NSH

Finite-lived assets:

<u>Additions</u>		\$ 26,900		
------------------	--	-----------	--	--

<u>Weighted average amortization period</u>		23 years		
---	--	----------	--	--

Non-Compete Agreements

Finite-lived assets:

<u>Purchase price adjustments</u>	\$ (3,200)			
-----------------------------------	------------	--	--	--

Non-Compete Agreements | NSH

Finite-lived assets:

Additions

\$ 100

Weighted average amortization period

3 years

**Goodwill and Intangible
Assets - Future Amortization
of Intangible Assets (Details)
- USD (\$)
\$ in Thousands**

4 Months Ended 8 Months Ended 12 Months Ended
Dec. 31, 2017 Aug. 31, 2017 Dec. 31, 2016 Dec. 31, 2015

Finite-Lived Intangible Assets [Line Items]

<u>Amortization expense</u>	\$ 1,822			
<u>2018</u>	4,966			
<u>2019</u>	4,576			
<u>2020</u>	4,172			
<u>2021</u>	3,730			
<u>2022</u>	2,874			
<u>Thereafter</u>	26,034			
<u>Total</u>	\$ 46,352			

Predecessor

Finite-Lived Intangible Assets [Line Items]

<u>Amortization expense</u>		\$ 6,040	\$ 9,555	\$ 9,100
<u>Total</u>			\$ 44,001	

**Long-Term Debt - Summary
of Long-Term Debt (Details)
- USD (\$)
\$ in Thousands**

	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>	\$ 2,186,291		
<u>Capital lease obligations</u>	27,594		
<u>Less: unamortized debt issuance costs and original issue discount</u>	0		
<u>Total debt</u>	2,189,282		
<u>Less: Current maturities</u>	58,726		
<u>Total long-term debt</u>	2,130,556		
<u>Line of Credit Revolving Credit Facility</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>	0		
<u>Line of Credit 2014 First Lien Credit Agreement</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>	0		
<u>Subordinated Notes</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>	0		
<u>Notes payable and secured loans</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>	101,921		
<u>Predecessor</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Capital lease obligations</u>			\$ 13,996
<u>Less: unamortized debt issuance costs and original issue discount</u>			(32,274)
<u>Total debt</u>			1,442,243
<u>Less: Current maturities</u>			27,822
<u>Total long-term debt</u>			1,414,421
<u>Predecessor Line of Credit Revolving Credit Facility</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>			85,000
<u>Predecessor Line of Credit 2014 First Lien Credit Agreement</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>			932,000
<u>Predecessor Subordinated Notes</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>			1,000
<u>Predecessor Notes payable and secured loans</u>			
<u>Debt Instrument [Line Items]</u>			
<u>Long-term debt</u>			42,521

[2017 Revolver Loan, Maturing 2022 | Secured Debt | Revolving Credit Facility](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) 0

[2017 Revolver Loan, Maturing 2022 | Predecessor | Secured Debt | Revolving Credit Facility](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) 0

[Unamortized fair value discount](#) \$ (9,400)

[2017 Term Loan, Maturing 2024 | Secured Debt](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) 1,280,532

[2017 Term Loan, Maturing 2024 | Predecessor | Secured Debt](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) 0

[Senior Unsecured Notes Due 2021 | Senior Notes](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) 409,235

[Unamortized fair value discount](#) (6,200)

[Unamortized \(discount\) premium](#) 9,200

[Senior Unsecured Notes Due 2021 | Predecessor | Senior Notes](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) 400,000

[Unamortized \(discount\) premium](#) \$ 10,000

[Senior Unsecured Notes Due 2025 | Senior Notes](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) \$ 370,000

[Senior Unsecured Notes Due 2025 | Predecessor | Senior Notes](#)

[Debt Instrument \[Line Items\]](#)

[Long-term debt](#) \$ 0

Long-Term Debt - 2014 Revolver Loan & 2014 First Lien Credit Agreement (Details) - USD (\$)	Aug. 31, 2017	1 Months Ended			4 Months Ended	8 Months Ended	12 Months Ended	
		Mar. 31, 2016	Sep. 30, 2016	Oct. 31, 2015	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]								
Loss on debt refinancing Predecessor					\$ 0			
Debt Instrument [Line Items]								
Loss on debt refinancing Predecessor Line of Credit 2017 Senior Secured Credit Facilities						\$ 18,211,000	\$ 11,876,000	\$ 16,102,000
Debt Instrument [Line Items]								
Loss on debt refinancing 2014 Revolver And First Lien Credit Agreement Loans Predecessor Line of Credit Revolving Credit Facility		\$ 8,300,000	\$ 3,600,000	\$ 16,100,000				
Debt Instrument [Line Items]								
Debt prepayment amount	\$ 1,030,000,000							
Repurchased outstanding principal	1,027,000,000.000					1,027,000,000.000		
Accrued interest paid	\$ 3,000,000							
Loss on debt extinguishment						\$ 18,200,000		

**Long-Term Debt - 2014
Second Lien Credit
Agreement (Details) - USD
(\$)
\$ in Thousands**

	1 Months Ended		4 Months Ended	8 Months Ended	12 Months Ended		
	Mar. 31, 2016	Sep. 30, 2016	Oct. 31, 2015	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015

Debt Instrument [Line Items]

Loss on debt refinancing

\$ 0

Predecessor

Debt Instrument [Line Items]

Loss on debt refinancing

\$ 18,211 \$ 11,876 \$ 16,102

Predecessor | 2017 Senior Secured Credit

Facilities | Line of Credit

Debt Instrument [Line Items]

Loss on debt refinancing

\$ 8,300 \$ 3,600 \$ 16,100

Long-Term Debt - 2017
Senior Secured Credit
Facilities (Details) - USD (\$)
\$ in Millions

12 Months
Ended
Aug. 31,
2017 **Dec. 31, 2017**

Revolving Credit Facility Line of Credit		
Debt Instrument [Line Items]		
Outstanding balance on debt		\$ 71.9
Letter of Credit Line of Credit		
Debt Instrument [Line Items]		
Outstanding balance on debt		\$ 3.1
2017 Term Loan, Maturing 2024 Secured Debt		
Debt Instrument [Line Items]		
Repayment threshold	50.00%	
Quarterly installment of original principal		0.25%
2017 Term Loan, Maturing 2024 Predecessor Secured Debt		
Debt Instrument [Line Items]		
Original balance of debt	\$ 1,290.0	
Debt issuance costs	18.8	
2017 Term Loan, Maturing 2024 Predecessor Fair Value, Inputs, Level 2 Secured Debt		
Debt Instrument [Line Items]		
Debt discount	\$ 6.5	
2017 Revolver Loan, Maturing 2022 Revolving Credit Facility Secured Debt		
Debt Instrument [Line Items]		
Repayment threshold	50.00%	
Commitment fee		0.50%
Net leverage ratio		9.50
Commitment threshold		35.00%
2017 Revolver Loan, Maturing 2022 Predecessor Revolving Credit Facility Secured Debt		
Debt Instrument [Line Items]		
Original balance of debt	\$ 75.0	
Debt discount	\$ 9.4	
Federal Funds Effective Swap Rate 2017 Senior Secured Credit Facility Secured Debt		
Debt Instrument [Line Items]		
Debt instrument, basis spread on variable rate		0.50%
One Month LIBOR 2017 Senior Secured Credit Facility Secured Debt		
Debt Instrument [Line Items]		
Debt instrument, basis spread on variable rate		1.00%
Base Rate 2017 Senior Secured Credit Facility Secured Debt		
Debt Instrument [Line Items]		
Debt instrument, basis spread on variable rate		2.00%
Minimum LIBOR 2017 Senior Secured Credit Facility Secured Debt		

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate 3.00%
Minimum | Base Rate | 2017 Senior Secured Credit Facility | Secured Debt

Debt Instrument [Line Items]

Debt instrument, margin in addition to base rate 2.00%
Maximum | LIBOR | 2017 Senior Secured Credit Facility | Secured Debt

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate 3.25%
Maximum | Base Rate | 2017 Senior Secured Credit Facility | Secured Debt

Debt Instrument [Line Items]

Debt instrument, margin in addition to base rate 2.25%

**Long-Term Debt - Senior
Unsecured Notes due 2021
(Details) - Senior Notes -
Senior Unsecured Notes Due
2021 - USD (\$)**

12 Months Ended

Dec. 31, 2017 Aug. 31, 2017 Mar. 31, 2016

Debt Instrument [Line Items]

<u>Debt instrument, stated rate</u>	8.875%
<u>Unamortized premium</u>	\$ 9,200,000

Redemption Period One

Debt Instrument [Line Items]

<u>Amount of principal available to be redeemed, percentage</u>	35.00%
<u>Cash proceeds of principal amount, percentage</u>	108.875%
<u>Minimum principal remaining, percentage</u>	50.00%
<u>Period after equity offering</u>	180 days
<u>Redemption price, percentage</u>	100.00%

Redemption Period Two

Debt Instrument [Line Items]

<u>Redemption price, percentage</u>	106.656%
-------------------------------------	----------

Redemption Period Three

Debt Instrument [Line Items]

<u>Redemption price, percentage</u>	104.438%
-------------------------------------	----------

Redemption Period Four

Debt Instrument [Line Items]

<u>Redemption price, percentage</u>	100.00%
-------------------------------------	---------

Redemption Period Five

Debt Instrument [Line Items]

<u>Redemption price, percentage</u>	101.00%
-------------------------------------	---------

Predecessor

Debt Instrument [Line Items]

<u>Original balance of debt</u>		\$ 400,000,000.0
<u>Debt issuance costs</u>	\$ 8,400,000	
<u>Unamortized premium</u>	\$ 10,000,000	

**Long-Term Debt - Senior
Unsecured Notes due 2025
(Details) - Senior Notes -
Senior Unsecured Notes Due
2025 - USD (\$)**

12 Months Ended

Dec. 31, 2017 Aug. 31, 2017 Jun. 30, 2017

Debt Instrument [Line Items]

Debt instrument, stated rate 6.75%

Redemption Period One

Debt Instrument [Line Items]

Amount of principal available to be redeemed, percentage 40.00%

Cash proceeds of principal amount, percentage 106.75%

Minimum principal remaining, percentage 50.00%

Period after equity offering 180 days

Redemption price, percentage 100.00%

Redemption Period Two

Debt Instrument [Line Items]

Redemption price, percentage 103.375%

Redemption Period Three

Debt Instrument [Line Items]

Redemption price, percentage 101.688%

Redemption Period Four

Debt Instrument [Line Items]

Redemption price, percentage 100.00%

Redemption Period Five

Debt Instrument [Line Items]

Redemption price, percentage 101.00%

Predecessor

Debt Instrument [Line Items]

Original balance of debt \$ 370,000,000.0

Debt issuance costs \$ 17,300,000

**Long-Term Debt -
Subordinated Notes, Notes
Payable, Secured Loans, and
Capital Lease Obligations
(Details) - USD (\$)**

Aug. 03, 2017 Dec. 31, 2017 Dec. 31, 2016

Debt Instrument [Line Items]

Long-term debt \$ 2,186,291,000

Capital leased assets 16,200,000

Subordinated Notes

Debt Instrument [Line Items]

Long-term debt 0

Notes payable and secured loans

Debt Instrument [Line Items]

Long-term debt \$ 101,921,000

Predecessor

Debt Instrument [Line Items]

Capital leased assets \$ 15,400,000

Predecessor | Subordinated Notes

Debt Instrument [Line Items]

Repurchased outstanding principal \$ 1,000,000.0

Debt instrument, stated rate 17.00%

Redemption price, percentage 100.00%

Long-term debt 1,000,000

Predecessor | Notes payable and secured loans

Debt Instrument [Line Items]

Long-term debt \$ 42,521,000

**Long-Term Debt - Summary
of Scheduled Maturities of Dec. 31, 2017
Debt Obligations (Details) USD (\$)
\$ in Thousands**

[Debt Disclosure \[Abstract\]](#)

<u>2018</u>	\$ 58,726
<u>2019</u>	36,857
<u>2020</u>	1,277,253
<u>2021</u>	411,748
<u>2022</u>	8,110
<u>Thereafter</u>	393,597
<u>Total debt</u>	\$ 2,186,291

Leases (Details) - USD (\$) \$ in Thousands	8 Months	12 Months Ended		
	Ended Aug. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Operating Leases</u>				
<u>2018</u>		\$ 67,513		
<u>2019</u>		67,136		
<u>2020</u>		62,735		
<u>2021</u>		56,558		
<u>2022</u>		52,582		
<u>Thereafter</u>		258,192		
<u>Total minimum payments</u>		564,716		
<u>Capital Leases</u>				
<u>2018</u>		9,100		
<u>2019</u>		7,404		
<u>2020</u>		5,020		
<u>2021</u>		3,505		
<u>2022</u>		1,986		
<u>Thereafter</u>		6,299		
<u>Total minimum payments</u>		33,314		
<u>Less: imputed interest</u>		(5,720)		
<u>Capital lease obligations</u>		27,594		
<u>Total future minimum rental payments to be received</u>		4,200		
<u>Operating Leased Assets [Line Items]</u>				
<u>Operating leases expense</u>		27,800		
<u>Operating lease agreements, with physician investors</u>				
<u>Operating Leased Assets [Line Items]</u>				
<u>Operating leases expense</u>		\$ 7,500		
<u>Predecessor</u>				
<u>Operating Leased Assets [Line Items]</u>				
<u>Operating leases expense</u>	\$ 39,200		\$ 47,300	\$ 40,100
<u>Predecessor Operating lease agreements, with physician investors</u>				
<u>Operating Leased Assets [Line Items]</u>				
<u>Operating leases expense</u>	\$ 9,800		\$ 14,400	\$ 12,900

Redeemable Preferred Stock (Details) \$ / shares in Units, \$ in Thousands	Aug. 31, 2017 USD (\$) \$ / shares shares	4 Months Ended	12 Months Ended	
		Dec. 31, 2017 USD (\$) \$ / shares	Dec. 31, 2017 USD (\$) trading_days \$ / shares	Dec. 31, 2015 USD (\$) shares
<u>Temporary Equity [Line Items]</u>				
<u>Dividends declared but unpaid</u>		\$ 3,900	\$ 3,900	
<u>Cumulative preferred dividends</u>			\$ 9,200	
<u>Cumulative preferred dividends (in USD per share) \$ / shares</u>			\$ 29.56	
<u>Increase (Decrease) in Temporary Equity [Roll Forward]</u>				
<u>September 1, 2017</u>		310,000		
<u>Dividends accrued</u>		10,481		
<u>Cash dividends declared</u>		(5,241)		
<u>Mark to redemption adjustment</u>		15,566		
<u>December 31, 2017</u>	\$ 310,000	\$ 330,806	\$ 330,806	
<u>Series A Preferred Stock</u>				
<u>Temporary Equity [Line Items]</u>				
<u>Preferred stock dividend rate</u>			10.00%	
<u>Trading days trading_days</u>			20	
<u>Consecutive trading days trading_days</u>			30	
<u>Threshold share price (in USD per share) \$ / shares</u>			\$ 42.00	
<u>Maximum cash dividend declarable</u>			50.00%	
<u>Redemption price (in USD per share) \$ / shares</u>		\$ 1,000.00	\$ 1,000.00	
<u>Series A Preferred Stock Common Stock</u>				
<u>Temporary Equity [Line Items]</u>				
<u>Share price (in USD per share) \$ / shares</u>		\$ 19.00	\$ 19.00	
<u>Predecessor</u>				
<u>Temporary Equity [Line Items]</u>				
<u>Initial public offering</u>				\$ 250,979
<u>Predecessor Common Stock</u>				
<u>Temporary Equity [Line Items]</u>				
<u>Stock issued during period (in shares) shares</u>	[1]			14,285,000
<u>Initial public offering</u>	[1]			\$ 143
<u>Predecessor NSH</u>				
<u>Temporary Equity [Line Items]</u>				
<u>Deferred equity issuance costs</u>		\$ 18,300		
<u>Majority Shareholder Series A Preferred Stock</u>				
<u>Temporary Equity [Line Items]</u>				
<u>Stock issued during period (in shares) shares</u>		310,000		

<u>Purchase price per share (in USD per share) \$ / shares</u>	\$ 1,000
<u>Initial public offering</u>	\$ 310,000

[1] As described in Note 1 herein, the common stock of the Company is that of Surgery Partners, Inc. as of December 31, 2017, 2016 and 2015 and that of Surgery Center Holdings, Inc. as of December 31, 2014.

Earnings Per Share (Details) - USD (\$)	1 Months Ended		2 Months Ended		3 Months Ended						4 Months Ended	8 Months Ended	12 Months Ended				
	Dec. 31, 2017	Sep. 30, 2017	Aug. 31, 2017	Mar. 16, 2018	Dec. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 15, 2018	Dec. 15, 2017
Numerator:																	
Net (loss) income attributable to Surgery Partners, Inc.		\$ (9,140,000)		\$	\$ (32,176,000)							\$ (41,316,000)					
Less: amounts allocated to participating securities												10,481,000					
Less: mark to redemption adjustment												15,566,000					
Net (loss) income attributable to common stockholders												\$ (67,363,000)					
Denominator:																	
Weighted average shares outstanding- basic (in shares)												48,319,193					
Effect of dilutive securities (in shares)												0					
Weighted average shares outstanding- diluted (in shares)												48,319,193					
Earnings (loss) per share:																	
Basic (in USD per share)		\$ (0.57)		\$ (0.83)								\$ (1.39)					
Diluted (in USD per share)		\$ (0.57)		\$ (0.83)								\$ (1.39)					
Stock repurchase program, authorized amount																	\$ 50,000,000
Shares repurchased	180,664																
Shares repurchased, average price per share (in dollars per share)	\$ 11.12																
Stock repurchase program, remaining authorized repurchase amount	\$ 48,000,000			\$ 48,000,000								\$ 48,000,000					
Stock options																	
Earnings (loss) per share:																	
Antidilutive securities excluded from computation of earnings per share (in shares)												0					
Restricted shares																	
Earnings (loss) per share:																	
Antidilutive securities excluded from computation of earnings per share (in shares)												62,850					
Convertible preferred stock																	
Earnings (loss) per share:																	
Antidilutive securities excluded from computation of earnings per share (in shares)												0					
Predecessor																	
Numerator:																	
Net (loss) income attributable to Surgery Partners, Inc.		\$ (4,444,000)		\$	\$ (4,471,000)	\$ (2,754,000)	\$ 16,862,000	\$ (2,338,000)	\$ 2,120,000	\$ (7,190,000)		\$ (11,669,000)	\$ 9,453,000	\$ 1,429,000			
Less: amounts allocated to participating securities												0	0	0			
Less: mark to redemption adjustment												0	0	0			
Net (loss) income attributable to common stockholders												\$ (11,669,000)	\$ 9,453,000	\$ 1,429,000			
Denominator:																	
Weighted average shares outstanding- basic (in shares)												48,121,404	48,018,944	36,066,233			
Effect of dilutive securities (in shares)												0	171,794	1,398,154			
Weighted average shares outstanding- diluted (in shares)												48,121,404	48,190,738 ^[1]	37,464,387 ^[1]			
Earnings (loss) per share:																	
Basic (in USD per share)		\$ (0.09)		\$ (0.09)	\$ (0.06)	\$ 0.35	\$ (0.05)	\$ 0.04	\$ (0.15)			\$ (0.24)	\$ 0.20	\$ 0.04			
Diluted (in USD per share)		\$ (0.09)		\$ (0.09)	\$ (0.06)	\$ 0.35	\$ (0.05)	\$ 0.04	\$ (0.15)			\$ (0.24)	\$ 0.20	\$ 0.04			
Predecessor Stock options																	
Earnings (loss) per share:																	
Antidilutive securities excluded from computation of earnings per share (in shares)												0	0	0			
Predecessor Restricted shares																	
Earnings (loss) per share:																	
Antidilutive securities excluded from computation of earnings per share (in shares)												105,944	0	0			
Subsequent Event																	
Earnings (loss) per share:																	
Shares repurchased				156,818													
Shares repurchased, average price per share (in dollars per share)				\$ 12.64													
Stock repurchase program, remaining authorized repurchase amount																	\$ 46,000,000

[1] The impact of potentially dilutive securities for four months ended December 31, 2017 and the eight months ended August 31, 2017 were not considered because the effect would be anti-dilutive in those periods.

Income Taxes and Tax Receivable Agreement - Additional Information (Details) - USD (\$)	Oct. 01, 2017	Sep. 08, 2017	4 Months	8 Months	12 Months Ended					
			Ended	Ended	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	May 09, 2017	May 08, 2017
<u>Income Tax Contingency</u>										
<u>[Line Items]</u>										
<u>Cash paid for income taxes</u>			\$ 485,000							
<u>U.S. federal statutory rate</u>					35.00%					
<u>Valuation allowance</u>			11,032,000		\$	11,032,000				
<u>Increase in valuation allowance</u>						3,600,000				
<u>Increase in valuation allowance recorded to goodwill</u>			300,000			300,000				
<u>Valuation allowance that if recognized, would credit directly to contributed capital</u>			1,800,000			1,800,000				
<u>Accrued interest and penalties related to uncertain tax positions</u>			100,000			100,000				
<u>Uncertain tax positions that would impact effective tax rate</u>			200,000			200,000				
<u>Provisional amount related to remeasurement of deferred tax</u>						64,000,000				
<u>Carrying value of liability</u>			160,699,000		\$	160,699,000				
<u>Gain on amendment to TRA</u>			1,100,000							
<u>Goodwill impairment</u>	\$ 0									
<u>Reduction in carrying value of liability due to tax cuts</u>			25,300,000							
<u>Effective tax rate</u>					24.00%					
<u>Total amount payable</u>			65,100,000		\$	65,100,000				
<u>Tax Receivable Agreement value</u>			44,300,000			44,300,000				
<u>Additional Paid-in Capital</u>										
<u>Income Tax Contingency</u>										
<u>[Line Items]</u>										
<u>Additional-paid-in-capital increase, due to tax effect of disposals of shares of noncontrolling interests</u>						400,000				
<u>Capital Loss Carryforward</u>										
<u>Income Tax Contingency</u>										
<u>[Line Items]</u>										
<u>Capital loss carryforwards</u>			12,600,000			12,600,000				
<u>Credit Carryforward</u>										
<u>Income Tax Contingency</u>										
<u>[Line Items]</u>										
<u>Capital loss carryforwards</u>			1,100,000			1,100,000				
<u>Federal Tax Authority</u>										

Income Tax Contingency**[Line Items]**

<u>Net operating loss carryforwards</u>	507,400,000	507,400,000		
---	-------------	-------------	--	--

State Tax Authority**Income Tax Contingency****[Line Items]**

<u>Net operating loss carryforwards</u>	619,600,000	\$	619,600,000	
---	-------------	----	-------------	--

Materially More Restrictive | LIBOR**Income Tax Contingency****[Line Items]**

<u>Variable interest rate on agreement</u>		5.00%		
--	--	-------	--	--

Not Materially More Restrictive | LIBOR**Income Tax Contingency****[Line Items]**

<u>Variable interest rate on agreement</u>		3.00%		
--	--	-------	--	--

Predecessor**Income Tax Contingency****[Line Items]**

<u>Cash paid for income taxes</u>	\$ 598,000	\$ 661,000	\$ 1,093,000	
-----------------------------------	------------	------------	--------------	--

Valuation allowanceAccrued interest and penalties related to uncertain tax positionsUncertain tax positions that would impact effective tax rate

<u>Carrying value of liability</u>	43,900,000	179,194,000		
------------------------------------	------------	-------------	--	--

<u>Gain on amendment to TRA</u>	15,300,000			
---------------------------------	------------	--	--	--

<u>Goodwill impairment</u>		\$ 0	\$ 0	
----------------------------	--	------	------	--

<u>Total amount payable</u>			\$ 120,500,000	\$ 123,400,000
-----------------------------	--	--	----------------	----------------

Pushdown Accounting |Predecessor**Income Tax Contingency****[Line Items]**

<u>Goodwill impairment</u>	\$ 28,600,000			
----------------------------	---------------	--	--	--

Former Chief Executive Officer**Income Tax Contingency****[Line Items]**

<u>Assignment of equity interest</u>	50.00%			
<u>Upfront payments</u>	\$ 5,100,000			

Employees**Income Tax Contingency****[Line Items]**

<u>Upfront payments</u>	\$ 4,800,000			
-------------------------	--------------	--	--	--

[Interest in future payments](#)

100.00%

Income Taxes and Tax Receivable Agreement - Income Tax Expense (Details) - USD (\$) \$ in Thousands	4 Months Ended		8 Months Ended		12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015		
Current:						
<u>Federal</u>	\$ (111)					
<u>State</u>	990					
Deferred:						
<u>Federal</u>	77,472					
<u>State</u>	(6,712)					
<u>Total income tax expense (benefit)</u>	\$ 71,639					
<u>Predecessor</u>						
Current:						
<u>Federal</u>		\$ 0	\$ (31)	\$ 0		
<u>State</u>		614	244	909		
Deferred:						
<u>Federal</u>		(17,288)	7,326	(132,311)		
<u>State</u>		(1,415)	(444)	(17,580)		
<u>Total income tax expense (benefit)</u>		\$ (18,089)	\$ 7,095	\$ (148,982)		

Income Taxes and Tax Receivable Agreement - Income Tax Rate Reconciliation (Details) - USD (\$) \$ in Thousands	4 Months	8 Months	12 Months Ended	
	Ended	Ended	Dec. 31,	Dec. 31,
	Dec. 31, 2017	Aug. 31, 2017	2016	2015
Income Tax Contingency [Line Items]				
<u>Tax expense (benefit) at U.S.federal statutory rate</u>	\$ 24,485			
<u>State income tax, net of U.S. federal tax benefit</u>	1,685			
<u>Change in valuation allowance</u>	529			
<u>Net income attributable to non-controlling interests</u>	(13,872)			
<u>Changes in measurement of uncertain tax positions</u>	(191)			
<u>Stock option compensation</u>	306			
<u>Differences related to divested facilities</u>	(429)			
<u>Nondeductible transaction costs</u>	2,058			
<u>Tax return reconciling differences</u>	0			
<u>Change in effective tax rate</u>	64,343			
<u>TRA liability</u>	(7,404)			
<u>Other</u>	129			
<u>Total income tax expense (benefit)</u>	\$ 71,639			
Predecessor				
Income Tax Contingency [Line Items]				
<u>Tax expense (benefit) at U.S.federal statutory rate</u>		\$ 4,315	\$ 32,263	\$ (26,648)
<u>State income tax, net of U.S. federal tax benefit</u>		(456)	(86)	1,059
<u>Change in valuation allowance</u>		1,324	354	(137,721)
<u>Net income attributable to non-controlling interests</u>		(14,731)	(26,470)	(24,996)
<u>Changes in measurement of uncertain tax positions</u>		20	(262)	(10)
<u>Stock option compensation</u>		37	(200)	0
<u>Differences related to divested facilities</u>		(1,708)	0	0
<u>Nondeductible transaction costs</u>		(977)	0	3,442
<u>Tax return reconciling differences</u>		(316)	1,635	(1,574)
<u>Change in effective tax rate</u>		(825)	0	(2,143)
<u>TRA liability</u>		(4,782)	(327)	39,428
<u>Other</u>		10	188	181
<u>Total income tax expense (benefit)</u>		\$ (18,089)	\$ 7,095	\$ (148,982)

**Income Taxes and Tax
Receivable Agreement -
Approx. Tax Effects of
Temporary Differences,
Deferred Tax Asset and
Liability (Details) - USD (\$)
\$ in Thousands**

Dec. 31, 2017 Aug. 31, 2017 Dec. 31, 2016

Deferred tax assets:

<u>Medical malpractice liability</u>	\$ 3,236
<u>Accrued vacation and incentive compensation</u>	2,125
<u>Net operating loss carryforwards</u>	137,794
<u>Allowance for bad debts</u>	2,545
<u>Capital loss carryforwards</u>	3,024
<u>Deferred rent</u>	0
<u>Depreciation on property and equipment</u>	0
<u>Deferred financing costs</u>	17,004
<u>TRA liability</u>	1,042
<u>Other deferred assets</u>	4,961
<u>Total gross deferred tax assets</u>	171,731
<u>Less: Valuation allowance</u>	(11,032)
<u>Total deferred tax assets</u>	160,699

Deferred tax liabilities:

<u>Deferred financing costs</u>	0
<u>Depreciation on property and equipment</u>	(12,098)
<u>Amortization of intangible assets</u>	(12,441)
<u>Basis differences of partnerships and joint ventures</u>	(2,399)
<u>Deferred rent</u>	(717)
<u>Other deferred liabilities</u>	(725)
<u>Total deferred tax liabilities</u>	(28,380)
<u>Net deferred tax assets</u>	\$ 132,319

Predecessor

Deferred tax assets:

<u>Medical malpractice liability</u>	\$ 4,194
<u>Accrued vacation and incentive compensation</u>	1,112
<u>Net operating loss carryforwards</u>	158,796
<u>Allowance for bad debts</u>	8,343
<u>Capital loss carryforwards</u>	2,785
<u>Deferred rent</u>	1,371
<u>Depreciation on property and equipment</u>	530
<u>Deferred financing costs</u>	0
<u>TRA liability</u>	4,542
<u>Other deferred assets</u>	4,879
<u>Total gross deferred tax assets</u>	186,552
<u>Less: Valuation allowance</u>	(7,358)

<u>Total deferred tax assets</u>	\$ 43,900	179,194
<u>Deferred tax liabilities:</u>		
<u>Deferred financing costs</u>		(8,797)
<u>Depreciation on property and equipment</u>		0
<u>Amortization of intangible assets</u>		(15,241)
<u>Basis differences of partnerships and joint ventures</u>		(68,160)
<u>Deferred rent</u>		0
<u>Other deferred liabilities</u>		(3,203)
<u>Total deferred tax liabilities</u>		(95,401)
<u>Net deferred tax assets</u>		\$ 83,793

**Income Taxes and Tax
Receivable Agreement -
Schedule of Gross
Unrecognized Tax Benefits
(Details) - USD (\$)
\$ in Thousands**

12 Months Ended

**Dec. 31, Dec. 31,
2017 2016**

**Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to
Examined Tax Returns [Roll Forward]**

<u>Unrecognized tax benefits at beginning of year</u>	\$ 1,061	
<u>Additions for acquired positions</u>	36	
<u>Additions for tax positions of prior years</u>	0	
<u>Reductions for tax positions of prior year</u>	(407)	
<u>Settlements</u>	0	
<u>Unrecognized tax benefits at end of year</u>	690	\$ 1,061
<u>Predecessor</u>		

**Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to
Examined Tax Returns [Roll Forward]**

<u>Unrecognized tax benefits at beginning of year</u>	\$ 1,061	1,403
<u>Additions for acquired positions</u>		0
<u>Additions for tax positions of prior years</u>		60
<u>Reductions for tax positions of prior year</u>		(398)
<u>Settlements</u>		(4)
<u>Unrecognized tax benefits at end of year</u>		\$ 1,061

Equity-Based Compensation - Additional Information (Details) - USD (\$) \$ in Thousands	1 Months Ended Apr. 30, 2013	4 Months Ended Dec. 31, 2017	8 Months Ended Aug. 31, 2017	12 Months Ended Dec. 31, Dec. 31, 2016 2015	
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Granted (in shares)</u>		0			
<u>Unrecognized compensation cost</u>		\$ 6,600			
<u>Equity-based compensation</u>		1,887			
<u>Additional Paid-in Capital</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Equity-based compensation</u>		\$ 1,887			
<u>Restricted Stock Awards</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Awards granted during period (in shares)</u>		112,107			
<u>Performance Restricted Stock Units</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Awards granted during period (in shares)</u>		0			
<u>Restricted units granted, earned during period (in shares)</u>		0			
<u>Restricted Shares</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Awards granted during period (in shares)</u>		112,107			
<u>2015 Omnibus Incentive Plan</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Shares authorized under plan (in shares)</u>		4,815,700			
<u>Shares available for future grant (in shares)</u>		3,716,809			
<u>Predecessor</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Granted (in shares)</u>			0	7,779	8,488
<u>Equity-based compensation</u>			\$ 3,697	\$ 2,021	\$ 7,502
<u>Predecessor Additional Paid-in Capital</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Equity-based compensation</u>			\$ 3,697	\$ 2,021	\$ 7,502
<u>Predecessor Restricted Stock Awards</u>					
<u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u>					
<u>Awards granted during period (in shares)</u>			251,904	384,629	569,114

Predecessor Performance Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Awards granted during period (in shares)	232,242	292,147	0
Restricted units granted, earned during period (in shares)		136,550	
Predecessor Leverage Performance			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Awards granted during period (in shares)	215,823		
Predecessor Restricted Shares			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Awards granted during period (in shares)	388,454	384,629	569,114
Accelerated vesting (in shares)			1,632,626
Accelerated vesting, cost			\$ 6,200
Predecessor Symbion, Inc B Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Number of additional instruments issued (in shares)	1,300,000		
Minimum Predecessor Performance Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Payable at end of period		0.00%	
Minimum Predecessor Leverage Performance			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Payable at end of period		0.00%	
Maximum Predecessor Performance Restricted Stock Units			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Payable at end of period		150.00%	
Maximum Predecessor Leverage Performance			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Payable at end of period		500.00%	

Equity-Based Compensation - Summary of Restricted Share Activity (Details) - Restricted Shares - \$ / shares	4 Months Ended	8 Months Ended	12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Unvested Shares				
<u>Outstanding, beginning of the period (in shares)</u>	613,044			
<u>Granted (in shares)</u>	112,107			
<u>Forfeited/Terminated (in shares)</u>	(54,622)			
<u>Vested (in shares)</u>	(96,073)			
<u>Outstanding, end of the period (in shares)</u>	574,456	613,044		
Weighted Average Grant Date Fair Value				
<u>Outstanding, beginning of the period (in USD per share)</u>	\$ 16.02			
<u>Granted (in USD per share)</u>	11.15			
<u>Forfeited/Terminated (in USD per share)</u>	10.94			
<u>Vested (in USD per share)</u>	17.03			
<u>Outstanding, end of the period (in USD per share)</u>	\$ 15.95	\$ 16.02		
<u>Predecessor</u>				
Unvested Shares				
<u>Outstanding, beginning of the period (in shares)</u>	613,044	462,242	167,654	1,242,065
<u>Granted (in shares)</u>		388,454	384,629	569,114
<u>Forfeited/Terminated (in shares)</u>		(67,771)	(53,003)	
<u>Vested (in shares)</u>		(169,881)	(37,038)	(1,643,525)
<u>Outstanding, end of the period (in shares)</u>		613,044	462,242	167,654
Weighted Average Grant Date Fair Value				
<u>Outstanding, beginning of the period (in USD per share)</u>	\$ 16.02	\$ 3.72	\$ 2.53	\$ 1.96
<u>Granted (in USD per share)</u>		18.40	15.09	6.31
<u>Forfeited/Terminated (in USD per share)</u>		18.01	11.85	
<u>Vested (in USD per share)</u>		10.29	6.31	3.79
<u>Outstanding, end of the period (in USD per share)</u>		\$ 16.02	\$ 3.72	\$ 2.53

**Equity-Based Compensation
- Fair Value Assumptions
(Details) - Stock Option**

**12 Months
Ended
Dec. 31, 2017
\$/ shares**

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]

<u>Expected dividends</u>	0.00%
<u>Average expected term (years)</u>	2 years 6 months 22 days

Minimum

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]

<u>Expected volatility</u>	29.00%
<u>Risk-free interest rate</u>	0.54%
<u>Fair value of stock options granted (in USD per share)</u>	\$ 2.64

Maximum

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]

<u>Expected volatility</u>	43.00%
<u>Risk-free interest rate</u>	1.36%
<u>Fair value of stock options granted (in USD per share)</u>	\$ 5.74

Equity-Based Compensation - Summary of Options Activity (Details) - \$ / shares	4 Months Ended	8 Months Ended	12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Options</u>				
<u>Outstanding, beginning of period (in shares)</u>	12,687			
<u>Granted (in shares)</u>	0			
<u>Exercised (in shares)</u>	0			
<u>Forfeited (in shares)</u>	0			
<u>Outstanding, end of period (in shares)</u>	12,687	12,687		
<u>Weighted Average Exercise Price</u>				
<u>Outstanding, beginning of period (in USD per share)</u>	\$ 20.10			
<u>Outstanding, end of period (in USD per share)</u>	\$ 20.10	\$ 20.10		
<u>Weighted Average Remaining Contractual Term (years)</u>				
<u>Outstanding</u>	1 year 1 month 28 days	1 year 6 months		
<u>Outstanding options, exercisable (in shares)</u>	7,058			
<u>Options</u>				
<u>Outstanding, beginning of period (in shares)</u>	12,687	16,267	8,488	0
<u>Granted (in shares)</u>		0	7,779	8,488
<u>Exercised (in shares)</u>		(3,580)	0	0
<u>Forfeited (in shares)</u>		0	0	0
<u>Outstanding, end of period (in shares)</u>		12,687	16,267	8,488
<u>Weighted Average Exercise Price</u>				
<u>Outstanding, beginning of period (in USD per share)</u>	\$ 20.10	\$ 19.05	\$ 20.03	
<u>Granted (in USD per share)</u>			17.99	\$ 20.03
<u>Exercised (in USD per share)</u>		15.36		
<u>Outstanding, end of period (in USD per share)</u>		\$ 20.10	\$ 19.05	\$ 20.03
<u>Weighted Average Remaining Contractual Term (years)</u>				
<u>Outstanding</u>		1 year 6 months	1 year 9 months 18 days	3 years
<u>Granted</u>			1 year 7 months 6 days	3 years

Employee Benefit Plans (Details) - USD (\$) \$ in Millions	4 Months	8 Months	12 Months Ended		
	Ended Dec. 31, 2017	Ended Aug. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
<u>Defined Contribution Plan Disclosure [Line Items]</u>					
<u>Matching contribution expense</u>	\$ 2.3				
<u>Supplemental Executive Retirement Savings Plan</u>					
<u>Defined Contribution Plan Disclosure [Line Items]</u>					
<u>Percent of payroll employee may defer</u>			25.00%		
<u>Percent of bonus employee may defer</u>			50.00%		
<u>Percent of base pay employee may contribute to receive employer match</u>			2.00%		
<u>Employer matching contribution percentage of employee base salary</u>			2.00%		
<u>Predecessor</u>					
<u>Defined Contribution Plan Disclosure [Line Items]</u>					
<u>Matching contribution expense</u>		\$ 2.8		\$ 5.1	\$ 2.2

**Related Party Transactions
(Details) - Predecessor -
Bayside Capital, Inc. -
Management and Investment
Advisory Services
Agreement - Affiliated
Entity
\$ in Millions**

12 Months Ended

**Dec. 31, 2015
USD (\$)**

Related Party Transaction [Line Items]

Annual management fee per agreement with related party \$ 3.0

Termination of management agreement and IPO costs \$ 5.4

Commitments and Contingencies (Details) \$ in Thousands	Apr. 20, 2017 USD (\$)	Dec. 24, 2009 USD (\$) Entity	3 Months Ended	4 Months Ended	8 Months Ended	12 Months Ended				
			Jun. 30, 2017 USD (\$)	Dec. 31, 2017 USD (\$)	Aug. 31, 2017 USD (\$) Practice	Dec. 31, 2018 USD (\$)	Dec. 31, 2016 USD (\$)	Dec. 31, 2015 USD (\$)	Jun. 30, 2016 USD (\$)	
Guarantor Obligations [Line Items]										
Gain on legal settlement				\$ 8,740						
Contingent acquisition compensation expense				1,900						
Q2 Period Ended, 2016 Acquisition										
Guarantor Obligations [Line Items]										
Gain on legal settlement				\$ 8,700						
Predecessor										
Guarantor Obligations [Line Items]										
Number of business entities acquired Practice					1					
Gain on legal settlement					\$ 3,794		\$ 14,101	\$ 0		
Contingent acquisition compensation expense					\$ 5,100		5,100			
Predecessor 2009 Acquisition										
Guarantor Obligations [Line Items]										
Number of business entities acquired Entity		36								
Maximum potential contingent consideration		\$ 10,000								
Gain on legal settlement	\$ 3,900		\$ 3,800				\$ 14,100			
Gain funded from escrow of seller	2,700									
Gain funded from seller	\$ 1,200									
Predecessor Q2 Period Ended, 2016 Acquisition										
Guarantor Obligations [Line Items]										
Fair value of contingent consideration liability										\$ 16,600

Scenario, Forecast | Q2 Period
Ended, 2016 Acquisition
Guarantor Obligations [Line
Items]
Contingent acquisition
compensation expense

\$ 1,500

Segment Reporting - Revenues by Reportable Segment (Details) \$ in Thousands	1 2 Months Months Ended Ended		3 Months Ended						4 8 Months Months Ended Ended		12 Months Ended			
	Sep. 30, 2017 USD (\$)	Aug. 31, 2017 USD (\$)	Dec. 31, 2017 USD (\$)	Jun. 30, 2017 USD (\$)	Mar. 31, 2017 USD (\$)	Dec. 31, 2016 USD (\$)	Sep. 30, 2016 USD (\$)	Jun. 30, 2016 USD (\$)	Mar. 31, 2016 USD (\$)	Dec. 31, 2017 USD (\$)	Aug. 31, 2017 USD (\$)	Dec. 31, 2017 segment USD (\$)	Dec. 31, 2016 USD (\$)	Dec. 31, 2015 USD (\$)
Segment Reporting [Abstract]														
Number of operating segments segment												3		
Segment Reporting Information [Line Items]														
Revenues	\$	\$							\$					
	132,258	460,346							592,604					
Surgical facility services														
Segment Reporting Information [Line Items]														
Revenues									564,458					
Ancillary services														
Segment Reporting Information [Line Items]														
Revenues									24,660					
Optical services														
Segment Reporting Information [Line Items]														
Revenues									\$ 3,486					
Predecessor														
Segment Reporting Information [Line Items]														
Revenues	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
	174,079	288,353	286,183	306,001	282,682	289,681	267,074		748,615			1,145,438	959,891	
Predecessor Surgical facility services														
Segment Reporting Information [Line Items]														
Revenues									688,725			1,042,097	884,144	
Predecessor Ancillary services														
Segment Reporting Information [Line Items]														
Revenues									52,261			90,836	61,175	
Predecessor Optical services														
Segment Reporting Information [Line Items]														
Revenues									\$ 7,629			\$ 12,505	\$ 14,572	

Segment Reporting - Segment Operating Income (Details) - USD (\$) \$ in Thousands	1 2		3 Months Ended						4 8		12 Months Ended			
	Months Ended	Months Ended	Sep. 30, 2017	Aug. 31, 2017	Dec. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]														
Total adjusted EBITDA												\$		
												78,737		
Net income attributable to non-controlling interests	\$ 6,492			\$								39,634		
Depreciation and amortization												(21,804)		
Interest expense, net												(48,740)		
Non-cash stock compensation expense												(1,887)		
Contingent acquisition compensation expense												(1,982)		
Termination of management agreement and IPO costs												0		
Management fee												0		
Merger transaction, integration and practice acquisition costs												(9,330)		
Gain on litigation settlement												8,740		
Gain on acquisition escrow release												167		
Gain (loss) on disposal or impairment of long-lived assets, net												(5)		
Gain on amendment to tax receivable agreement												1,098		
Tax receivable agreement benefit (expense)												25,329		
Loss on debt refinancing												0		
Income (loss) before income taxes												69,957		
Merger transaction and integration costs												7,470		
Practice acquisition costs												1,800		
Operating Segments Surgical facility services														
Segment Reporting Information [Line Items]														
Total adjusted EBITDA												103,760		
Operating Segments Ancillary services														
Segment Reporting Information [Line Items]														
Total adjusted EBITDA												(2,255)		
Operating Segments Optical services														
Segment Reporting Information [Line Items]														
Total adjusted EBITDA												736		
All other														

Segment Reporting**Information [Line Items]**Total adjusted EBITDA\$
(23,504)Predecessor**Segment Reporting****Information [Line Items]**Total adjusted EBITDA\$ \$ \$
85,564 179,263 158,053Net income attributable to non-controlling interests\$ 8,813 \$ \$ \$ \$ \$ \$
16,098 17,176 21,238 16,672 20,173 17,547

42,087 75,630 71,416

Depreciation and amortization

(30,124) (39,551) (34,545)

Interest expense, net

(68,929) (100,571) (100,980)

Non-cash stock compensation expense

(3,697) (2,021) (7,502)

Contingent acquisition compensation expense

(5,057) (5,092) 0

Termination of management agreement and IPO costs

0 0 (5,834)

Management fee

0 0 (2,250)

Merger transaction, integration and practice acquisition costs

(7,677) (11,617) (20,579)

Gain on litigation settlement

3,794 14,101 0

Gain on acquisition escrow release

1,000 0 0

Gain (loss) on disposal or impairment of long-lived assets, net

(1,715) (2,355) 2,097

Gain on amendment to tax receivable agreement

15,294 0 0

Tax receivable agreement benefit (expense)

0 (3,733) (119,911)

Loss on debt refinancing

(18,211) (11,876) (16,102)

Income (loss) before income taxes

12,329 92,178 (76,137)

Merger transaction and integration costs

5,584 8,738 17,920

Practice acquisition costs

2,100 2,900 2,700

Predecessor | Operating Segments | Surgical facility services

125,912 214,218 180,113

Segment Reporting**Information [Line Items]**Total adjusted EBITDAPredecessor | Operating Segments | Ancillary servicesPredecessor | Operating Segments | Optical services**Segment Reporting****Information [Line Items]**Total adjusted EBITDA

(6,526) 12,685 18,715

Predecessor | Operating Segments | Optical servicesPredecessor | All other

2,214 3,308 3,905

Segment Reporting**Information [Line Items]**Total adjusted EBITDAPredecessor | All other

2,214 3,308 3,905

Segment Reporting
Information [Line Items]

Total adjusted EBITDA

\$ \$ \$
(36,036) (50,948) (44,680)

Segment Reporting - Assets by Operating Segment (Details) - USD (\$) \$ in Thousands	Dec. 31, 2017	Oct. 01, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]					
Total assets	\$ 4,622,773				
Goodwill	3,346,838		\$ 3,269,225		
Surgical facility services Pushdown Accounting					
Segment Reporting Information [Line Items]					
Goodwill		\$ 3,158,000			
Ancillary services Pushdown Accounting					
Segment Reporting Information [Line Items]					
Goodwill		74,300			
Optical services Pushdown Accounting					
Segment Reporting Information [Line Items]					
Goodwill		\$ 38,400			
Operating Segments					
Segment Reporting Information [Line Items]					
Total assets	4,622,773				
Operating Segments Surgical facility services					
Segment Reporting Information [Line Items]					
Total assets	4,072,521				
Operating Segments Ancillary services					
Segment Reporting Information [Line Items]					
Total assets	104,274				
Operating Segments Optical services					
Segment Reporting Information [Line Items]					
Total assets	48,309				
All other					
Segment Reporting Information [Line Items]					
Total assets	\$ 397,669				
Predecessor					
Segment Reporting Information [Line Items]					
Total assets			\$ 2,304,958		
Goodwill			\$ 2,414,572	1,555,204	\$ 1,407,927
Predecessor Operating Segments					
Segment Reporting Information [Line Items]					
Total assets			2,304,958		
Predecessor Operating Segments Surgical facility services					
Segment Reporting Information [Line Items]					
Total assets			1,914,842		

[Predecessor | Operating Segments | Ancillary services](#)

[Segment Reporting Information \[Line Items\]](#)

[Total assets](#)

184,002

[Predecessor | Operating Segments | Optical services](#)

[Segment Reporting Information \[Line Items\]](#)

[Total assets](#)

22,478

[Predecessor | All other](#)

[Segment Reporting Information \[Line Items\]](#)

[Total assets](#)

\$ 183,636

Segment Reporting - Cash Purchases of Property and Equipment (Details) - USD (\$) \$ in Thousands	4 Months Ended	8 Months Ended	12 Months Ended	
	Dec. 31, 2017	Aug. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Operating Segments	\$ 10,827			
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Operating Segments Surgical facility services	10,827			
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Operating Segments Ancillary services	9,334			
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Operating Segments Optical services	191			
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net All other	83			
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Predecessor	\$ 1,219			
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Predecessor Operating Segments		\$ 18,773	\$ 39,109	\$ 33,439
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Predecessor Operating Segments Surgical facility services		18,773	39,109	33,439
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Predecessor Operating Segments Ancillary services		14,582	29,157	26,723
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Predecessor Operating Segments Optical services		1,875	5,388	1,051
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net Predecessor All other		73	351	128
Segment Reporting Information [Line Items] Total cash purchases of property and equipment, net		\$ 2,243	\$ 4,213	\$ 5,537

Quarterly Financial Information (Unaudited) (Details) - USD (\$) \$/ shares in Units, \$ in Thousands	1 2		3 Months Ended						4 8		12 Months Ended		
	Months Ended	Months Ended	Dec. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Months Ended	Months Ended	Dec. 31, 2016	Dec. 31, 2015
<u>Schedule Of Quarterly Financial Information [Line Items]</u>													
<u>Revenues</u>	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
	132,258	460,346	592,604										
<u>Cost of revenues</u>	102,924	338,704	441,628										
<u>Net income (loss)</u>	(2,648)	966	(1,682)										
<u>Net income attributable to non-controlling interests</u>	(6,492)	(33,142)	(39,634)										
<u>Net (loss) income attributable to Surgery Partners, Inc.</u>	\$ (9,140)	\$ (32,176)	\$ (41,316)										
<u>Basic net (loss) income per share (in USD per share)</u>	\$ (0.57)	\$ (0.83)	\$ (1.39)										
<u>Diluted net (loss) income per share (in USD per share)</u>	\$ (0.57)	\$ (0.83)	\$ (1.39)										

Predecessor

Schedule Of Quarterly Financial Information [Line Items]

<u>Revenues</u>	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
	174,079	288,353	286,183	306,001	282,682	289,681	267,074	748,615	1,145,438	959,891			
<u>Cost of revenues</u>	143,772	216,452	211,948	214,247	201,394	208,852	196,703	572,172	821,196	669,326			
<u>Net income (loss)</u>	4,369	11,627	14,422	38,100	14,334	22,293	10,357	30,418	85,083	72,845			
<u>Net income attributable to non-controlling interests</u>	(8,813)	(16,098)	(17,176)	(21,238)	(16,672)	(20,173)	(17,547)	(42,087)	(75,630)	(71,416)			
<u>Net (loss) income attributable to Surgery Partners, Inc.</u>	\$ (4,444)	\$ (4,471)	\$ (2,754)	\$ 16,862	\$ (2,338)	\$ 2,120	\$ (7,190)	\$ (11,669)	\$ 9,453	\$ 1,429			
<u>Basic net (loss) income per share (in USD per share)</u>	\$ (0.09)	\$ (0.09)	\$ (0.06)	\$ 0.35	\$ (0.05)	\$ 0.04	\$ (0.15)	\$ (0.24)	\$ 0.20	\$ 0.04			
<u>Diluted net (loss) income per share (in USD per share)</u>	\$ (0.09)	\$ (0.09)	\$ (0.06)	\$ 0.35	\$ (0.05)	\$ 0.04	\$ (0.15)	\$ (0.24)	\$ 0.20	\$ 0.04			

Subsequent Events (Details)
\$ in Millions

Mar. 01, 2018
USD (\$)

[Surgical Facility Acquisitions | Subsequent Event](#)

[Subsequent Event \[Line Items\]](#)

[Cash consideration](#)

\$ 21.9